WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.

Contraindications
- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

Warnings and Precautions
- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.
- Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome-like reactions have been reported with SNRIs and SSRIs alone, including PRISTIQ treatment, but particularly with concomitant use of serotonergic drugs, including triptans, with drugs that impair the metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. If concomitant use with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.

Important Safety Information for PRISTIQ
PRISTIQ is indicated for the treatment of major depressive disorder in adults.

Visit booth #1816
Find out whether PRISTIQ is appropriate for your patients suffering from MDD
SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.

Mydriasis has been reported in association with PRISTIQ; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.

PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.

As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania, or with a history of seizure disorder.

Caution is advised in administering PRISTIQ to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders. Increases in blood pressure and small increases in heart rate were observed in clinical studies with PRISTIQ. PRISTIQ has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease.

Dose-related elevations in fasting serum total cholesterol, LDL (low density lipoprotein) cholesterol, and triglycerides were observed in clinical studies. Measurement of serum lipids should be considered during PRISTIQ treatment.

On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended whenever possible.

The recommended dose in patients with severe renal impairment or end-stage renal disease (ESRD) is 50 mg every other day. The dose should not be escalated in patients with moderate or severe renal impairment or ESRD.

Products containing desvenlafaxine and products containing venlafaxine should not be used concomitantly with PRISTIQ.

Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions

The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarking studies (incidence ≥5% and at least twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).


Please see brief summary of Prescribing Information on adjacent pages.

For more information on PRISTIQ, please visit www.PristiqHCP.com.

Wyeth is a wholly owned subsidiary of Pfizer Inc. To learn more, please visit www.pfizer.com.
A major depressive episode may be the initial presentation of bipolar disorder. It is generally
palpitations, tachycardia, blood pressure increased; gastrointestinal disorders.

There are no adequate and well-controlled studies in patients with bipolar depression, especially in children, adolescents, or patients with mania. It is unknown whether treatment with Pristiq will delay the onset of mania or Mixed Features Disorder in patients with bipolar depression.

The following changes were observed in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

Several studies have compared the efficacy of Pristiq with placebo and other antidepressants in the treatment of MDD. In a 12-week, placebo-controlled, fixed-dose study of 11 antidepressants in over 77,000 patients with MDD, the efficacy of Pristiq (50 and 100 mg/day) was compared to placebo in a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.

Patients receiving Pristiq ≥50 mg/day who discontinued treatment because of an adverse event constituted 6% of patients (n = 205) and 4% of patients (n = 122) discontinuing treatment because of an adverse event in the placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, respectively, in adults with MDD.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.

The most common adverse reactions leading to discontinuation in at least 2% of the
major depressive disorder (MDD) population in placebo-controlled, short-term, premarketing MDD studies with Pristiq, 50 and 100 mg/day, in adults with MDD. Discontinuation of treatment at doses of 50 mg/day or higher results in dose-related increases in vital signs. Patients should be advised that signs and symptoms of a panic attack may be worsened by Pristiq. Although symptoms of a panic attack can occur with placebo, signs and symptoms of a panic attack were more common during Pristiq treatment in these studies.
The Human Rights Award was established to recognize an individual and an organization whose efforts exemplify the capacity of human beings to act courageously and effectively to prevent human rights violations and to promote human rights and their consequent consequences, and to help victims recover from human rights abuses.

The nomination letter should succinctly describe the contributions that are the basis for the nomination and be accompanied by a one page vita or resume. The Council on Psychiatry and Law will serve as the award panel in determining the recipients of this award. The recipients will receive a plaque which will be awarded during the Convocation at the APA’s Annual Meeting in May 2011.

The Isaac Ray Award

The Isaac Ray Award is presented to an individual who has demonstrated a sustained commitment to the protection of human rights. The award is given by the American Psychiatric Association and the American Academy of Psychiatry and the Law to individuals who have made significant contributions to the protection of human rights.

Nominations are requested as follows:
1. Primary nominating letter (sent with the consent of the candidate), which includes a curriculum vitae and specific details regarding the candidate's qualifications for the Award.
2. Supplemental letter from a second nominator in support of the candidate. Additional letters related to any particular candidate will not be accepted or reviewed by the Award Committee. Nominators should not submit letters on behalf of more than one candidate.

The deadline for receipt of nominations is July 1, 2010. Nominations will be kept in the pool of applicants for two years.

Nominations, as outlined above, should be submitted to:

Renee L. Binder, M.D., Chairperson c/o Yoshi Davison, Staff Liaison
American Psychiatrist Association 1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
E-mail: advocacy@psych.org
Your One-Stop Educational eResource Library

- 100+ hours of sessions with presenter slides and synchronized audio
- DVD-ROM with online access available for purchase
- Exclusive on-site attendee pricing* - save up to $500
- Earn AMA PRA Category 1 Credit™

For more information or to purchase, visit the booths located in Lobby B1 or near the Registration Area in Hall B2.

The 2010 APA ANNUAL MEETING ONLINE
www.psych.org/amlibrary

* On-site pricing expires May 26, 2010. Residents/Students save $500, other attendees save $400.

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. The APA designates (each of the presentations) in this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
his book contains the Program Book, New Research Program Book and Exhibits Guide. Listed below you will find the Table of Contents for ease in locating information about this meeting and the City of New Orleans. Located within the Program Book you will find a topic index in addition to subspecialty, topic and other program tracks that will assist you in finding scientific sessions of interest. The individual program for each day of the meeting is separated by pull-out tabs so that you can easily find the day(s) of the meeting that interests you. The program is listed by start time with the formats listed alphabetically under those times. To make it even easier to plan your day a separate Days-at-a-Glance has been included with your registration materials. The New Research Program Book contains all of the posters that will be presented at this meeting, along with a topic index that contains only the posters that are on the New Research Program. The Exhibits Guide contains a list of the exhibitors and a floor plan of the exhibit hall, along with information about the Product Theaters.

If you have any questions about this book or the scientific program, please feel free to stop by the Scientific Programs Office, Room 204, Second Level, Morial Convention Center and an APA staff person will be happy to assist you. All central office APA staff will be wearing green badges. Please feel free to direct your questions to any APA staff.

CONTENTS

Guide to this Book .......................................................... 5
Table of Contents.......................................................... 5
Scientific Program Committee Photo .......................... 6
Welcome Letter from APA President, Alan F. Schatzberg, M.D. ...................................................... 6
Welcome Letter from Scientific Program Co-Chairs: Julio Licinio, M.D. and Donald M. Hilty, M.D. .......... 7
General Information and Key Locations ...................... 8
Shuttle Bus Schedule ...................................................... 12
Hotel Locations and City Map ..................................... 15
Floor Plans .................................................................. 16
Presidents of U.S. Allied Organizations ....................... 22
Presidents of International Allied Organizations .......... 24
Special Acknowledgements ......................................... 28
Disclosure Index ........................................................... 32
Program Book .................................................................. 57
Format Descriptions ..................................................... 58
Daily Attendance Log .................................................... 60
Saturday’s Program ....................................................... 61
Sunday’s Program .......................................................... 75
Mondays’ Program ........................................................ 85
TUESDAY’S PROGRAM ................................................. 103
WEDNESDAY’S PROGRAM ........................................... 117
TOPIC INDEX ............................................................... 126
NEW RESEARCH PROGRAM BOOK .......................... 137
MONDAY’S PROGRAM ................................................ 138
TUESDAY’S PROGRAM ................................................ 150
WEDNESDAY’S PROGRAM .......................................... 159
TOPIC INDEX ............................................................... 165
EXHIBITS GUIDE ......................................................... 169
GENERAL INFORMATION ............................................ 171
PRODUCT THEATERS .................................................. 177
ALPHABETICAL LIST OF EXHIBITORS ....................... 183
EXHIBITORS WITH PRODUCT/ SERVICE DESCRIPTIONS .......... 189
EXHIBITORS BY PRODUCT/ SERVICE LISTING .......... 210
CAREER FAIR AND PUBLISHING BOOK FAIR EXHIBITORS ......... 214
NUMERICAL LIST OF EXHIBITORS BY BOOTH NUMBER .......... 218
EXHIBIT HALL FLOOR PLAN ........................................ 219
LIST OF ADVERTISERS .................................................. 225
AUTHOR/PRESENTER INDEX ....................................... 226
Dear Colleagues and Guests:

Welcome to the 163rd Annual Meeting of the American Psychiatric Association in New Orleans, a unique American city and world-class conference location noted for its rich cultural diversity, arts and entertainment, and outstanding restaurants. I think you’ll find the program stronger than ever this year, reflecting a combination of new science and clinical advances.

“Pride and Promise: Toward a New Psychiatry” is my theme for the meeting. To implement this theme, we called on our academic leaders to develop a comprehensive and balanced program, inviting the best psychiatrist-scientists from around the world to present their work in special lectures, scientific symposia, workshops and other interactive sessions. Senior scholars such as Daniel Weinberger, M.D., Florian Holsboer, M.D., Ph.D., Eve Johnstone, M.D., Mario Maj, M.D., Ph.D., Raquel Gur, M.D., Ph.D., and Francene Benes, MD, PhD, will address us on their exciting work in depression and schizophrenia. We will also have some of the top young M.D./Ph.D.s from around the country—such as Karl Deisseroth, Kerry Ressler, Vikas Sohol, Amit Etkin, and others—show us where the field is heading.

We are delighted to be partnering once again with the National Institute on Drug Abuse (NIDA) to show how cutting-edge science on substance use disorders is informing clinical practice. Lectures by its director, Nora Volkow, M.D., and A. Thomas McLeod, Ph.D., deputy director of the White House Office of National Drug Control Policy, are headlining the NIDA track.

FocusLive, the Advances In series (in partnership with the American Psychiatric Publishing Inc.), Advances in Medicine, and Advances in Research (the latter chaired by former NIMH director and APA president Herbert Pardes, M.D.), all return by popular demand. Attendees also have the opportunity to be in the vanguard regarding DSM-5. A special track of DSM-5 sessions will provide insight into the evolving manual and will solicit attendees’ opinions on a number of key issues.

Look for symbols throughout the Program Book to help you find sessions in a variety of topical tracks that may relate to your research interests and clinical practice as well as subspecialty tracks published in the Days-At-a-Glance brochure. We hope these tools will make it easier for you to navigate the meeting and we would appreciate your feedback on this innovation.

My thanks go to co-chairs, Julio Licinio, M.D., and Donald Hilty, M.D., and members of the Scientific Program Committee, and to the APA staff members who have all worked so diligently to ensure the breadth and quality of the 2010 Annual Meeting program.

Sincerely,

Alan F. Schatzberg, M.D.
Dear APA Members and Guests:

Welcome to New Orleans for the 163rd Annual Meeting of the American Psychiatric Association. We are proud to contribute to the resurgence of this unique American city. As always, APA members will not want to miss two activities on Sunday: the Business Meeting (12:30 p.m.-1:30 p.m.) and the Opening Session (4:30 p.m.-5:45 p.m.). Please also make sure to attend the Convocation of Distinguished Fellows on Monday beginning at 5:30 p.m., which recognizes newly inducted fellows and distinguished fellows and honors this year’s award recipients. We are excited to have acclaimed actor and author, Carrie Fisher, present the William C. Menninger Memorial Lecture following the Convocation.

This year the Scientific Program Committee (SPC) collaborated with APA President, Dr. Alan F. Schatzberg, to plan an exciting and eventful program reflecting his theme, Pride and Promise: Toward a New Psychiatry. We’ve taken “Toward a New Psychiatry” to heart in crafting some major innovations in the meeting. Two changes are most notable: 1) the core Scientific Program now starts on Saturday, thus enabling clinicians to take less time away from their offices; and 2) a new publication, the Annual Meeting Guide, combining the Program Book, the New Research Poster Program and the Exhibits Guide in one handy volume.

The Scientific Program Committee selected sessions in a broad spectrum of approaches to teaching and learning: symposia, workshops and other small interactive sessions, lectures, case conferences, and forums. This year we are the introducing the seminar format, an extended-learning session, and we are experimenting with evening (7 p.m.-10 p.m.) media workshops. All are part of the CME Scientific Program open to all registrants.

We would like to encourage you particularly to attend the five Presidential Symposia on the neurobiology of antidepressant treatment response (with the Society of Biological Psychiatry), comparative effects of psychotropic drugs, basic and translational neuroscience to improve treatment, psychiatric genetics and health care reform.

We encourage all attendees to either fill out an evaluation here or to do so online following the meeting as you reflect on your experiences. Your feedback on the relevance and quality of this year’s program to your practice needs as well as your insights into gaps in knowledge and clinical practice that we can address in future meetings is highly valued. Once again, welcome to New Orleans, a city, which like our meeting, can also be defined by “Pride and Promise.” We are delighted to have the privilege of sharing with you the best that our field has to offer.

Sincerely,

Julio Licinio, M.D.
Co-Chairperson
Scientific Program Committee

Don Hilty, M.D.
Co-Chairperson
Scientific Program Committee
KEY LOCATIONS IN THE MORIAL CONVENTION CENTER

APA Alliance .......................... Halls A/B Lobby, First Level
APA Art Association ..................... Hall A Lobby, First Level
APA Job Bank and Placement Center ................. Exhibit Halls B-D, First Level
APA Member Center .................. Exhibit Halls B-D, First Level
APA News Room ....................... Rooms 211-213, Second Level
APA Periodicals ......................... Exhibit Halls B-D, First Level
Audiovisual Preview Room .......... Room 207, Second Level
CME Certificate of ....................... Exhibit Halls B/C, First Level
Attendance and Evaluation Course Enrollment ................. Exhibit Halls B/C, First Level
Daily Bulletin ........................... Room 216, Second Level
DVD, MP3, and APA Online Library Sales .................. Halls A/B Lobby, First Level
Exhibitor Registration .............. Hall B Lobby, First Level
Exhibits/Publishers’ Book Fair ............... Exhibit Halls B-D, First Level
First Aid ........................................ Medical Services 1, (outside of Exhibit Hall B, First Level)
Housing Desk ......................... Halls A/B Lobby, First Level
Lost and Found .......................... Room 214, Second Level
Meetings and Conventions Office .......... Room 214, Second Level
Message Centers ..................... Halls A/B Lobby, First Level; Exhibit Halls B/C, First Level; and North Skylight, Second Level
Registration ............................ Exhibit Halls B/C, First Level
Scientific Programs Office .......... Room 204, Second Level
Shuttle Bus Desk ...................... Room 204, Second Level

APA ALLIANCE

Located in Halls A/B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 9:00 a.m.-4:00 p.m. Stop by to obtain information on the Alliance’s program schedule and information on membership.

APA ART ASSOCIATION

Located in Hall A Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Sunday, 10:00 a.m.-4:30 p.m.; Monday-Tuesday, 10:00 a.m.-5:00 p.m.; and Wednesday, 10:00 a.m.-3:00 p.m. This exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA JOB BANK AND PLACEMENT CENTER

Visit the APA Job Bank, located in Exhibit Halls B-D, First Level, Morial Convention Center, to search the most comprehensive online listing of psychiatric positions! The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:00 p.m. Candidates: Register to post your resume; receive instant job alerts, use the career tools and more. Employers: Post your job opening during the meeting to get results as soon as possible. For more information on the Job Bank, visit www.psych.org/jobbank. A representative will be available on-site to provide assistance.

APA MEMBER CENTER

Located in Exhibit Halls B-D, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 10:00 a.m.-4:00 p.m. A few of the many APA activities exhibited include: Membership; APA’s Internet-Based Programs; Continuing Medical Education; Quality Improvement; Psychiatric Services; Clinical Resources; Advocacy Tools; Career Development; Practice Management; and APA Periodicals.

APA NEWS ROOM AND COMMUNICATIONS OFFICE

Located in Rooms 211-213, Second Level, Morial Convention Center. The days and hours of operation are as follows: Saturday, 11:00 a.m.-5:00 p.m.; Sunday-Tuesday, 8:00 a.m.-6:00 p.m.; and Wednesday, 8:00 a.m.-1:00 p.m. These rooms are for the use of registered press and credentialed public relations representatives only.

APA PERIODICALS

Editorial staff from the American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychosomatics, and APA’s CME journal, Focus, will be on hand to demonstrate online access for subscribers, and answer questions regarding submissions. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the APPI booth, located in the Exhibit Hall. Complimentary copies of Psychiatric News will be
available at stands located throughout the Morial Convention Center. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Meetings and Conventions Office, located in Room 214, Second Level, Morial Convention Center. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper’s consideration may be left with staff at the Periodicals Exhibit in the APA Member Center, located in Exhibit Halls B-D, First Level, Morial Convention Center.

**AUDIOVISUAL PREVIEW ROOM**

Located in Room 207, Second Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:30 p.m.; and Wednesday, 7:30 a.m.-2:00 p.m. The Scientific Program Committee expects all presenters to preview their audiovisual materials prior to their sessions to familiarize themselves with the equipment. For your convenience, an audiovisual technician will be available to assist you and answer your questions.

**CME CERTIFICATE OF ATTENDANCE AND EVALUATION**

The Scientific Program Committee needs your recommendations and evaluations to assess the effectiveness of the program and plan next year’s Annual Meeting. The general evaluation is available online at the CME Certificate of Attendance booth, located in Exhibit Halls B-C, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Tuesday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-5:30 p.m. After you complete the general evaluation you will receive a personalized Certificate of Attendance. This certificate can either be obtained on-site by visiting the CME Certificate of Attendance booth OR you may access the web-based evaluation from your own computer either during or after the meeting by visiting www.psych.org/annualmeetingcme. You will need your badge number to obtain the CME Certificate of Attendance and access the evaluation form using the web. **Please Note: APA no longer offers a paper version of the general evaluation form.**

**CONTINUING MEDICAL EDUCATION**

**EDUCATIONAL OBJECTIVES**

At the conclusion of this meeting the participant will be able to:

1. Review new research findings in the fields of psychiatry and neuroscience and address gaps in knowledge;

2. Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care;

3. Identify and remove barriers to the transfer of new knowledge for your practice, including provision of culturally competent care for diverse populations;

4. Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and

5. Recognize mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Please note: Formats on the scientific program, as outlined below, have been approved for CME credit.**

The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for AMA PRA Category 1 Credit™. Sessions in the following program formats are designated as category 1: Advances in … Series; Case Conferences; CME Courses; Focus Live; Forums; Industry-Supported Symposia; Lectures; Master Courses; Presidential Symposia; Scientific and Clinical Reports; Seminars; Small Interactive Sessions; Symposia; and Workshops.

**New Research Poster Sessions are not designated for AMA PRA Category 1 Credit™.**

Scientific sessions are open to all Annual Meeting registrants with the exception of Case Conferences, which are open to APA members only. CME Courses and Master Courses require an additional fee.

**To document CME credit** earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A daily attendance log is provided in this book for listing your sessions and credits.

**COURSE ENROLLMENT**

**Ticket Purchase Is Required For All Courses.**

Located in Exhibit Halls B/C, First Level, Morial Convention Center. The days and hours of operation are the same as registration. Course tickets not sold in advance will be available on-site at the Course Enrollment Area beginning at 12 noon on Friday. You must be registered for the meeting before you can enroll in courses.

**DAILY BULLETIN**

Located in Room 216, Second Level, Morial Convention Center, the Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday and Wednesday issues can be dropped off in Room 216 by 12 noon the day before the publication date.

**DVD, MP3, AND APA ONLINE LIBRARY SALES**

Located in Halls A/B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Saturday-Wednesday, 9:00 a.m.-5:00 p.m. Over 100 hours of CME programs will be available for purchase on DVD, MP3, and the APA Online Library.
EXHIBITOR REGISTRATION

Located in Hall B Lobby, First Level, Morial Convention Center. The days and hours of operation are as follows: Wednesday-Friday, 8:00 a.m.-5:00 p.m.; Saturday, 8:00 a.m.-6:00 p.m.; Sunday, 7:30 a.m.-4:00 p.m.; and Monday-Tuesday, 8:00 a.m.-4:00 p.m. Registered exhibitors will receive red badges that will permit access only to his/her exhibit booth in the Exhibit Hall and to ride the APA shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

EXHIBITS/PUBLISHERS’ BOOK FAIR

Commercial and educational exhibits will be located in Exhibit Halls B-D, First Level, Morial Convention Center, along with the Publishers’ Book Fair. For your convenience, the Publishers’ Book Fair will be open on Saturday, from 10:00 a.m.-4:00 p.m. Educational and commercial exhibit hours are as follows: Sunday-Tuesday, 10:00 a.m.-4:00 p.m. The exhibits and Publishers’ Book Fair close at 4:00 p.m. on Tuesday.

FIRST AID

Located in Medical Services 1, (outside of Exhibit Hall B), First Level, Morial Convention Center, the hours of operation are as follows: Monday, May 17-Wednesday, May 26. First aid opens 30 minutes prior to the show opening and closes 30 minutes after the last event of the evening.

LOST AND FOUND

Located in Room 214, Second Level, Morial Convention Center. The days and hours of operation are listed under Meetings and Conventions Office.

MEETINGS AND CONVENTIONS OFFICE

Located in Room 214, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 8:00 a.m.-5:00 p.m.; Saturday, 6:30 a.m.-4:30 p.m.; Sunday, 7:00 a.m.-5:30 p.m.; Monday, 7:00 a.m.-6:30 p.m.; and Tuesday-Wednesday, 7:00 a.m.-5:30 p.m. The staff located in the Meetings and Conventions Office is in charge of the logistics for the meeting. Lost and found is also located in this office.

MESSAGE CENTERS

Located in Halls A/B Lobby, First Level; Exhibit Halls B/C, First Level; and North Skylight, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-4:00 p.m.; Saturday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-4:00 p.m. Messages can be left and retrieved at any of the Message Centers. Registrants whose names appear on these monitors should pick up their message at one of the three Message Centers.

REGISTRATION

Admission To All Sessions Is By Registration Badge Only. Located in Exhibit Halls B/C, First Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-5:00 p.m.; Saturday-Tuesday, 7:30 a.m.-4:00 p.m.; and Wednesday, 7:30 a.m.-2:00 p.m. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book/New Research Program Book/Exhibits Guide, APA Member Center Guide, New Research Program Abstracts, and for most categories, the Syllabus. Registration badges are required for all sessions and the Exhibit Hall. Only an APA member badge will admit you to the Business Meeting.

Badge Color Codes:
Blue=Members;
Yellow=Nonmembers;
Silver=Press;
Red=Exhibitors;
Green=APA Staff; and
Clear=Temporary Personnel.

SCIENTIFIC PROGRAMS OFFICE

Located in Room 204, Second Level, Morial Convention Center. The days and hours of operation are as follows: Friday, 12 noon-4:00 p.m.; and Saturday-Wednesday, 7:30 a.m.-5:00 p.m. Come to this office if you have questions about:

1. Scientific sessions listed in the Program Book or Syllabus;
2. Adding audiovisual equipment to scientific sessions;
3. Scientific program changes;
4. Submitting a scientific session for the 2011 Annual Meeting; and
5. The 2010 Institute on Psychiatric Services.

SCIENTIFIC SESSION CAPACITY GUIDELINES

If overcrowding occurs in a scientific session we ask your assistance so that all in attendance can benefit. Please abide by the following guidelines if you are in a crowded room.

1. Take a seat as close to the front of the room as possible;
2. Move to the center of the row and fill all seats, so that chairs are available on the aisles for additional attendees;
3. Don't stand or sit in the aisles or lean against walls. Overcrowding of meeting rooms may subject the session to shut down by the Fire Marshall; therefore, please either find a seat or attend another session; and
4. If there are no seats available, a DVD of the session might be available. Please check the DVD order form that is included with your registration materials.
SHUTTLE BUS SERVICE

You must be a registered attendee or a registered exhibitor to ride on the courtesy shuttle bus. Shuttle bus service will begin on Saturday, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Wednesday, at 5:00 p.m. The Morial Convention Center will serve as the “hub” for all shuttle bus routes. The Shuttle Bus Desk is located in Halls A/B Lobby, First Level, Morial Convention Center. A detailed shuttle bus schedule will be available upon receipt of your registration materials and will be posted in the lobbies of participating hotels.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the Exhibit Hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Attendees are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional firm to tape sessions. Badges of personnel representing this firm will clearly identify them. Attendees are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

May 14-18, 2011  Honolulu, HI
May 5-9, 2012  Philadelphia, PA
May 18-22, 2013  San Francisco, CA

INSTITUTES ON PSYCHIATRIC SERVICES

October 14-17, 2010  Boston, MA
October 27-30, 2011  San Francisco, CA
October 4-7, 2012  New York, NY

The Preliminary Program for the 2010 Institute on Psychiatric Services, which includes registration, housing, air travel, and program information is available on the web at <www.psych.org/IPS>.
Complimentary shuttle service is provided between the Ernest N. Morial Convention Center (ENMCC) and the official APA hotels listed below. The ENMCC will operate as the “hub” of the APA shuttle bus system. All routes will begin and end there. Shuttle information signs will be posted in the lobby of each shuttle hotel. Check the sign in your hotel lobby for additional information and changes.

### SHUTTLE SCHEDULE

<table>
<thead>
<tr>
<th>SATURDAY, May 22, 2010</th>
<th>7:00 am-5:30 pm *</th>
<th>Every 20 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUNDAY, May 23, 2010</td>
<td>7:30 am-10:00 am</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td></td>
<td>10:00 am-3:30 pm</td>
<td>Every 20 minutes</td>
</tr>
<tr>
<td></td>
<td>3:30 pm-6:30 pm</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td></td>
<td>6:30 pm-7:30 pm *</td>
<td>Every 20 minutes</td>
</tr>
<tr>
<td>MONDAY, May 24, 2010</td>
<td>7:30 am-10:00 am</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td></td>
<td>10:00 am-3:30 pm</td>
<td>Every 20 minutes</td>
</tr>
<tr>
<td></td>
<td>3:30 pm-7:30 pm *</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td>TUESDAY, May 25, 2010</td>
<td>7:30 am-10:00 am</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td></td>
<td>10:00 am-3:30 pm</td>
<td>Every 20 minutes</td>
</tr>
<tr>
<td></td>
<td>3:30 pm-6:30 pm</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td>WEDNESDAY, May 26, 2010</td>
<td>7:30 am-11:00 am</td>
<td>Every 10-15 minutes</td>
</tr>
<tr>
<td></td>
<td>11:00 am-3:30 pm</td>
<td>Every 20 minutes</td>
</tr>
<tr>
<td></td>
<td>3:30 pm-5:30 pm *</td>
<td>Every 10-15 minutes</td>
</tr>
</tbody>
</table>

* This is the time that the last shuttle departs from ENMCC returning to hotels. Last shuttle from hotels to ENMCC departs 1 hour prior to this time.

### HOTELS LISTED IN ORDER OF PICK UP

<table>
<thead>
<tr>
<th>HOTEL</th>
<th>BOARDING LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Westin New Orleans Canal Place</td>
<td>Curboide en Bernerville</td>
</tr>
<tr>
<td>Doubletree New Orleans</td>
<td>Curboide en Tchoupitoulas, across the street</td>
</tr>
<tr>
<td>W New Orleans</td>
<td>At Doubletree New Orleans</td>
</tr>
<tr>
<td>Windsor Court Hotel</td>
<td>At Doubletree New Orleans</td>
</tr>
<tr>
<td>Loews New Orleans</td>
<td>Curboide en Poydras</td>
</tr>
<tr>
<td>Staybridge Suite New Orleans</td>
<td>At Loews</td>
</tr>
<tr>
<td>New Orleans Marriott</td>
<td>Curboide en Canal</td>
</tr>
<tr>
<td>Holiday Inn French Quarter</td>
<td>At New Orleans Marriott</td>
</tr>
<tr>
<td>Omni Royal Crescent Hotel</td>
<td>Corner of Camp and Gravier</td>
</tr>
<tr>
<td>Sheraton</td>
<td>Curboide en Canal</td>
</tr>
<tr>
<td>St. James Hotel</td>
<td>Curboide en Magazine</td>
</tr>
<tr>
<td>Country Inn &amp; Suites</td>
<td>At St. James Hotel</td>
</tr>
<tr>
<td>Pelham Hotel</td>
<td>At St. James Hotel</td>
</tr>
<tr>
<td>Astor Crowne Plaza</td>
<td>Curboide en Canal</td>
</tr>
<tr>
<td>Ritz Carlton</td>
<td>Curboide en Canal</td>
</tr>
<tr>
<td>Chateau Bourbon</td>
<td>At Ritz Carlton</td>
</tr>
<tr>
<td>InterContinental New Orleans</td>
<td>Curboide en Poydras, at St. Charles</td>
</tr>
<tr>
<td>Hilton Saint Charles Avenue</td>
<td>At InterContinental</td>
</tr>
<tr>
<td>Hampton Inn Downtown French Quarter</td>
<td>Curboide en Carondelet</td>
</tr>
<tr>
<td>Hilton Garden Inn French Quarter</td>
<td>At Hampton Inn</td>
</tr>
<tr>
<td>Holiday Inn Express French Quarter</td>
<td>At Hampton Inn</td>
</tr>
<tr>
<td>Renaissance Pere Marquette</td>
<td>At Hampton Inn</td>
</tr>
<tr>
<td>JW Marriott</td>
<td>Curboide en Canal</td>
</tr>
<tr>
<td>Courtyard Downtown St. Charles</td>
<td>At JW Marriott</td>
</tr>
<tr>
<td>The Roosevelt, Waldorf Astoria</td>
<td>Curboide en Baronne</td>
</tr>
<tr>
<td>Le Pavillon</td>
<td>Curboide en Baronne</td>
</tr>
<tr>
<td>Drury Inn &amp; Suites</td>
<td>Curboide en Poydras</td>
</tr>
<tr>
<td>Whitney</td>
<td>Curboide en Poydras</td>
</tr>
<tr>
<td>Hotel Monteleone</td>
<td>On Bienville at Royal</td>
</tr>
<tr>
<td>St. Ann Marie Antoinette Hotel</td>
<td>On Bienville at Royal</td>
</tr>
<tr>
<td>Saint Louis Hotel</td>
<td>On Bienville at Bourbon</td>
</tr>
<tr>
<td>Chateau LeMoyne French Quarter</td>
<td>On Bienville at Dauphine</td>
</tr>
<tr>
<td>Maison Dupuy Hotel</td>
<td>On Toulouse at Burgundy</td>
</tr>
<tr>
<td>Inn on Bourbon Ramada Plaza</td>
<td>On Toulouse at Bourbon</td>
</tr>
<tr>
<td>Omni Royal Orleans</td>
<td>On Toulouse at Chateau</td>
</tr>
</tbody>
</table>

### HOTELS WITHIN WALKING DISTANCE TO THE ENMCC

- Courtyard Convention Center
- Embassy Suites
- Hampton Inn & Suites Convention Center
- Hilton Garden Inn Convention Center
- Hilton New Orleans Riverside
- Hotel New Orleans
- New Orleans Marriott Convention Center
- Renaissance Arts Hotel
- Residence Inn Convention Center
- Springhill Suites Convention Center
- Wyndham Riverfront New Orleans
Please join us for a **Product Theater Presentation** at the

163rd Annual Meeting of the American Psychiatric Association

### Rethinking Schizophrenia Management:
A Once-Monthly Medication Option for Schizophrenia

**Monday, May 24, 2010**

Ernest N. Morial Convention Center
New Orleans, Louisiana
Room 231/232
9:30 AM – 10:00 AM

**Speaker**

Henry A. Nasrallah, MD
Professor of Psychiatry and Neuroscience
University of Cincinnati College of Medicine
Cincinnati, Ohio

-------------------------

If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements. Your name, the value, and purpose of any educational item, meal or other items of value you received may be reported as required by state or federal law. Once reported, this information may be publicly accessible. Thank you for your cooperation.

- This promotional educational activity is not accredited
- The program content is developed by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines
- Invitations to participants may not be extended to include spouses or other guests

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APF.

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010 May 2010 01PM10020E

---

Please join us for a Product Theater Presentation at the 163rd Annual Meeting of the American Psychiatric Association

### Acute Treatment of Schizoaffective Disorder:
Addressing the Clinical Challenges

**Tuesday, May 25, 2010**

Ernest N. Morial Convention Center
New Orleans, Louisiana
Room 231/232
9:30 AM – 10:00 AM

**SPEAKER**

Jelena L. Kunovac, MD, MS
Founder and Medical Director
Excell Research
Oceanside, California

-------------------------

If you are licensed in any state or other jurisdiction or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements. Your name, the value, and purpose of any educational item, meal or other items of value you received may be reported as required by state or federal law. Once reported, this information may be publicly accessible. Thank you for your cooperation.

- This promotional educational activity is not accredited
- The program content is developed by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
- Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines
- Invitations to participants may not be extended to include spouses or other guests

The Industry Product Theater's content and the views expressed therein are those of the sponsor and not of APA or APF.

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010 May 2010 01JN10023F
Join APA at the Annual Meeting and Qualify for a Rebate!

How Do I Qualify?
You may qualify if you:
1. Are a psychiatrist residing in the U.S. or Canada and,
2. Have paid the full-time non-member registration fee for the Annual Meeting ($905.00 advance, $950.00 on-site).

How Do I Apply?
1. Stop by one of the APA Membership Booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Halls B–D) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.
2. Additional documentation—proof of ACGME-AOA or RCPs(C)—approved psychiatry residency training and a current, valid medical license must be received by APA no later than June 30, 2010.

How Does the Rebate Work?
1. Your local psychiatric district branch must approve the application no later than September 30, 2010.
2. The difference between the member and non-member Annual Meeting registration fee will be applied towards your pro-rated 2010 national and local dues. The remaining balance of the rebate amount will be applied toward future years’ dues.*

Why Should I Join?
When you join the APA, you become part of a 38,000 member organization of physicians who specialize in the diagnosis, treatment, and prevention of mental illnesses. The APA unites psychiatrists from around the world and brings together practice, education, and research at all levels. As the largest psychiatric membership organization in the world, we are dedicated to promoting the highest quality care for patients, providing continuing education and research into mental illnesses, and advocating for psychiatrists and their profession.

Please visit www.psych.org/membership for additional information or stop by one of the APA Membership Booths at the Annual Meeting to learn more about the benefits of membership.

*Outstanding dues from previous years may be deducted in some cases.
For Exhibit Hall information please see Exhibit Guide in the back of the book.
Join Pine Rest
A Leader in Behavioral Health for 100 Years

- One of the five largest free-standing behavioral health providers in the U.S.
- Access to diverse career experiences in a behavioral health environment
- Adjunct assistant professor appointment with Michigan State University’s College of Human Medicine
- Full continuum of services for children, adolescents and adults
- Christian integrity and compassion

Remember to visit us at the APA Annual Meeting!
(Booth 2013)
NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

NeuroStar Transcranial Magnetic Stimulation Therapy® is the only FDA-cleared, non-drug, non-invasive treatment for depression.

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

Meet the TMS Experts at the APA Booth # 224. For schedule and topics visit www.neurostartms.com/meettheexperts

For a free information pack on how NeuroStar® TMS may work for you and your patients contact us at 877-600-7555 or visit us on the web at www.neurostartms.com
<table>
<thead>
<tr>
<th><strong>PRESIDENTS OF U.S. ALLIED ORGANIZATIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Academy of Cognitive Therapy</td>
</tr>
<tr>
<td><em>Robert Leahy, M.D.</em></td>
</tr>
<tr>
<td>Academy of Organizational and Occupational Psychiatry</td>
</tr>
<tr>
<td><em>Steven E. Pflanz, M.D.</em></td>
</tr>
<tr>
<td>American Academy of Addiction Psychiatry</td>
</tr>
<tr>
<td><em>Joseph G. Liberto, M.D.</em></td>
</tr>
<tr>
<td>American Academy of Child and Adolescent Psychiatry</td>
</tr>
<tr>
<td><em>Laurence L. Greenhill, M.D.</em></td>
</tr>
<tr>
<td>American Academy of Family Physicians</td>
</tr>
<tr>
<td><em>Lori J. Heim, M.D., FAAFP</em></td>
</tr>
<tr>
<td>American Academy of Neurology</td>
</tr>
<tr>
<td><em>Robert C. Griggs, M.D., FAAN</em></td>
</tr>
<tr>
<td>American Academy of Psychiatry and the Law</td>
</tr>
<tr>
<td><em>Stephen G. Billick, M.D.</em></td>
</tr>
<tr>
<td>American Academy of Psychoanalysis and Dynamic Psychiatry</td>
</tr>
<tr>
<td><em>Cesar A. Alfonso, M.D.</em></td>
</tr>
<tr>
<td>American Association for Emergency Psychiatry</td>
</tr>
<tr>
<td><em>Scott L. Zeller, M.D.</em></td>
</tr>
<tr>
<td>American Association for Social Psychiatry</td>
</tr>
<tr>
<td><em>Charles W. Huffine, Jr., M.D.</em></td>
</tr>
<tr>
<td>American Association for the Advancement of Science</td>
</tr>
<tr>
<td><em>Alice X. Huang, M.D.</em></td>
</tr>
<tr>
<td>American Association of Chairs of Departments of Psychiatry</td>
</tr>
<tr>
<td><em>Laura W. Roberts, M.D.</em></td>
</tr>
<tr>
<td>American Association of Community Psychiatrists</td>
</tr>
<tr>
<td><em>Hunter L. McQuistion, M.D.</em></td>
</tr>
<tr>
<td>American Association of Directors of Psychiatric Residency Training</td>
</tr>
<tr>
<td><em>Sheldon Benjamin, M.D.</em></td>
</tr>
<tr>
<td>American Association of Psychiatric Administrators</td>
</tr>
<tr>
<td><em>Douglas M. Brandt, M.D.</em></td>
</tr>
<tr>
<td>American Association on Mental Retardation</td>
</tr>
<tr>
<td><em>Joanna Pierson, Ph.D.</em></td>
</tr>
<tr>
<td>American Association of Practicing Psychiatrists</td>
</tr>
<tr>
<td><em>Janis G. Chester, M.D.</em></td>
</tr>
<tr>
<td>American Board of Psychiatry and Neurology, Inc.</td>
</tr>
<tr>
<td><em>Larry R. Faulkner, M.D.</em></td>
</tr>
<tr>
<td>American College of Emergency Physicians</td>
</tr>
<tr>
<td><em>Angela Gardner, M.D., FACEP</em></td>
</tr>
<tr>
<td>American College of Obstetricians and Gynecologists</td>
</tr>
<tr>
<td><em>Richard N. Waldman, M.D.</em></td>
</tr>
<tr>
<td>American College of Physicians-American Society of Internal Medicine</td>
</tr>
<tr>
<td><em>J. Freda Ralston, Jr., M.D., FACD</em></td>
</tr>
<tr>
<td>American College of Psychiatrists</td>
</tr>
<tr>
<td><em>John M. Oldham, M.D.</em></td>
</tr>
<tr>
<td>American College of Psychoanalysts</td>
</tr>
<tr>
<td><em>Varmik D. Volkan, M.D.</em></td>
</tr>
<tr>
<td>American College of Surgeons</td>
</tr>
<tr>
<td><em>LaMar S. McGinnis, Jr., M.D., FACS</em></td>
</tr>
<tr>
<td>American Group Psychotherapy Association</td>
</tr>
<tr>
<td><em>Jeffrey Kleinberg, Ph.D., CGP, FAGPA</em></td>
</tr>
<tr>
<td>American Medical Association</td>
</tr>
<tr>
<td><em>Ardis Dee Hoven, M.D.</em></td>
</tr>
<tr>
<td>American Medical Women's Association</td>
</tr>
<tr>
<td><em>Eliza L. Chin, M.D.</em></td>
</tr>
<tr>
<td>American Neurological Association</td>
</tr>
<tr>
<td><em>Robert L. Macdonald, M.D., Ph.D.</em></td>
</tr>
<tr>
<td>American Neuro-psychoanalytic Association</td>
</tr>
<tr>
<td><em>Paula T. Trzepacz, M.D.</em></td>
</tr>
<tr>
<td>American Nurses Association</td>
</tr>
<tr>
<td><em>Rebecca M. Patton, M.S.N., R.N., CNOR</em></td>
</tr>
<tr>
<td>American Orthopsychiatric Association</td>
</tr>
<tr>
<td><em>Andres J. Pumariega, M.D.</em></td>
</tr>
<tr>
<td>American Psychiatric Association Alliance</td>
</tr>
<tr>
<td><em>Kay Brada</em></td>
</tr>
<tr>
<td>American Psychoanalytic Association</td>
</tr>
<tr>
<td><em>Prudy Gourguechan, M.D.</em></td>
</tr>
<tr>
<td>American Psychological Association</td>
</tr>
<tr>
<td><em>Carol D. Goodheart, Ed.D.</em></td>
</tr>
<tr>
<td>American Society for Addiction Medicine</td>
</tr>
<tr>
<td><em>Louis E. Baxter, M.D.</em></td>
</tr>
<tr>
<td>American Society of Clinical Psycho-pharmacology, Inc.</td>
</tr>
<tr>
<td><em>John M. Kane, M.D.</em></td>
</tr>
<tr>
<td>Association for Academic Psychiatry</td>
</tr>
<tr>
<td><em>Michele T. Pato, M.D.</em></td>
</tr>
<tr>
<td>Association for Behavioral and Cognitive Therapies</td>
</tr>
<tr>
<td><em>Frank Andrasik, Ph.D.</em></td>
</tr>
<tr>
<td>Association of American Medical Colleges</td>
</tr>
<tr>
<td><em>Darrell G. Kirch, M.D.</em></td>
</tr>
<tr>
<td>ACMNA, The College for Behavioral Health Leadership</td>
</tr>
<tr>
<td><em>Pamela Greenberg, M.P.P.</em></td>
</tr>
<tr>
<td>Association of Chinese American Psychiatrists</td>
</tr>
<tr>
<td><em>Edmond H. Pi, M.D.</em></td>
</tr>
<tr>
<td>Association of Gay and Lesbian Psychiatrists</td>
</tr>
<tr>
<td><em>Ubaldo Leli, M.D.</em></td>
</tr>
<tr>
<td>Association of Women Psychiatrists</td>
</tr>
<tr>
<td><em>Eva M. Szigethy, M.D.</em></td>
</tr>
<tr>
<td>Black Psychiatrists of America</td>
</tr>
<tr>
<td><em>Napoleon B. Higgins, Jr., M.D.</em></td>
</tr>
<tr>
<td>Council of Medical Specialty Societies</td>
</tr>
<tr>
<td><em>James H. Scully, Jr, M.D.</em></td>
</tr>
<tr>
<td>Depression and Bipolar Support Alliance</td>
</tr>
<tr>
<td><em>Peter C. Ashenden, M.D.</em></td>
</tr>
<tr>
<td>Group for the Advancement of Psychiatry</td>
</tr>
<tr>
<td><em>Dave A. Baron, D.O.</em></td>
</tr>
<tr>
<td>Indo-American Psychiatric Association</td>
</tr>
<tr>
<td><em>Shirkumar S. Hatti, M.D., M.B.A.</em></td>
</tr>
<tr>
<td>Latin American Psychiatry Association</td>
</tr>
<tr>
<td><em>Edgardo Belfort, M.D.</em></td>
</tr>
<tr>
<td>National Alliance for Research on Schizophrenia and Depression</td>
</tr>
<tr>
<td><em>Benita Strobe, M.D.</em></td>
</tr>
<tr>
<td>National Alliance on Mental Illness (NAMI)</td>
</tr>
<tr>
<td><em>Stephen H. Feinstein, Ph.D.</em></td>
</tr>
<tr>
<td>National Association of Psychiatric Health Systems</td>
</tr>
<tr>
<td><em>Kevin Sheehan, M.D.</em></td>
</tr>
<tr>
<td>National Association of Social Workers, Inc.</td>
</tr>
<tr>
<td><em>James J. Kelly, Ph.D., A.C.S.W.</em></td>
</tr>
<tr>
<td>National Council for Community Behavioral Healthcare</td>
</tr>
<tr>
<td><em>Linda Rosenberg, M.D.</em></td>
</tr>
<tr>
<td>National Institute on Alcohol Abuse and Alcoholism</td>
</tr>
<tr>
<td><em>Kenneth Warren, Ph.D.</em></td>
</tr>
<tr>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td><em>Thomas R. Insel, M.D.</em></td>
</tr>
<tr>
<td>National Institute on Drug Abuse, NIH</td>
</tr>
<tr>
<td><em>Nora D. Volkow, M.D.</em></td>
</tr>
<tr>
<td>National Mental Health Association</td>
</tr>
<tr>
<td><em>David Sherar, M.D.</em></td>
</tr>
<tr>
<td>Philippine Psychiatrists in America</td>
</tr>
<tr>
<td><em>Pia N. Reyes, M.D.</em></td>
</tr>
<tr>
<td>Turkish American Neuropsychiatric Association</td>
</tr>
<tr>
<td><em>Erol Ucer, M.D.</em></td>
</tr>
</tbody>
</table>
Albanian
Psychiatric Association
Professor Afrim Dangella

Argentinian
Association of Psychiatrists (AAP)
Professor Juan Carlos Stagnaro

Armenian
Association of Psychiatrists and Nercologists
Dr. Armen Soghoyan

Azerbaijan
Psychiatric Association
Professor Nadiir Ismayilov

Bangladesh
Association of Psychiatrists
Professor Abdus Sobhan

Barbados
Association of Psychiatrists
Dr. Sharon Harvey

Byelorussian
Psychiatric Association
Professor Roman A. Evgenev

Royal Society of Mental Medicine of Belgium
Professor Jean Bertrand

Society of Flemish Neurologists and Psychiatrists (Belgium)
Professor Bernard Sabbe

Psyciatric Association of Bosnia and Herzegovina
Professor Marija Burgic-Radmanovic

Brazilian
Association of Psychiatry
Dr. João Alberto Carvalho

Bulgarian
Psychiatric Association
Dr. Temenuzka Mateva

Canadian
Psychiatric Association
Dr. Stanley Yaren

Chinese
Society of Psychiatry
Dr. Jingping Zhao

Colombian
Psychiatric Association
Dr. Louis Alfredo Montenegro Chamorro

Costa Rican
Psychiatric Association
Dr. Sisy Castillo-Ramirez

Croatian
Psychiatric Association
Professor Ljubomir Hotujac

Cuban
Society of Psychiatry
Dr. Miguel Valdes Mier

Cyprus
Psychiatric Association
Dr. Neophytos Papancoiphvou

Czech
Psychiatric Association
Professor Jiri Raboch

Danish
Psychiatric Association
Dr. Anders Fink-Jensen

Dominican
Society of Psychiatry
Dr. Fior Solis de Mendez

Ecuadorean
Association of Psychiatry
Dr. José Cruz Dueñas

Egyptian
Psychiatric Association
Professor Ahmed Okasha

Salvadoran
Association of Psychiatry
Dr. Claudia Beatriz Barahona Navarrete

Estonian
Psychiatric Association
Dr. Andres Lehtmets

Ethiopian
Psychiatric Association
Dr. Mesfin Araya

Finnish
Psychiatric Association
Professor Jyrki Korkeila

French
Association of Psychiatrists in Private Practice
Dr. Olivier Schmitt

Icelandic
Psychiatric Association
Dr. Kristi Revfjoisson

Indian
Psychiatric Society
Dr. E. Mohandas

Indonesian
Psychiatric Association
Dr. Tun Kurniasih Bastaman

Iranian
Psychiatric Association
Dr. S. Ahmad Jalili

Iraqi
Society of Psychiatrists
Dr. Qassim Hadi Al-Awadi

The Psychiatric Evolution (France)
Dr. Yves Thoret

Society of Georgian Psychiatrists
Professor George Naneishvili

German
Association for Psychiatry and Psychotherapy (formerly: German Society of Psychiatry, Psychotherapy and Nervous Disorders DGPPN)
Professor Norbert Schmidt

Ghana
Psychiatric Association
Dr. Sammy Ohene

Hellenic Psychiatric Association (Greece)
Professor Nikolaos Tsavaras

Hellenic Society of Neurology and Psychiatry (Greece)
Professor Costas Stefanis

Guatemalan
Psychiatric Association
Dr. See King Emilio Quinto

Honduran
Society of Psychiatry
Dr. Mario Mendoza

Hungarian
Psychiatric Association
Professor Janos Harmatta

Icelandic
Psychiatric Association
Dr. Kristi Revfjoisson

Indian
Psychiatric Society
Dr. E. Mohandas

Indonesian
Psychiatric Association
Dr. Tun Kurniasih Bastaman

Iranian
Psychiatric Association
Dr. S. Ahmad Jalili

Iraqi
Society of Psychiatrists
Dr. Qassim Hadi Al-Awadi
College of Psychiatry of Ireland (formerly, Irish College of Psychiatrists)

Dr. Justin Brophy

Israeli Psychiatric Association

Dr. Zeev Kaplan

Italian Association for Research in Schizophrenia

Professor Carlo Lorenzo Cazzullo

Italian Psychiatric Association

Dr. Alberto Siracusano

Jamaica Psychiatric Association

Dr. Yvonnie Bailey-Davidson

Japanese Society of Psychiatry and Neurology

Professor Haruo Kashima

Jordan Association of Psychiatrists

Dr. Tawfik Daradkeh

Kazakh Association of Psychiatrists and Narcologists

Professor Sullanat Nurmagambetova

Kenya Psychiatric Association

Dr. Marx M. Okonji

Korean Neuropsychiatric Association

Dr. Byoung Hoon Oh

Kuwait Psychiatric Association

Professor Essam A. Al-Ansari

Kyrgyz Psychiatric Association

Dr. Abjalal Begmatov

Latvian Psychiatric Association

Dr. Elmars Terauds

Lebanese Psychiatric Society

Dr. Nabil Mikati

Libyan Association of Psychiatry, Neurology and Neurosurgery

Dr. Ali Elroy

Lithuanian Psychiatric Association

Professor Algirdas Dembinskas

Luxembourgeois Society of Psychiatry, Neurology and Psychotherapy

Dr. Chretien Jacoby

Psychiatric Association of Macedonia (Republic of Macedonia, FYROM)

Dr. Antoni Novotni

Malaysian Psychiatric Association

Dr. Yen Teck Hoe

Mauritius Psychiatric Association

Dr. Parmanan Jagaunath

Mexican Psychiatric Association

Professor Martha Patricia Ontiveros Uribe

Mexican Society of Neurology and Psychiatry

Dr. Juan Ignacio Rosales

League for Mental Health from Republic of Moldova

Dr. Mihail Hotineanu

Mongolian Mental Health Association

Dr. Ayushjav Bayanhuu

Montenegrin Psychiatric Association

Dr. Lidija Injac-Stevovic

Moroccan Society of Psychiatry

Dr. Tazi Imane

Myanmar Medico-Psychological Society

Professor Sao Sai Lon

Psychiatrists’ Association of Nepal

Dr. Surendra Sherchan

Netherlands Psychiatric Association

Professor Rutger Jan van der Gaag

Nicaraguan Psychiatric Association

Dr. José Santiago Sequeira Molina

Association of Psychiatrists in Nigeria

Dr. Owodoho Udofa

Norwegian Psychiatric Association

Dr. Jan Olav Johannesen

Pakistan Psychiatric Society

Dr. Haroon Chaudhry

Palestinian Psychiatric Association

Dr. Bassam Ashhab

Panamanian Society of Psychiatry

Dr. Miguel Angel Cedeño Tello

Papua New Guinea Psychiatric Association

Dr. Umadevi Ambiaipahar

Paraguayan Society of Psychiatry

Dr. José Britez Cantero

Peruvian Psychiatric Association

Dr. Hugo Esteben Chávez Ortiz

Philippine Psychiatric Association

Dr. Imelda Batar

Polish Psychiatric Association

Professor Aleksander Araszkiewicz

Portuguese Association of Psychiatry

Professor Jose C. Dias Cordeiro

Portuguese Society of Psychiatry and Mental Health

Professor Adriano S. Vaz-Serra

Association of Free Psychiatriasts of Romania

Professor Aurel Romila

Romanian Psychiatric Association

Professor Dan Prepilceanu

Independent Psychiatric Association of Russia

Professor Yury Savenko

Russian Society of Psychiatrists

Professor Valery N. Krasnov

Saudi Psychiatric Association

Dr. Mahdi S. Abumadini

Society of Psychopathology and Mental Hygiene of Dakar (Senegal)

Dr. Daouda Sow

Association of Psychiatric Institutions of Serbia - UPUS

Dr. Tatjana Vokresenski

Serbian Psychiatric Association

Professor Miroslava Jasovic-Gasic

Singapore Psychiatric Association

Dr. Alex Hsin Chuan Su

Slovak Psychiatric Association

Professor Livia Vavrusova

Psychiatric Association of Slovenia

Dr. Peter Pregelj

South African Society of Psychiatrists (SASOP)

Dr. Jan Chabalala

Spanish Association of Neuropsychiatry

Dr. Maria Fé Bravo Ortiz

Spanish Society of Psychiatry

Professor Jerónimo Saiz

Sri Lanka College of Psychiatrists

Dr. Balapuwadige Jayan Mendis

Sudanese Association of Psychiatrists

Dr. Abdullah Abdelrahman
International psychiatrists –
Join APA at the Annual Meeting and receive immediate member savings!

Are you planning to visit the American Psychiatric Publishing, Inc. (APPI) bookstore while in New Orleans to purchase your psychiatry, mental health and behavioral science books and journals? Join the APA before you buy to take advantage of member savings immediately. APA Members receive a special 15% discount for purchases made at the APPI Bookstore at the 2010 Annual Meeting. APA Members receive a 10% discount throughout the year.

How do I join?
Complete an International membership application onsite (available at one of the membership desks in the Member Center or in the main registration hall) and submit it along with a copy of your medical license, psychiatry residency training certificate and your membership dues to the membership desk located in the main registration hall, next to the APA Store. APA staff will process your membership and issue your APA membership card. Show your card when making APPI purchases to receive your member discount!

How much are International membership dues?
APA’s International membership dues are based on your country of residence income group category defined by the World Bank. There are four categories:

<table>
<thead>
<tr>
<th>Income Category</th>
<th>Group Category</th>
<th>APA Dues</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Income</td>
<td>HI</td>
<td>$205 USD</td>
</tr>
<tr>
<td>Upper Middle Income</td>
<td>UMI</td>
<td>$175 USD</td>
</tr>
<tr>
<td>Lower Middle Income</td>
<td>LMI</td>
<td>$125 USD</td>
</tr>
<tr>
<td>Low Income</td>
<td>LI</td>
<td>$50 USD</td>
</tr>
</tbody>
</table>

Defined by the World Bank
As of July 2009
at the
APA 163rd Annual Meeting

Hilton New Orleans Riverside

Join us at the APA international discussion groups. These discussions afford psychiatrists the opportunity to meet and discuss relevant medical and mental health issues pertinent to the world. These groups are open to all Annual Meeting attendees and chaired by APA members.

Sunday, May 23, 2010

10:00am – noon
Middle East Discussion Group
Ascot Room, Third Floor

1:00 – 3:00pm
International Lesbian, Gay, Bisexual, and Transgender Discussion Group
Norwich Room, Third Floor

3:00 – 5:00pm
Africa Discussion Group
Elmwood Room, Third Floor

Monday, May 24, 2010

1:00 – 3:00pm
Pacific Rim Discussion Group
Grand Salon C, Section 15, First Level

2:00 – 4:00pm
South Asia Discussion Group
Grand Salon C, Section 16, First Level

Tuesday, May 25, 2010

12:30 – 2:30pm
Europe Discussion Group
Prince of Wales Room, Second Floor

Those interested in mental health issues in Latin America may wish to attend the Latin American Psychiatric Association (APAL) allied organization meeting Sunday, May 23 from 8:30 AM to 1:00 PM. Further information is available in the Directory of Activities.
Yale-New Haven Hospital is the primary teaching hospital of Yale School of Medicine and is ranked among the nation’s best hospitals by U.S. News & World Report.

Yale-New Haven Psychiatric Hospital is a place where the exciting advances in science are working for our patients.
American Academy of Psychiatry and the Law: co-support of the Manfred S. Guttmacher Award Lecture.

American Association of Chairs of Departments of Psychiatry: support of the APA/AACDP Research Mentorship Award.

American Association of Psychiatric Administrators: co-support of the Administrative Psychiatry Award Lecture

American Psychiatric Association/Hurricane Disaster Relief Fund: Support of the Disaster Psychiatry Fellowship.

American Psychiatric Foundation: support of the APIRE Practice Research Network; Award for Research in Psychiatry

Association of Professional Chaplains: partial support of the Oskar Pfister Award Lecture

Association of Women Psychiatrists: support of the joint AWP/APA Women's Caucus reception and meeting, and co-support of the Alexander Symonds Award Lecture

AstraZeneca Pharmaceuticals, LP: support of the APA/AstraZeneca Minority Fellowship, minority fellows poster session and receptions, the American Psychiatric Foundation "Conversations" event, and the APIRE/ AstraZeneca Young Minds in Psychiatry Award; Mind Games resident competition.

Bristol-Myers Squibb Company: support of the President's Dessert and Reception; and the Solomon Carter Fuller Award and partial support of the American Psychiatric Foundation Annual Benefit; APA Fellowship on Public Psychiatry.

Bristol-Myers Squibb, Sweden: Support of the Global Psychiatry: A session for US and International Residents

Center for Mental Health Services: support of the APIRE Practice Research Network (PRN); and the APAs HIV-related education programs and materials.

Center for Substance Abuse Treatment: support of the APIRE Practice Research Network (PRN); and an audience response system for the course, "Office-Based Buprenorphine Treatment of Opioid-Dependent Patients.

Dainippon Sumitomo Pharma America: support of the Symposium "New Developments in Schizophrenia Research and Practice: From the Pipeline to the Clinic."

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Judd Marmor, M.D.: support of the Judd Marmor Award Lecture

Forest Laboratories, Inc.: partial support of the American Psychiatric Foundation's Annual Benefit

Harding Foundation: partial support of the Oskar Pfister Award Lecture.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Lilly USA LLC: support of the Adolf Meyer Award Lecture; the APA/Lilly Psychiatric Research Fellowship; and the APA/Lilly Resident Research Awards, Chief Resident Leadership Program, International Dinner Symposium, and partial support of the American Psychiatric Foundation's Annual Benefit; and support of the Symposium, "Novel Approaches to Assessing and Treating Depression in the Medically-Ill."

Merck & Co., Inc.: support of the Internet Café, Bottled Water.

National Institute of Mental Health (NIMH): co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees

Ortho-McNeil-Janssen Pharma Inc.: partial support of the American Psychiatric Foundation Annual Benefit; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Pfizer, Inc: support of the APIRE/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship, co-support of the Alexander Symonds Award Lecture and partial support of the American Psychiatric Foundation's Annual Benefit.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture and the Resident & Early Career Psychiatrist Town-Hall Meeting with Dr. Carol Bernstein.


Shire US, Inc.: support of the APA Child and Adolescent Psychiatry Fellowship.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.
Please Join Us for a Product Theater Presentation at the 163rd Annual Meeting of the American Psychiatric Association
Ernest N. Morial Convention Center • New Orleans, Louisiana

Important Clinical Information About **Bipolar I Disorder**

Sunday, May 23, 2010
4:00 pm – 4:30 pm
Room 231/232

Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
www.mdpu.ca
University Health Network
Toronto, Ontario
Canada

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Thank you for your cooperation.

This is a promotional event. CME credit will not be available for this session. Speakers are presenting on behalf of Merck.

The Industry Product Theater’s content and the views expressed therein are those of the sponsor and not of APA or APF.

Important Clinical Information About **Schizophrenia**

Monday, May 24, 2010
4:00 pm – 4:30 pm
Room 231/232

Steven G. Potkin, MD
Professor of Psychiatry and Human Behavior
Director of Research Robert R. Sprague Endowed Chair in Brain Imaging
Director of UCI Brain Imaging Center
University of California
Irvine, California
USA

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. Thank you for your cooperation.

This is a promotional event. CME credit will not be available for this session. Speakers are presenting on behalf of Merck.

The Industry Product Theater’s content and the views expressed therein are those of the sponsor and not of APA or APF.
Certificate of Attendance
How do you obtain it?

Get your certificate in person or online.

To receive your certificate in person:
complete the general evaluation form at the CME Certificate of Attendance Booth located in Hall B/C in the Convention Center.

Types of Certificate
• Certificate of Credit for physicians
• Certificate of Attendance for non-physicians

CME Certificate of Attendance Booth
Located in Hall B/C
Hours of Operation:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>May 22</td>
<td>7:30am–4:00pm</td>
</tr>
<tr>
<td>Sunday</td>
<td>May 23</td>
<td>7:30am–4:00pm</td>
</tr>
<tr>
<td>Monday</td>
<td>May 24</td>
<td>7:30am–4:00pm</td>
</tr>
<tr>
<td>Tuesday</td>
<td>May 25</td>
<td>7:30am–4:00pm</td>
</tr>
<tr>
<td>Wednesday</td>
<td>May 26</td>
<td>7:30am–5:00pm</td>
</tr>
</tbody>
</table>

Certificate is Available During or After the Meeting

To receive your Certificate Online:
complete the online evaluation at: psych.org/annualmeetingCME

The website will remain active until August 15 2010.

Follow these simple steps:
1. Use your 6-digit badge number to access the General Evaluation form
2. Complete the Evaluation
3. Confirm your personal details
4. Enter the number of credits earned
5. Email the certificate to yourself
6. Print certificate for your records

Accreditation & Designation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this educational activity for a maximum of 50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The scientific program offers a variety of sessions that meet the criteria for AMA PRA Category 1 Credit™.

For questions, contact the American Psychiatric Association Department of CME

E-mail: educme@psych.org
Take the Mystery Out of “Insurance Speak”

Bring your medical professional liability insurance and risk management questions to The Psychiatrists’ Program’s Booth #916. Litigation specialists, risk managers and insurance underwriting specialists from Professional Risk Management Services, Inc. will provide you with insurance information and individualized risk management advice to help you protect your practice.

Stop by Booth #916 to learn more about The Program’s features* including:

- Top-notch legal counsel with a proven track record
- Risk Management Consultation Service (RMCS) helpline
- Administrative and Governmental Billing Defense Costs Endorsement
- Coverage for forensic psychiatric services included in the policy
- Discounts such as early career, child and adolescent, moonlighting residents, part-time and risk management education

If you are a participant in The Psychiatrists’ Program, be sure to stop by and ask for your complimentary "For Participants Only" customer service resource.

The Psychiatrists’ Program

*Professional Liability Insurance Designed for Psychiatrists

For more information:
Call: (800) 245-3333, ext. 389 • E-mail: TheProgram@prms.com
Visit: www.psychprogram.com

Managed by Professional Risk Management Services, Inc.
(In California, d/b/a Transatlantic Professional Risk Management and Insurance Services)

* may vary by state
The American Psychiatric Association requires disclosure by all program planners and presenters at CME activities of any financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the educational activity. A “financial interest” may include, but is not limited to: being an employee and/or being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers’ bureau or some other role or benefit to a supporting organization.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all conflicts of interest are identified, managed and resolved prior to the educational activity. Additionally, the prospective audience must be informed of the presenters’ or program planners’ affiliations with every commercial interest by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). Disclosing to learners the relevant financial relationships that were present and resolved assists learners in assessing the potential for bias in the information that is presented. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member have a financial interest or other affiliation with a commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients; the company name and affiliation is also listed. Providers of clinical service directly to patients are not considered to be commercial interests.

The second group of presenters has indicated neither they nor an immediate family member has any significant relationship to disclose. All presenters and planners must complete a disclosure in order to participate in an APA CME activity.

This disclosure listing includes the presenters of the Scientific Program and New Research Poster Sessions.
<table>
<thead>
<tr>
<th>NAME</th>
<th>STOCK</th>
<th>CONSULTANT</th>
<th>GRANT-RESEARCH SUPPORT</th>
<th>FULL-TIME EMPLOYEE</th>
<th>SPEAKER BUREAU</th>
<th>OTHER FINANCIAL INTEREST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaronson, Scott T</td>
<td>Neuronetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abouzaid, Safiya</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agid, Ofer</td>
<td>Pfizer, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apriquin, Royello</td>
<td>Janssen Cilag</td>
<td></td>
<td></td>
<td></td>
<td>Janssen Cilag, AZ</td>
<td></td>
</tr>
<tr>
<td>Appelbaum, Paul</td>
<td>COVR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arnold, Lesley M</td>
<td>Eli Lilly, Cypress Bioscience, Wyeth-Ayerst, Boehringer Ingelheim, Forest, Allergan, Takeda, UCB Pharma, Pfizer</td>
<td>Eli Lilly, Pfizer, Cypress Bioscience, Wyeth-Ayerst, Boehringer Ingelheim, Allergan, Forest</td>
<td>Eli Lilly, Pfizer, Forest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascher-Svanum, Haya</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly</td>
<td>Royalties: Guilford Pub. and Healthcare Technology Systems.</td>
</tr>
<tr>
<td>Ash, Peter</td>
<td>Boehringer Ingelheim, BMS, Eli Lilly, Pfizer, Sanofi Aventis, Labopharm, PGsHealth, Takeda, Wyeth-Ayerst</td>
<td>Boehringer Ingelheim, BMS, Eli Lilly, Pfizer, Sanofi Aventis, Labopharm, PGsHealth, Takeda, Wyeth-Ayerst</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baldwin, David</td>
<td>Pfizer</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balfour, Margaret</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS sponsored APA Fellowship</td>
</tr>
<tr>
<td>Barber, Jacques</td>
<td>NIMH, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guilford Pub. Author</td>
</tr>
<tr>
<td>Barkley, Russell A</td>
<td>Shire, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>Janssen Cilag, Janssen-Ortho, Novartis</td>
<td></td>
</tr>
<tr>
<td>Barlow, Carolee</td>
<td>Brain Cells Inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Batki, Steven</td>
<td>Akermes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bauer, Michael</td>
<td>Servier, Janssen-Cilag, Lundbeck, BMS, Otsuka</td>
<td>Stanley Medical Research Institute, NARSAD, AZ, Eli Lilly</td>
<td>GSK, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beechold, Julian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ, Eli Lilly, Janssen Cilag</td>
<td></td>
</tr>
<tr>
<td>Benjamin, Sheldon</td>
<td>Advanced Neuromodulation Systems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brain Educators, LLC, Publisher of the Brain Card</td>
</tr>
<tr>
<td>Bennett, Robert M</td>
<td>Jazz, Eli Lilly, Pfizer</td>
<td></td>
<td></td>
<td>Jazz, Pfizer, Merck</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Berk, Michael</td>
<td>AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Lundbeck, Servier</td>
<td>MBF Biosciences, BMS, Stanley Medical Research Institute, Eli Lilly, GSK, Organon, Novartis, Mayne Pharma, Servier</td>
<td>AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Lundbeck, Pfizer, Sanofi-Synthelabo, Servier, Solvay, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisaga, Adam</td>
<td>Akermes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black, Donald W.</td>
<td>AZ, Forest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blanco, Roberto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS sponsored APA Fellowship</td>
</tr>
<tr>
<td>Brans, Mathew</td>
<td>Eli Lilly, Novartis, McNeil, Shine US</td>
<td>AZ, BMS, Forest, GSK R&amp;D, McNeil, Shine US, Novartis, Sanofi Aventis, Eli Lilly</td>
<td>Eli Lilly, Shire US, Novartis, Pfizer, McNeil, AZ, Cephalon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brooks, John</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ, Eli Lilly, Pfizer, Schering</td>
</tr>
<tr>
<td>Brottman, Glenn</td>
<td>Neuronetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brown, Thomas E.</td>
<td>Novartis, Abbott, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Bryan, Dirks</td>
<td>Shire, Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buckley, Peter</td>
<td>Janssen</td>
<td>Janssen, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Busner, Joan</td>
<td></td>
<td></td>
<td></td>
<td>United BioSource</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cameron, Carter</td>
<td>Merck, Eli Lilly, Eli Lilly, Pfizer, Servier</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carpenter, Linda</td>
<td>Neuronetics, Wyeth-Ayerst</td>
<td>Dept. of Defense, NIMH, Medtronic, Cyberonics, Neuronetics, Nat'l Alliance for Research in Schizophrenia and Affective Disorders, Speracor, UCB Pharma</td>
<td></td>
<td></td>
<td>Neuronetics</td>
<td></td>
</tr>
<tr>
<td>Carpenter, William</td>
<td>Eli Lilly, Schering-Plough, France</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case, Michael G</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Casey, David</td>
<td></td>
<td>Pfizer, Eisai</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Castilla-Puentes, Ruby</td>
<td>GSK</td>
<td></td>
<td></td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
</tr>
<tr>
<td>Cazorla, Pilar</td>
<td></td>
<td>Schering</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chalk, Mady</td>
<td></td>
<td>Alkermes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chang, Kiki</td>
<td>Eli Lilly, Abbott, GSK, Otsuka, Otsuka</td>
<td>AZ, Otsuka, Eli Lilly</td>
<td></td>
<td></td>
<td>Eli Lilly, AZ, Abbott</td>
<td></td>
</tr>
<tr>
<td>Childress, Ann</td>
<td>Shire, Novartis</td>
<td>Eli Lilly, Shire, Novartis, BMS, Somerset, Abbott, Ortho-McNeil Janssen, Johnson &amp; Johnson</td>
<td></td>
<td>Shire, Novartis, BMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chilton, Julie</td>
<td></td>
<td>Shire US Fellowship, Eli Lilly Travel Grant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cia, Alfredo</td>
<td>Roche Labs.</td>
<td>Wyeth-Ayerst Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clark, Michael</td>
<td>Eli Lilly, Pfizer</td>
<td>Eli Lilly, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Classi, Peter</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clayton, Anita</td>
<td>Concert, New England Research Institute, TransTech Pharma, Boehringer Ingelheim, BMS, Eli Lilly, Sandol Aventis, Takoda</td>
<td>Biosante, Boehringer Ingelheim, BMS</td>
<td></td>
<td></td>
<td></td>
<td>Ballantine Books Royalty, Eli Lilly Honorarium</td>
</tr>
<tr>
<td>Coffey, Barbara</td>
<td></td>
<td>Tourette Syndrome Assoc., Boehringer Ingelheim, BMS, NIMH, Novartis</td>
<td></td>
<td></td>
<td>Tourette Syndrome Assoc.</td>
<td></td>
</tr>
<tr>
<td>Conant-Norville, David</td>
<td></td>
<td>McNeil, Novartis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Connor, Daniel F</td>
<td>Shire</td>
<td>Shire, Abbott</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coppola, Danielle</td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cucciare, Josephine</td>
<td></td>
<td>Danippon Sumitomo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHERFINANCIAL INTEREST</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Daniel, David</td>
<td></td>
<td></td>
<td></td>
<td>United BioSource</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darwish, Mona</td>
<td>Cephalon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Datto, Catherine</td>
<td></td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DeBiase, Charles</td>
<td>Concept Therapeutics</td>
<td>CNS Response, Brain Resource Ltd., Neuropace, GSK, Wyeth-Ayerst, Lilly Research Labs., Cephalon, Cyberonics, Neuronetics, Novartis, AZ, Forest, Medtronic, Boehringer Ingelheim, Advanced Neurostimulation Systems, Pfizer</td>
<td></td>
<td>Lilly Research Labs., GSK, Pfizer, Cephalon, Wyeth-Ayerst, BMS, AZ, Cyberonics, Concept Therapeutics, Forest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demitrack, Mark</td>
<td>Lilly Research Labs., Wyeth-Ayerst</td>
<td></td>
<td></td>
<td>Neuronetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derstine, Timothy</td>
<td></td>
<td></td>
<td></td>
<td>AZ, BMS, Eli Lilly, Forest, Wyeth-Ayerst, Neuronetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desai, Abhilash</td>
<td>Forest</td>
<td></td>
<td></td>
<td>Forest, Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dirdale, Joel</td>
<td>Sepracor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D’Mello, Dale</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, AZ, Schering</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doghranji, Karl</td>
<td>Merck</td>
<td>Assurance RX, Sanofi-Synthelabo, Sepracor, Sanofi Aventis</td>
<td></td>
<td>GSK, Boehringer Ingelheim, Sepracor, Sanofi Aventis, Jazz, Takeda, Forest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donevan, Sean</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dougherty, Darin</td>
<td>Medtronic, Inc.</td>
<td></td>
<td></td>
<td>Forest, Eli Lilly, Cyberonics, Medtronic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dubovsky, Steven</td>
<td>Pfizer, Otsuka, Sumitomo, Biogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dulcan, Mina</td>
<td>Care Management Technologies, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>American Psychiatric Pub. Back Royalties, Eli Lilly ADHD Advisory Board</td>
</tr>
<tr>
<td>Durkin, Michael</td>
<td></td>
<td></td>
<td></td>
<td>Ortho-McNeil, Janssen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earley, Willie W</td>
<td></td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edinger, Jack</td>
<td>Philips</td>
<td></td>
<td></td>
<td>Philips</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellison, James</td>
<td>Elan</td>
<td></td>
<td></td>
<td>Eli Lilly, Forest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epperzon, C. Neil</td>
<td>Pfizer</td>
<td>Wyeth-Ayerst, Eli Lilly</td>
<td></td>
<td>Janssen-Cilag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ercan, Eyup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eriksson, Hans</td>
<td></td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etkin, Amit</td>
<td></td>
<td></td>
<td></td>
<td>NeoStim</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fahim, Raafat</td>
<td></td>
<td></td>
<td></td>
<td>NABI Biopharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatemi, S. Hossain</td>
<td></td>
<td></td>
<td></td>
<td>NIH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Feltner, Douglas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferando, Stephen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ, Pfizer</td>
<td></td>
</tr>
<tr>
<td>Fingan, Michael W</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First, Michael B.</td>
<td></td>
<td>MedAvante, Novartis, Cephalon, Memory Pharma, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fishman, Robert S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alcoza</td>
<td></td>
</tr>
<tr>
<td>Forester, Brent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frank, Ellen</td>
<td>Server</td>
<td></td>
<td></td>
<td></td>
<td>Elf Lilly, AZ, Novartis, Pfizer</td>
<td></td>
</tr>
<tr>
<td>Frazier, Karell J</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freeman, Ellen</td>
<td></td>
<td>Forest Research Inst., Janosyn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freudenreich, Oliver</td>
<td></td>
<td>Beacon Health Strategies</td>
<td>Cephalon, Pfizer</td>
<td></td>
<td>Reed Medical Education, Lippincott royalties</td>
<td></td>
</tr>
<tr>
<td>Frey, Benicio</td>
<td></td>
<td>Wyeth-Ayerst</td>
<td>Wyeth-Ayerst, Bristol-Myers, Eli Lilly</td>
<td></td>
<td>AZ, Wyeth-Ayerst</td>
<td></td>
</tr>
<tr>
<td>Friedman, Joseph</td>
<td></td>
<td>Acadia, Teva, EMD Serono</td>
<td>Acadia, Teva, GSK, Pfizer, Novartis, Ingelheim-Boehringer, Eprex</td>
<td></td>
<td>AZ, Teva, GSK, Ingelheim-Boehringer</td>
<td></td>
</tr>
<tr>
<td>Frye, Mark</td>
<td></td>
<td>Dai nippon Sumitomo, Cephalon, Medtronic, Inc., Ortho-McNeil Janssen, Schering-Plough, France, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fu, Dong-Jing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaebel, Wolfgang</td>
<td></td>
<td>Janssen Cilag, Lundbeck</td>
<td></td>
<td></td>
<td>Lilly Research Labs.</td>
<td></td>
</tr>
<tr>
<td>Gaebriend, David R.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gau, Susan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gawis, Silvia</td>
<td></td>
<td>Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelenberg, Alan</td>
<td></td>
<td>Cyberonics, Eli Lilly, Forest, GSK, Novartis, Pfizer, Teakeda, Wyeth-Ayerst, AZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------</td>
<td>--------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>George, Mark S.</td>
<td></td>
<td>BrainSonix, Cephalos, NeoSilm,</td>
<td>Force Protection, MECTA Corp, Brainway Inc, Dept. of Defense, NARSAD, NIDA, NIMH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NeoSync, PureTech Ventures, MECTA Corp, BrainSonix, Cephalos, NeoSilm, NeoSync, PureTech Ventures, GSK, Jazz, Cyberonics, Neurapace, Brainway Inc, Neurontics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghaemi, S. Nassir</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ginsberg, Lawrence D.</td>
<td></td>
<td></td>
<td>Abbott, Alkermes, AZ, BMS, Cephalos, Cyberonics, Forest, GSK, Janssen, Jazz, Eli Lilly, McNeil, Neuracrine Biosciences, Novartis, Noven, Organon USA, Ortho McNeil, Otseka, Pam Lab LLC, Pfizer, Sanofi Aventis, Shire, Tokedra, UCB Pharma, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gluck, Ira</td>
<td>Janssen</td>
<td>Janssen, Medivation, Lundbeck</td>
<td>Otsuka, Boots, Pfizer, Lundbeck</td>
<td>AZ, Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goff, Donald</td>
<td></td>
<td></td>
<td>Cephalon, Novartis, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gogineni, R. Rao</td>
<td></td>
<td></td>
<td>BMS, Novartis, Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldberg, Joseph</td>
<td></td>
<td>Cephalon, Eli Lilly</td>
<td>A, Eli Lilly, GSK, Pfizer, Janssen-Cilag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldfinger, Stephen M.</td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td>Merck, attended speaker training group; Pfizer and Janssen, members of my department receive grant support.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly, Teva</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldman, Morris</td>
<td></td>
<td></td>
<td>GSX Beechum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gommoll, Carl</td>
<td></td>
<td></td>
<td>Forest Research Inst.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Godkin, Karl</td>
<td></td>
<td>Amgen</td>
<td>Merck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodman, David W.</td>
<td></td>
<td></td>
<td>GSK, Forest, Lilly Research Labs., Shine US, McNeil, Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Forest, Shine US, McNeil, Cephalon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GSK, Forest, Lilly Research Labs., Shine US, McNeil, Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gould, Todd</td>
<td></td>
<td></td>
<td>Merck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graham, Stephen M</td>
<td></td>
<td></td>
<td>Astellas Pharma US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greene, IV, Nicholas</td>
<td></td>
<td></td>
<td>Abbott</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Green, Alan L.</td>
<td></td>
<td></td>
<td>Lilly Research Labs., Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greenberg, William</td>
<td></td>
<td></td>
<td>Forest Research Inst.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Green, John</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grossberg, George</td>
<td></td>
<td></td>
<td>Elan, Forest Research Inst., BMS, Novartis, NIH, NIMH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guico-Pavia, Christine J</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hanneman, Stephanie</td>
<td></td>
<td></td>
<td>McNeil, BMS, Novartis, Pam Lab LLC, Shire US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------</td>
<td>------------------------------------------------</td>
<td>------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Hammemess, Paul G</td>
<td></td>
<td></td>
<td>Shire US, Ortho-McNeil</td>
<td></td>
<td></td>
<td>CME/professional writing: Abbott, Eli Lilly, Forest</td>
</tr>
<tr>
<td>Harbin, Henry</td>
<td></td>
<td>CNS Response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harris, Herbert W</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvey, Philip D.</td>
<td></td>
<td>Eli Lilly, Janssen Research Foundation, Merck,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shire, Solvay, Dai nippon Sumitomo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hasler, Gregor</td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hendren, Robert</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirschowitz, Max</td>
<td></td>
<td></td>
<td>Cephalon, Merck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi Aventis, Cephalon, Takeda</td>
</tr>
<tr>
<td>Hollander, Eric</td>
<td></td>
<td></td>
<td>Lundbeck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holtsbeor, Florian</td>
<td></td>
<td>Affects, Cauticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holtzheimer, Paul</td>
<td></td>
<td>Advanced Neurorheological Systems</td>
<td>NARSAD, NIH, Dana</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Foundation, Stanley</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hosch, Cyril</td>
<td></td>
<td></td>
<td>Servier</td>
<td></td>
<td></td>
<td>Eli Lilly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lundbeck LINF faculty member</td>
</tr>
<tr>
<td>Josipsoo, Dan</td>
<td></td>
<td></td>
<td>Aspect Medical Systems,</td>
<td></td>
<td></td>
<td>Eli Lilly, Forest, Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Forest, Janssen, NARSAD, NIH</td>
<td></td>
<td></td>
<td>Reed Medical Education Honoraria</td>
</tr>
<tr>
<td>Ishiyama, Takeo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jain, Rakesh</td>
<td></td>
<td></td>
<td>Shire US, Lilly Research Labs.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Shire US</td>
<td></td>
<td></td>
<td>Shire US, Lilly Research Labs., Lilly Research Labs., Forest, Pfizer</td>
</tr>
<tr>
<td>Janicak, Philip G</td>
<td></td>
<td>BMS, Otsuka, Neuronetics</td>
<td>Otsuka, Neuronetics</td>
<td></td>
<td></td>
<td>Pfizer, AZ, BMS, Otsuka, Janssen, Neuronetics</td>
</tr>
<tr>
<td>Jeste, Dilip</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jibson, Michael</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeep, Schoemaker</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalali, Amir H</td>
<td></td>
<td>Cypress Bioscience</td>
<td>AZ, Ortho-McNeil Janssen, Vanda</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quintiles</td>
<td></td>
<td></td>
<td>AZ, GSK</td>
</tr>
<tr>
<td>Kane, Ceselia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kane, John M.</td>
<td></td>
<td>MedAvante</td>
<td>BMS, Cephalon, Johnson &amp; Johnson, Lundbeck, Otsuka, Pfizer, AZ, Eli Lilly, Janssen, Vanda, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td>AZ, BMS, Eli Lilly, Janssen</td>
</tr>
<tr>
<td>Kapczinski, Flavio</td>
<td></td>
<td></td>
<td>Eli Lilly, GSX</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karayal, Omur N</td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karlsson, Hazze</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katon, Wayne</td>
<td></td>
<td>Eli Lilly, Pfizer, Forest, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly Advisory Board</td>
</tr>
<tr>
<td>Kilner, Charles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Kern Silwa, Jennifer</td>
<td></td>
<td>Merck, Shire US, GSK, Traceptive Pharm, Takeda, Ortho-McNeil, Pfizer</td>
<td>EPI-Q, Sanofi Aventis, Janssen-Ortho, NIH, Shire US, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kirby, Mary</td>
<td></td>
<td></td>
<td>Cephalon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kagan, Jane N</td>
<td></td>
<td></td>
<td>Ortho-McNeil Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kohn, Robert</td>
<td></td>
<td></td>
<td>NIH</td>
<td></td>
<td></td>
<td>Forest, Pfizer, Novartis</td>
</tr>
<tr>
<td>Kaslow, Stephen</td>
<td></td>
<td>Brain Resource Ltd.</td>
<td>Brain Resource Ltd.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kosten, Thomas</td>
<td></td>
<td>Pfizer, Johnson &amp; Johnson</td>
<td>Alkermes, Synocea</td>
<td></td>
<td></td>
<td>Reckitt Benckiser</td>
</tr>
<tr>
<td>Kazma, Chris</td>
<td></td>
<td></td>
<td>Ortho-McNeil Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kupchek, Eugene M</td>
<td></td>
<td></td>
<td>Alkermes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kyomen, Helen H.</td>
<td></td>
<td>AZ, Bayer Corp. Pharma Div., BMS, Merck, Eli Lilly, Roche Labs., GSK,</td>
<td>Bayer Corp. Pharma Div., BMS, Eli Lilly, Roche Labs., UCB Pharma, Wyeth-Ayerst, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lavetsky, Helen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lawrie, Stephen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lazarus, Arthur</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le, Trong K</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levenon, James</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levakovitz, Yochiel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levouris, Petros</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewis-Fernández,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lewy, Alfred</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Licinio, Julio</td>
<td></td>
<td>DeCode Genetics</td>
<td>Nature Publishing Group</td>
<td></td>
<td></td>
<td>NIH</td>
</tr>
</tbody>
</table>

**DISCLOSURE INDEX**

163rd Annual Meeting 39
<table>
<thead>
<tr>
<th>Name</th>
<th>Stock</th>
<th>Consultant</th>
<th>Grant-Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker Bureau</th>
<th>Other Financial Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lieberman, Jeffrey</td>
<td></td>
<td></td>
<td>Allon Therapeutics, Forest, Merck, Pfizer</td>
<td></td>
<td></td>
<td>Eli Lilly Advisory Board, Repligen Patent, Bioline Advisory</td>
</tr>
<tr>
<td>Links, Paul</td>
<td></td>
<td></td>
<td>Eli Lilly Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisanby, Sarah</td>
<td>Eli Lilly</td>
<td></td>
<td>Brainway Inc., St. Jude Medical, Advanced Neuromodulation Systems, Cybermics, NARSAD, Neuraneutics, NIH, Stanley Medical Research Institute</td>
<td></td>
<td></td>
<td>Equipment support: Magstim and Magventure.</td>
</tr>
<tr>
<td>Litman, Robert E</td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu, Xiachen</td>
<td>Eli Lilly</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luckier, Julie</td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lusskin, Shari</td>
<td></td>
<td></td>
<td>Wyeth-Ayerst, AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mandel, Francine</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mangurian, Christina</td>
<td></td>
<td></td>
<td>Honoraria from APIRE/Janssen to mentor a resident who won a research scholarship.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manohar, Velandy</td>
<td></td>
<td></td>
<td>Eli Lilly, Pfizer, AZ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mao, Alice</td>
<td>Eli Lilly, Novartis</td>
<td></td>
<td>Eli Lilly, BMS, McNeil, Shire US, Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marler, Stephen</td>
<td>BMS, Lundbeck, Otsuka, Wyeth-Ayerst, Pfizer, Schering, Roche Biosciences, BMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Markowitz, John</td>
<td></td>
<td></td>
<td>NIMH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marsh, Laura</td>
<td></td>
<td></td>
<td>Forest Research Inst.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martin, Peter</td>
<td></td>
<td></td>
<td>栲MPS APA/BMS Public Psychiatry Fellowship</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macand, Prakash</td>
<td>Orexigen, Titan Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McCarthy, Kevin</td>
<td></td>
<td></td>
<td>NIMH, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McDonald, William M.</td>
<td></td>
<td></td>
<td>Neumnetics, GSK, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McDougall, Christopher</td>
<td></td>
<td>BMS, Forest Research Inst.</td>
<td>BMS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McGorry, Patrick</td>
<td>Janssen Cilag, AZ</td>
<td></td>
<td>Janssen Cilag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McInnis, Melvin G.</td>
<td>Wyeth-Ayerst</td>
<td></td>
<td>Janssen, BMS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McQuistion, Hunter</td>
<td>Janssen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------</td>
<td>------------</td>
<td>-------------------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Manza, Matthew</td>
<td>BMS</td>
<td>Labopharm, Inc</td>
<td>AZ, Boehringer Ingelheim, BMS, Forest, GSK, Lilly Research Labs., Merck, Pfizer, Sanofi Aventis, Sepracor, Takeda, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meyer, Jonathan M</td>
<td>AZ, BMS, Wyeth-Ayerst, Dainippon Sumitomo, Jansen, Vanda, Organon, Pfizer,</td>
<td>NIMH, BMS, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meyer-Lindenberg, Andreas</td>
<td></td>
<td>Lundbeck, GSK, Hoffman-LaRoche</td>
<td></td>
<td>Eli Lilly, Jansen Cileg, AZ, Pfizer, Servier</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milic, Roumen</td>
<td></td>
<td></td>
<td>AZ, Eli Lilly Canada, JanssenCanada, Pfizer Canada, Servier Canada, Wyeth-Ayerst Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mischoulon, David</td>
<td>BMS</td>
<td>Pam Lab LLC, Amarin, Nordic Naturals, Caneden</td>
<td></td>
<td>Reed Medical Education, Nordic Naturals</td>
<td>Back Bay Scientific Royalties</td>
<td></td>
</tr>
<tr>
<td>Mori, Shalia</td>
<td>AZ Canada, Forest Research Inst.</td>
<td>AZ Canada, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitchell, James</td>
<td></td>
<td>Eli Lilly, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montaner, Julio</td>
<td>Panacos</td>
<td>Argos Therapeutics, Bioject Inc., Merck Frosst, Abbott, Boehringer Ingelheim, BMS, Gilead Sciences, GSK, Hoffman-LaRoche, Janssen-Ortho, Pfizer, Schering, Serono, Tibotec-Virco, Theratechnologies, Trimeris</td>
<td>Merck Frosst, Abbott, Boehringer Ingelheim, Gilead Sciences, GSK, Pfizer, Tibotec-Virco</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montgomery, Stuart A</td>
<td>Lundbeck, Merck, Merz, Roche Biosciences, Sanofi-Aventis, Shire, Takeda, Takeda, Lilly Research Labs., Pfizer, PharmaNeuroBoost, Sepracor, Servier, UCB Pharma, Wyeth-Ayerst</td>
<td>BMS, Johnson &amp; Johnson, AZ, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mazak, David</td>
<td></td>
<td></td>
<td></td>
<td>Assure Rx; Assure Rx has licensed intellectual property and I have an interest in this</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mukherjee, Dahlia</td>
<td>NIMH, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muniz, Rafael</td>
<td>Novartis</td>
<td></td>
<td>Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musgnung, Jeff</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muskin, Philip</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mustafa, Husain</td>
<td>NIMH, NIMH, NIH, Advanced Neuramodulation Systems, Neurocentics, Stanley Medical Research Institute, Stanley Foundation, Cyberonics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nahas, Ziad H.</td>
<td>Neuronetics</td>
<td>Cyberonics, Medtronic, Inc., Brainway Inc, NIMH, National Alliance for Research in Schizophrenia and Affective Disorders, Neurocentics</td>
<td>Neuronetics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narasimhan, Meera</td>
<td>Forest, AZ, BMS, Otsuka, Janssen</td>
<td>AZ, BMS, Schering-Plough, France</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neal, Derita</td>
<td>PRMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelson, Randy</td>
<td>Oxford Press</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newcomer, John W</td>
<td>AZ, Lundbeck, Jansen, Otsuka, Pfizer, Silex, Vanda, Wyeth-Ayerst, BMS</td>
<td>NIMH, NARSAD, Janssen, Pfizer, Wyeth-Ayerst</td>
<td></td>
<td>Data Safety Monitoring Committee; Schering, Dainippon Sumitomo, Organon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Nielsen, Jimmi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS</td>
<td></td>
</tr>
<tr>
<td>Ninan, Philip</td>
<td>Wyeth-Ayerst</td>
<td></td>
<td></td>
<td>Wyeth-Ayerst</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyberg, Svante</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
</tr>
<tr>
<td>O’Brien, Charles</td>
<td>Abbott, Reckitt Benckiser, Pfizer, Embora Neuro-Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O’Gorman, Cedric</td>
<td>Novartis</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td>Novartis</td>
<td></td>
</tr>
<tr>
<td>Olin, Jason T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O’Reardon, John</td>
<td></td>
<td></td>
<td></td>
<td>Medtronic, Cyberonics</td>
<td></td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Ostacher, Michael J</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td>Pfizer</td>
<td>AZ, BMS, Eli Lilly, Pfizer, GSK, Janssen, Pfizer</td>
<td></td>
</tr>
<tr>
<td>Ozerdem, Aysegul</td>
<td>AZ, BMS, Eli Lilly, GSK, Janssen Cilag, Schering-Plough, France, Egis</td>
<td></td>
<td></td>
<td>AZ, BMS, Eli Lilly, GSK, Egis, Janssen Cilag</td>
<td>Sanofi Aventis Travel grant for conference attendance</td>
<td></td>
</tr>
<tr>
<td>Pappadopulos, Elizabeth</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parikh, Sagar</td>
<td></td>
<td></td>
<td>Apotex, AZ, Biovail Laboratories Inc., BMS, GSK, Janssen Cilag, Lilly Research Labs., Lundbeck, Novartis, Pfizer, Wyeth-Ayerst Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patel, Amita</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ, BMS, Eli Lilly, Pfizer, Wyeth-Ayerst</td>
<td></td>
</tr>
<tr>
<td>Patel, Jayendra</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Johnson &amp; Johnson, BMS, Forest, Wyeth-Ayerst</td>
<td></td>
</tr>
<tr>
<td>Patkar, Ashwin A.</td>
<td>BMS, Reckitt Benckiser, Forest</td>
<td></td>
<td>Akermes, BMS, Cephalon, GSK, Merck, Lundbeck, Jazz, Titan, Shire, Pfizer, Forest</td>
<td></td>
<td>BMS, Pfizer, Reckitt Benckiser, Akermes, Merck</td>
<td></td>
</tr>
<tr>
<td>Perahia, David G.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Perle, Roy H.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AZ, Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>Petitjean, Francois</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS, Servier</td>
<td></td>
</tr>
<tr>
<td>Petry, Nancy M.</td>
<td></td>
<td></td>
<td>NIDA, NIMH, NH, NIAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phillips, Katharine A</td>
<td>AFSP, NIMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pollack, Mark</td>
<td>Brain Cells Inc, Eli Lilly, Pfizer, MedAvante</td>
<td></td>
<td>BMS, Forest, Forest, GSK, Eli Lilly, Sapraco</td>
<td></td>
<td>CME Activities: AZ, Sapraco, Pfizer, MedAvante Equity</td>
<td></td>
</tr>
<tr>
<td>Pope, Harrison</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sinovay, Ortho McNeil</td>
<td></td>
</tr>
<tr>
<td>Pope, Laura</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Avanir</td>
<td></td>
</tr>
<tr>
<td>Preskorn, Sheldon H.</td>
<td>Abbott, Aventis, Bayer Corp, Pharma, Div, Biovail Labs., Boehringer Ingelheim, BMS, Eli Lilly, Innapharma, Jazz, Merck, Novartis, Organon, Otsuka, Allergan, Eisai, Fabre-Kramer Phar, Forest, Glaxo, Johnson &amp; Johnson, KV Lilly Research Labs, Lundbeck, Mallinckrodt, Memory Pharma., NIH, Pfizer, Roche Labs., Sanofi, Schering-Plough, France, Sapraco, Transcept Pharm, Somarset, AZ, Cyberonics, Dainippon Sumitomo, Neurocrine, Shire US, Solvay, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------------------------------</td>
<td>------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>----------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Prince, Jefferson</td>
<td>AZ, Eli Lilly, Shire US</td>
<td></td>
<td></td>
<td></td>
<td>McNeil</td>
<td></td>
</tr>
<tr>
<td>Qian, Minhua</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>Rapaport, Mark</td>
<td>Astellas Pharma US, BCI, Wyeth-Ayerst, NIMH, Danippon Sumitomo, BrainCells, Inc, Quintiles, Pfizer, Takeda</td>
<td>National Center for Complementary and Alternative Medicine, CME Outfitters, CME Institute, NIMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raasnick, Mark</td>
<td>Lundbeck, Eli Lilly, Stroke-Med</td>
<td>NIH, Dept. of Defense, Lundbeck, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>Pax Neuroscience Significant Financial Interest</td>
</tr>
<tr>
<td>Raag, Natalie</td>
<td>Forest, Wyeth-Ayerst</td>
<td>Forest, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reed, Robin</td>
<td></td>
<td>BMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renner, John</td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reynolds, Charles</td>
<td></td>
<td>Lilly Research Labs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ries, Richard</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reckitt Benckiser, Eli Lilly, AZ, Janssen Cilag, Pfizer</td>
</tr>
<tr>
<td>Robbins, Trevor</td>
<td>Pfizer, Eli Lilly, Roche Labs, GSK, Cambridge, UK Cognition, Allon Therapeutics</td>
<td>Pfizer, Eli Lilly, GSK, Cambridge, UK Cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romeo, Sarah A</td>
<td></td>
<td>AZ, Boehringer Ingelheim, BMS, Eli Lilly, Forest, Janssen, Pfizer, Shire, Sanofi Aventis, Takeda, GSK, Cephalon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenbaum, Jerrold</td>
<td>MedAvante</td>
<td>Auspex Pharm, MedAvante, Neuronetics, Supuran, Compellis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosett, Allen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sole Owner: Cabernet Pharma., Shire Pharma, Zentandel Pharma.</td>
</tr>
<tr>
<td>Rothschild, Anthony</td>
<td>Pfizer, GSK, Forest, Eli Lilly</td>
<td>Cyberonics, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruano, Guadiberto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genomas Inc</td>
<td></td>
</tr>
<tr>
<td>Rubin, Jonathan</td>
<td></td>
<td>Shire</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Russo, Leo</td>
<td></td>
<td>Shire</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sagman, Donin</td>
<td>Eli Lilly Canada</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly Canada</td>
<td></td>
</tr>
<tr>
<td>Sahakian, Barbara</td>
<td>Cambridge, UK Cognition, Novartis, Shire, GSK, Lilly Research Labs., Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sajatovic, Martha</td>
<td>AZ, GSK, The Cognition Group, United BioSource, ePharma Solutions</td>
<td>NIMH, AZ, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schiffer, Randolph</td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schlaepfer, Thomas</td>
<td>PNB Inc., Belgium</td>
<td>PNB Inc., Belgium, Eli Lilly, BMS, AZ</td>
<td></td>
<td></td>
<td>Eli Lilly, AZ</td>
<td></td>
</tr>
<tr>
<td>Scheidel, Kerri</td>
<td></td>
<td>Avanti Corporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schulz, S. Charles</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>AZ</td>
<td></td>
</tr>
<tr>
<td>Sharma, Verinder</td>
<td>AZ, BMS, Eli Lilly, Janssen, Pfizer</td>
<td>AZ, BMS, Eli Lilly, Lundbeck, Servier, Stanley Foundation</td>
<td></td>
<td></td>
<td>Pfizer, AZ, Eli Lilly, Janssen</td>
<td></td>
</tr>
<tr>
<td>Shea, Shawn</td>
<td></td>
<td>Merck</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------</td>
<td>--------------------------------------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Sheehan, David V</td>
<td>Solvay, Jazz, GSK, AZ, Wyeth-Ayerst, BMS, Pfizer, Lilly Research Labs., Takeda, Labopharm, Sanofi Aventis</td>
<td>AZ, BMS, GSK, Jazz, Pfizer, Sanofi Aventis, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheline, Yvette</td>
<td>Eli Lilly</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shrivastava, Amresh</td>
<td>Reche Labs., Eli Lilly</td>
<td></td>
<td>AZ Canada, Janssen-Ortho, Janssen Olg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sikirica, Mirko</td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singh, Jackaran</td>
<td></td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sirinbeglu, Yusuf</td>
<td>Novartis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sledge, William</td>
<td>Pfizer</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith, David</td>
<td></td>
<td></td>
<td>AZ, Eli Lilly, Forest, Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith, Eric</td>
<td>Forest Research Inst.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sohal, Vikasa</td>
<td>Neuropace</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spiera, Allan</td>
<td></td>
<td>Forest Research Inst.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stahl, Stephen</td>
<td>AZ, Arena, Avera Pharm, Boehringer Ingelheim, BMS, Cypress Bioscience, Daiichippon Sumitomo, Eli Lilly, Forest, GSK, Jazz, Labopharm, Janssen, Lundbeck, Neuronetics, Marinus, Novartis, Noven, Pam Lab LLC, Pfizer, Sanofi Pharmaceuticals Inc., Shire, Wyeth-Ayerst, Wyeth-Ayerst, Takeda, Solvay</td>
<td>Aileramea, AZ, Boehringer Ingelheim, Cephalon, Daiichippon Sumitomo, Forest, Johnson &amp; Johnson, Novartis, Organon, Pam Lab LLC, Pfizer Canada, Pfizer, Schering, Supraco, Shire US, Takeda, Vanda, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Starr, Harriette L.</td>
<td></td>
<td></td>
<td>Ortho-McNeil Janseen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stein, Bradley D</td>
<td></td>
<td></td>
<td>Ortho-McNeil Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stein, Murray</td>
<td>AZ, Brain Cells Inc, BMS, Comprehensive Neuroscience, Eli Lilly, Forest, Jazz, Johnson &amp; Johnson, Mindstate, Pfizer, Supraco, Transcept Pharm</td>
<td>Eli Lilly, GSK, Hoffman-LaRoche</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stewart, Donna</td>
<td>Eli Lilly, Wyeth-Ayerst, Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stigler, Kimberly A.</td>
<td></td>
<td>BMS, Janssen, NIMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strakowski, Stephen</td>
<td>Pfizer</td>
<td>Eli Lilly, Janssen, Pfizer, Forest, AZ, BMS, Martek Biosciences, Nutrition 21, Repligen, Johnson &amp; Johnson, Shire, Someriset, NIDA, NIAAA, NARSAD, Thrasher Foundation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroupis, T. Scott</td>
<td>Janssen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sukhara, Jaweed</td>
<td>SAB</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sullivan, Patrick</td>
<td></td>
<td></td>
<td>AZ Recipient of funded APA travel fellowship.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suppes, Trisha</td>
<td>Drexigen</td>
<td>AZ, NIMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>STOCK</td>
<td>CONSULTANT</td>
<td>GRANT-RESEARCH SUPPORT</td>
<td>FULL-TIME EMPLOYEE</td>
<td>SPEAKER BUREAU</td>
<td>OTHER FINANCIAL INTEREST</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Swanson, James M.</td>
<td>Alza/McNeil, Trascept Pharm, UCB Pharma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS Honoraria for Book Chapter, Servier Honoraria for Book Chapter, Eli Lilly CME speaking honorarium, AZ CME speaking honorarium</td>
</tr>
<tr>
<td>Swartz, Holly</td>
<td>Pfizer, Server</td>
<td>BMS</td>
<td>AZ, Eli Lilly, WebMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Szpindel, Isaac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly Canada, JanssenCanada, Shire US, Purdue Pharma</td>
</tr>
<tr>
<td>Tafesse, Eskinder</td>
<td>AZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targum, Steven</td>
<td>Brain Cells, Inc. United BiSource</td>
<td>Brain Cells, Inc. GSK R&amp;D, Johnson &amp; Johnson, Memory Pharmaceuticals, Daihann Sumitomo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tohen, Mauricio</td>
<td>AZ, BMS, Eli Lilly, GSK, Johnson &amp; Johnson, Sepracor, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ElI Lilly Spouse current employee and minor stockholder of Eli Lilly</td>
</tr>
<tr>
<td>Townsend, Mark</td>
<td>Jazz</td>
<td>Otsuka, BMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimble, Michael</td>
<td>Pfizer, Sandi Aventis, Janssen Cilag</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trzepacz, Paula</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsueng, John</td>
<td></td>
<td>Lily Research Labs., Janssen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkington, Douglas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turner, Norris</td>
<td></td>
<td>Ortho-McNeil</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varughese, Sajan</td>
<td></td>
<td>Shire</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaswani, Sanjay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wyeth-Ayerst, GSK</td>
</tr>
<tr>
<td>Viguer, Adele</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vince, Bradley</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

163rd Annual Meeting 45
<table>
<thead>
<tr>
<th>NAME</th>
<th>STOCK</th>
<th>CONSULTANT</th>
<th>GRANT-RESEARCH SUPPORT</th>
<th>FULL-TIME EMPLOYEE</th>
<th>SPEAKER BUREAU</th>
<th>OTHER FINANCIAL INTEREST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vogel-Schibila, Suzanne E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wahlstrom, Carl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walkup, John</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang, Pe</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly, Forest, Dainippon Sumitomo</td>
<td>GSK, Pfizer, BMS, AZ</td>
<td></td>
</tr>
<tr>
<td>Weiden, Peter</td>
<td></td>
<td></td>
<td>AZ, BMS, Otsuka, Ortho-McNeil Jansen, Organon, Pfizer, Shire, Vanda, Wyeth-Ayerst</td>
<td>AZ, BMS, Otsuka, Ortho-McNeil Jansen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weiss, Roger</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weisneth, Myrna</td>
<td></td>
<td></td>
<td></td>
<td>NIMH, NIDA, NARSAD</td>
<td></td>
<td>MultiHealth Systems Inc. Receive royalties</td>
</tr>
<tr>
<td>West, Joyce</td>
<td></td>
<td></td>
<td>AZ, BMS, Eli Lilly, Forest, Pfizer, Janssen-Ortho, Wyeth-Ayerst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wigal, Sharon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ortho-McNeil Jansen</td>
</tr>
<tr>
<td>Wilens, Timothy E</td>
<td></td>
<td>Abbott, AZ, McNeil, Eli Lilly, NIDA, Novartis, Merck, Shire</td>
<td>Abbott, McNeil, Eli Lilly, NIDA, Merck, Shire</td>
<td>Eli Lilly, McNeil, Novartis, Shire</td>
<td></td>
<td>Guilford Publications Published book</td>
</tr>
<tr>
<td>Wise, Michael</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wise, Thomas</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>BMS, Eli Lilly, Lundbeck</td>
</tr>
<tr>
<td>Wisner, Katherine</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td>Eli Lilly, Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis donation of active and placebo estradiol patches for an NIMH funded randomized controlled trial</td>
</tr>
<tr>
<td>Woodbury-Farina, Michael</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woods, Scott</td>
<td></td>
<td>Schering-Pleugh, France</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wright, Jesse</td>
<td></td>
<td>Mindstreet</td>
<td></td>
<td></td>
<td></td>
<td>Wyeth-Ayerst</td>
</tr>
<tr>
<td>Yathum, Lakhmi</td>
<td></td>
<td>Pfizer, Janssen, BMS, Servier, AZ, Schering Pleugh, Cephalon, Sanofi Aventis</td>
<td>BMS, Servier</td>
<td>AZ, Janssen, Pfizer, BMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yehuda, Rachel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yohanan, Monique</td>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yousha, Sharon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Shire</td>
</tr>
<tr>
<td>Zeana, Charles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guilford Publications Book royalties</td>
</tr>
<tr>
<td>Ziegler, Penelope</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medicam Worldwide Inc.</td>
</tr>
<tr>
<td>Zun, Leslie</td>
<td></td>
<td>Alexza Molecular Delivery</td>
<td></td>
<td></td>
<td></td>
<td>Sanofi Aventis</td>
</tr>
</tbody>
</table>
DISCLOSURE INDEX

The following presenters indicated neither they nor an immediate member of their family have any significant relationship to disclose.

Abbas, Muhammad A
Abbey, Susan
Abdallah, Chadi
Abela, John
Abrams, Alan
Abramson, Ronald
Abreu, Lena
Acosta-Uribe, Juliana
Adams, Jr., Curtis
Adams, Julie
Addington, Jean
Adelson, Stewart
Adler, Lawrence
Affi, Samah
Aggarwal, Neil
Ahmed, Serge
Aizenstein, Howard
Akkisi Kumsar, Nselihan
Akin, Will
Alam, Faouzi
Alao, Adekola
Alarisetinen, Antti
Alarcon, Renato
Alcorn, Harry
Ali, Asghar-All
Ali, Mohamed
Almeida, Karla
Al-Seadi, Sam
Amini, Mona
Amir, Asad
An, Hoyoung
Anson, Andrew
Anzla, Joan
Apter, Gisele
Arean, Patricia
Artinghaus, Kimberly
Aslam, Sunny P
Asmal, Laila
Atdjian, Sylvia
Atkins, Robert
Atri, Ashutosh
Axelson, Alan
Aydin, Cahide
Ayuso, Jose Luis
Azeem, Muhammad Waqar
Baez-Sierra, Deyadira
Baig, Muhammad R
Bailey, John
Bailey, Rahn
Baker, Allison
Baler, Ruben
Balis, Theodora
Ball, Valdesha
Balon, Richard
Bandstra, Belinda
Baptista, Trino J
Barak, Yoram
Barber, Mary
Barr, Ellen
Barreiro, Paul
Bateman, Anthony
Bates, Lisa
Bauer, Amy
Baum, Antonia
Becker, Daniel
Beighley, Paul
Belfort, Edgard
Belnao, Barri
Bender, Donna
Benedek, Elissa
Benes, Francine
Benitez, Joachim
Benyamina, Amine
Berelin, Eugene
Berksong, Sarah
Berlin, Jon
Bernstein, Carol
Bertoud, Hans-Rudolf
Bestha, Durga
Bhuagra, Dinesh
Bishnoi, Ram Jeevan
Bishop-Baier, Margaret
Biskin, Robert
Bjork, James
Bjorhansson, Andri S
Blake, Martin
Blasco-Fontecilla, Hilario
Block, Jerald
Boetger, Soneke
Bokarius, Vladimir
Boland, Robert J
Bolton, James
Bonnie, Richard
Book, Howard
Boothe, Andrew
Boutros, Nash
Boycie, Cheryl Anne
Boyer, Jenny
Bradley, John
Brady, Kathleen
Brendel, David H.
Brendel, Rebecca
Bretzke, Eliza
Briones, David
Briscoe, Brian
Brod, Thomas M.
Bromander, Sara
Brooks, Beth Ann
Broudy, Carolyn
Brown, Richard
Brum Moraes, Juliana
Budney, Alan
Buie, Stephen
Buist, Anne
Bullock, Karen
Buoli, Massimiliano
Burd, Ronald
Burke, Jack
Burpee, Stacey
Burton, M. Caroline
Byatt, Nancy
Cabaniss, Deborah
Cain, Tonier
Calderon-Abbo, Jose
Caligor, Eve
Calzada, Esther
Camarena, Enrique
Campayo, Antonio
Campbell, Frank
Campbell, Herbert
Campbell, William
Candilis, Philip
Canuso, Amy
Cao, Xiaohua
Caplan, Jason
Carballo, Juan J
Caring, Joanne
Carney, Colleen
Carroll, Ian
Carroll, Kathleen
Carver, Anne
Carter, Diana
Casey, B.J.
Castellano, F. Xavier
Castellanos, Daniel
Castilla-Puentes, Wilma
Castro-Loli, Piero I
Caudill, Marissa
Cavender, Jennifer
Cebollia, Susana S
Ceranoglu, Tolga
Cernovsky, Zack
Certa, Kenneth
Chan, Carlye
Chan, Jonathan K
Chandra, Prakash
Chanen, Andrew
Chang, Charlene
Chang, Hun Soo
Chao, Faye
Chapman, Daniel P.
Chaudhary, Ayesha
Cheema, Faiz A
Chen, Donna
Cheon, Jin Sook
Chiasson, Ann Marie
Childress, Anna Rose
Chiu, Simon
Cho, Young Ju
Choi, Jungmi
Choi-Kain, Lois
Chung, Bowen
Clark, David
Clarkin, John
Clayton, Paula
Cloninger, C. Robert
Cobb, Robert
Coconcea, Cristinel
Coenson, Craig
Coffey, C. Edward
Coffey, M. Justin
Cohen, Carl I.
Cohen, Lewis
Cohen, Mitchell
Cole, Steven
Compton III, Wilson
Condon, Timothy
Conrad, Erich
Constant, Eric E
Copen, John
Cora, Gabriella
Cornblatt, Barbara
Courchesne, Eric
Cournos, Francine
Cristancho, Pilar
Crocq, Marc-Antoine
Crone, Catherine
Crowley, Thomas
Cuhadaroglu-Cetin, Fusun
Curtis, Laurie
Cutrone, Candace
Dackis, Charles
Dalsac, Gregory
Daniels, Allen
Dannon, Pinhas
Daskalakis, Zafiris
Davidoff, Donald
Davidson, Laurie
Davies, Gordon
Davis, Jeri
Daviss, Steven
De Beaurepaire, Renaud
De Bellocourt, Carel
De Jonghe, Frans
De la Fuente, Camilo
Declan, Barry
<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degruy, Frank</td>
</tr>
<tr>
<td>Deisseroth, Karl</td>
</tr>
<tr>
<td>Dekker, Jack</td>
</tr>
<tr>
<td>Dekleva, Kenneth</td>
</tr>
<tr>
<td>Delgado, Mauricio</td>
</tr>
<tr>
<td>Delgado, Pedro</td>
</tr>
<tr>
<td>Delgiannidis, Kristina</td>
</tr>
<tr>
<td>Dell’osso, Bernardo</td>
</tr>
<tr>
<td>Denisso, Richard</td>
</tr>
<tr>
<td>DeSalvo, Karen</td>
</tr>
<tr>
<td>Desserles, Martin</td>
</tr>
<tr>
<td>Deutsch, Stephen</td>
</tr>
<tr>
<td>Devlin, Michael</td>
</tr>
<tr>
<td>Devulapalli, Kavi K</td>
</tr>
<tr>
<td>Dewan, Mantosh</td>
</tr>
<tr>
<td>Dhand, Sara</td>
</tr>
<tr>
<td>Diaz, David</td>
</tr>
<tr>
<td>Dickstein, Leah</td>
</tr>
<tr>
<td>Dierker, Lisa</td>
</tr>
<tr>
<td>Dike, Charles</td>
</tr>
<tr>
<td>Diller, Kathleen C</td>
</tr>
<tr>
<td>Dimaggio, Giuseppe</td>
</tr>
<tr>
<td>Giancarlo</td>
</tr>
<tr>
<td>Dobbins, Mary</td>
</tr>
<tr>
<td>Domnittel, Diana</td>
</tr>
<tr>
<td>Domschke, Katharina</td>
</tr>
<tr>
<td>Donovan, Abigail</td>
</tr>
<tr>
<td>Dorrreapla, Ethy</td>
</tr>
<tr>
<td>Downey, Jennifer</td>
</tr>
<tr>
<td>Drescher, Jack</td>
</tr>
<tr>
<td>Drevets, Wayne</td>
</tr>
<tr>
<td>Drury, Stacy</td>
</tr>
<tr>
<td>Druss, Benjamin</td>
</tr>
<tr>
<td>Duckworth, Kenneth S.</td>
</tr>
<tr>
<td>Duffy, Farifteh</td>
</tr>
<tr>
<td>Dunn, Laura</td>
</tr>
<tr>
<td>Durden, Emily</td>
</tr>
<tr>
<td>Duval, Fabrice</td>
</tr>
<tr>
<td>Dwaikat, Samah</td>
</tr>
<tr>
<td>Dzirasa, Erika</td>
</tr>
<tr>
<td>Eells, Gregory</td>
</tr>
<tr>
<td>Eld, Beatrice</td>
</tr>
<tr>
<td>Ellis, Robert</td>
</tr>
<tr>
<td>Elsayed, Yasser</td>
</tr>
<tr>
<td>El-Shafei, Ahmed</td>
</tr>
<tr>
<td>Embley, Scott</td>
</tr>
<tr>
<td>Engel, Charles C.</td>
</tr>
<tr>
<td>Eraslan, Defne</td>
</tr>
<tr>
<td>Erten, Evrim</td>
</tr>
<tr>
<td>Evans, Liz</td>
</tr>
<tr>
<td>Everett, Anita</td>
</tr>
<tr>
<td>Faulkner, Larry</td>
</tr>
<tr>
<td>Fauman, Beverly</td>
</tr>
<tr>
<td>Feeney, Norah</td>
</tr>
<tr>
<td>Fenley, Gareth</td>
</tr>
<tr>
<td>Fernandez, Antony</td>
</tr>
<tr>
<td>Fernandez, Francisco</td>
</tr>
<tr>
<td>Ferreira, Luiz K</td>
</tr>
<tr>
<td>Fetterolf, Frank A.</td>
</tr>
<tr>
<td>Fier, Jennifer</td>
</tr>
<tr>
<td>Fine, Carla</td>
</tr>
<tr>
<td>Finnerty, Molly</td>
</tr>
<tr>
<td>Fiorillo, Andrea</td>
</tr>
<tr>
<td>Fitelson, Elizabeth</td>
</tr>
<tr>
<td>Fitzpatrick, Kathleen</td>
</tr>
<tr>
<td>Flynn, Christopher</td>
</tr>
<tr>
<td>Flynn, David</td>
</tr>
<tr>
<td>Flynn, Meredith B</td>
</tr>
<tr>
<td>Fochtmann, Laura</td>
</tr>
<tr>
<td>Fonagy, Peter</td>
</tr>
<tr>
<td>Forro, Jorge</td>
</tr>
<tr>
<td>Forstein, Marshall</td>
</tr>
<tr>
<td>Fosdick, Cara</td>
</tr>
<tr>
<td>Fouks, Edward</td>
</tr>
<tr>
<td>Foundas, Anne</td>
</tr>
<tr>
<td>Franch Pato, Clara</td>
</tr>
<tr>
<td>Franco, Kathleen</td>
</tr>
<tr>
<td>Frank, Julia</td>
</tr>
<tr>
<td>Frascella, Joseph</td>
</tr>
<tr>
<td>Freedman, Robert</td>
</tr>
<tr>
<td>Friedman, Joshua</td>
</tr>
<tr>
<td>Friedman, Matthew J.</td>
</tr>
<tr>
<td>Friedman, Nora</td>
</tr>
<tr>
<td>Friedman, Richard</td>
</tr>
<tr>
<td>Friedman, Susan Hatters</td>
</tr>
<tr>
<td>Frometa, Ayme</td>
</tr>
<tr>
<td>Fuji, Ryuichi</td>
</tr>
<tr>
<td>Fung, Kenneth</td>
</tr>
<tr>
<td>Furukawa, Toshiaki A.</td>
</tr>
<tr>
<td>Gabbard, Glen</td>
</tr>
<tr>
<td>Gable, Mary S</td>
</tr>
<tr>
<td>Galanter, Marc</td>
</tr>
<tr>
<td>Gallion, Joan E</td>
</tr>
<tr>
<td>Galvez, Juan F</td>
</tr>
<tr>
<td>Galynker, Igor</td>
</tr>
<tr>
<td>Garrett, Michael</td>
</tr>
<tr>
<td>Gaspar, Enrique</td>
</tr>
<tr>
<td>Gastelum, Emily</td>
</tr>
<tr>
<td>Gathright, Molly</td>
</tr>
<tr>
<td>Gaudiano, Brandon</td>
</tr>
<tr>
<td>Geddies, John</td>
</tr>
<tr>
<td>Geller, Jeffrey</td>
</tr>
<tr>
<td>Georges, Hebert</td>
</tr>
<tr>
<td>Georgievna, Galina J</td>
</tr>
<tr>
<td>Gerberg, Patricia</td>
</tr>
<tr>
<td>Gerbert, Barbara</td>
</tr>
<tr>
<td>Germain, Anne</td>
</tr>
<tr>
<td>Gerschwind, Daniel</td>
</tr>
<tr>
<td>Ghanem, Mohamed</td>
</tr>
<tr>
<td>Giedd, Jay</td>
</tr>
<tr>
<td>Gillece, Joan</td>
</tr>
<tr>
<td>Ginzburg, Harold</td>
</tr>
<tr>
<td>Girard, Kristine</td>
</tr>
<tr>
<td>Gitlin, David</td>
</tr>
<tr>
<td>Glenn, Tasha</td>
</tr>
<tr>
<td>Glick, Rachel</td>
</tr>
<tr>
<td>Gluck, Mark</td>
</tr>
<tr>
<td>Goethe, John</td>
</tr>
<tr>
<td>Gold, Mark</td>
</tr>
<tr>
<td>Goldberg, David</td>
</tr>
<tr>
<td>Goldman, Howard</td>
</tr>
<tr>
<td>Goldman, Marina</td>
</tr>
<tr>
<td>Goldstein, Stacia</td>
</tr>
<tr>
<td>Goldstein, Tina</td>
</tr>
<tr>
<td>Gonzalez, Hector</td>
</tr>
<tr>
<td>Goodman, Jeanne</td>
</tr>
<tr>
<td>Gopal, Arun</td>
</tr>
<tr>
<td>Gordy, Tracy</td>
</tr>
<tr>
<td>Gorelick, David</td>
</tr>
<tr>
<td>Graber, Cheryl</td>
</tr>
<tr>
<td>Graceious, Barbara L</td>
</tr>
<tr>
<td>Grady-Weikly, Tana</td>
</tr>
<tr>
<td>Granacher, Robert</td>
</tr>
<tr>
<td>Grant, Steven</td>
</tr>
<tr>
<td>Grau, Arturo</td>
</tr>
<tr>
<td>Gray, Sheila Hafter</td>
</tr>
<tr>
<td>Green, Stephen</td>
</tr>
<tr>
<td>Greenfield, Shelly</td>
</tr>
<tr>
<td>Griffin, Margaret L</td>
</tr>
<tr>
<td>Griffith, Ezra</td>
</tr>
<tr>
<td>Griffith, James</td>
</tr>
<tr>
<td>Gunderson, John</td>
</tr>
<tr>
<td>Gunter, Gariane</td>
</tr>
<tr>
<td>Gupta, Aarti A-G</td>
</tr>
<tr>
<td>Gupta, Swapnil</td>
</tr>
<tr>
<td>Gur, Raquel</td>
</tr>
<tr>
<td>Guerra, Ronald J</td>
</tr>
<tr>
<td>Ha, Ju-Won</td>
</tr>
<tr>
<td>Habi, Samar</td>
</tr>
<tr>
<td>Hackman, Ann</td>
</tr>
<tr>
<td>Haeri, Sophia SH</td>
</tr>
<tr>
<td>Hales, Deborah</td>
</tr>
<tr>
<td>Halfon, Olivier</td>
</tr>
<tr>
<td>Hall, James</td>
</tr>
<tr>
<td>Hami, Katherine</td>
</tr>
<tr>
<td>Halpern, John</td>
</tr>
<tr>
<td>Haltzman, Scott</td>
</tr>
<tr>
<td>Halverson, Jerry</td>
</tr>
<tr>
<td>Hamlin, Ed</td>
</tr>
<tr>
<td>Han, Doug Hyun</td>
</tr>
<tr>
<td>Han, Sang Ick</td>
</tr>
<tr>
<td>Haney, Margaret</td>
</tr>
<tr>
<td>Hankins, Brandi</td>
</tr>
<tr>
<td>Haq, Fasihra</td>
</tr>
<tr>
<td>Hare, Todd</td>
</tr>
<tr>
<td>Harpel, Joanne</td>
</tr>
<tr>
<td>Harris, Todi</td>
</tr>
<tr>
<td>Harvey, Renee</td>
</tr>
<tr>
<td>Hasin, Deborah S.</td>
</tr>
<tr>
<td>Hassan, Farah S</td>
</tr>
<tr>
<td>Hatters Friedman, Susan</td>
</tr>
<tr>
<td>Hatti, Shivkumar</td>
</tr>
<tr>
<td>Heckel, Sally</td>
</tr>
<tr>
<td>Heim, Christine</td>
</tr>
<tr>
<td>Helmer, Amanda</td>
</tr>
<tr>
<td>Henderson, Melinda</td>
</tr>
<tr>
<td>Hendriksen, Marielle</td>
</tr>
<tr>
<td>Herazo, Edwyn</td>
</tr>
<tr>
<td>Herbert, Sarah</td>
</tr>
<tr>
<td>Herbst, Luis G.</td>
</tr>
<tr>
<td>Herman, Barry</td>
</tr>
<tr>
<td>Hernández-Ribas, Rosa</td>
</tr>
<tr>
<td>Herrig, Matthew P.</td>
</tr>
<tr>
<td>Heru, Alison</td>
</tr>
<tr>
<td>Hien, Denise</td>
</tr>
<tr>
<td>Hilderbrand, Richard</td>
</tr>
<tr>
<td>Hilty, Donald</td>
</tr>
<tr>
<td>Hinton, Devon</td>
</tr>
<tr>
<td>Hinton, Ladson</td>
</tr>
<tr>
<td>Hira-Brar, Shabneet</td>
</tr>
<tr>
<td>Hlaastula, Stefanie</td>
</tr>
<tr>
<td>Hoffman, Perry</td>
</tr>
<tr>
<td>Hoffmann, William F</td>
</tr>
<tr>
<td>Hoffpaur, Sarah</td>
</tr>
<tr>
<td>Hoge, Steven</td>
</tr>
<tr>
<td>Hoglend, Per</td>
</tr>
<tr>
<td>Hong, Chang Hyung</td>
</tr>
<tr>
<td>Hong, Elliot</td>
</tr>
<tr>
<td>Hong, Minha</td>
</tr>
<tr>
<td>Hong, Yang</td>
</tr>
<tr>
<td>Hong, Youjin</td>
</tr>
<tr>
<td>Honore, Russel</td>
</tr>
<tr>
<td>Hoogenboom, Wouter S</td>
</tr>
<tr>
<td>Hoop, Jinger</td>
</tr>
<tr>
<td>Horey, Jonathan</td>
</tr>
<tr>
<td>Horowitz, Mardi</td>
</tr>
<tr>
<td>Houchins, Rachel A</td>
</tr>
<tr>
<td>Houston, Michael</td>
</tr>
<tr>
<td>Howe, Edmund</td>
</tr>
<tr>
<td>Hristov, Svetoslav</td>
</tr>
<tr>
<td>Hsiung, Robert</td>
</tr>
<tr>
<td>Huang, David</td>
</tr>
<tr>
<td>Huang, Rex</td>
</tr>
<tr>
<td>Huang, Tiao-Lai</td>
</tr>
<tr>
<td>Huguelet, Philippe</td>
</tr>
<tr>
<td>Hunt, Justin</td>
</tr>
<tr>
<td>Hunter, Jon</td>
</tr>
<tr>
<td>Huremovic, Damir</td>
</tr>
<tr>
<td>Hurley, Robin</td>
</tr>
<tr>
<td>Hunwitz, Thomas</td>
</tr>
<tr>
<td>Husain, Arshad</td>
</tr>
<tr>
<td>Husni, Mariwan</td>
</tr>
<tr>
<td>Hussain, Arshad</td>
</tr>
<tr>
<td>Hutchens, Steven</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Hwang, Soonjo</td>
</tr>
<tr>
<td>Hyun, Aerin</td>
</tr>
<tr>
<td>Iarovici, Doris</td>
</tr>
<tr>
<td>Ibrahim, Fayaz</td>
</tr>
<tr>
<td>Inczedy-Farkas, Gabriella</td>
</tr>
<tr>
<td>Insel, Thomas</td>
</tr>
<tr>
<td>Isenberk, Keith</td>
</tr>
<tr>
<td>Islam, Sadaf</td>
</tr>
<tr>
<td>Ismail, Mostafa</td>
</tr>
<tr>
<td>Jadresic, Enrique</td>
</tr>
<tr>
<td>Jaffe, Eli</td>
</tr>
<tr>
<td>Janardhanan, Thulasiram</td>
</tr>
<tr>
<td>Javed, Qaiser</td>
</tr>
<tr>
<td>Javier, Peña</td>
</tr>
<tr>
<td>Jeevarakshagan, Shamala</td>
</tr>
<tr>
<td>Jennings, Gillian</td>
</tr>
<tr>
<td>Jensen, Signe</td>
</tr>
<tr>
<td>Jeong-Ho, Seok</td>
</tr>
<tr>
<td>Jermedy, Agnes</td>
</tr>
<tr>
<td>Jimenez-Trevino, Luis</td>
</tr>
<tr>
<td>Jimerson, David</td>
</tr>
<tr>
<td>Jisun, Kim</td>
</tr>
<tr>
<td>Johnson, Paula</td>
</tr>
<tr>
<td>Johnson, Sarah</td>
</tr>
<tr>
<td>Johnston, Megan</td>
</tr>
<tr>
<td>Johnstone, Eve</td>
</tr>
<tr>
<td>Jones, Ashley B</td>
</tr>
<tr>
<td>Jones, Cheryl W.</td>
</tr>
<tr>
<td>Jones, Hendree</td>
</tr>
<tr>
<td>Jorge, Rita</td>
</tr>
<tr>
<td>Jørgensen, Anders</td>
</tr>
<tr>
<td>Jorgensen, Linda</td>
</tr>
<tr>
<td>Joseph, Robert C.</td>
</tr>
<tr>
<td>Jun, Tae-Youn</td>
</tr>
<tr>
<td>Jung, Han-Young</td>
</tr>
<tr>
<td>Jung, Seungho</td>
</tr>
<tr>
<td>Jung, Wocyul</td>
</tr>
<tr>
<td>Juthani, Nalini</td>
</tr>
<tr>
<td>Kahn, Tara A</td>
</tr>
<tr>
<td>Katin, Kenneth</td>
</tr>
<tr>
<td>Kalvas, Peter</td>
</tr>
<tr>
<td>Kalkay, Asl Funda</td>
</tr>
<tr>
<td>Kalman, Thomas</td>
</tr>
<tr>
<td>Kanner, Andres</td>
</tr>
<tr>
<td>Kaplan, Alan</td>
</tr>
<tr>
<td>Karasu, Sylvia</td>
</tr>
<tr>
<td>Karnik, Niranjani</td>
</tr>
<tr>
<td>Katz, Curren E.</td>
</tr>
<tr>
<td>Katz, Maor</td>
</tr>
<tr>
<td>Katz-Beanot, Sherry</td>
</tr>
<tr>
<td>Katzman, Martin</td>
</tr>
<tr>
<td>Kaufmann, Walter</td>
</tr>
<tr>
<td>Kautz, Mary</td>
</tr>
<tr>
<td>Kay, Jerald</td>
</tr>
<tr>
<td>Kaye, Walter</td>
</tr>
<tr>
<td>Kelly, Meredith</td>
</tr>
<tr>
<td>Kennedy, Robert</td>
</tr>
<tr>
<td>Kent, Laura</td>
</tr>
<tr>
<td>Kernberg, Otto</td>
</tr>
<tr>
<td>Kerner, Melissa</td>
</tr>
<tr>
<td>Kesebir, Sermin</td>
</tr>
<tr>
<td>Kessler, David</td>
</tr>
<tr>
<td>Khalil, Afaf</td>
</tr>
<tr>
<td>Khan, Anf</td>
</tr>
<tr>
<td>Khan, Rizwan</td>
</tr>
<tr>
<td>Klipatrick, Michael</td>
</tr>
<tr>
<td>Kim, Eun Jin</td>
</tr>
<tr>
<td>Kim, Hwanglyong</td>
</tr>
<tr>
<td>Kim, Jin-woo</td>
</tr>
<tr>
<td>Kim, Jun Won</td>
</tr>
<tr>
<td>Kim, Scott</td>
</tr>
<tr>
<td>Kim, Shin Gyeom</td>
</tr>
<tr>
<td>Kim, Yong-Hwan</td>
</tr>
<tr>
<td>King, Alisha E</td>
</tr>
<tr>
<td>King, Bryan</td>
</tr>
<tr>
<td>King, Jeffrey</td>
</tr>
<tr>
<td>King-Casas, Brooks</td>
</tr>
<tr>
<td>Kingdon, David</td>
</tr>
<tr>
<td>Kinzie, John David</td>
</tr>
<tr>
<td>Kissel, Olga</td>
</tr>
<tr>
<td>Knobler, Haim</td>
</tr>
<tr>
<td>Knoll, James</td>
</tr>
<tr>
<td>Ko, Young-Hoon</td>
</tr>
<tr>
<td>Koenig, Barbara</td>
</tr>
<tr>
<td>Koenigsberg, Harold</td>
</tr>
<tr>
<td>Kogan, Richard</td>
</tr>
<tr>
<td>Koh, Steve</td>
</tr>
<tr>
<td>Kohrt, Brandon</td>
</tr>
<tr>
<td>Kolling, Pieteren</td>
</tr>
<tr>
<td>Kontis, Dimitrios</td>
</tr>
<tr>
<td>Koo, Bon-Hoon</td>
</tr>
<tr>
<td>Kool, Simone</td>
</tr>
<tr>
<td>Kopelowicz, Alex</td>
</tr>
<tr>
<td>Koszyci, Diana</td>
</tr>
<tr>
<td>Krain, Lewis</td>
</tr>
<tr>
<td>Krakowski, Menahem</td>
</tr>
<tr>
<td>Kramer, Milton</td>
</tr>
<tr>
<td>Kramer, Peter</td>
</tr>
<tr>
<td>Krasnik, Catherine</td>
</tr>
<tr>
<td>Kravos, Matej</td>
</tr>
<tr>
<td>Krishna, Sowmya</td>
</tr>
<tr>
<td>Kukoyi, Oladipo</td>
</tr>
<tr>
<td>Kulkarni, Gaurav</td>
</tr>
<tr>
<td>Kumari, Anand</td>
</tr>
<tr>
<td>Kung, Simon</td>
</tr>
<tr>
<td>Kunik, Mark</td>
</tr>
<tr>
<td>Kupfer, David</td>
</tr>
<tr>
<td>Kyung Yeol, Bae</td>
</tr>
<tr>
<td>LaBar, Kevin</td>
</tr>
<tr>
<td>LaFrance, Jr., W. Curt</td>
</tr>
<tr>
<td>Landsberger, Sarah A</td>
</tr>
<tr>
<td>Laor, Nathaniel</td>
</tr>
<tr>
<td>Lapid, Maria</td>
</tr>
<tr>
<td>Le Grange, Daniel</td>
</tr>
<tr>
<td>LeBourgeois Ill, H</td>
</tr>
<tr>
<td>Lecours, Serge</td>
</tr>
<tr>
<td>Lee, Elliott</td>
</tr>
<tr>
<td>Lee, Hwa-Young</td>
</tr>
<tr>
<td>Lee, Jonathan C</td>
</tr>
<tr>
<td>Lee, Leilani</td>
</tr>
<tr>
<td>Lee, Sang Kyu</td>
</tr>
<tr>
<td>Lehman, Anthony</td>
</tr>
<tr>
<td>Leibowitz, Scott</td>
</tr>
<tr>
<td>Leight, Kristin</td>
</tr>
<tr>
<td>Leistedt, Samuel</td>
</tr>
<tr>
<td>Leli, Ubaldos</td>
</tr>
<tr>
<td>Lentz, Vanessa</td>
</tr>
<tr>
<td>León-Andrade, Carlos</td>
</tr>
<tr>
<td>Lester, Natalie A</td>
</tr>
<tr>
<td>Leszcz, Molyln</td>
</tr>
<tr>
<td>Leung, Joey Shuk Yan JSY</td>
</tr>
<tr>
<td>Levander, Eric</td>
</tr>
<tr>
<td>Levinson, Hanna</td>
</tr>
<tr>
<td>Levin, Frances</td>
</tr>
<tr>
<td>Levine, Ruth</td>
</tr>
<tr>
<td>Levine, Stephen</td>
</tr>
<tr>
<td>Levinson, Douglas</td>
</tr>
<tr>
<td>Levy, Kenneth</td>
</tr>
<tr>
<td>Levy, Norman</td>
</tr>
<tr>
<td>Lewis, Janet</td>
</tr>
<tr>
<td>Lewis, Jerry</td>
</tr>
<tr>
<td>Lewy, Colleen S</td>
</tr>
<tr>
<td>Lim, Russell</td>
</tr>
<tr>
<td>Lin, Chin-Chuen</td>
</tr>
<tr>
<td>Lin, Jin-Jia</td>
</tr>
<tr>
<td>Lindberg, Marc A</td>
</tr>
<tr>
<td>Lindeman, Jeffrey</td>
</tr>
<tr>
<td>Lineberry, Timothy</td>
</tr>
<tr>
<td>Link, Patrick</td>
</tr>
<tr>
<td>Lipsitt, Don</td>
</tr>
<tr>
<td>Liu, Timothy</td>
</tr>
<tr>
<td>Liu, Zhifen</td>
</tr>
<tr>
<td>Livesley, John</td>
</tr>
<tr>
<td>Lobo, Antonio</td>
</tr>
<tr>
<td>LoboPrabhu, Sheila</td>
</tr>
<tr>
<td>Lock, James</td>
</tr>
<tr>
<td>Lomax, James</td>
</tr>
<tr>
<td>Low, Yinghui Yh</td>
</tr>
<tr>
<td>Lowe, Matthew</td>
</tr>
<tr>
<td>Lowenkopf, Eugene</td>
</tr>
<tr>
<td>Lu, Francis</td>
</tr>
<tr>
<td>Lukas, Scott E</td>
</tr>
<tr>
<td>Luna, Beatriz</td>
</tr>
<tr>
<td>Luo, John</td>
</tr>
<tr>
<td>Luty, Suzanne</td>
</tr>
<tr>
<td>Lynch, Linda</td>
</tr>
<tr>
<td>Lysaker, Paul</td>
</tr>
<tr>
<td>Mabe, P. Alex</td>
</tr>
<tr>
<td>Mack, Avram</td>
</tr>
<tr>
<td>Mackey, Sean</td>
</tr>
<tr>
<td>Madaan, Vishal</td>
</tr>
<tr>
<td>Maddox, Jill</td>
</tr>
<tr>
<td>Maffei, Cesare</td>
</tr>
<tr>
<td>Mago, Rajnish</td>
</tr>
<tr>
<td>Maj, Mario</td>
</tr>
<tr>
<td>Maki, Pirjo H.</td>
</tr>
<tr>
<td>Maldonado, Jose</td>
</tr>
<tr>
<td>MalMQ, Carl</td>
</tr>
<tr>
<td>Manuel, Partam</td>
</tr>
<tr>
<td>Mambr, Rachel</td>
</tr>
<tr>
<td>Manepalli, Jothika</td>
</tr>
<tr>
<td>Markad, Mehul</td>
</tr>
<tr>
<td>Mannelli, Paolo</td>
</tr>
<tr>
<td>Mantovani, Antonio</td>
</tr>
<tr>
<td>Manzardo, Ann</td>
</tr>
<tr>
<td>Marcu, Jahan</td>
</tr>
<tr>
<td>Marella, Srimannarayana</td>
</tr>
<tr>
<td>MargeryBertoglia, Solange</td>
</tr>
<tr>
<td>Marissen, Marlies</td>
</tr>
<tr>
<td>Markov, Dimitri</td>
</tr>
<tr>
<td>Marks, Saul</td>
</tr>
<tr>
<td>Maruyama, Nancy C</td>
</tr>
<tr>
<td>Matharu, Yogi</td>
</tr>
<tr>
<td>Matorn, Anu</td>
</tr>
<tr>
<td>Matthews, Annette</td>
</tr>
<tr>
<td>Mayers-Elder, Chanda</td>
</tr>
<tr>
<td>McCann, David</td>
</tr>
<tr>
<td>McCarron, Robert</td>
</tr>
<tr>
<td>McCarthy, Maia</td>
</tr>
<tr>
<td>McClellan, Andrew</td>
</tr>
<tr>
<td>McCormick, Laurie</td>
</tr>
<tr>
<td>McCormick, Richard</td>
</tr>
<tr>
<td>McElroy, Susan</td>
</tr>
<tr>
<td>McFarlane, William</td>
</tr>
<tr>
<td>McGee, Michael</td>
</tr>
<tr>
<td>McGraw, Deven</td>
</tr>
<tr>
<td>McIntyre, Kathryn</td>
</tr>
<tr>
<td>McLay, Robert</td>
</tr>
<tr>
<td>McLean, Alexandra</td>
</tr>
<tr>
<td>McNicholas, Laura</td>
</tr>
<tr>
<td>McNulty, Karen</td>
</tr>
<tr>
<td>Meesala, Anil AM</td>
</tr>
<tr>
<td>Meh-H-Madrona, Lewis</td>
</tr>
<tr>
<td>Meier, Linda</td>
</tr>
<tr>
<td>Mendez, Mario</td>
</tr>
<tr>
<td>Mendonca, James D</td>
</tr>
<tr>
<td>Mensah, Jason</td>
</tr>
<tr>
<td>Mervielle, Edgardo</td>
</tr>
<tr>
<td>Mercader, Carolina</td>
</tr>
<tr>
<td>Merkel, Richard</td>
</tr>
<tr>
<td>Meyer, Donald</td>
</tr>
<tr>
<td>Meyer, Fremonta</td>
</tr>
<tr>
<td>Meyers, Diana</td>
</tr>
<tr>
<td>Mian, Ayeshia</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Miciano, Armando S</td>
</tr>
<tr>
<td>Miettunen, Jouko</td>
</tr>
<tr>
<td>Mihai, Adriana</td>
</tr>
<tr>
<td>Miller, Earl</td>
</tr>
<tr>
<td>Miller, Gary</td>
</tr>
<tr>
<td>Miller, Gregory</td>
</tr>
<tr>
<td>Min, Jungwon</td>
</tr>
<tr>
<td>Miner, Luucinda</td>
</tr>
<tr>
<td>Mintz, David</td>
</tr>
<tr>
<td>Mirza, Bushra F</td>
</tr>
<tr>
<td>Misra, Sahana</td>
</tr>
<tr>
<td>Mittal, Sukriti</td>
</tr>
<tr>
<td>Moamai, Javad</td>
</tr>
<tr>
<td>Moen, Richelle</td>
</tr>
<tr>
<td>Moffic, Evan</td>
</tr>
<tr>
<td>Mohandas, E.</td>
</tr>
<tr>
<td>Montoya, Ivan</td>
</tr>
<tr>
<td>Morse, Eric</td>
</tr>
<tr>
<td>Morse, Gary</td>
</tr>
<tr>
<td>Mosier, Jessica</td>
</tr>
<tr>
<td>Moutier, Christine</td>
</tr>
<tr>
<td>Mucic, Davor</td>
</tr>
<tr>
<td>Muñoz, San José, Ainoa</td>
</tr>
<tr>
<td>Munoz, Kristine</td>
</tr>
<tr>
<td>Munoz, Rodrigo A.</td>
</tr>
<tr>
<td>Musalek, Michael</td>
</tr>
<tr>
<td>Mushatt, David</td>
</tr>
<tr>
<td>Mushier, Jeremy</td>
</tr>
<tr>
<td>Myers, Michael</td>
</tr>
<tr>
<td>Myers, Wade</td>
</tr>
<tr>
<td>Na, Haeran Hrn</td>
</tr>
<tr>
<td>Nace, David</td>
</tr>
<tr>
<td>Nadelson, Carol</td>
</tr>
<tr>
<td>Naenm, Faroq</td>
</tr>
<tr>
<td>Nanda, Aarti</td>
</tr>
<tr>
<td>Nardi, Antonio</td>
</tr>
<tr>
<td>Narrow, William</td>
</tr>
<tr>
<td>Nascimento, Antonio</td>
</tr>
<tr>
<td>Nasr, Mohammed</td>
</tr>
<tr>
<td>Naylor, Magdalena</td>
</tr>
<tr>
<td>Nejad, Shamim</td>
</tr>
<tr>
<td>Netlner, Matthew</td>
</tr>
<tr>
<td>Nemat, Ali</td>
</tr>
<tr>
<td>Newton, Thomas</td>
</tr>
<tr>
<td>Nicol, Ginger E</td>
</tr>
<tr>
<td>Nicolo, Giuseppe</td>
</tr>
<tr>
<td>Nino, Johanna</td>
</tr>
<tr>
<td>Nivoli, Alessandra</td>
</tr>
<tr>
<td>Noel, Richard</td>
</tr>
<tr>
<td>Nordon, Clementine CN</td>
</tr>
<tr>
<td>Noteboom, Annemieke</td>
</tr>
<tr>
<td>Notmann, Malik</td>
</tr>
<tr>
<td>Nunez, Edward</td>
</tr>
<tr>
<td>Nunez, Sandra Odebrecht</td>
</tr>
<tr>
<td>Vargas SOVN</td>
</tr>
<tr>
<td>Nurenberg, Jeffry R</td>
</tr>
<tr>
<td>Nyhus, Nadine</td>
</tr>
<tr>
<td>Ochsner, Kevin</td>
</tr>
<tr>
<td>Odaug, Brian L</td>
</tr>
<tr>
<td>Oepen, Godehard</td>
</tr>
<tr>
<td>Oh, Hyun Young</td>
</tr>
<tr>
<td>Oldham, John</td>
</tr>
<tr>
<td>Olsen, John L</td>
</tr>
<tr>
<td>Ong, Jason</td>
</tr>
<tr>
<td>Osinski, Alphonse</td>
</tr>
<tr>
<td>Oslin, David</td>
</tr>
<tr>
<td>Ososky, Howard</td>
</tr>
<tr>
<td>Ososky, Joy</td>
</tr>
<tr>
<td>Osiona, Jorge</td>
</tr>
<tr>
<td>Ostrow, David</td>
</tr>
<tr>
<td>O’Sullivan, Michael</td>
</tr>
<tr>
<td>Owen, Randall</td>
</tr>
<tr>
<td>Pain, Clare</td>
</tr>
<tr>
<td>Palmer, Brian</td>
</tr>
<tr>
<td>Pang, Peng</td>
</tr>
<tr>
<td>Parides, Herbert</td>
</tr>
<tr>
<td>Paris, Joel</td>
</tr>
<tr>
<td>Park, Han Kyul</td>
</tr>
<tr>
<td>Passik, Steve</td>
</tr>
<tr>
<td>Patti, Uday</td>
</tr>
<tr>
<td>Pato, Michele</td>
</tr>
<tr>
<td>Paulsen, Jane</td>
</tr>
<tr>
<td>Payne, Kate</td>
</tr>
<tr>
<td>Pechnich, Robert</td>
</tr>
<tr>
<td>Pedersen, Charlotte</td>
</tr>
<tr>
<td>Peeters, Frenk</td>
</tr>
<tr>
<td>Pelaez, Clara</td>
</tr>
<tr>
<td>Peluso, Erica</td>
</tr>
<tr>
<td>Penninx, Brenda</td>
</tr>
<tr>
<td>Penska, Keith</td>
</tr>
<tr>
<td>Perkins, Matthew</td>
</tr>
<tr>
<td>Perlick, Deborah A.</td>
</tr>
<tr>
<td>Perroud, Nader</td>
</tr>
<tr>
<td>Perry, Dana</td>
</tr>
<tr>
<td>Peselow, Eric</td>
</tr>
<tr>
<td>Peteet, John</td>
</tr>
<tr>
<td>Peterson, Bradley</td>
</tr>
<tr>
<td>Petroni, Mark</td>
</tr>
<tr>
<td>Pflanz, Steven</td>
</tr>
<tr>
<td>Pinalls, Debra</td>
</tr>
<tr>
<td>Pincus, Harold</td>
</tr>
<tr>
<td>Plekun, Eric</td>
</tr>
<tr>
<td>Pleak, Richard</td>
</tr>
<tr>
<td>Plovnick, Robert</td>
</tr>
<tr>
<td>Pollack, David</td>
</tr>
<tr>
<td>Poncelet, Jean Luc</td>
</tr>
<tr>
<td>Pontius, Edward</td>
</tr>
<tr>
<td>Pope, Kayla</td>
</tr>
<tr>
<td>Potash, Mordecai</td>
</tr>
<tr>
<td>Powsner, Seth</td>
</tr>
<tr>
<td>Prabhakar, Deepak</td>
</tr>
<tr>
<td>Preston, Kenzie</td>
</tr>
<tr>
<td>Preven, David</td>
</tr>
<tr>
<td>Primm, Annelle</td>
</tr>
<tr>
<td>Prudent, Vasthie</td>
</tr>
<tr>
<td>Prudic, Joan</td>
</tr>
<tr>
<td>Puchalski, Christina</td>
</tr>
<tr>
<td>Quintanilla, Beatriz</td>
</tr>
<tr>
<td>Rachal, Funmilayo</td>
</tr>
<tr>
<td>Ragns, Mark</td>
</tr>
<tr>
<td>Ramananathan, Anita</td>
</tr>
<tr>
<td>Ramirez, Luis</td>
</tr>
<tr>
<td>Randhawa, Jyoti</td>
</tr>
<tr>
<td>Rao, Nyapatil</td>
</tr>
<tr>
<td>Rappaport, Lance M</td>
</tr>
<tr>
<td>Rappaport, Nancy</td>
</tr>
<tr>
<td>Rasic, Daniel</td>
</tr>
<tr>
<td>Rasmussen, Andrew</td>
</tr>
<tr>
<td>Rasyidi, Ernest</td>
</tr>
<tr>
<td>Rathod, Shanaya</td>
</tr>
<tr>
<td>Ravitz, Paula</td>
</tr>
<tr>
<td>Rawen, Simha E</td>
</tr>
<tr>
<td>Rawkins, Sian</td>
</tr>
<tr>
<td>Rawlings, Joseph</td>
</tr>
<tr>
<td>Reardon, Claudia</td>
</tr>
<tr>
<td>Rebas-Harrelson, Lauren</td>
</tr>
<tr>
<td>Recupero, Patricia</td>
</tr>
<tr>
<td>Redish, A. David</td>
</tr>
<tr>
<td>Reed, Geoffrey</td>
</tr>
<tr>
<td>Reed, Hannah E</td>
</tr>
<tr>
<td>Regier, Darrel A.</td>
</tr>
<tr>
<td>Reich, James</td>
</tr>
<tr>
<td>Reichborn-Kennerud, Ted</td>
</tr>
<tr>
<td>Reid, William</td>
</tr>
<tr>
<td>Reider, Eve</td>
</tr>
<tr>
<td>Reiffer, Burton V.</td>
</tr>
<tr>
<td>Reese, Allan</td>
</tr>
<tr>
<td>Rej, Schom</td>
</tr>
<tr>
<td>Remedi, Carolina</td>
</tr>
<tr>
<td>Ren, Yan</td>
</tr>
<tr>
<td>Resnick, Philip</td>
</tr>
<tr>
<td>Reus, Victor</td>
</tr>
<tr>
<td>Reusche, Christian</td>
</tr>
<tr>
<td>Reyes, Raymond</td>
</tr>
<tr>
<td>Riba, Erica</td>
</tr>
<tr>
<td>Riba, Michelle</td>
</tr>
<tr>
<td>Richane, Abderrahmane AR</td>
</tr>
<tr>
<td>Richards, Lawrence</td>
</tr>
<tr>
<td>Richardson, Jarrett</td>
</tr>
<tr>
<td>Richeimer, Steven</td>
</tr>
<tr>
<td>Richter, Peggy</td>
</tr>
<tr>
<td>Riefer, Melody</td>
</tr>
<tr>
<td>Rigamer, Elmore</td>
</tr>
<tr>
<td>Riggio, Silvana</td>
</tr>
<tr>
<td>Ritchie, Eispeth</td>
</tr>
<tr>
<td>Robert, R.</td>
</tr>
<tr>
<td>Roberts, Kimberly</td>
</tr>
<tr>
<td>Roberts, Laura W.</td>
</tr>
<tr>
<td>Robinowitz, Carolyn B.</td>
</tr>
<tr>
<td>Robinson, David</td>
</tr>
<tr>
<td>Robinson, Donald</td>
</tr>
<tr>
<td>Robinson, Gail</td>
</tr>
<tr>
<td>Roca, Robert</td>
</tr>
<tr>
<td>Rogers, Hollister</td>
</tr>
<tr>
<td>Rohde, Paul</td>
</tr>
<tr>
<td>Roman Mazuecos, Eva</td>
</tr>
<tr>
<td>Romanowicz, Magdalena</td>
</tr>
<tr>
<td>Rondon, Marta</td>
</tr>
<tr>
<td>Rooningstam, Elsa</td>
</tr>
<tr>
<td>Rosario, Vernon</td>
</tr>
<tr>
<td>Rose, Richard</td>
</tr>
<tr>
<td>Rosenberg, Ilyse IR</td>
</tr>
<tr>
<td>Rosenquist, Peter B.</td>
</tr>
<tr>
<td>Rosenthal, Richard</td>
</tr>
<tr>
<td>Ross, Stephen</td>
</tr>
<tr>
<td>Roy-Blyme, Peter</td>
</tr>
<tr>
<td>Ruditis, Ize</td>
</tr>
<tr>
<td>Rue, David</td>
</tr>
<tr>
<td>Rueda-Jairnes, German E</td>
</tr>
<tr>
<td>Rueda-Lara, Maria Adelaida</td>
</tr>
<tr>
<td>Ruiz, Amanda</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
</tr>
<tr>
<td>Rumijo, Anne</td>
</tr>
<tr>
<td>Rundell, James</td>
</tr>
<tr>
<td>Runnels, Patrick</td>
</tr>
<tr>
<td>Russakoff, L. Mark</td>
</tr>
<tr>
<td>Rutherford, BRET R</td>
</tr>
<tr>
<td>Ryan, Deirdre</td>
</tr>
<tr>
<td>Rychik, Abe</td>
</tr>
<tr>
<td>Saad, Emma</td>
</tr>
<tr>
<td>Sachdeva, Shilpa</td>
</tr>
<tr>
<td>Sacks, Stanley</td>
</tr>
<tr>
<td>Sadid, Afia</td>
</tr>
<tr>
<td>Saeed, Sy</td>
</tr>
<tr>
<td>Safar, Laura</td>
</tr>
<tr>
<td>Safer, Debra</td>
</tr>
<tr>
<td>Safran, Marc</td>
</tr>
<tr>
<td>Szizer, Alicia</td>
</tr>
<tr>
<td>Samuel, Janine</td>
</tr>
<tr>
<td>Sands, Diana</td>
</tr>
<tr>
<td>Savin, Daniel</td>
</tr>
<tr>
<td>Saxon, Andrew</td>
</tr>
<tr>
<td>Schlozman, Steven</td>
</tr>
<tr>
<td>Schmidt, Chester</td>
</tr>
<tr>
<td>Schmidt, Winsor</td>
</tr>
<tr>
<td>Schnurr, Paula</td>
</tr>
<tr>
<td>Schoener, Gary</td>
</tr>
<tr>
<td>Schottenfeld, Richard</td>
</tr>
<tr>
<td>Schubmehl, James</td>
</tr>
<tr>
<td>Schuckit, Marc</td>
</tr>
<tr>
<td>Schulden, Jeffrey</td>
</tr>
<tr>
<td>Schuppert, Marieke</td>
</tr>
<tr>
<td>Schuster, James</td>
</tr>
</tbody>
</table>
Lexapro (escitalopram oxalate) is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and adolescents aged 12-17 years. Lexapro is also indicated for the acute treatment of generalized anxiety disorder (GAD) in adults.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially within the first few months of treatment or when changing the dose. Consideration should be given to changing the therapeutic regimen, including discontinuing medication, in patients whose depression is persistently worse, who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Families and caregivers of patients treated with antidepressants should be alerted about the need to monitor patients daily for the emergence of agitation, irritability, unusual changes in behavior, or the emergence of suicidality, and report such symptoms immediately. Prescriptions for Lexapro should be written for the smallest quantity of tablets, consistent with good patient management, in order to reduce the risk of overdose.

- A major depressive episode may be the initial presentation of bipolar disorder. In patients at risk for bipolar disorder, treating such an episode with an antidepressant alone may increase the likelihood of precipitating a mixed/manic episode. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder. Lexapro should be used cautiously in patients with a history of mania or seizure disorder. Lexapro is not approved for use in treating bipolar depression.

- The concomitant use of Lexapro with other SSRIs, SNRIs, triptans, tryptophan, antipsychotics or other dopamine antagonists is not recommended due to potential development of life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions. Reactions have been reported with SNRIs and SSRIs alone, including Lexapro, but particularly with drugs that impair metabolism of serotonin (including MAOIs). Management of these events should include immediate discontinuation of Lexapro and the concomitant agent and continued monitoring.

- Patients should be monitored for adverse reactions when discontinuing treatment with Lexapro. During marketing of Lexapro and other SSRIs and SNRIs, there have been spontaneous reports of adverse events occurring upon discontinuation, including dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias), anxiety, confusion, headache, lethargy, emotional lability, insomnia and hypomania. A gradual dose reduction rather than abrupt cessation is recommended whenever possible.

- SSRIs and SNRIs have been associated with clinically significant hyponatremia. Elderly patients and patients taking diuretics or who are otherwise volume-depleted appear to be at a greater risk. Discontinuation of Lexapro should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.

- SSRIs (including Lexapro) and SNRIs may increase the risk of bleeding. Patients should be cautioned that concomitant use of aspirin, NSAIDs, warfarin or other anticoagulants may add to the risk.

- Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Lexapro does not affect their ability to engage in such activities.

- Lexapro should be used with caution in patients with severe renal impairment or with diseases or conditions that alter metabolism such as hepatic impairment. Clearance of racemic citalopram was decreased and plasma concentrations were increased. The recommended dose of Lexapro in hepatically impaired patients is 10 mg/day.

- For pregnant or nursing mothers, Lexapro should be used only if the potential benefit justifies the potential risk to the fetus or child.

Adverse Reactions

- In clinical trials of MDD, the most common adverse reactions in adults treated with Lexapro (approximately 5% or greater and at least twice the incidence of placebo) were nausea (15% vs 7%), insomnia (9% vs 4%), ejaculation disorder (9% vs <1%), fatigue (5% vs 2%), somnolence (6% vs 2%), and increased sweating (5% vs 2%). In pediatric patients, the overall profile of adverse reactions was similar to that seen in adults; however, the following additional adverse reactions were reported at an incidence of at least 2% for Lexapro and greater than placebo: back pain, urinary tract infection, vomiting, and nasal congestion.

- In clinical trials of GAD, the most common adverse reactions in adults treated with Lexapro (approximately 5% or greater and at least twice the incidence of placebo) were nausea (18% vs 8%), ejaculation disorder (14% vs 2%), insomnia (12% vs 6%), fatigue (8% vs 2%), decreased libido (7% vs 2%) and anorgasmia (6% vs <1%).


Please see Boxed Warning and Contraindications on back cover.
Please see accompanying brief summary of Prescribing Information for LEXAPRO.
See the effect of LEXAPRO

Proven efficacy in MDD in adolescents aged 12 to 17, and in MDD and GAD in adults

Contraindications

- Lexapro is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). There have been reports of serious, sometimes fatal, reactions with some cases resembling neuroleptic malignant syndrome (NMS) and serotonin syndrome. Features may include hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Serotonin syndrome was reported for two patients who were concomitantly receiving linezolid, an antibiotic which has MAOI activity. Lexapro should not be used in combination with an MAOI or within 14 days of discontinuing an MAOI. MAOIs should not be initiated within 14 days of discontinuing Lexapro.

- Lexapro is contraindicated in patients taking pimozide or with hypersensitivity to escitalopram or citalopram.

Please see additional Important Safety Information on preceding page.

© 2010 Forest Laboratories, Inc.  Printed in U.S.A.  41-1015421B  3/10

Visit the LEXAPRO website at www.lexapro.com

There is no generic available for LEXAPRO
**INDICATIONS AND USAGE: Major Depressive Disorder**

Lexapro (escitalopram oxalate) is indicated for the acute and maintenance treatment of major depressive disorder in patients 18 years of age and older. Major depression is a disease that typically requires long-term management, even after clinical response has occurred. In clinical trials, the majority of patients required treatment for 6 to 9 months, and some patients required treatment for more than 1 year to maintain a clinically meaningful response.

**ADVERSE REACTIONS: Clinical Worsening and Suicide Risk**

Patients with MDD and other psychiatric disorders may be at increased risk for developing suicidality and/or unusual changes in behavior. Therefore, it is important to monitor for the emergence of suicidality, particularly during the initial few months of a course of drug therapy and/or when a dose change is made. Patients should be closely monitored, especially during treatment, for clinical worsening and the emergence of suicidality, including symptoms such as: new or worsening depression or suicidal thoughts or behavior, or any other change in behavior that concerns the patient or the prescriber. Patients, their families, and caregivers should be advised of the need to monitor patients for the emergence of such symptoms, or for any exacerbation of symptoms. Patients should be advised to take the drug exactly as prescribed, and to avoid discontinuing it suddenly.In patients who are potential suicide risk patients, suicide risk evaluations should be performed periodically throughout therapy.

**WARNINGS AND PRECAUTIONS: Clinical Worsening and Suicide Risk**

Patients with a history of MDD and other psychiatric disorders may be at increased risk for developing suicidality and/or changes in behavior. Therefore, it is important to monitor for the emergence of suicidality, particularly during the initial few months of a course of drug therapy and/or when a dose change is made. Patients should be closely monitored, especially during treatment, for clinical worsening and the emergence of suicidality, including symptoms such as: new or worsening depression or suicidal thoughts or behavior, or any other change in behavior that concerns the patient or the prescriber. Patients, their families, and caregivers should be advised of the need to monitor patients for the emergence of such symptoms, or for any exacerbation of symptoms. Patients should be advised to take the drug exactly as prescribed, and to avoid discontinuing it suddenly.In patients who are potential suicide risk patients, suicide risk evaluations should be performed periodically throughout therapy.

**ADVERSE REACTIONS: Clinical Worsening and Suicide Risk**

Patients with a history of MDD and other psychiatric disorders may be at increased risk for developing suicidality and/or changes in behavior. Therefore, it is important to monitor for the emergence of suicidality, particularly during the initial few months of a course of drug therapy and/or when a dose change is made. Patients should be closely monitored, especially during treatment, for clinical worsening and the emergence of suicidality, including symptoms such as: new or worsening depression or suicidal thoughts or behavior, or any other change in behavior that concerns the patient or the prescriber. Patients, their families, and caregivers should be advised of the need to monitor patients for the emergence of such symptoms, or for any exacerbation of symptoms. Patients should be advised to take the drug exactly as prescribed, and to avoid discontinuing it suddenly.In patients who are potential suicide risk patients, suicide risk evaluations should be performed periodically throughout therapy.

**ADVERSE REACTIONS: Clinical Worsening and Suicide Risk**

Patients with a history of MDD and other psychiatric disorders may be at increased risk for developing suicidality and/or changes in behavior. Therefore, it is important to monitor for the emergence of suicidality, particularly during the initial few months of a course of drug therapy and/or when a dose change is made. Patients should be closely monitored, especially during treatment, for clinical worsening and the emergence of suicidality, including symptoms such as: new or worsening depression or suicidal thoughts or behavior, or any other change in behavior that concerns the patient or the prescriber. Patients, their families, and caregivers should be advised of the need to monitor patients for the emergence of such symptoms, or for any exacerbation of symptoms. Patients should be advised to take the drug exactly as prescribed, and to avoid discontinuing it suddenly.In patients who are potential suicide risk patients, suicide risk evaluations should be performed periodically throughout therapy.
LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

TREATMENT EMERGENT ADVERSE REACTIONS Observed During a Program of 24-28% Greater Than Placebo For Selected Efficacy Studies

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed During the Premarketing Evaluation of Lexapro

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>

LEXAPRO® (escitalopram oxalate) TABLETS/TABLET SOLUTION

Adverse Reactions Observed in Patients with Major Depressive Disorder

<table>
<thead>
<tr>
<th>Event</th>
<th>Adverse Reactions/Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>6%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
</tr>
<tr>
<td>Headache</td>
<td>3%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
</tr>
</tbody>
</table>
McLean Hospital
A HARVARD MEDICAL SCHOOL AFFILIATE

Ranked first among all freestanding psychiatric hospitals...
U.S. News & World Report

Patient Care

A Full Continuum of Psychiatric Care For All Ages

- Inpatient
- Acute and longer-term residential
- Partial hospitalization
- Outpatient services
- Specialized schools and camp

Education

Research

Leading Through Excellence and Innovation
Belmont, Mass. mclean.harvard.edu 800.333.0338
Visit us at Booth 1735
APPI AUTHOR SESSIONS at the American Psychiatric Association 163rd Annual Meeting

Master Courses
Attend a Master Course at the 2010 American Psychiatric Association Annual Meeting and receive an accompanying reference as part of your admission!

Price for Each Master Course: $350.00 Onsite
Book Included in Each Course!

Child and Adolescent Psychopharmacology
Saturday, May 22  9:00am-4:00pm
Presented by Christopher J. Kratochvil, M.D., with John T. Walkup, M.D., Christopher J. McDougle, M.D., and Karen Dineen Wagner, M.D., Ph.D.

Cutting-Edge Psychopharmacology
Saturday, May 22  9:00am-4:00pm
Presented by Alan F. Schatzberg, M.D., and Ira D. Glick, M.D., with Charles DeBattista, M.D., Terrence Ketter, M.D., Kiki Chang, M.D., and Natalie Rasgon, M.D.

Additional Courses by APPI Authors
Price for Each Course: $250.00 Onsite
Book Included in Each Course!

Advances in Neuropsychiatry
The Neuropsychiatry of Emotion and Its Disorders
Monday, May 24  8:00am-12:00pm
Presented by C. Edward Coffey, M.D., and Randolf B. Schiffer, M.D., with Matthew Menza, M.D., Michael Trimble, M.D., and Robert G. Robinson, M.D.

Practical Cognitive-Behavior Therapy
Sunday, May 23  9:00am-4:00pm
Director: Jesse Wright, M.D., Ph.D., with Judith Beck, Ph.D., Robert Goisman, M.D., and Donna Sudak, M.D.

Practical Psychodynamic Psychotherapy
Sunday, May 23  9:00am-4:00pm
Director: Glen O. Gabbard, M.D., with Robert Michels, M.D., John Gunderson, M.D., and Gabrielle Hobday, M.D.

Neuropsychiatry for Veterans
Wednesday, May 26  8:00am-12:00pm
Presented by Stuart C. Yudofsky, M.D., and Thomas Kosten, M.D., with Thomas Newton, M.D., Kimberly Arlinghaus, M.D., and Robin Hurley, M.D.

Psychopharmacologic, ECT, and Psychotherapeutic Treatment of Psychotic (Delusional) Depression
Monday, May 24  1:00pm-5:00pm
Presented by Anthony J. Rothschild, M.D., with Brandon Guadiano, Ph.D.

How to Practice Evidence-Based Psychiatry
Principles and Case Studies
Tuesday, May 25  8:00am-12:00pm
Presented by C. Barr Taylor, M.D.

Purchase books and journals published by APPI at www.appi.org

The First and Last Word in Psychiatry
Priority code AH1017

APPI Bookstore Hours: Saturday, May 22 to Tuesday, May 25, 10:00am - 4:00pm
APPI ADVANCES In SESSIONS
at the American Psychiatric Association
163rd Annual Meeting

Saturday, May 22 – Wednesday, May 26

Advances In Sessions

Advances In Sessions provide meeting attendees with an opportunity to gain in-depth information on clinical and research advances in specific areas of psychiatry. These 3-hour didactic lecture series feature well-known experts presenting clinical and research findings and allowing time for questions and answers. No registration is necessary for these sessions.

Advances in Correctional Psychiatry
Monday, May 24  9:00am-12:00pm
Chairperson: Charles L. Scott, M.D.

Advances in Psychosomatic Medicine
Monday, May 24  9:00am-12:00pm
Chairperson: James L. Levenson, M.D.

Advances in Forensic Psychiatry
Monday, May 24  2:00pm-5:00pm
Chairperson: Robert I. Simon, M.D.

Advances in Psychotherapeutic Treatments
Monday, May 24  2:00pm-5:00pm
Chairperson: Glen O. Gabbard, M.D.

Advances in the Use of Antipsychotic Medications
Tuesday, May 25  9:00am-12:00pm
Co-Chairpersons: Anthony J. Rothschild, M.D., Kristina Deligiannidis, M.D.

Advances in Personality Disorders
Tuesday, May 25  2:00pm-5:00pm
Co-Chairpersons: John M. Oldham, M.D., Andrew E. Skodol, M.D.

Advances in Substance Abuse Treatment
Tuesday, May 25  2:00pm-5:00pm
Co-Chairpersons: Marc Galanter, M.D., Herbert D. Kleber, M.D.

APPI Bookstore
Be sure to stop by the APPI bookstore to check out APPI’s latest selections, from the newest textbooks, clinical manuals, and journals, to electronic products for your handheld, smartphone, or iPad.

Bookstore Hours:
Saturday, May 22 to Tuesday, May 25, 10:00am - 4:00pm
CONTENTS

FORMAT DESCRIPTIONS .............................................................. 58
DAILY ATTENDANCE LOG ........................................................... 60
SATURDAY SESSIONS ............................................................... 61
SUNDAY SESSIONS ................................................................. 75
MONDAY SESSIONS ............................................................... 85
TUESDAY SESSIONS .............................................................. 103
WEDNESDAY SESSIONS ....................................................... 117
TOPIC INDEX ........................................................................ 126
These sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. Some of these sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc. (APPI), and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online. During the Advances in Research Session, leading clinical researchers present the latest developments in research. Other types of advances in sessions include topics designed to provide psychiatrists with the latest in clinical developments in other areas of medicine. The intent is to give the audience an update from a physician in a particular specialty. These sessions will help attendees keep pace with the rapidly expanding knowledge base and technology in various branches of medicine.

Case Conferences

During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case.

Course Master Courses

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Attendees must be registered for the meeting and purchase tickets to attend.

Focus Live

These 90-minute sessions allow attendees to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. By using the ARS, attendees will feel like they are involved in a small group consultation with an expert clinician, even though the session is being attended by a large number of people. Experts, who served as guest editors of FOCUS, will lead lively multiple choice question-based discussions, and the audience will enter their answers using hand-held devices. The results are instantly tallied and projected on the screen.

Forums

These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists and other mental health professionals. Speakers and panel members are chosen by the Scientific Program Committee for their expertise and leadership in the field.

Lectures

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers. Award lectures are selected by the various APA Award Boards and/or Councils. All award lecturers are approved by the Board of Trustees.

New Research

This format allows for presentation of very recent findings. Posters, which are visual, are self-explanatory presentations. Two poster sessions on Monday will be designated as Young Investigators’ Poster Sessions, which will contain poster presentations from young investigators, residents, medical students, and research or clinical fellows.

Scientific and Clinical Reports

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with discussion from the audience following the presentation of each paper. There is no formal discussant.

Seminars

Seminars are designed to emphasize in-depth learning experiences that actively involve participants and include the opportunity for informal exchange with the presenters. Offered in four-hour (half-day) sessions, seminars either review basic concepts in a special subject area or present advanced material on a circumscribed topic.

Small Interactive Sessions

This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to discuss topics chosen by the expert; to obtain consultations for problems in research from senior researchers; or utilize clinical material offered by the attendee and hear, clinically-based seminars presented by outstanding educators. Small Interactive Sessions are reserved for residents only. These sessions are limited to 25 attendees on a first-come, first-served basis.

Symposia (Industry-Supported and Presidential)

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment on a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as Industry-Supported Symposia in this Program Book.

Workshops (Media)

Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive. Media Workshops are three-hour sessions where a feature-length film is shown and discussed.
Novel Approaches to Assessing and Treating DEPRESSION
in the MEDICALLY ILL

A Symposium Held During the APA 2010 Annual Meeting

WHO SHOULD PARTICIPATE
The activity is designed for clinical psychiatrists and other healthcare professionals interested in the assessment and management of major depressive disorder in medically ill patients.

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
1. Identify evidence-based strategies for diagnosing depression in medically ill populations.
2. Recognize the emerging evidence supporting the role of cytokines and the inflammatory response in the development of depressive illness.
3. Distinguish between clinical trial evidence of phamacologic and nonpharmacologic treatments for depression in the medically ill population, including patients who are defined as treatment-resistant.

ACCREDITATION STATEMENT
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The APA designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE STATEMENT
Participating faculty will disclose any industry affiliations, sponsorships, honoraria, monetary support, and other potentially biasing factors to the audience.

Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be on a first-come, first-served basis. For more information about the meeting, please visit the APA Web site at www.psych.org or contact the APA toll free at 1.800.357.7924 (within the US or Canada) or 703.907.7300.
<table>
<thead>
<tr>
<th>DATE, HOURS</th>
<th>TITLE OF SESSION</th>
<th># OF HOURS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TOTAL
SATURDAY
8:00 A.M. - NOON
Room 221, Second Level, Morial Convention Center

NEUROPSYCHIATRIC MASQUE RADIES: MEDICAL AND NEUROLOGICAL DISORDERS THAT PRESENT WITH PSYCHIATRIC SYMPTOMS

Academy of Psychosomatic Medicine

Co-Directors:
Jose R. Maldonado, M.D.
Paula Trzepacz, M.D.

8:00 A.M. - NOON
Room 235, Second Level, Morial Convention Center

LOSING A PATIENT TO SUICIDE

Director:
Michael F. Myers, M.D.

Faculty:
Carla Fine, M.S.
Frank R. Campbell, Ph.D., L.C.S.W.

8:00 A.M. - NOON
Room 351, Third Level, Morial Convention Center

EXAMINING PROFESSIONAL BOUNDARIES: WEIGHING RISKS VERSUS OPPORTUNITIES

Director:
Gail E. Robinson, M.D.

Faculty:
Gary R. Schoener, M.A.
Linda M. Jorgenson, J.D., M.A.
Howard E. Book, M.D.

8:00 A.M. - NOON
Room 220, Second Level, Morial Convention Center

MANAGING MALPRACTICE RISK FOR PSYCHIATRISTS: THE BASICS AND BEYOND

Co-Chairs:
Jacqueline M. Melonas, J.D., R.N.
Donna Vanderpool, J.D., M.B.A.

Presenter:
Denita Neal, J.D.

This seminar will be repeated today in the same room at 1:00 p.m.

8:00 A.M. - NOON
Room 342, Third Level, Morial Convention Center

EVIDENCE-BASED PSYCHOTHERAPY FOR CHRONIC MAJOR DEPRESSION

Co-Chairs:
Eric Levander, M.D., M.P.H.
Toshiaki A. Furukawa, M.D., Ph.D.

9:00 A.M. - 10:30 A.M.
Rooms R07-R09, Second Floor, Morial Convention Center

TRANSLATIONAL RESEARCH IN SCHIZOPHRENIA: CHALLENGES AND PROMISES

Director:
Raquel E. Gur, M.D., Ph.D.

Chair:
Sukriti Mittal, M.D.

BIO

Raquel E. Gur, M.D. Ph.D., is professor of psychiatry, neurology and radiology at the University of Pennsylvania in Philadelphia. Her academic career has been devoted to the study of brain function in schizophrenia. Dr. Gur has directed the Neuropsychiatry Section and the Schizophrenia Research Center and has established an interdisciplinary program dedicated to advancing the understanding of the pathophysiology of this complex disorder through the application of diverse strategies, from neurobehavioral to molecular. The research has been supported by NIMH, including a Mental Health Clinical Research Center, a MERIT Award, a Senior Scientist Award, a Conte Center for Neuroscience of Mental Disorders, and a training grant. Over the years, the research findings have been presented in professional meetings and published in leading scientific journals. This work has been carried out in large and well-characterized samples of research participants, with commitment to advancing knowledge while meeting patient care needs.

9:00 A.M. - 10:30 A.M.
Room 237, Second Level, Morial Convention Center

MANAGEMENT OF THE SUICIDAL OUTPATIENT: BEYOND THE CONTRACT FOR SAFETY

Chair:
Jeanne Goodman, M.D.

Presenters:
Barbara H. Stanley, Ph.D.
Mark J. Petrini, M.D., Ph.D.

9:00 A.M. - 10:30 A.M.
Room 333, Third Level, Morial Convention Center

THE DEADLY YEARS: PREVENTING SUICIDE IN ASIAN-AMERICAN COLLEGE STUDENTS

Caucus of Asian-American Psychiatrists
Co-Chairs: Russell F. Lim, M.D. Velandy Manohar, M.D.

Presenters: Dan Tzuan, M.D. Aradhana Sood, M.D., M.H.Sc. Kristine A. Girard, M.D. Jack Yen, M.D.

WORKSHOP 3
9:00 A.M.-10:30 A.M.
Room 334, Third Level, Morial Convention Center

A MEDICINAL CANNABIS UPDATE FOR 2010: USE, ABUSE, NEW RESEARCH, NEW FORENSIC AND NEW POLITICAL REALITIES
For APA Members Only

Chair: Lawrence K. Richards, M.D.

Presenters: Ronald Abramson, M.D. David G. Ostrow, M.D., Ph.D. John H. Halpern, M.D. Jahan Marcu

WORKSHOP 4
9:00 A.M.-10:30 A.M.
Room 336, Third Level, Morial Convention Center

UNCONSCIOUS PROJECTIONS: THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chair: Steven E. Pflanz, M.D.

WORKSHOP 5
9:00 A.M.-10:30 A.M.
Room 337, Third Level, Morial Convention Center

PSYCHIATRIC CARE AT THE END OF LIFE

Chair: Jonathan T. Stewart, M.D.

WORKSHOP 6
9:00 A.M.-10:30 A.M.
Room 338, Third Level, Morial Convention Center

ENHANCING RISK-ASSESSMENT ACROSS SERVICES IN MENTAL HEALTH

Chair: Amresh Shrivastava, M.D., D.P.M.

Presenter: Megan Johnston, M.A.

WORKSHOP 7
9:00 A.M.-10:30 A.M.
Room 340, Third Level, Morial Convention Center

THE “NEGATIVE OUTCOME” IN PSYCHOTHERAPY: WHO IS RESPONSIBLE AND HOW?

Chair: Janet L. Lewis, M.D.

WORKSHOP 8
9:00 A.M.-10:30 A.M.
Room 341, Third Level, Morial Convention Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chair: Judith S. Beck, Ph.D.

WORKSHOP 9
9:00 A.M.-10:30 A.M.
Room 342, Third Level, Morial Convention Center

THE IMG JOURNEY: SNAPSHOTs ACROSS THE PROFESSIONAL LIFESPAN

Co-Chairs: Vishal Madaan, M.D., M.B.B.S. Durga Bestha, M.B.B.S.

Presenters: Renato D. Alarcon, M.D. Shamala Jeevarakshagan, M.D., B.S.

WORKSHOP 10
9:00 A.M.-10:30 A.M.
Room 343, Third Level, Morial Convention Center

A DISCUSSION ABOUT WEIGHT GAIN DURING MEDICATION TREATMENT FOR SCHIZOPHRENIA: HOW MUCH AND WHAT TO DO ABOUT IT

Chair: Peter F. Buckley, M.D.

Presenter: Peter F. Buckley, M.D.

WORKSHOP 11
9:00 A.M.-10:30 A.M.
Room 344, Third Level, Morial Convention Center

A PROGRAM OF PSYCHOTHERAPY FOR COMBATANTS’ DEPENDENTS—THE EFFECT ON RECALL RATES: “THEY ARE NOT GOING FOR THREE WEEKS AND THE FIGHTING HAS BEGUN”

Chair: Michael Jan Wise, M.B.B.S., M.S.C.

Presenter: Inge Wise

WORKSHOP 12
9:00 A.M.-10:30 A.M.
Room 350, Third Level, Morial Convention Center

NEW APA PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Co-Chairs: Joel Yager, M.D. Alan J. Gelenberg, M.D.

Presenter: Laura J. Fochtmann, M.D.
6. APA/APIRE PTSD Performance in Practice Tools
   Farifeth F. Duffy, Ph.D.
   Thomas Craig, M.D.
   Eve K. Moscicki, Sc.D., M.P.H.
   Joyce C. West, Ph.D., M.P.P.
   Laura J. Fochtman, M.D.

   SYMPOSIUM 2
   9:00 A.M.-NOON
   Room 218, Second Level, Morial Convention Center

   RECENT RESEARCH ON EATING DISORDERS
   Co-Chairs:
   James E. Mitchell, M.D.
   Walter Kaye, M.D.

   1. Recent Findings in the Longitudinal Assessment of Bariatric Surgery (LABS) Study
      James E. Mitchell, M.D.

   2. Neurocircuitry of Anorexia Nervosa
      Walter Kaye, M.D.

   3. Bariatric Surgery in Adolescents: Clinical Characteristics and Eating Behavior
      Michael J. Devlin, M.D.

   4. Stress Response to Food Portion Size in Anorexia Nervosa
      Katherine A. Halmi, M.D.

   SYMPOSIUM 3
   9:00 A.M.-NOON
   Room 223, Second Level, Morial Convention Center

   SMOKING AND PSYCHIATRIC DISORDERS: CLUES ABOUT CAUSAL PATHWAYS AND INNOVATIVE TREATMENT APPROACHES National Institute on Drug Abuse
   Co-Chairs:
   Jeffrey D. Schulden, M.D.
   Wilson M. Compton III, M.D.

   1. Psychiatric Disorders as Signals of Sensitivity for Nicotine Dependence
      Lisa Dierker, Ph.D.
      Jennifer Rose, Ph.D.
      Robin Mermelstein, Ph.D.

   2. Nicotine Receptors and Their Genes in Psychosis
      Robert Freedman, M.D.

   3. Integrating Tobacco Dependence Treatment Into Mental Health and Addiction Treatment

   SYMPOSIUM 4
   9:00 A.M.-NOON
   Room 224, Second Level, Morial Convention Center

   SHARED DECISION MAKING IN MENTAL HEALTH CARE: A RECOVERY AND PERSON-CENTERED APPROACH
   Co-Chairs:
   Celia E. Wills, Ph.D.
   Kenneth S. Thompson, M.D.

   1. Shared Decision-Making in Mental Health Care
      Melody J. Riefer, M.S.W.

   2. Supporting Consumers’ Recovery Through Joint Consumer and Clinician Use of Shared Decision-Making Tools
      James Schuster, M.D., M.B.A.

   3. Shared Decision-Making: Making Recovery Real in Mental Health
      Laurie C. Curtis, M.A.

   SYMPOSIUM 5
   9:00 A.M.-NOON
   Room 239, Second Level, Morial Convention Center

   NEW DEVELOPMENTS IN INTERPERSONAL PSYCHOTHERAPY (IPT)
   Chair:
   John C. Markowitz, M.D.

   1. Interpersonal Psychotherapy: A Three-Session Evaluation, Support and Triage (IPT-EST)
      Helena Verdela, M.D.

   2. Interpersonal Psychotherapy for Depressed Women Undergoing Fertility Treatment: A Randomized Controlled Trial
      Diana Koszycki, Ph.D.
      Jean-Claude Bisserbe, M.D.
      Pierre Blier, M.D.
      Jacques Bradwejn, M.D.
      John C. Markowitz, M.D.

   3. Interpersonal Psychotherapy for Patients With Chronic Posttraumatic Stress Disorder (IPT-PTSD)
      John C. Markowitz, M.D.
      Barbara Mirolod, M.D.
      Kathryn Bleiberg, Ph.D.
      Randall D. Marshall, M.D.

   SYMPOSIUM 6
   9:00 A.M.-11:00 A.M.
   Room R01, Second Level, Morial Convention Center

   UPDATE ON TREATMENTS FOR CHILD AND ADOLESCENT EATING DISORDERS
   Chair:
   James Lock, M.D., Ph.D.

   1. Family-Based Treatment for Child and Adolescent Eating Disorders
      Daniel le Grange, Ph.D.

   2. Adolescent Focused Individual Therapy for Anorexia Nervosa
      James Lock, M.D., Ph.D.

   3. Cognitive Remediation Therapy for Adolescent Anorexia Nervosa
      Kathleen K. Fitzpatrick, Ph.D.

   SYMPOSIUM 7
   9:00 A.M.-NOON
   Room 338, Third Level, Morial Convention Center

   NEURODEVELOPMENTAL DISORDERS IN DSM-5: AN UPDATE FROM THE WORK GROUP
   Chair:
   Susan E. Swedo, M.D.

   1. The Neurodevelopmental Disorders in DSM-5: What’s Changed? What’s Staying the Same?
      Susan E. Swedo, M.D.

   2. DSM-5 and the Core Features of Autism Spectrum Disorders
      Catherine Lord, Ph.D.
      Eva Petkova, Ph.D.
      So Hyun Kim, M.A.
      Sanghan Lee, Ph.D.
3. Intellectual Disability in DSM-5
Walter E. Kaufmann, M.D.
Bryan H. King, M.D., Ph.D.
Sally J. Rogers, Ph.D.

4. Sex Differences in Autism Spectrum Disorder; Risk Factors, Changes Over Time, Early Signs and Core Autism Symptoms
Poul Thorsen, M.D., Ph.D.

5. The Autism Spectrum: How Deep and How Wide?
Bryan H. King, M.D., Ph.D.

SYMPOSIA

SYMPOSIUM 8
9:00 A.M.-NOON
Room 339, Third Level, Morial Convention Center

AGGRESSIVE BEHAVIORS IN GEROPSychiatric Patients: NEuroBiology, ASSESSment and MANAGEMENT
American Association for Geriatric Psychiatry
Chair:
Helen H. Kyomen, M.D., M.S.
Discussant:
Mark E. Kunik, M.D., M.P.H.

1. The Neurobiology of Aggression
Randy J. Nelson, Ph.D.

2. Non-Pharmacologic Assessment and Management of Aggressive Behaviors in Geropsychiatric Patients
Patricia A. Arean, Ph.D.
Liat Ayalon, Ph.D.
Leilani Feliciano, Ph.D.

3. Pharmacologic/Somatic Assessment and Management of Aggressive Behaviors in Geropsychiatric Patients
Helen H. Kyomen, M.D., M.S.

SYMPOSIUM 9
9:00 A.M.-NOON
Rooms 343-345, Third Level, Morial Convention Center

ADVANCES IN THE MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION
Co-Chairs:
Charles B. Nemeroff, M.D., Ph.D.
Michael E. Thase, M.D.

1. The Neurobiology of Depression: Implications for Treatment-Resistant Depression and Personalized Medicine in Psychiatry
Charles B. Nemeroff, M.D., Ph.D.

2. Unmet Needs in the Treatment of Depression
Michael E. Thase, M.D.

3. Augmentation and Combination Strategies in Treatment-Resistant Depression
Linda L. Carpenter, M.D.

4. Management of Comorbid Depression and Substance Abuse
Ihsan M. Salloum, M.D., M.P.H.

SYMPOSIUM 10
9:00 A.M.-NOON
Room 353, Third Level, Morial Convention Center

CLINICAL TRENDS IN BIPOLAR DISORDERS
APA and the International Society of Bipolar Disorder
Co-Chairs:
Flavio Kapczinski, M.D.
Benicio Frey, M.D.

1. The International Society of Bipolar Disorders (ISBD) Task Force on the Nomenclature of Course and Outcome in Bipolar Disorders
Mauricio Tohen, M.D.

2. Evidence-Based Treatment Guidelines for Bipolar Disorder
Lakshmi Yatham, M.B.B.S.

3. The Use of Biomarkers in Bipolar Disorder
Flavio Kapczinski, M.D.

4. Redox Biology and Glutathione: From Pathophysiology to Novel Treatments in Bipolar Disorder
Michael Berk, M.D.

5. Women’s Issues in Bipolar Disorder
Aysegul Ozerdem, M.D.

SYMPOSIUM 11
9:00 A.M.-NOON
Room 354, Third Level, Morial Convention Center

CULTURALLY SENSITIVE ASSESSMENT OF PSYCHOLOGICALLY DISTRESSED ETHNIC AND NON-ENGLISH SPEAKING POPULATIONS
Co-Chairs:
Devon Hinton, M.D., Ph.D.
Roberto Lewis-Fernández, M.D.

1. Change in Culturally Specific Complaints and PTSD Severity Across Initial Treatment: Results of a Psychiatric Clinic Survey of Cambodian Refugee Patients
Devon Hinton, M.D., Ph.D.
Mark H. Pollack, M.D.

2. Culturally Sensitive Care for Older Adults: A Critical Examination of the DSM-IV Cultural Formulation
Ladson Hinton, M.D.

3. Cultural Sensitivity and External Validity of Mental Health and Psychosocial Assessments for Child Soldiers in Nepal
Brandon A. Kohrt, M.D., Ph.D.

4. Dissociation, Traumatic Exposure, and Self-Reported Psychotic Symptoms in U.S. Latinos
Roberto Lewis-Fernández, M.D.

5. Assessing Family Conflict in West African Immigrant Families
Andrew Rasmussen, Ph.D.
Adeyinka Akinsulure-Smith, Ph.D.
Tracy Chu, Ph.D.

SYMPOSIUM 12
9:00 A.M.-NOON
Room 355, Third Level, Morial Convention Center

ANXIETY TREATMENT: NEW RESEARCH FINDINGS FOR THE CLINICIAN
Co-Chairs:
Peter Roy-Byrne, M.D.
Murray B. Stein, M.D., M.P.H.

1. Acute Treatment for Chronic PTSD: Prolonged Exposure Versus Sertraline
Norah C. Feeny, Ph.D.

2. Social Anxiety Pharmacotherapy Improvement (SAPIENT): Response to Initial SSRI Treatment
Murray B. Stein, M.D., M.P.H.
3. DCS: A Novel Pharmacological Strategy to Enhance CBT for Anxiety
Mark H. Pollack, M.D.

4. CALM: Improving Primary Care Anxiety Outcomes
Peter Roy-Byrne, M.D.

SYMPOSIUM 13
9:00 A.M.-NOON
Rooms 356/357, Third Level, Morial Convention Center

FAMILY AND BEHAVIORAL GENETIC STUDIES OF BORDERLINE PERSONALITY DISORDER

Chair:
Joel Paris, M.D.

Discussant:
John M. Oldham, M.D., M.S.

1. Behavioral Genetics of Borderline Personality Disorder
Ted Reichborn-Kjenerud, M.D.
Steven H. Aggen, Ph.D.
Nikolai Czajkowski, M.A., M.S.
Kristian Tambs, Ph.D.
Esben Rysaamb, Ph.D.
Ragnhild E. Ørstavik, M.D.
Michael C. Neale, Ph.D.
Svenn Torgersen, Ph.D.
Kenneth S. Kendler, M.D.

2. Childhood Adversity Associated With Adolescent-Onset Borderline Personality Disorder
Mary C. Zanarini, Ed.D.
Marianne S. Goodman, M.D.

3. Outcome in Women Diagnosed With Borderline Personality Disorder in Adolescence
Robert Biskin, M.D., B.S.
Joel Paris, M.D.
Joanne Renaud, M.D.
Amir Kaz, Ph.D.
Phyllis Zelkowitz, Ed.D.

4. Trauma and Psychopathology in Patients With Borderline Personality Disorder and Their Sisters
Joel Paris, M.D.
Lise Laporte, Ph.D.
Herta Guttman, M.D.

5. Vulnerability to Depressive Symptoms Among Children of Parents With Major Depressive Disorder With or Without Comorbid Borderline Personality Disorder
John Abela, Ph.D., B.A.
Philippe Adams
Warren Lewin

COUPLES 4-7

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

Course 4:
9:00 A.M.-4:00 P.M.
Rooms 231/232, Second Level, Morial Convention Center

AN OVERVIEW OF SLEEP MEDICINE FOR THE MENTAL HEALTH PROVIDER

Co-Directors:
R. Robert Auger, M.D.
Thomas D. Hurwitz, M.D.

Faculty:
Elliott K. Lee, M.D.
Max Hirshkowitz, Ph.D.

Course 5:
9:00 A.M.-4:00 P.M.
Room 238, Second Level, Morial Convention Center

A PRACTICAL APPROACH TO RISK ASSESSMENT

Director:
William H. Campbell, M.D., M.B.A.

Course 6:
9:00 A.M.-4:00 P.M.
Room R06, Second Level, Morial Convention Center

CHILD AND ADOLESCENT PSYCHIATRY FOR THE GENERAL PSYCHIATRIST

Co-Directors:
Robert L. Hendren, D.O.
Malia McCarthy, M.D.

Course 7:
9:00 A.M.-4:00 P.M.
Room 352, Third Level, Morial Convention Center

COMPLEMENTARY AND INTEGRATIVE TREATMENTS FOR STRESS, DEPRESSION, ANXIETY, PTSD, MASS TRAUMA, COGNITIVE FUNCTION, ADD, AND SCHIZOPHRENIA

Co-Directors:
Patricia L. Gerbarg, M.D.
Richard P. Brown, M.D.

Faculty:
Monica Vermani, M.A., Psy.D.
Martin Katzman, M.D.

MASTER COURSE 1-2
MASTER COURSE 1
9:00 A.M.-4:00 P.M.
Rooms R02/R03, Second Level, Morial Convention Center

UPDATE ON PEDIATRIC PSYCHOPHARMACOLOGY

Director:
Christopher J. Kratochvil, M.D.

Faculty:
John T. Walkup, M.D.
Christopher J. McDougle, M.D.
Karen D. Wagner, M.D., Ph.D.

MASTER COURSE 2
9:00 A.M.-4:00 P.M.
Rooms R04/R05, Second Level, Morial Convention Center

ESSENTIAL PSYCHOPHARMACOLOGY

Co-Directors:
Alan F. Schatzberg, M.D.
Ira Glick, M.D.

Faculty:
Kiki Chang, M.D.
Terence A. Ketter, M.D.
Natalie L. Rasgon, M.D., Ph.D.
Charles DeBattista, M.D.

10:00 A.M.-4:00 P.M.

APA Member Center and Publishers’ Book Fair Are Open.

Exhibit Halls B-D, First Level, Morial Convention Center

11:00 A.M.-SECTIONS LECTURES
LECTURE 2
11:00 A.M.-12:30 P.M.
Rooms R07-R09, Second Floor, Morial Convention Center

THE FUTURE OF DEPRESSION RESEARCH
International Lecture

Florian Holsboer, M.D.

Chair:
Madhukar Trivedi, M.D.
BIO

Florian Holsboer, M.D. was born in Munich, Germany, and studied chemistry and medicine at the University of Munich, where he completed his residency in psychiatry. His areas of study include: affective disorders, depression, anxiety, central regulation of stress hormones, sleep physiology, molecular and clinical psychopharmacology, pharmacogenetics and personalized medicine. In 1989 Professor Holsboer became director of the Max Planck Institute for Psychiatry. The institute is a research center for disorders of the central nervous system. Research is conducted by 28 research groups in a broad range of areas: molecular biology, pharmacology, human and mouse genetics, proteomics and chemical genomics. With his extensive knowledge and research of mental health issues, he will give attendees an overview of how current research trends are shaping the future of mental health research.

WORKSHOP 15
11:00 A.M.-12:30 P.M.
Room 334, Third Level, Morial Convention Center


Co-Chairs:
Darnir Huremovic, M.D., M.P.P.
Shabneet Hira-Brar, M.D.

Presenters:
Jacob E. Sperber, M.D.
Sameh Dwaikat, M.D.
Reena Trivedi, M.D.

WORKSHOP 16
11:00 A.M.-12:30 P.M.
Room 336, Third Level, Morial Convention Center

TELEPSYCHIATRY EDUCATION: TEACHING TO THE NEAR AND FAR ENDS

Chair:
John S. Teshima, M.D., M.Ed.

WORKSHOP 17
11:00 A.M.-12:30 P.M.
Room 337, Third Level, Morial Convention Center

PREPARING INTERNATIONAL MEDICAL GRADUATE PSYCHIATRY RESIDENTS FOR A CAREER IN ACADEMIC PSYCHIATRY APA/GlaxoSmithKline Fellows

Co-Chairs:
Sosunmolu O. Shoyinka, M.B.B.S.
Oladipo Kukoyi, M.D., M.S.

Presenters:
Richard Balon, M.D.
Charles C. Dike, M.D., M.P.H.
Milton Kramer, M.D.
Ezra E. Griffith, M.D.
Nalini V. Juthani, M.D.
Paulo Shiroma, M.D.

WORKSHOP 18
11:00 A.M.-12:30 P.M.
Room 340, Third Level, Morial Convention Center

IS THAT AN UNCONSCIOUS FANTASY OR A CORE BELIEF? A RESIDENT’S PERSPECTIVE ON LEARNING MULTIPLE THERAPIES SIMULTANEOUSLY

Co-Chairs:
Emily Gastelum, M.D.
Aerin Hyun, M.D., Ph.D.

Presenters:
Donna M. Sudak, M.D.
David Goldberg, M.D.
Deborah Cabaniss, M.D.
Barbara H. Stanley, Ph.D.
## Workshop 23
11:00 A.M. - 12:30 P.M.
Room 349, Third Level, Morial Convention Center

### Oral Boards Boot Camp 2010: Focus on Diagnostic Interviewing

**Co-Chairs:**
Elyse D. Weiner, M.D.
Eric D. Peselow, M.D.

**Faculty:**
Mario F. Mendez, M.D., Ph.D.

**Time:**
1:00 P.M. - 5:00 P.M.
Room 351, Third Level, Morial Convention Center

### Neuroanatomy of Behavior: An Introduction

**Co-Directors:**
David L. Clark, Ph.D.
Nash N. Boutros, M.D.

**Faculty:**
Hanna Levenson, Ph.D.

**Time:**
1:00 P.M. - 5:00 P.M.
Room 351, Third Level, Morial Convention Center

### Workshop 24
11:00 A.M. - 12:30 P.M.
Room 350, Third Level, Morial Convention Center

### The Behavioral Health Action Network: Reorganizing the Behavioral Health Delivery System in Post-Katrina New Orleans

**Chair:**
Elmore F. Rigamer, M.D., M.P.A.

**Presenters:**
Candace A. Cutrone, M.D.
Craig J. Coenson, M.D.
Sarah Hoffpauir, L.C.S.W.
Jose Calderon-Abbo, M.D.

**Time:**
1:00 P.M. - 1:30 P.M.
Room 220, Second Level, Morial Convention Center

### Course 9
1:00 P.M. - 5:00 P.M.
Room 235, Second Level, Morial Convention Center

### Seminar 3
1:00 P.M. - 5:00 P.M.
Room 220, Second Level, Morial Convention Center

### Seminar 4
1:00 P.M. - 5:00 P.M.
Room 342, Third Level, Morial Convention Center

### Course 8
1:00 P.M. - 5:00 P.M.
Room 221, Second Level, Morial Convention Center

### Brain Stimulation Therapies in Psychiatry

**Director:**
Ziad H. Nahas, M.D.

**Faculty:**
Linda L. Carpenter, M.D.
Darin D. Dougherty, M.D.
Husain Mustafa, M.D.

**Time:**
1:00 P.M. - 1:30 P.M.
Room 334, Third Level, Morial Convention Center

### Workshops 25-32
1:30 P.M. - 3:00 P.M.
Room 334, Third Level, Morial Convention Center

### Workshop 25
1:30 P.M. - 3:00 P.M.
Room 334, Third Level, Morial Convention Center

**Co-Chairs:**
Soonjo Hwang, M.D.
Mathew Brams, M.D.

### Bridging the Cultural Divide: Challenges of First-Generation Immigrants With Children With Mental Illness

**Co-Chairs:**
Timothy C. Liu, M.D.
Steve Koh, M.D., M.P.H.

**Presenters:**
Arshad Husain, M.D.
David S. Rue, M.D.
Kiet T.V. Truong, M.D.
Ranj An Astha, M.D.

**Time:**
1:00 P.M. - 1:30 P.M.
Room 334, Third Level, Morial Convention Center

### Evaluation and Management of Patients with Excessive Daytime Sleepiness in Psychiatric Practice

**Chair:**
Dimitri D. Markov, M.D.

**Presenters:**
Karl Doghramji, M.D.
Nidhi Tewari, M.D.

**Time:**
1:00 P.M. - 1:30 P.M.
Room 334, Third Level, Morial Convention Center

### Vulnerability and Resilience: Katrina’s Widespread Impact on First Responders, Clinicians, Youth and Relocated Survivors

**Chair:**
Scott D. Haltzman, M.D.

**Time:**
1:00 P.M. - 1:30 P.M.
Room 334, Third Level, Morial Convention Center

---

**Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C. First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.**
Co-Chairs:  
Phebe M. Tucker, M.D.  
Howard J. Osofsky, M.D., Ph.D.

Presenter:  
Joy D. Osofsky, Ph.D.

WORKSHOP 29  
1:30 P.M.-3:00 P.M.  
Room 337, Third Level,  
Morial Convention Center

WHEN ADULTS  
WITH PERVERSIVE  
DEVELOPMENTAL DISORDERS  
PRESENT IN A COMMUNITY  
MENTAL HEALTH SETTING  
American Association of Community Psychiatrists

Chair:  
Ann L. Hackman, M.D.

Presenters:  
Theodora G. Balis, M.D.  
Curtis N. Adams, Jr., M.D.  
Steven E. Hutchens, M.D.

WORKSHOP 30  
1:30 P.M.-3:00 P.M.  
Room 340, Third Level,  
Morial Convention Center

FROM OUTREACH TO  
ASSERTIVE COMMUNITY  
TREATMENT: TRANSFERRING  
RESEARCH TO PRACTICE  
in COMPREHENSIVE CARE  
FOR UNSERVED  
PEOPLE LIVING WITH  
HIV/AIDS

Chair:  
Gary Morse, Ph.D.

Presenters:  
John Winn, L.C.S.W.  
Maurice Redden, M.D.  
Sheila Jackson

WORKSHOP 31  
1:30 P.M.-3:00 P.M.  
Room 341, Third Level,  
Morial Convention Center

SEXUAL MINORITY YOUTH:  
CLINICAL COMPETENCIES  
AND TRAINING NEEDS FOR  
THE 21ST CENTURY  
American Academy of Child &  
Adolescent Psychiatry

Chair:  
Scott Leibowitz, M.D.

Presenters:  
Edgardo J. Menvielle, M.D., M.S.  
Joel Stoddard, M.D.

WORKSHOP 32  
Withdrawn

2:00 P.M. SESSIONS  
PRESIDENTIAL SYMPOSIUM 1  
2:00 P.M.-5:00 P.M.  
Rooms R07-R09, Second Floor,  
Morial Convention Center

THE EMERGING  
NEUROBIOLOGY OF  
ANTIDEPRESSANT  
TREATMENT RESPONSE  
Co-Chairs:  
Katharina Domschke, M.D., M.A.  
Yvette Sheline, M.D.

1. Connectivity of the Subgenual  
Cortex and HPA Axis in Depression  
Alan F. Schatzberg, M.D.

2. Prediction of Antidepressant  
Treatment Response:  
A Pharmacological and Imaging  
Genetic Contribution  
Katharina Domschke, M.D.

3. The Role of the Default  
Mode Network (DMN) in Understanding Emotional  
Circuitry in MDD Pre- and Post-Antidepressant  
Treatment  
Yvette Sheline, M.D.

4. Resetting Chemical  
Dysbalance to Modulating Networks: Lessons on the  
Neurobiology of Treatment-Resistant Depression From  
Deep Brain Stimulation  
Thomas Schlaeperf, M.D.

SYMPOSIUM 14  
2:00 P.M.-4:00 P.M.  
Room 210, Second Level,  
Morial Convention Center

EXAMINING THE OUTCOME  
CONTINUUM OF  
SCHIZOPHRENIA  
INTO LATER LIFE  
Co-Chairs:  
Carl I. Cohen, M.D.  
Sukriti Mittal, M.D.

Discussant:  
Kenneth S. Thompson, M.D.

1. Community Integration  
and Associated Factors  
Among Older Adults  
With Schizophrenia  
Chadi Abdallah, M.D.  
Carl I. Cohen, M.D.  
Miguel Sanchez-Almira, M.D.  
Pia Reyes, M.D.  
Paul M. Ramirez, Ph.D.

2. Successful Aging in  
Older Adults With  
Schizophrenia: Prevalence  
and Associated Factors  
Fayaz A. Ibrahim, M.D.  
Carl I. Cohen, M.D.  
Paul M. Ramirez, Ph.D.

3. Clinical Remission and  
Recovery in Schizophrenia  
Carl I. Cohen, M.D.  
Richa Pathak, M.D.  
Paul M. Ramirez, Ph.D.

4. Well-Being and Associated  
Factors: Quality of Life and Subjective Successful Aging  
in Older Persons With  
Schizophrenia  
Sukriti Mittal, M.D.  
A.O. Bankole, M.D.  
Carl I. Cohen, M.D.  
Paul M. Ramirez, Ph.D.

SYMPOSIUM 15  
2:00 P.M.-5:00 P.M.  
Room 218, Second Level,  
Morial Convention Center

SPIRITUALITY AND MENTAL  
HEALTH: WHAT IS THE  
PSYCHIATRIST’S ROLE?  
Chair:  
John R. Peteet, M.D.

1. The Evolving Role of  
Meditation and Other  
Mindfulness Practices  
in Psychotherapy  
William M. Greenberg, M.D.

2. Positive Emotions:  
Psychiatry’s Great Blind Spot  
George E. Vaillant, M.D.

3. Introducing Spirituality  
Into Psychiatric Education  
and Care  
Marc Galanter, M.D.

4. Spiritual Aspects of the  
Treatment of Personality  
Disorders  
C. Robert Cloninger, M.D.

5. Spiritual Healing:  
The Psychiatrist as a  
Facilitator of Integration  
Nadine J. Nyhus, M.D., M.A.

SYMPOSIUM 16  
2:00 P.M.-5:00 P.M.  
Room 223, Second Level,  
Morial Convention Center

BURN PSYCHIATRY:  
TREATMENT AND OUTCOMES  
Chair:  
Frederick J. Stoddard, M.D.
1. Trauma and Grief After the Coconut Grove and Station Nightclub Fires, 1942 and 2003
Frederick J. Stoddard, M.D.

2. Psychopharmacology of Neuropsychiatric Disorders in Burn Patients
Shamim H. Nejad, M.D.

3. An Intervention to Reduce Stress in 0- to 5-Year Olds With Burns
Eriska Sorrentino, M.A.
Frederick J. Stoddard, M.D.
Michael D. Jibson, M.D., Ph.D.
Glenn Saxe, M.D.
Gwyne White, B.A.
Taya Zbell, LICSW
Teresa Doyne, R.N.
Katia Canenguez, Ed.M.
Jenny K.M. Man, B.S.
Gwyne White, B.A.
Glenn Saxe, M.D.
David Chedekel, Ed.D.
J. Michael Murphy, Ed.D.
Frederick J. Stoddard, M.D.
Erica Sorrentino, M.A.

4. Pain Management During Acute Burn Treatment in Children: A Multicenter Study and Psychosocial Outcome Analysis
Tolga A. Ceranoglu, M.D.
Frederick J. Stoddard, M.D.
Michael D. Jibson, M.D.
Gwyne White, B.A.
Erica Sorrentino, M.A.

SYMPOSIUM 17
2:00 P.M.-5:00 P.M.
Room 224, Second Level, Morial Convention Center

UPDATE ON INTERVENTIONS FOR ADULT EATING DISORDERS
Chair: James Lock, M.D., Ph.D.

1. Stepped Care Versus Best-Available Treatment for Patients With Bulimia Nervosa
James Mitchell, M.D.

2. Dialectical Behavior Therapy for Bulimia Nervosa and Binge Eating Disorder
Debra L. Safer, M.D.

3. Cognitive Remediation Therapy for Adults With Anorexia Nervosa
James Lock, M.D., Ph.D.

4. How to Prevent Eating Disorders
Craig B. Taylor, M.D.

SYMPOSIUM 18
2:00 P.M.-5:00 P.M.
Room 239, Second Level, Morial Convention Center

TRANSLATING THE PSYCHOPHARMACOLOGY EVIDENCE BASE INTO PRACTICE: A SAMPLER FROM THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY
Co-Chairs: Michael D. Jibson, M.D., Ph.D. Ira Glick, M.D.

1. Quality of Care in Psychopharmacology: Doing an Actual Visit
John M. Kane, M.D.

2. Combination Therapy: Psychopharmacology and Psychotherapy
Ira Glick, M.D.

3. Focus on a Specific Patient Group: Geriatric Patients
James M. Ellison, M.D., M.P.H.

4. An Ethical Framework for Clinician/Industry Interactions
Michael D. Jibson, M.D., Ph.D.

SYMPOSIUM 19
2:00 P.M.-5:00 P.M.
Room R01, Second Level, Morial Convention Center

PATHOPHYSIOLOGY OF PSYCHOTIC AND MOOD DISORDERS: DO WE HAVE ANY SOLID EVIDENCE OF INTEREST TO CLINICIANS?
Chair: Mario Maj, M.D., Ph.D.

1. What Do We Know for Sure About the Pathophysiology of Schizophrenia?
Stephen M. Lawrie, M.D.

2. Clinically Relevant Neurobiological Findings in Depression
Gregor Hasler, M.D.

3. What Do We Know About the Causes of Bipolar Disorders?
Stephen M. Strakowski, M.D.

4. Shared and Distinct Neurogenetic Mechanisms for Schizophrenia and Bipolar Disorder
Andreas Meyer-Lindenberg, M.D.

SYMPOSIUM 20
2:00 P.M.-5:00 P.M.
Room 338, Third Level, Morial Convention Center

UPDATING THE APA GUIDELINES FOR THE TREATMENT OF BORDERLINE PERSONALITY DISORDER
Association for Research in Personality Disorders
Chair: James H. Reich, M.D., M.P.H.

Discussant: Donald W. Black, M.D.

1. Updating the APA Guidelines for the Treatment of Borderline Personality Disorder: Neurobiology and Genetics of Borderline Personality Pathology
Simone S. Kool, M.D., Ph.D. Moniek Thunnissen, M.D., Ph.D.

2. Emergency Management of Suicidal Crises in Patients With Borderline Personality Disorder
Paul S. Links, M.D. Yvonne Bergmans, M.S.W., R.S.W.

3. Approaches to Prioritizing Treatment of Borderline Personality Disorder in the Presence of Other Significant Axis I and Axis II Disorders
James H. Reich, M.D., M.P.H.

4. New Considerations in the Pharmacologic Treatment of Borderline Personality Disorder
Kenneth R. Silk, M.D.

5. Psychotherapy for Borderline Personality Disorder
John Livesley, M.D.

SYMPOSIUM 21
2:00 P.M.-5:00 P.M.
Room 339, Third Level, Morial Convention Center

HOW TO GET THE CORNER OFFICE: PRACTICAL LEADERSHIP STRATEGIES FOR WOMEN PSYCHIATRISTS
Association of Women Psychiatrists
Chair: Tana A. Grady-Weliky, M.D.

1. Thriving—Not Just Surviving—as a Clinical Researcher
Eva Szeghy, M.D., Ph.D.

2. Ditching the Corner Office to Address Global Health
Mary Kay Smith, M.D.

**SYMPOSIUM 22**
2:00 P.M.–5:00 P.M.
Rooms 343-345, Third Level, Morial Convention Center

**CULTURE AND PSYCHIATRIC DIAGNOSIS: IMPLICATIONS FOR THE INTERNATIONAL IMPACT OF DSM-5**

Chair:
Renato D. Alarçon, M.D.

1. Cultural Perspectives on the Current DSM-5 Work
Renato D. Alarçon, M.D.

2. The Outline for Cultural Formulation: Current Status and DSM-5 Revision
Roberto Lewis-Fernández, M.D.

3. Cultural Syndromes Around the World and in DSM-5: Why and How Should They Be Included?
Joseph Westermeyer, M.D., Ph.D.

**SYMPOSIUM 23**
2:00 P.M.–5:00 P.M.
Room 346, Third Level, Morial Convention Center

**RECENT CHANGES TO ACUTE PSYCHIATRIC CARE: AN INTERNATIONAL PERSPECTIVE**

Co-Chairs:
Julian Beezhold, M.D.
Abigail L. Donovan, M.D.

1. Coercive Measures in Acute Psychiatric Care: An Italian Perspective
Andrea Fiorillo, M.D., Ph.D.

2. Recent Changes in Acute Psychiatric Care: A Romanian Perspective
Adriana A. Mihai, M.D., Ph.D.

**SYMPOSIUM 24**
2:00 P.M.–5:00 P.M.
Room 347, Third Level, Morial Convention Center

**PREVENTION OF PTSD: RECENT ISRAELI PRACTICES**

Co-Chairs:
Haim Y. Knobler, M.D., M.A.
Yoram Barak, M.D., M.H.A.

1. The IDF PTSD Prevention Program for Combat Medical Teams
Yoram Barak, M.D., M.H.A.

2. Follow-Up of an Acutely Traumatized Reserve Unit for the Prevention of Combat PTSD
Nathanial Laor, M.D., Ph.D.
Yoram Ben Yehuda, M.A.
Leo Wolmer, M.A.
Yoram Barak, M.D., M.H.A.
Haim Y. Knobler, M.D., M.A.

3. Chronic Follow-Up of Traumatized Reserve Units for Prevention and Treatment of Combat PTSD
Haim Y. Knobler, M.D., M.A.

**SYMPOSIUM 25**
2:00 P.M.–5:00 P.M.
Room 349, Third Level, Morial Convention Center

**PSYCHIATRY ACROSS BORDERS: WORKING FOR THE U.S. GOVERNMENT IN THE DEPARTMENT OF STATE AS A PSYCHIATRIST**

Chairperson:
Herbert L. Campbell, M.D., M.P.H.

3. Acute Psychiatric Care in Turkey
Defne Eraslan, M.D.
Aytul Karabekiroglu, M.D.
Ozgur Ozturk, M.D.

4. Acute Psychiatric Care in the U.S.
Abigail L. Donovan, M.D.

Julian Beezhold, M.D.
Pete Williams
Andy Harris
Jenny Taylor
Sumati Kandasamy, M.D.
James Currie, M.D.

**SYMPOSIUM 26**
2:00 P.M.–5:00 P.M.
Room 350, Third Level, Morial Convention Center

**TRANSCULTURAL PSYCHIATRY FOR MENTAL HEALTH IN A CHANGING WORLD**

Chair:
Richard L. Merkel, M.D., Ph.D.

1. Cultural Psychiatry
Issues in Schizophrenia
Robert Kohn, M.D.

2. Cultural Contexts of Patient and Family Explanations of Suicidal Behavior
Mitchell G. Weiss, M.D., Ph.D.
Shubhangi R. Parkar, M.D.
Arabinda N. Chowdhury, M.D.
Anita Riecher, M.D.

3. Transcultural Psychiatry
John David Kinzie, M.D.

4. Integrating Traditional and Western Mental Health Care
Richard L. Merkel, M.D., Ph.D.

**SYMPOSIUM 27**
2:00 P.M.–5:00 P.M.
Room 353, Third Level, Morial Convention Center

**NON-PYSCHOTIC ISSUES OF SCHIZOPHRENIC PATIENTS**

Chair: S. Charles Schulz, M.D.

1. Cognitive Rehabilitation of Schizophrenia: Treatment and Research
Raquel E. Gur, M.D., Ph.D.
Irene Hurd, M.D.
Ruben C. Gur, Ph.D.

2. Smoking and Schizophrenia: Efficacy of New Treatments
S. Hossein Fatemi, M.D., Ph.D.
Timothy D. Folsom, M.S.
Stephanie Liesch, M.S.
Rachel Kneeland, B.A.

3. Schizophrenia and Substance Abuse
Alan I. Green, M.D.
Mary F. Brunette, M.D.

4. Approaches to Suicide in Schizophrenia
Lawrence Adler, M.D.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMPOSIUM 28</td>
<td>Doping in Athletes: The Role of the Sport Psychiatrist International Society for Sport Psychiatry</td>
<td>2:00 P.M.-5:00 P.M.</td>
<td>Room 354, Third Level, Morial Convention Center</td>
<td>Richard Hilderbrand, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>1. The Ethics in Doping Control</td>
<td>2:00 P.M.</td>
<td>Room 354, Third Level, Morial Convention Center</td>
<td>Eric D. Morse, M.D.</td>
</tr>
<tr>
<td></td>
<td>2. Helping the Athlete Through the Therapeutic Use Exemption Process</td>
<td>3:00 P.M.</td>
<td>Room 354, Third Level, Morial Convention Center</td>
<td>David O. Conant-Norville, M.D. Richard Hilderbrand, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>3. Doping Control in Elite Athletics</td>
<td>4:00 P.M.</td>
<td>Room 354, Third Level, Morial Convention Center</td>
<td>Saul I. Marks, M.D.</td>
</tr>
<tr>
<td>SYMPOSIUM 29</td>
<td>Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction National Institute on Drug Abuse</td>
<td>2:00 P.M.-5:00 P.M.</td>
<td>Room 355, Third Level, Morial Convention Center</td>
<td>Mary A. Kautz, Ph.D. Minda R. Lynch, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>1. Prefrontal Circuits for Rules, Concepts, and Cognitive Control</td>
<td>2:00 P.M.</td>
<td>Room 355, Third Level, Morial Convention Center</td>
<td>Earl K. Miller, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>2. Basic Neurobiology of Self-Control in Decision Making</td>
<td>3:00 P.M.</td>
<td>Room 355, Third Level, Morial Convention Center</td>
<td>Todd Hare, M.D.</td>
</tr>
<tr>
<td></td>
<td>3. Key Circuits and Regions Implicated in Executive Dysfunction and Disruptions of Cognitive Control in Schizophrenia: Genetic Influences and Dopamine Regulation</td>
<td>4:00 P.M.</td>
<td>Room 355, Third Level, Morial Convention Center</td>
<td>Karen Faith Berman, M.D.</td>
</tr>
<tr>
<td></td>
<td>4. Core Cognitive Systems for Controlling Craving and Negative Emotion in Substance Abuse and Psychiatric Disorders</td>
<td>5:00 P.M.</td>
<td>Room 355, Third Level, Morial Convention Center</td>
<td>Kevin N. Ochsner, Ph.D.</td>
</tr>
<tr>
<td>SYMPOSIUM 30</td>
<td>Addiction Research, Prevention and Treatment in the U.S. and France: Vive la Difference! National Institute on Drug Abuse</td>
<td>2:00 P.M.-5:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>John A. Talbott, M.D. Francois C. Petitjean, M.D. Audra F. Miller, M.D.</td>
</tr>
<tr>
<td></td>
<td>1. Progress in Addiction Research</td>
<td>2:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>Nora D. Volkow, M.D.</td>
</tr>
<tr>
<td></td>
<td>2. Patterns of Addiction in High School and University Students</td>
<td>3:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>Marc-Antoine Crocq, M.D. Alexis Boehler, Psy.D.</td>
</tr>
<tr>
<td></td>
<td>3. The FDA and Tobacco Regulation</td>
<td>4:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>Joshua Sharfstein, M.D.</td>
</tr>
<tr>
<td></td>
<td>4. Do Psychiatric Patients Smoke to Self-Medicate, or Is It for Other Reasons?</td>
<td>5:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>Renaud de Beaurepaire, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td>5. The State of Treatment of Addictive Disorders in the United States</td>
<td>2:00 P.M.-5:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>David Oslin, M.D.</td>
</tr>
<tr>
<td></td>
<td>6. Organization and Health Care Networks for Cannabis Treatment in France</td>
<td>3:00 P.M.-5:00 P.M.</td>
<td>Rooms 356/357, Third Level, Morial Convention Center</td>
<td>Amine Benyamina, M.D. Lisa Blecha, M.D. Michel Reynaud, M.D., Ph.D.</td>
</tr>
<tr>
<td>WORKSHOP 33</td>
<td>Making the Most of Your Twenty-Minute Hour: Maximizing the Therapeutic Experience</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 237, Second Level, Morial Convention Center</td>
<td>Frederick G. Guggenheim, M.D. Robert J. Boland, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 34</td>
<td>Patient Suicide During Psychiatry Residency: A Workshop Discussion</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 333, Third Level, Morial Convention Center</td>
<td>Allison S. Baker, M.D. Christina Y. Mangurian, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 35</td>
<td>Withdrawn</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 336, Third Level, Morial Convention Center</td>
<td>Michael D. McGee, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 36</td>
<td>Meditation and Psychiatry</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 337, Third Level, Morial Convention Center</td>
<td>Lewis M. Cohen, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 37</td>
<td>Publishing Books for the General Public</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 340, Third Level, Morial Convention Center</td>
<td>Carl P. Malmquist, M.D. Jeffrey W. King, J.D., LL.M. Wade Myers, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 38</td>
<td>Ethical, Clinical and Legal Challenges Created by Information Technology</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 341, Third Level, Morial Convention Center</td>
<td>Richard G. Guggenheim, M.D.</td>
</tr>
<tr>
<td>WORKSHOP 39</td>
<td>Where Science and Social Justice Meet: The Example of Smoking in Persons With Bipolar Disorder</td>
<td>3:30 P.M.-5:00 P.M.</td>
<td>Room 341, Third Level, Morial Convention Center</td>
<td>Andrew Booty, M.D. Meredith A. Kelly, M.D. Aerin Hyun, M.D., Ph.D. Emily Gastelum, M.D.</td>
</tr>
</tbody>
</table>
Chair: Annette M. Matthews, M.D.

WORKSHOP 4
3:30 P.M. - 5:00 P.M.
Room 348, Third Level,
Morial Convention Center

COGNITIVE-BEHAVIORAL THERAPY: TROUBLESHOOTING COMMON CHALLENGES

Chair: Donna M. Sudak, M.D.

Presenters:
Judith S. Beck, Ph.D.
Jesse H. Wright, M.D., Ph.D.

1. Obstacles and Opportunities in New CNS Drug Development
Kenneth Kaitin, Ph.D.

2. Do Pharmacogenetics Have a Role in Treating Schizophrenia?
Roy H. Perlis, M.D., M.S.C.

3. Switching Antipsychotic Therapy: Lessons for the Clinician
Prakash S. Masand, M.D.

4. Innovative Strategies to Improve Adherence in Schizophrenia
Mehul V. Mankad, M.D.

7:00 P.M. SESSION MEDIA WORKSHOP 1
7:00 P.M. - 10:00 P.M.
Grand Salon B, First Level,
Hilton New Orleans Riverside

Isn’t all Horror Psychological?

Horror film director, George Romero, and Steven Schlozman, M.D., discuss Polanski’s classic film, “Repulsion.”

Chair: Steven Schlozman, M.D.

VISIT THE EXHIBITS

Publishers Book Fair and APA Member Center
Open Saturday 10 am - 4:00 pm

All Exhibits Open
Sunday 10:00 am - 4:00 pm
Monday 10:00 am - 4:00 pm
Tuesday 10:00 am - 4:00 pm

Exhibit Hall Reception
Monday 12:30 - 1:30 pm

NOTE: Final closing of exhibits is Tuesday at 4:00 pm
Experience the Southern Elegance of New Orleans with the American Psychiatric Foundation

“A Night in New Orleans”

Monday, May 24, 2010
7:00 - 10:00 pm
Grand Oaks Mansion at Mardi Gras World

The American Psychiatric Foundation invites you to our annual fundraising event, “A Night in New Orleans” a special evening at the Grand Oaks Mansion at Mardi Gras World. Enjoy tasty cuisine and live music in this festive venue. The evening’s program includes a silent auction and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation’s grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable. Tickets only cost $150 and are available in the Member Center during Exhibit Hall hours, or at the door of the event.

“Conversations” featuring Terry Bradshaw

Tuesday, May 25, 2009
5:30 - 6:30 pm
Hall A, New Orleans Convention Center

Don’t miss our 9th annual “Conversations” event, an interactive series that offers meeting attendees an opportunity to hear unique perspectives on mental illness. Conversations is free to all APA Annual Meeting attendees.

“Conversations” is supported by a charitable contribution from AstraZeneca to the American Psychiatric Foundation
Experience the Southern Elegance of New Orleans with the American Psychiatric Foundation "A Night in New Orleans" Monday, May 24, 2010 7:00 - 10:00 pm Grand Oaks Mansion at Mardi Gras World The American Psychiatric Foundation invites you to our annual fundraising event, "A Night in New Orleans" at the Grand Oaks Mansion at Mardi Gras World. Enjoy tasty cuisine and live music in this festive venue. The evening's program includes a silent auction and the presentation of the Awards for Advancing Minority Mental Health. Event proceeds support the foundation's grants, programs, research funding and awards that advance public understanding that mental illnesses are real and treatable. Tickets only cost $150 and are available at the event.

Conversations Tuesday, May 25, 2010 5:30 - 6:30 pm Hall A, New Orleans Convention Center Don't miss our 9th annual "Conversations" event, an interactive series that offers meeting attendees an opportunity to hear unique perspectives on mental illness. Conversations is free to all APA Annual Meeting attendees. "Conversations" is supported by a charitable contribution from AstraZeneca to the American Psychiatric Foundation.

SUNDAY
Program changes are printed each day in the Daily Bulletin. You can pick up the Daily Bulletin in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center.

**8:00 A.M. SESSIONS Courses 11-18**

**Course 11**
8:00 A.M.-NOON  
Room 224, Second Level, Morial Convention Center

**How to Give a More Effective Lecture: Punch, Passion and Polish**

Director: Phillip J. Resnick, M.D.

**Course 12**
8:00 A.M.-NOON  
Rooms 225/226, Second Level, Morial Convention Center

**Emergency Psychiatry: Theory to Practice**  
American Association for Emergency Psychiatry

Director: Anthony T. Ng, M.D.

Faculty: Seth Powsner, M.D.  
Jon S. Berlin, M.D.  
Rachel L. Glick, M.D.

**Course 13**
8:00 A.M.-NOON  
Rooms 228/229, Second Level, Morial Convention Center

**Psychiatric Disorders in Pregnant and Postpartum Women: Infant Morbidity and Mortality**

Co-Directors:  
Margaret Spinelli, M.D.  
Katherine L. Wisner, M.D., M.S.

**Course 14**
8:00 A.M.-NOON  
Room 230, Second Level, Morial Convention Center

**Motivational Interviewing for Routine Psychiatric Practice**

Director: Steven Cole, M.D.

**Course 15**
8:00 A.M.-NOON  
Room 238, Second Level, Morial Convention Center

**Cognitive Behavioral Therapy for Insomnia Comorbid With Depressive and Anxiety Disorders**

Director: Rachel Manber, Ph.D.

Faculty:  
Anne Germain, Ph.D.  
Jack D. Edinger, Ph.D.  
Colleen E. Carney, Ph.D.  
Jason Ong, Ph.D.

**Course 16**
8:00 A.M.-NOON  
Room 239, Second Level, Morial Convention Center

**Mood Disorders in Later Life**

Co-Directors:  
James M. Ellison, M.D., M.P.H.  
Yusuf Sivrioglu, M.D.

Faculty:  
Brent P. Forester, M.D.  
Donald A. Davidoff, Ph.D.  
Patricia A. Arean, Ph.D.

**Session Tracks**

1. Affective Disorders (Mood and Anxiety)
2. Personality Disorders
3. Psychopharmacology
4. Psychotherapy
5. Schizophrenia and Other Psychotic Disorders
6. NIDA
7. DSM-5

**SUNDAY, MAY 23**

**9:00 A.M. SESSIONS**

**Workshop 41**
9:00 A.M.-10:30 A.M.  
Room 237, Second Level, Morial Convention Center

**After a Parent’s Suicide: Children’s Grief and Healing**

Chair: Nancy Rappaport, M.D.

Presenters: Joanne Harpel, J.D.  
Diana Sands, Ph.D.

**Workshop 42**
9:00 A.M.-10:30 A.M.  
Room 237, Second Level, Morial Convention Center

**From Narrative and Theory to Evidence-Based Support for Psychiatrists Working Under Extreme Stress**  
APA Lifers

Chair: Sheila Hafter Gray, M.D.

Presenters: Milton Kramer, M.D.  
Jane G. Tillman, Ph.D.  
Leah J. Dickstein, M.D., M.A.  
Captane P. Thomson, M.D.
John C. Bradley, M.D.
David Huang, M.D.

WORKSHOP 43
9:00 A.M.-10:30 A.M.
Room 333, Third Level,
Morial Convention Center

PHYSICIAN HEAL ThySELF:
SCANDALS, SUICIDES, AND
SUBSTANCE ABUSE AMONG US

Co-Chairs:
Margaret Bishop-Baier, M.D.
Scott Embley, L.C.S.W.

WORKSHOP 44
9:00 A.M.-10:30 A.M.
Room 346, Third Level,
Morial Convention Center

MOOD DISORDERS
IN WOMEN OF
REPRODUCTIVE AGE

Chair:
Natalie L. Rasgon, M.D., Ph.D.

WORKSHOP 45
9:00 A.M.-10:30 A.M.
Room 347, Third Level,
Morial Convention Center

COGNITIVE-BEHAVIORAL
STRATEGIES FOR
WEIGHT LOSS

Co-Chairs:
Sarah B. Johnson, M.D., M.S.C.
Joyce A. Spurgeon, M.D.

WORKSHOP 46
9:00 A.M.-10:30 A.M.
Room 350, Third Level,
Morial Convention Center

CHANGING PARADIGMS
OF PSYCHIATRIC PRACTICE IN AN
ERA OF HEALTH CARE REFORM
APA Council on Advocacy e-
Government Relations

Co-Chairs:
Javeed Sukhera, M.D.
Sarah Vinson, M.D.

Presenters:
Catherine E. Krasnik, M.D., Ph.D.
Margaret Balfour, M.D., Ph.D.
Peter S. Martin, M.D., M.P.H.
Robin Reed, M.D.

WORKSHOP 47
9:00 A.M.-10:30 A.M.
Room 351, Third Level,
Morial Convention Center

AMBULATORY MEDICAL
CLINICS AS TRAINING SITES FOR
RESIDENTS AND FELLOWS IN
PSYCHOSOMATIC MEDICINE

Chair:
Robert C. Joseph, M.D., M.S.

Presenters:
Arun Gopal, M.D., B.A.
Fremont Meyer, M.D.
Amy M. Bauer, M.D., M.S.

SYMPOSIA 31-35
9:00 A.M.-NOON
Room 301, Second Level,
Morial Convention Center

UNDERSTANDING PERSONALITY
DISORDERS IN CHILDREN
AND ADOLESCENTS:
CURRENT STATUS AND
FUTURE DIRECTIONS

Chairs:
Paul S. Links, M.D.
Joel F. Paris, M.D.

1. Advancing From Understanding Personality Disorders in Young People Toward Early Detection and Intervention
   Andrew M. Chanen, M.B.B.S.

2. Measurement and Assessment of PD Precursors: Links to Normal Personality and Axis I Problems
   Jennifer Tackett, M.D.

3. Why and Under What Circumstances Should We Make the Diagnosis of Personality Disorders in Children and Adolescents?
   Joel F. Paris, M.D.

SYMPOSIA 32
9:00 A.M.-NOON
Rooms R04/R05, Second Level,
Morial Convention Center

TREATMENT OF DEPRESSION
IN ETHNIC MINORITIES

Co-Chairs:
Julio Licinio, M.D.
William B. Lawson, M.D., Ph.D.

1. Disparity in Depression Treatment Among Racial and Ethnic Minority Populations in the United States
   Alegria Margarita, Ph.D.

2. Diagnosing Depression in People of African Ancestry: National and International Perspectives
   William B. Lawson, M.D., Ph.D.

3. Ethical and Cultural Considerations in Treating Depression in Patients of Chinese Background
   Albert Yeung, M.D., Sc.D.

SYMPOSIA 33
9:00 A.M.-NOON
Room 348, Third Level,
Morial Convention Center

APPROACHES TO SCHIZOPHRENIA
THROUGH PHASES OF THE ILLNESS

Chair:
S. Charles Schulz, M.D.

1. Early Identification of the Psychosis Prodrome and Clinical Practice
   Kristin S. Cadenhead, M.D.

2. Management of First Episode Schizophrenia
   John M. Kane, M.D.

3. Approaches to Schizophrenia
   Peter Weiden, M.D.

4. Evaluation and Intervention for the Persistently Ill Schizophrenic Person
   S. Charles Schulz, M.D.
Peter Milev, M.D., Ph.D.

SYMPOSIUM 34
9:00 A.M.-NOON
Room 349, Third Level,
Morial Convention Center

DIAGNOSING AND
TREATING THE NARCISSISTIC
PERSONALITY DISORDER:
AWAITING DSM-5
International Society for the
Study of Personality Disorders

Co-Chairs:
Elsa Ronningenstam, Ph.D.
Giuseppe Giancarlo Dimaggio, M.D.

Discussant:
Kenneth N. Levy, Ph.D.

1. Observing Narcissistically Vulnerable Traits
   Mardi Horowitz, M.D.

2. Treatment Implications of the Proposed DSM-5
   Representation of Narcissism
   Donna S. Bender, Ph.D.

3. A Self-Regulatory Model and Strategies for Treatment of Narcissistic Personality Disorder
   Elsa Ronningenstam, Ph.D.
4. Promoting Awareness of Mental States and Their Triggers and Reducing Feelings of Rejection in Treatment of Narcissistic Pathology
   Giuseppe Giancarlo Dimaggio, M.D.
   Giuseppe Nicolo, M.D.
   Giampaolo Salvatore, M.D.
   Michele Procacci, M.D.

5. Implications of Research on Trait Narcissism for the Conceptualization of Narcissistic Personality Disorder
   W. Keith Campbell, Ph.D.
   Joshua D. Miller, Ph.D.

---

**COURSES 19-31**

**COURSE 19**
9:00 A.M.-4:00 P.M.
Room 210, Second Level, Morial Convention Center

**ESSENTIALS OF ASSESSING AND TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN ADULTS AND CHILDREN**
Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.
          Anthony L. Rostain, M.D., M.A.

**COURSE 20**
9:00 A.M.-4:00 P.M.
Room 219, Second Level, Morial Convention Center

**HOW TO BLOG, TWEET, FRIEND, WIKI, AND NOT GET ADDICTED: 21ST CENTURY INTERNET TECHNOLOGIES FOR BEGINNERS**
Director: Robert C. Hsiung, M.D.
Faculty: Jerald J. Block, M.D.
          Steven R. Daviss, M.D.

**COURSE 21**
9:00 A.M.-4:00 P.M.
Room 223, Second Level, Morial Convention Center

**EEG FEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS**
Co-Directors: Thomas M. Brod, M.D.
              Michael Cohen, B.S.
Faculty: Ed Hamlin, Ph.D.
          Anne W. Stevens, Ph.D.
          Stephen E. Buie, M.D.

**COURSE 22**
9:00 A.M.-4:00 P.M.
Room 227, Second Level, Morial Convention Center

**BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I**
American Association of Psychiatric Administrators
Co-Directors: Barry K. Herman, M.D.
              Douglas M. Brandt, M.D.

---

**SYMPOSIUM 35**
9:00 A.M.-NOON
Room 333, Third Level, Morial Convention Center

**SEX/GENDER DIFFERENCES AND WOMEN-SPECIFIC ISSUES IN DRUG ABUSE: PREDICTING AND IMPROVING TREATMENT OUTCOMES**
National Institute on Drug Abuse

Co-Chairs:
Cora Lee Wetherington, Ph.D.
Shelly F. Greenfield, M.D., M.P.H.

1. **Gender Differences in Psychiatric Comorbidity With Substance Use Disorder: Implications “Telescoping” and Treatment**
   Kathleen Brady, M.D.

2. **Significant Role of Sex-Based Biology in Predicting Relapse and Clinical Outcomes in Drug Abuse**
   Rajita Sinha, Ph.D.
   Helen Fox, Ph.D.
   Peter Morgan, M.D., Ph.D.
   Keri Bergquist, Psy.D.

3. **Women-Focused Treatment for Substance Use Disorders: Results From the Women’s Recovery Group Study**
   Shelly F. Greenfield, M.D., M.P.H.

4. **Substance-Abusing Women With PTSD: How Best to Treat?**
   Denise Hien, Ph.D.

5. **The Use of Motivational Enhancement Therapy and Vouchers to Improve Treatment Utilization and Outcome in Pregnant Substance Users**
   Theresa Winhusen, Ph.D.
Yoga of the East and West: Integrating Breath Work and Meditation Into Clinical Practice

Co-Directors:
Patricia L. Gerbarg, M.D.
Richard P. Brown, M.D.

Faculty:
Monica Vermani, M.A., Psy.D.
Martin Katzman, M.D.

Advanced Interviewing Techniques

Director:
Shawn C. Shea, M.D.

Autism Spectrum Disorders: Diagnostic Classification, Neurobiology, Biopsychosocial Interventions and Pharmacologic Management

Co-Directors:
Kimberly A. Stigler, M.D.
Alice R. Mao, M.D.

Faculty:
James Sutcliffe, Ph.D.
Mathew Brams, M.D.
Eric Courchesne, Ph.D.
Nora Friedman, M.D.
Stephanie Hamarman, M.D.
Julie A. Chilton, M.D.

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.
I'M VIOLENT; ADMIT ME IF YOU DARE: HOW AND WHERE TO MANAGE POTENTIALLY VIOLENT INDIVIDUALS WITH UNCLEAR DIAGNOSES PRESENTING TO EMERGENCY SERVICES

Co-Chairs:
Kenneth M. Certa, M.D.
Jessica Mosier, M.D.

Presenter:
Solange Margery Bertoglia, M.D.

SCOPE OF PRACTICE CHALLENGES: EXPERIENCES, SUCCESSES, AND TRIBULATIONS FROM ACROSS THE COUNTRY

Co-Chairs:
Jerry L. Halverson, M.D.
Claudia L. Reardon, M.D.

Presenters:
John T. Bailey, D.O.
Joan M. Anzia, M.D.
Harold M. Ginzburg, M.D., J.D.
Paula Johnson, Ph.D.
Jenny Boyer, M.D.
Melinda L. Young, M.D.

12:30 P.M.
APA BUSINESS MEETING
(For Voting APA Members Only*)
12:30 P.M.-1:30 P.M.
La Louisiane Rooms A/B, First Level, Morial Convention Center

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Registration badge and/or APA membership card necessary for admission. No cameras or tape recorders are permitted in this meeting.

CALL TO ORDER
Alan F. Schatzberg, M.D.
President

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS

Eliot Sorel, M.D.
Chair, Committee of Tellers

REPORTS TO THE MEMBERSHIP

David Fassler, M.D.
Secretary-Treasurer

Gary S. Weinstein, M.D.
Speaker

Bruce A. Hershfield, M.D.
Speaker-Elect

John O. Gaston, M.D.
Chair, By-Laws Committee

Kathleen M. Mogul, M.D.
Chair, Elections Committee

Joseph E. V. Rubin, M.D.
Chair, Membership Committee

James H. Scully, Jr., M.D.
Medical Director

Chairs of Councils
(write reports only)

ANNUAL FORUM

ADJOURNMENT

1:00 P.M.

COURSES 32-40

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

COURSE 32
1:00 P.M.-5:00 P.M.
Room 224, Second Level, Morial Convention Center

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

Co-Directors:
Vladimir Bokarius, M.D., Ph.D.
Steven Richeimer, M.D.

Faculty:
Yogi Matharu, D.P.M.
Ali Nemat, M.D.
Karen McNulty, O.T.D., O.T.R./L.
Faye M. Weinstein, Ph.D.

COURSE 33
1:00 P.M.-5:00 P.M.
Rooms 225/226, Second Level, Morial Convention Center

NEUROANATOMY OF EMOTIONS

Director:
Ricardo M. Vela, M.D.

COURSE 34
1:00 P.M.-5:00 P.M.
Rooms 228/229, Second Floor, Morial Convention Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN
Co-Directors:
Shaila Misri, M.D.
Diana Carter, M.D.

Faculty:
Shari I. Lusskin, M.D.
Deirdre Ryan, M.D.

**COURSE 35**
1:00 P.M.-5:00 P.M.
Room 230, Second Level,
Morial Convention Center

MENTALIZATION-BASED TREATMENT FOR BORDERLINE PERSONALITY DISORDER: INTRODUCTION TO CLINICAL PRACTICE

Co-Directors:
Anthony W. Bateman, M.B.B.S., M.R.C.
Peter Fonagy, Ph.D.

**COURSE 36**
1:00 P.M.-5:00 P.M.
Room 238, Second Level,
Morial Convention Center

FOSTERING ADHERENCE TO PSYCHOTROPIC MEDICATIONS: A PRACTICAL RESOURCE FOR CLINICIANS

Co-Directors:
Luis F. Ramirez, M.D.
Richard A. McCormick, Ph.D.

**COURSE 37**
1:00 P.M.-5:00 P.M.
Room 239, Second Level,
Morial Convention Center

INTERPERSONAL PSYCHOTHERAPY

Director:
John C. Markowitz, M.D.

**COURSE 38**
1:00 P.M.-5:00 P.M.
Room R01, Second Level,
Morial Convention Center

INTERNAL MEDICINE UPDATE: WHAT PSYCHIATRISTS NEED TO KNOW

Co-Directors:
Monique Yohanan, M.D.
Michele T. Pato, M.D.

Faculty:
Robert Cobb, M.D.

**COURSE 39**
1:00 P.M.-5:00 P.M.
Room 336, Third Level,
Morial Convention Center

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP AND OTHER BODY CLOCK DISORDERS

Director:
Alfred J. Lewy, M.D., Ph.D.

SEMINAR 6
1:00 P.M.-5:00 P.M.
Room 334, Third Level,
Morial Convention Center

OVERVIEW OF RECOVERY FOR PSYCHIATRISTS

Chair:
Mark Ragins, M.D.

**SCN 3**
1:30 P.M.-3:00 P.M.
Room 236, Second Level,
Morial Convention Center

MOOD DISORDERS

Chair:
Chadi Abdallah, M.D.

4. Significant Bipolar Risk Factors in Patients Presenting a Current Major Depressive Episode
   Charles Bowden, M.D.
   J. Angst, Ph.D.
   J.M. Azorin, Ph.D.
   G. Perugi, M.D.
   E. Vieta, Ph.D.
   Allan H. Young, Ph.D.

5. The Prevalence and Clinical Consequences of Concurrent Hypertension in Patients with Bipolar Disorder
   Dale D’Mello, M.D.

6. Association of Medication Adherence with Therapeutic Alliance in Individuals with Bipolar Disorder
   Louisa G. Sylvia, Ph.D.
   Aleena C. Hay, B.A.
   Andrew A. Nierenberg, M.D.
**Co-Chairs:**
Rex W. Huang, M.D.
Jonathan T. Horey, M.D.

**Presenters:**
Allison S. Baker, M.D.
Laura K. Kent, M.D.
Belinda S. Bandstra, M.D.
Maor Katz, M.D.

---

**Co-Chaps(s):**
Richard A. Denisico, M.D., M.P.H.
Will M. Aklin, Ph.D.

1. **Why Do Some Patients Have Persistent Pain and Persistent Opioid Use Following Surgery?**
   An Inception Cohort Study
   - Ian R. Carroll, M.D., M.S.
   - Peter Barelka, M.D.
   - Charlie Kiat Meng Wang, B.S.
   - Bing Mei Wang
   - Rebecca McCue, B.A.
   - Jarred Younger, Ph.D.
   - Jodie Trafton, Ph.D.
   - Keith Humphreys
   - Stuart B. Goodman, M.D., Ph.D.
   - Fredrick M. Dirbas, M.D.
   - Richard I. Whyte, M.D., M.B.A.
   - Jessica S. Donninning, M.D.
   - Walter B. Cannon, M.D.
   - Sean C. Mackey, M.D., Ph.D.

2. **Clinical Aspects of Risk Management in Opioid Therapy**
   - Steve Passik, Ph.D.

3. **Behavioral Treatment for Co-Occurring Chronic Pain and Opioid Addiction**
   - Declan Barry, Ph.D.

4. **Results of the Prescription Opioid Addiction Treatment Study:**
   A Multi-Site Trial of the NIDA Clinical Trials Network
   - Roger D. Weiss, M.D.
   - Jennifer Sharpe Potter, Ph.D. M.P.H.
   - Petra Jacobs, M.D.
   - Scott Provost, M.S.W.
   - Pearl Zakrovsly, B.A.
   - Zhen Huang, M.S.
   - Robert Lindblad, M.D.
   - Walter Ling, M.D.

5. **Overview of the Treatment of Acute and Chronic Pain in the Patient With a History of Addiction**
   - Sean Mackey, M.D., Ph.D.

---

**Workshop 55**

1:30 P.M.-3:00 P.M.
Room 333, Third Level, Morial Convention Center

**Promoting International Medical Graduates: Psychosocial Support During Residency Training**

**Co-Chairs:**
Anu A. Matorin, M.D.
Pedro Ruiz, M.D.

**Presenters:**
R. Rao Gogineni, M.D.
Ashutosh Atri, M.D., M.S.
Safad Islam, M.D.
Ayasha Mian, M.D.

---

**Workshop 56**

1:30 P.M.-3:00 P.M.
Room 346, Third Level, Morial Convention Center

**Maintenance Treatment for Opiate Dependence: Terminable or Interminable?**

**National Institute on Drug Abuse**

**Co-Chairs:**
Ivan D. Montoya, M.D., M.P.H.
Herbert D. Kleber, M.D.

**Presenters:**
Kenzie L. Preston, Ph.D.
Robert P. Schwartz, M.D.
Steven L. Batki, M.D.

---

**Symposium 36-40**

2:00 P.M.-5:00 P.M.
Room 347, Third Level, Morial Convention Center

**Sundae Seminar 3**

2:00 P.M.-3:30 P.M.
Rooms R04/R05, Second Level, Morial Convention Center

---

**Symposium 37**

2:00 P.M.-5:00 P.M.
Room 348, Third Level, Morial Convention Center

**Culturally Sensitive Treatment of Psychologically Distressed Ethnic and Non-English-Speaking Populations**

**Co-Chairs:**
Devon Hinton, M.D., Ph.D.
Roberto Lewis-Fernández, M.D.

1. **Efficacy of a Culturally Adapted Parent-Training Program for Ethnic Minority Families From Low-Income Communities**
   - Esther J. Calzada, Ph.D.
2. Culturally Sensitive Treatment of Traumatized Refugees and Ethnic Populations: Emotion Regulation Therapy for PTSD
   Devon Hinton, M.D., Ph.D.

3. Psychosocial Treatments for Mexican Americans With Schizophrenia
   Alex Kopelowicz, M.D.

4. Using Culturally Adapted Motivational Interviewing to Improve Retention of Latino Outpatients in Antidepressant Therapy
   Roberto Lewis-Fernández, M.D.

5. Preventive Interventions for Refugee Families in Resettlement
   Stevan Weine, M.D.

**SYMPOSIUM 33**

2:00 P.M.-5:00 P.M.
Room 350, Third Level,
Morial Convention Center

**NEUROENDOCRINE AND NEUROIMMUNOLOGICAL CORRELATES OF BIPOLAR DISORDER IN WOMEN**

Co-Chairs:
Natalie L. Rasgon, M.D., Ph.D.
Roger S. McIntyre, M.D.

1. Reproductive Endocrine Function in Women With Bipolar Disorder and Control
   Natalie L. Rasgon, M.D., Ph.D.

2. Should Bipolar Disorder Be Reclassified as Metabolic Syndrome Type II?
   Roger S. McIntyre, M.D.

3. Inflammatory and Oxidative Pathways in Mood Disorders: Novel Mechanisms and Therapeutic Opportunities
   Michael Berk, M.D., Ph.D.

4. Serum B12 Levels and Thyroid Function in Bipolar Disorder: Is There a Gender Difference?
   Aysegul Ozerdem, M.D.

**SYMPOSIUM 39**

2:00 P.M.-4:00 P.M.
Room 351, Third Level,
Morial Convention Center

**THE MEDICAL HOME: IS THERE A PLACE FOR PSYCHIATRY IN IT?**
APA Council on Children, Adolescents & Their Families

Chair:
Eliot Sorel, M.D.

1. A Primary Care Perspective
   Frank Degruiy, M.D.

2. The Pediatric Medical Home: Where Does the Child and Adolescent Psychiatrist Fit In?
   Michael Houston, M.D.

3. Psychiatry and Primary Care Integration: Challenges and Opportunities
   Eliot Sorel, M.D.

**SYMPOSIUM 40**

2:00 P.M.-4:00 P.M.
Room 353, Third Level,
Morial Convention Center

**PRIVACY IN ELECTRONIC MEDICAL RECORDS**

Co-Chairs:
Zebulon Taintor, M.D.
Laura J. Fochtmann, M.D.

Discussant:
Edward Pontius, M.D.

1. Privacy Violations and Consequences
   Zebulon Taintor, M.D.

2. Privacy and Control in Health Information Exchanges: More Than an Illusion?
   Glenn A. Martin, M.D.

3. The Perspective of Family Members on Privacy in Electronic Medical Records
   Edward F. Foulks, M.D.

4. Health IT and Privacy: Critical Pathways to Improving Mental Health Care
   Deven C. McGraw, J.D., M.P.H.

5. General Medical Views of Electronic Medical Record Privacy
   Laura J. Fochtmann, M.D.

**SCCR 5**

3:30 P.M.-5:00 P.M.
Room 349, Third Level,
Morial Convention Center

**PSYCHOSOMATIC MEDICINE AND HEALTH SERVICES RESEARCH**

Chair:
Josephine Mokonogho, M.D.

13. Psychiatric Vital Signs
   Mark Zimmerman, M.D.
   Diane Young, Ph.D.
   Iwona Chelminski, Ph.D.
   Kristy Dalrymple, Ph.D.
   Janine Galione, B.S.

14. Characteristics of Delirium in the Severely Medically Ill Cancer Population
   Soenke Boettger, M.D.
   Steven Passik, Ph.D.
   William Breitbart, M.D.

15. Pilot of Measurement-Based Care for Depression in an HIV Outpatient Clinic
   Julie Adams, M.D.
   R. Scott Pollard, L.C.S.W.
   Kristen G. Shirey, M.D.
   Brian W. Pence, Ph.D.
Presenters:
Allison S. Baker, M.D.
Laura K. Kent, M.D.
Belinda S. Bandstra, M.D.
Maor Katz, M.D.

**WORKSHOP 58**
3:30 P.M.- 5:00 P.M.
Room 346, Third Level, Morial Convention Center

**Pharmacological Approaches to Autism Spectrum Disorders for Clinicians**

Chair:
Christopher J. McDougle, M.D.

**4:30 P.M.**
OPENING SESSION
4:30 P.M.-5:45 P.M.
Hall A, First Level, Morial Convention Center

**Call to Order**
Alan F. Schatzberg, M.D.
President, American Psychiatric Association

**INTRODUCTION OF STAGE GUESTS**

**INTRODUCTION OF SCIENTIFIC PROGRAM COMMITTEE**

Julio Licinio, M.D.
Donald Hilty, M.D.
Co-Chairs, Scientific Program Committee

**INTRODUCTION OF VISITING DIGNITARIES**

**PRESIDENTIAL ADDRESS**

Alan F. Schatzberg, M.D.
*Introduced by David J. Kupfer, M.D.*

**RESPONSE FROM THE PRESIDENT-ELECT**

Carol A. Bernstein, M.D.
*Introduced by Carol C. Nadelson, M.D.*

**ADJOURNMENT**

**6:00 P.M.**
SESSION

**MIND GAMES**
6:00 P.M.-7:00 P.M.
Rooms 343-345, Third Level, Morial Convention Center

Moderator:
Glen O. Gabbard, M.D.

_MindGames_ is a national team competition for residents that tests the depth and breadth of their knowledge of psychiatry. This final round pits the three top-scoring residency programs against each other.

**Finalists for the 2010 Championship:**

- Boston University Medical Center
- Brown University (Butler Hospital)
- Carilion Clinic-Virginia Tech School of Medicine

---

**DON’T MISS THIS YEAR’S CONVOCATION SPEAKER!**

The Convocation will take place on Monday, May 24, 2010 in Hall A, Level One, Morial Convention Center, 5:30-6:30, p.m.

_CARRIE FISHER_

- Recognized for her role as Princess Leia in _Star Wars_ and the sequels.
- Just completed a major run of her hit autobiographical one-woman show, _Wishful Drinking_.
- She is also a leading mental health advocate.
MONDAY

[Clock icons]
Program changes are printed each day in the Daily Bulletin. You can pick up the Daily Bulletin in Exhibit Halls B/C, First Level, Morial Convention Center and at many other locations throughout the convention center.

Course descriptions are available in the Course Brochure. You can pick up a Course Brochure and purchase a course ticket in the Course Enrollment Area, located in Exhibit Halls B/C, First Level, Morial Convention Center. Admission to all courses, including Master Courses, is by ticket only.

COUSE 41
8:00 A.M.-NOON
Bayside Room B,
Fourth Floor,
Sheraton New Orleans

SHORT-TERM
PSYCHODYNAMIC
SUPPORTIVE
PSYCHOTHERAPY FOR DEPRESSION

Co-Directors:
Henricus Van, M.D.
Frans F. De Jonghe, M.D., Ph.D.

Faculty:
Simone S. Kool, M.D., Ph.D.
Annemieke A. Noteboom, M.S.C.
Mariëlle M. Hendriksen, M.A.
Jack Dekker, M.S.C., Ph.D.

COUSE 42
8:00 A.M.-NOON
Bayside Room C,
Fourth Floor,
Sheraton New Orleans

EXPLORING TECHNOLOGIES IN PSYCHIATRY
American Association for Technology in Psychiatry

Co-Directors:
Robert S. Kennedy, M.A.
John Luo, M.D.

Faculty:
Carlyle H. Chan, M.D.

COUSE 43
8:00 A.M.-NOON
Nottoway Room, Fourth Floor,
Sheraton New Orleans

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: ADVANCED COURSE

Co-Directors:
Abhilash K. Desai, M.D.
George T. Grossberg, M.D.

COUSE 44
8:00 A.M.-NOON
Grand Ballroom A, Fifth Floor,
Sheraton New Orleans

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT OF DUAL DIAGNOSIS PATIENTS

Director:
John W. Tsuang, M.D.

Faculty:
Todd Zorick, M.D., Ph.D.
Stephen Ross, M.D.
Sara Dhand, M.D.

COUSE 45
8:00 A.M.-NOON
Grand Ballroom B, Fifth Floor,
Sheraton New Orleans

THE DETECTION OF MALINGERED MENTAL ILLNESS

Director:
Phillip J. Resnick, M.D.

COUSE 46
8:00 A.M.-NOON
Grand Ballroom D, Fifth Floor,
Sheraton New Orleans

ADVANCES IN NEUROPSYCHIATRY: THE NEUROPSYCHIATRY OF EMOTION AND ITS DISORDERS

Co-Directors:
C. Edward Coffey, M.D.
Randolph B. Schiffer, M.D.

Faculty:
Robert G. Robinson, M.D.
Matthew A. Menza, M.D.
Michael Trimble, M.D.

COUSE 47
8:00 A.M.-NOON
Salons 825/829, Eighth Floor,
Sheraton New Orleans

TREATING MEDICAL STUDENTS AND PHYSICIANS

Co-Directors:
Michael F. Myers, M.D.
Leah J. Dickstein, M.D., M.A.

Faculty:
Penelope Ziegler, M.D.

COUSE 48
8:00 A.M.-NOON
Salons 816/820, Eighth Floor,
Sheraton New Orleans

CULTURALLY APPROPRIATE ASSESSMENT MADE INCREDIBLY CLEAR: A SKILLS-BASED COURSE WITH HANDS-ON EXPERIENCES

Director:
Russell F. Lim, M.D.

Faculty:
Francis Lu, M.D.
Anita S. Ramanathan, M.D.

9:00 A.M. SESSIONS

ADVANCES IN MEDICINE 1
9:00 A.M.-10:30 A.M.
Rooms 217-219, Second Level,
Morial Convention Center

DELIURION: NEUROBIOLOGY, PREVENTION AND TREATMENT APPROACHES

Chair:
Jose R. Maldonado, M.D.

FOCUS LIVE 1
9:00 A.M.-10:30 A.M.
Rooms 343-345, Third Level,
Morial Convention Center

PSYCHOTHERAPY

Presented by:
Priyanthy Weerasekera, M.D., M.Ed.

Moderators:
Deborah J. Hales, M.D.
Mark H. Rapaport, M.D.
BIO

Dr. Halmi is board certified in both pediatrics and psychiatry. She began her eating disorder research career while on the faculty in the Department of Psychiatry at the University of Iowa and later moved to Cornell University Medical College and The New York Hospital: Westchester Division in 1979. She established a clinical research and treatment program for eating disorders and is a professor of psychiatry at Cornell. Dr. Halmi is a past president of the American Psychopathological Association, past president of the Society of Biological Psychiatry, past president of Psychiatric Research Society, and past president of Eating Disorder Research Society. Dr. Halmi is conducting a multicenter family therapy study on the treatment of adolescent anorexia nervosa. She is also part of a multicenter genetic study of eating disorders.

BIO

Glen O. Gabbard, M.D., is the Brown Foundation Chair of Psychoanalysis and a professor of psychiatry at Baylor College of Medicine in Houston, Tx. He is the former joint editor-in-chief of the International Journal of Psychoanalysis and a former Associate Editor of American Journal of Psychiatry. He is the author or editor of 22 books, including Psychodynamic Psychiatry in Clinical Practice 4th Edition, Gabbard’s Treatments of Psychiatric Disorders 4th Edition, and The American Psychiatric Publishing Textbook of Psychotherapeutic Treatments. He is the author of 290 papers and book chapters and has received numerous honors. These include the 2000 Mary Sigourney Award for outstanding contributions to psychoanalysis, the 2004 American Psychiatric Association Adolf Meyer Award, and the 2008 Cornell-Westchester Borderline Personality Disorder Resource Center Award for distinguished contributions to the field of severe personality disorders.

LECTURE 4

9:00 A.M.-10:30 A.M.
La Louisiane Rooms A/B, First Level, Morial Convention Center

WHY I TEACH

APA/NIMH Vestermark Award Lecture

Glen O. Gabbard, M.D.

Co-Chairs:
Frederick G. Guggenheim, M.D.
David Goldberg, M.D.

Chair:
Barton Blinder, M.D.

NEW RESEARCH/ YOUNG INVESTIGATORS POSTER SESSION 1

9:00 A.M.-10:30 A.M.
La Louisiane C, First Level, Morial Convention Center

For further information on New Research/Young Investigator submissions please refer to the New Research Program section in the back of this book.

LECTURE 5

9:00 A.M.-10:30 A.M.
Rooms 353-355, Third Level, Morial Convention Center

THE PERPLEXITIES AND PROVOCATIONS OF EATING DISORDERS

Distinguished Psychiatrist Lecture

Katherine A. Halmi, M.D.

Chair:
Dilipkumar Patel, M.D.

PSYCHOTHERAPY AND DEPRESSION

16. Short-Term Psychodynamic Psychotherapy Versus Pharmacotherapy Versus Pill Placebo for Major Depressive Disorder in an Urban, Disadvantaged Sample
Jacques P. Barber, Ph.D.
Marna S. Barrett, Ph.D.
Robert Gallop, Ph.D.
Moira Rynn, M.D.
Karl Rickels, M.D.

17. Sudden Gains in Supportive-Expressive Psychotherapy in Depression: A Replication and Extension
Dahlia Mukherjee, M.A.
Jacques P. Barber, Ph.D.

18. The Relation of Specific, Common, and Unintended Factors to Outcome in Psychodynamic Therapy for Depression

9:00 A.M.-10:30 A.M.
Rooms 228-229, Second Floor, Morial Convention Center

SCIENTIFIC AND CLINICAL REPORTS: SESSIONS 6-7

19. Neural Sensitization as a Possible Mechanism of Emotional Reactivity: A Comparison of Borderline and Avoidant Personality Disorder Patients and Healthy Control Subjects
Harold W. Koenigsberg, M.D.
Jin Fan, Ph.D.
Kevin Guise
Kevin Ochsner, Ph.D.
Stephanie Guerrerri
Antonia S. New, M.D.
Marianne Goodman, M.D.
Larry J. Siever, M.D.

20. Short- Versus Long-Term Dialectical Behavior Therapy for Patients With Borderline Personality Disorder: Predictors of Response and Elements of Choice
Nader Perroud, M.D.
Huguelet Philippe, M.D.

21. Dysregulated Brain Networks in the Cognitive Control of Emotion in Borderline Personality Disorder: An fMRI Study
Harold W. Koenigsberg, M.D.
Jin Fan, Ph.D.
Kevin Ochsner, Ph.D.
Xun Liu, Ph.D.
Scott Pizzarello
Kevin Guise
Stephanie Guerrerri
Lucia Tecuta
Antonia S. New, M.D.
Marianne Goodman, M.D.
Larry J. Siever, M.D.

SMALL INTERACTIVE SESSIONS 1-4

These sessions are limited to 50 participants on a first-come first-served basis.
WORKSHOP 62
9:00 A.M.-10:30 A.M.
Rooms 225/226, Second Level,
Morial Convention Center

Disaster Preparedness,
Evacuation and Rebuilding:
Lessons Learned From
Katrina Applied to
Gustav and Ike

Chair:
Erich J. Conrad, M.D.

Presenters:
Howard J. Osofsky, M.D., Ph.D.
Mark H. Townsend, M.D., M.S.
Ruth E. Levine, M.D.

WORKSHOP 63
9:00 A.M.-10:30 A.M.
Room 227, Second Level,
Morial Convention Center

The Explosion of Social Media:
Why, Where, When
and How can
Psychiatrists
Catch up With
the Trend?
APa Council on
Communications

Chair:
Gabriella Cora, M.D., M.B.A.

Presenters:
Roberto A. Blanco, M.D.
Gariane Gunter, M.D.
Felicia K. Wong, M.D.

WORKSHOP 64
9:00 A.M.-10:30 A.M.
Room 230, Second Level,
Morial Convention Center

Treating the Aggressive
Child and Teen: Integrated
Techniques for Management
and Intervention

Co-Chairs:
Niranjan S. Karnik, M.D., Ph.D.
Hans Steiner, M.D.

WORKSHOP 65
9:00 A.M.-10:30 A.M.
Room 235, Second Level,
Morial Convention Center

Guided Self-Help:
A new Intervention
to Overcome Anxiety
Complaints

Chair:
Christine A. Van Boeijen, M.D., Ph.D.

WORKSHOP 66
9:00 A.M.-10:30 A.M.
Room 335, Third Level,
Morial Convention Center

 Preventing Late-Life Sequelae
Resulting From
Early-Life Trauma

Chair:
Erikka Dzirasa, M.D., M.P.H.

Presenters:
Joy D. Osofsky, Ph.D.
Stacy S. Drury, M.D., Ph.D.
Charles Zeanah, M.D.

WORKSHOP 67
9:00 A.M.-10:30 A.M.
Rooms 340/341, Third Level,
Morial Convention Center

Behavioral Complications
of Dementia: A Comprehensive
Multidisciplinary
Treatment Approach

Chair:
Sanjay Vaswani, M.D.

Presenters:
Amita R. Patel, M.D.

WORKSHOP 68
9:00 A.M.-10:30 A.M.
Room 342, Third Level,
Morial Convention Center

Core Competencies and
Maintenance of Competency
in Europe and the United
States of America:
An Educational Model

Co-Chairs:
Pedro Ruiz, M.D.
Deborah J. Hales, M.D.

Presenters:
Cyril Hosch, M.D., D.Sc.
Livia Vavrusova, M.D., Ph.D.
Michael Musalek, M.D.
Wolfgang Gaebel, M.D.
2. Continuous Quality Improvement and Documentation
Amanda Ruiz, M.D.

3. Juvenile Offenders and Correctional Mental Health
Christopher Thompson, M.D.

4. Legal Issues Regarding the Provision of Care in a Correctional Setting
Charles Scott, M.D.

5. Managing the Disruptive or Aggressive Inmate
Robert L. Trestman, M.D.

6. Supermax Units and Death Row
James Knoll, M.D.

ADVANCES IN SERIES 1-2
9:00 A.M.-NOON
Rooms 238-239, Second Level, Morial Convention Center

Advances in Correctional Psychiatry: From Provision of Care to Malpractice Prevention

Chair: Charles Scott, M.D.

1. Conducting Mental Health Assessments in Correctional Settings
Humberto D. Temporini, M.D.
3. The French System: “Health Security” for All?  
Gisèle Apter, M.D., Ph.D.

4. Mental Health Care in the United Kingdom  
Dinesh Bhugra, M.B.B.S., Ph.D.

**SYMPOSIUM 42**

*9:00 A.M.-NOON*

**9:00 A.M.-4:00 P.M.**

**COARSE 49**

356/357, Third Floor, Morial Convention Center

**SESSION TRACKS**

1. Personality Disorders
2. Schizophrenia and Other Psychotic Disorders
3. DSM-5
4. Cognitive-Behavior Therapy for Severe Mental Illness
5. Affective Disorders (Mood and Anxiety)
6. NIDA
7. Psychopharmacology
8. Psychotherapy

**Update on Medications Development: Promising New Treatments for Drug Addiction**  
National Institute on Drug Abuse

**Co-Chairs:**

Nora D. Volkow, M.D.  
David J. McCann, Ph.D.

**Discussant:**

Herbert D. Kleber, M.D.

**Faculty:**

Douglas Turkington, M.D.  
Michael E. Thase, M.D.  
David G. Kingdom, M.D.

**Director:**

Jesse H. Wright, M.D., Ph.D.

**Basic Concepts in Administrative Psychiatry II**  
American Association of Psychiatric Administrators

**Co-Directors:**

Douglas M. Brandt, M.D.  
Barry K. Herman, M.D.

**Faculty:**

Alan Axelson, M.D.  
Arthur L. Lazarus, M.D., M.B.A.  
Jeri Davis, M.B.A.  
William H. Reid, M.D., M.P.H.  
Robert M. Atkins, M.D., M.P.H.

**Course 50**

**9:00 A.M.-4:00 P.M.**

**Bayside Room A, Fourth Floor, Sheraton New Orleans**

**Course 51**

**9:00 A.M.-4:00 P.M.**

**Galier Room A/B, Fourth Floor, Sheraton New Orleans**

**Seeing the Forest and the Trees: An Approach to Biopsychosocial Formulation**

**Director:**

William H. Campbell, M.D., M.B.A.

**Course 52**

**9:00 A.M.-4:00 P.M.**

**Oak Alley Room, Fourth Floor, Sheraton New Orleans**

**Traumatic Brain Injury: Neuropsychiatric Assessment**  
American Academy of Psychiatry & Law

**Director:**

Robert P. Granacher, M.D., M.B.A.

**Course 53**

**9:00 A.M.-4:00 P.M.**

This course has been moved to Tuesday at 9:00 a.m.

**Adult Sexual Love and Infidelity**

**Chair:**

Stephen B. Levine, M.D.
10:00 A.M.—4:00 P.M.

Exhibit Hall, APA Member Center and Publishers’ Book Fair Are Open

Exhibit Halls B-D, First Level, Morial Convention Center

10:30 A.M. SESSIONS

ADVANCES IN RESEARCH 1

10:30 A.M.—12:30 P.M.
Rooms R02-R05, Second Level, Morial Convention Center

ADVANCES IN RESEARCH

Chair:
Herbert Pardes, M.D.

1. Update on Clinical Research in Schizophrenia
Stephen R. Marder M.D.

2. The Search for Brain-Based Biomarkers of Childhood Psychiatric Disorders
Bradley S. Peterson M.D.

3. Fear and Anxiety: Neurocircuitry and Genetics
Kerry Ressler M.D., Ph.D.

4. Research Advances and the Treatment of Mood Disorders
Jerrold F. Rosenbaum M.D.

FORUMS 1-2

FORUM 1

11:00 A.M.—12:30 P.M.
Rooms 220-222, Second Level, Morial Convention Center

CHOPIN AT 200: His Mind and His Music

Chair: Richard Kogan, M.D.

FORUM 2

11:00 A.M.—12:30 P.M.
Room 224, Second Level, Morial Convention Center

DSM-5: PROGRESS IN RESEARCH AND DEVELOPMENT

Chair: David J. Kupfer, M.D.

Presenters:
Darrel A. Regier, M.D., M.P.H.
Lawson R. Wulsin, M.D.
Jack D. Burke, M.D., M.P.H.
Geoffrey M. Reed, Ph.D.
Jane S. Paulsen, Ph.D.

LECTURE 7

11:00 A.M.—12:30 P.M.
Rooms 353-355, Third Level, Morial Convention Center

NEUROIMAGING CLUE TO THE CAUSES OF BIPOLAR DISORDER: WHERE WE ARE AND WHERE WE’RE GOING

Distinguished Psychiatrist Lecture

Stephen M. Strakowski, M.D.

Chair:
Josephine Monkonogho, M.D.

11:00 A.M. SESSIONS

ADVANCES IN MEDICINE 2

11:00 A.M.—12:30 P.M.
Rooms 217-219, Second Level, Morial Convention Center

Top 10 Medical Articles of 2009: A Comprehensive and Practical Review of What We Need to Know

Chair:
Monique Yohanan, M.D.

FOCUS LIVE 2

11:00 A.M.—12:30 P.M.
Rooms 343-345, Third Level, Morial Convention Center

GENETICS AND GENOMICS

Presented by:
Michele T. Pato, M.D.
Carlos N. Pato, M.D.

Moderators:
Deborah J. Hales, M.D.
Mark H. Rapaport, M.D.

LECTURE 8

11:00 A.M.—12:30 P.M.
Rooms 228/229, Second Level, Morial Convention Center

PERSONALITY DISORDER

Distinguished Psychiatrist Lecture

Chair:
Derya Iren Akbiyik, M.D.

2.2. Gender Differences in the Development of Borderline Personality Disorder
Uday Patil, M.A.
Joseph Triebwasser, M.D.
Marianne Goodman, M.D.

SCIENTIFIC AND CLINICAL REPORTS: SESSION 8

11:00 A.M.—12:30 P.M.
Rooms 228/229, Second Level, Morial Convention Center

Borderline Personality Disorder

Chair:
Derya Iren Akbiyik, M.D.

163rd Annual Meeting 91
23. Recurrent Suicide Attempts and Medical Lethality in Borderline Personality Disorder
   Paul H. Soloff, M.D.

24. Time-to-Attainment of Recovery From Borderline Personality Disorder and Its Stability: A Ten-Year Prospective Follow-Up Study
   Mary C. Zanarini, Ed.D.
   Frances R. Frankenburg, M.D.
   D. Bradford Reich, M.D.
   Garrett Fitzmaurice, Sc.D.

**CHILDHOOD ABUSE**

Chair: Prakash Chandra, M.D.

25. Clinical Phenomenology of Childhood Abuse-Related Complex PTSD Patients: Differential Patterns of Personality Disturbance
   Ethy E. Dor repa al, M.D.
   Kathleen K. Thomaes, M.D.
   Johannes H. Smit, Ph.D.
   Adriaan W. Hoogendoorn, Ph.D.
   Dick J. Veltman, M.D., Ph.D.
   Anton J.L.M. van Balkom, M.D., Ph.D.
   Nel Draijer, Ph.D.

26. Effect of Cognitive Behavioral Stabilizing Group Treatment on Brain Activity in Childhood Abuse-Related Complex PTSD Patients
   Kathleen K. Thomaes, M.D.
   Ethy E. Dor repa al, M.D.
   Nel Draijer, Ph.D.
   Michiel B. de Ruiter, Ph.D.
   Bernet M. Elzinga, Ph.D.
   Johannes H. Smit, Ph.D.
   Anton J.L.M. van Balkom, M.D., Ph.D.
   Dick J. Veltman, M.D., Ph.D.

27. Childhood Maltreatment in Women With Binge-Eating Disorder: Associations With Psychiatric Comorbidity, Psychological Functioning, and Eating Pathology
   Daniel F. Becker, M.D.
   Carlos M. Grilo, Ph.D.

**SMALL INTERACTIVE SESSIONS 5-8**

These sessions are limited to 50 participants on a first-come, first-served basis.

**WORKSHOPS 72-83**

**WORKSHOP 72**

11:00 A.M.-12:30 P.M.
Room 210, Second Level, Morial Convention Center

**AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY UPDATE: CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES**

Chair: Larry R. Faulkner, M.D.

Presenters:
Beth Ann Brooks, M.D., M.S.
Victor I. Reus, M.D.
David A. Mrazek, M.D.

**WORKSHOP 73**

11:00 A.M.-12:30 P.M.
Rooms 225/226, Second Level, Morial Convention Center

**TRANSCRANIAL MAGNETIC STIMULATION IN CLINICAL PRACTICE: A PRAGMATIC APPROACH TO A NEW PSYCHIATRIC PROCEDURE**

Chair: Timothy H. Deristine, M.D.

Presenters:
Carl M. Wahlstrom, M.D.
Karl I. Lanocha, M.D.
Todd M. Hutton, M.D.

**WORKSHOP 74**

11:00 A.M.-12:30 P.M.
Room 227, Second Level, Morial Convention Center

**TO FILE OR NOT TO FILE: GUARDIANSHIP FOR OLDER ADULTS WITH DEMENTIA**

Co-Chairs:
Asghar Ali A. Ali, M.D.
Sheila M. LoboPrabhu, M.D.

Presenters:
Jeffrey B. Lindeman, Psy.D.
Ellen F. Barr, M.S.N.

**WORKSHOP 75**

11:00 A.M.-12:30 P.M.
Room 230, Second Level, Morial Convention Center

**THE VICISSITUDES OF THE DOCTOR-PATIENT RELATIONSHIP IN MODERN MEDICINE: ENDURANCE, EROSION OR TRANSFORMATION**

Chair: Robert C. Joseph, M.D., M.S.

Presenters:
Donald R. Lipsitt, M.D., M.A.
Malkah T. Notman, M.D.
Donald J. Meyer, M.D.

**WORKSHOP 76**

11:00 A.M.-12:30 P.M.
Room 235, Second Level, Morial Convention Center

**WHEN IS PSYCHIATRIC ILLNESS TERMINAL?**

Co-Chairs:
Melinda S. Henderson, M.D.
Kate Payne, J.D., R.N.
WORKSHOP 77
11:00 A.M.-12:30 P.M.
Room 335, Third Level,
Morial Convention Center

NEONATICIDE:
PHENOMENOLOGY
AND PREVENTION

Chair:
Renee M. Sorrentino, M.D.

Presenters:
Susan Hatters Friedman, M.D.
Joy Stankowski, M.D.

WORKSHOP 78
11:00 A.M.-12:30 P.M.
Rooms 338/339, Third Level,
Morial Convention Center

INTEGRATING
COMPLEMENTARY
ALTERNATIVE
MEDICINE (CAM)
IN PSYCHIATRIC
CARE: NEW PARADIGMS
AND PERSPECTIVES

Chair:
Simon Chiu, M.D., Ph.D.

Presenters:
Zack Z. Cernovsky, Ph.D.
John Copen, M.D., M.S.C.
Michael A. Woodbury-Farina, M.D.
Mariwan Husni, M.D.

WORKSHOP 79
11:00 A.M.-12:30 P.M.
Rooms 340/341, Third Level,
Morial Convention Center

THE USE OF RESEARCH
MEASURES IN CLINICAL
PRACTICE

Chair:
Joan Busner, Ph.D.

Presenters:
Stuart L. Kaplan, M.D.
Nicholas Greco IV, M.S.

WORKSHOP 80
11:00 A.M.-12:30 P.M.
Room 342, Third Level,
Morial Convention Center

“TAKING IT PERSONAL”:
INTEGRATING
PHARMACOGENETICS
INTO THE
MANAGEMENT
OF DEPRESSION

Chair:
Sheldon H. Preskorn, M.D.

Presenters:
Melvin G. McInnis, M.D.

WORKSHOP 81
11:00 A.M.-12:30 P.M.
Rooms 346/347, Third Level,
Morial Convention Center

TELEPSYCHIATRY AND
THE CHANGING FACE OF
ACCESS FOR RURAL
AMERICA’S CHILDREN
AND ADOLESCENTS
APA Council on Children,
Adolescents & Their Families

Chair:
L. Charolette Lippolis, D.O., M.P.H.

Presenters:
Michael Houston, M.D.
Mary I. Dobbins, M.D.
Daniel M. Savin, M.D.
Paula Zuccano, F.N.P.

WORKSHOP 82
11:00 A.M.-12:30 P.M.
Rooms 348/349, Third Level,
Morial Convention Center

GUARDIANSHIP AND
POWERS OF ATTORNEY:
ISSUES IN GERIATRIC
PSYCHIATRY

Co-Chairs:
David A. Casey, M.D.
Robert P. Roca, M.D., M.P.H.

Presenters:
Helen H. Kyomen, M.D., M.S.
Winsor C. Schmidt, J.D., LL.M.

WORKSHOP 83
11:00 A.M.-12:30 P.M.
Rooms 350/351, Third Level,
Morial Convention Center

PRACTICAL
PHARMACOTHERAPY
OF MOOD DISORDERS

Co-Chairs:
Gary E. Miller, M.D.
Richard L. Noel, M.D.
**COURSE 59**
1:00 P.M.-5:00 P.M.
Nottoway Room, Fourth Floor, Sheraton New Orleans

**Psychiatric Pharmacogenomics**

**Director:**
David A. Mrazek, M.D.

**COURSE 60**
1:00 P.M.-5:00 P.M.
Grand Ballroom A, Fifth Floor, Sheraton New Orleans

**Psychopharmacologic, ECT and Psychotherapeutic Treatment of Psychotic (Delusional) Depression**

**Director:**
Anthony J. Rothschild, M.D.

**Faculty:**
Brandon A. Gaudiano, Ph.D.

**COURSE 61**
1:00 P.M.-5:00 P.M.
Grand Ballroom B, Fifth Floor, Sheraton New Orleans

**The Psychiatrist as Expert Witness**

**Director:**
Phillip J. Resnick, M.D.

**Faculty:**
Jefferson B. Prince, M.D.

**COURSE 62**
1:00 P.M.-5:00 P.M.
Grand Ballroom D, Fifth Floor, Sheraton New Orleans

**Advanced Assessment and Treatment of Attention-Deficit/ Hyperactivity Disorder**

**Director:**
Thomas E. Brown, Ph.D.

**Faculty:**
Jefferson B. Prince, M.D.
Anthony L. Rostain, M.D., M.A.

**COURSE 63**
1:00 P.M.-5:00 P.M.
Salon 801, Eighth Floor, Sheraton New Orleans

**Current Procedural Terminology: Coding and Documentation**

**Co-Directors:**
Chester W. Schmidt, M.D.
Tracy R. Gordy, M.D.

**Faculty:**
Ronald M. Burd, M.D.
David K. Nace, M.D.
Jeremy S. Mushar, M.D.
Allan A. Anderson, M.D.

**COURSE 64**
1:00 P.M.-5:00 P.M.
Salons 816/820, Eighth Floor, Sheraton New Orleans

**A Primer on Acceptance and Commitment Therapy**

**Co-Directors:**
Kenneth D. Fung, M.D., M.S.
Mateusz Zurowski, M.D., M.S.

**SESSIONS 1:30 P.M.**

**FOCUS LIVE 3**

1:30 P.M.-3:00 P.M.
Rooms 343-345, Third Floor, Morial Convention Center

**Disorders of Sex and Sleep**

**Presented by:**
Stephen B. Levine, M.D.

**Moderators:**
Deborah J. Hales, M.D.
Mark H. Rapaport, M.D.

**LECTURE 8:9**

1:30 P.M.-3:00 P.M.
La Louisiane Rooms A/B, First Level, Morial Convention Center

**The Audacity Principle in Science**

**Solomon H. Snyder, M.D.**

**Chair:**
David Baron, M.S.Ed., D.O.

---

**BIO**

**Solomon H. Snyder** was born in Washington, D.C., and received his undergraduate and medical training at Georgetown University; research associate training with Julius Axelrod at NIH (1963-1965); and psychiatric training at the Johns Hopkins Hospital (1965-1968). In 1966, he joined the faculty of the Johns Hopkins University School of Medicine (Asst Professor Pharmacology, 1966-1968; Associate Professor Pharmacology/Psychiatry, 1968-1970; Professor, 1970). In 1980 he established the Department of Neuroscience and served as Director (1980-2006). He is presently Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry.

---

**LECTURE 9**

1:30 P.M.-3:00 P.M.
Rooms R02-R05, Second Level, Morial Convention Center

**“Your Bipolar Dad Is a Bad Reason to Become a Psychiatrist”: Advocacy Adventures of a Bewildered Boy Who Grew Up to Become NAMI’s Medical Director**

**Patient Advocacy Award Lecture**

**Kenneth S. Duckworth, M.D.**

**Chairs:**
Stephen M. Goldfinger, M.D.
Josephine Mokonogho, M.D.

---

**BIO**

**Ken Duckworth, M.D.** serves as the medical director for the National Alliance on Mental Illness. He is triple board certified by the American Board of Psychiatry and Neurology in adult, child and adolescent, and forensic psychiatry and has extensive experience in the public health arena. Dr. Duckworth is an assistant professor at Harvard University Medical School and serves as a board member of the American Association of Community Psychiatrists. Dr. Duckworth has served as a school consultant for a decade and, in addition to his role with NAMI, works in community mental health with Vinfen Corporation in Boston as its medical director. Dr. Duckworth attended the University of Michigan, where he graduated with honors, and Temple University School of Medicine, where he was named to the medical honor society. While at Temple, he won awards for his work in psychiatry and neurology.

---

**LECTURE 10**

1:30 P.M.-3:00 P.M.
Room 230, Second Level, Morial Convention Center

**Cognitive Disorders**

**Chair:**
Saleem Ismail, M.D.

---

28. Incidence Rates and Probability to Develop Dementia and Alzheimer’s Disease in a Southern European City: The Zarademp Project

**Antonio Lobo, M.D., Ph.D.**
Raul Lopez-Anton, M.Sc.
Pedro Saz, M.D., Ph.D.
Javier Santabarbara, M.Sc.
Concepcion de-la-Camara, M.D., Ph.D.
Tirso Ventura, M.D., Ph.D.
Jose L. Dia, M.D., Ph.D.
Miguel A. Quintanilla, M.D., Ph.D.
Juan F. Roy, Ph.D.
Antonio J. Campayo, M.D.
Elena Lobo, Ph.D.
Antonio Lobo-Escobar, M.D., Ph.D.
Maria F. Barcones, M.D., Ph.D.
Guillermo Marcos, M.D., Ph.D.
Farifeh F. Duffy, Ph.D.
Darrel A. Regier, M.D., M.P.H.

29. Art and Dementia: Pathological and Clinical Features of Different Subtypes of Dementia, With a Focus on the Changes in Art Production
Laura Safar, M.D., M.A.

30. Metacognitive Capacity Mediates the Impact of Neurocognitive Deficits on Function in Schizophrenia
Paul H. Lysaker, Ph.D.
Amanda M. Shea, B.A.
Giancarlo Dimaggio, M.D.
Giuseppe Nicolò, M.D.
Kevin L. Rand, Ph.D.

31. Intellectual Disability in DSM-5
Walter E. Kaufmann, M.D.
Bryan H. King, M.D., Ph.D.
Sally J. Rogers, Ph.D.

32. Adding Dimensional Assessments of Psychopathology to Psychiatric Diagnoses: Implications for DSM-5
William E. Narrow, M.D., M.P.H.
Joyce C. West, Ph.D., M.P.P.
Donald S. Rae, M.A.
Maritza Rubio-Stupiec, Sc.D.
Eve K. Moscicki, Sc.D., M.P.H.

33. Nosology for Beginners: Historical and Current Perspectives on the Fundamental Issues and Problems in the Classification of Psychiatric Disorders
Avram H. Mack, M.D.
Discusant:
Thomas Insel, M.D.

Kerry Ressler, M.D., Ph.D.

2. Emotion Regulation: Toward a Neurobiological Understanding of Psychotherapy
Amit Etkin, M.D., Ph.D.

3. Optogenetics: Development and Application
Karl Deisseroth, M.D.

4. Using Optogenetic Tools and Information Theory to Elucidate Prefrontal Microcircuit Dysfunction in Schizophrenia
Vikaas Sohal, M.D.

5. At Clinical High Risk for Psychosis: What Is the Outcome?
Jean M. Addington, Ph.D.

Jeffrey A. Lieberman, M.D.

Co-Chairs:
Maurizio Fava, M.D.
Steven D. Targum, M.D.

1. Placebo Response Is Not Necessarily Response to Placebo: Factors Inflating Placebo Response in CNS Trials
Armin Szegedi, M.D.

2. Does De-Coupling of Entry Criteria Improve Outcomes in CNS Trials?
Charlotte Kremer, M.D., M.B.A.
Eric J. Watsky, M.D.
Ilise D. Lombardo, M.D.

3. Comparison of Site-Based Versus Centralized Ratings in a Study of Generalized Anxiety Disorder
Judith Dunn, Ph.D.

4. Evaluation of Centralized Ratings in a Clinical Trial of Major Depressive Disorder
Steven D. Targum, M.D.
Leo Bleicher, Ph.D.
Andrew Nierenberg, M.D.

5. The Use of Independent Assessments for Patient Eligibility for CNS Trials
Maurizio Fava, M.D.
Steven D. Targum, M.D.

Co-Chairs:
Jeffrey A. Lieberman, M.D.

Discussant:
Holly A. Swartz, M.D.
Ellen Frank, Ph.D.

1. Comparison of IPSRT Monotherapy and Quetiapine for the Treatment of Bipolar II Depression: A Proof of Concept Trial
Holly A. Swartz, M.D.

2. Early Intervention for Adolescent Offspring of Parents With Bipolar Disorder: Pilot Study of IPSRT
Tina Goldstein, Ph.D.

3. IPSRT for Adolescents With Bipolar Disorder: Treatment Development and Results From an Open Trial
Stefanie A. Hlastala, Ph.D.

4. IPSRT for Bipolar Disorder in the Perinatal Period
Suzanne Luty, Ph.D., M.B.B.S.

5. Group Interpersonal and Social Rhythm (IPSRT) Therapy Across the Continuum of Care in Routine Practice Settings
Ellen Frank, Ph.D.

Co-Chairs:
Benjamin Springgate, M.D., M.P.H.

Discussant:
Kenneth B. Wells, M.D., M.P.H.

1. A Public Health Initiative to Address Depression and Posttraumatic Stress Disorder in a Post-Disaster Setting
Benjamin Springgate, M.D., M.P.H.

2. CBPR in the Arkansas Delta: Developing an Implementation Partnership With Rural Under-served Community Health Centers
Justin B. Hunt, M.D.
Angie Shaffner, R.N., L.N.C.
Geoff Curran, Ph.D.
John Fortney, Ph.D.
3. A Partnership for Wellness: Addressing Stress and Violence in West and Southwest Philadelphia
Glenda Wrenn, M.D.
Jane Sue, M.D.
Lorraine Thomas

4. GROOVI Care: A Community Coalition to Engage With Veterans of Operations Enduring Freedom and Iraqi Freedom About Their Mental Health
Patrick E. Link, M.D., M.P.H.
Casey MacGregor, M.S.W.
Lawrence A. Palinkas, Ph.D.
Kenneth B. Wells, M.D., M.P.H.
Michael Kilmer, M.S.W.
Barbara Powell, M.A.
Isabel Moriarty, M.S.W.
Alexander Young, M.D., M.S.H.S.

5. Using a Community Partnered Participatory Research Approach to Implement a Randomized Controlled Trial: Designing of Community Partners in Care
Bowen Chung, M.D., M.S.
Loretta Jones, M.A.
Elizabeth Dixon, Ph.D., R.N.
Jim Gilmore, M.B.A.
Kenneth B. Wells, M.D., M.P.H.
Michael Kilmer, M.S.W.
Barbara Powell, M.A.
Isabel Moriarty, M.S.W.
Alexander Young, M.D., M.S.H.S.

Authors of the American Journal of Psychiatry papers that will appear in the June issue will present overviews of their findings, with discussion of why the papers were selected for publication by the editor, Robert Freedman, M.D. Among the presenters are David Spiegel, M.D., (evidence for a dissociative subtype of PTSD); Mary C. Zanarini, Ed.D., (recovery from borderline personality disorder and its stability); and Alexandre Dombrovski, M.D., (reward/punishment reversal learning in older suicide attempters).

**SYMPOSIUM 48**
2:00 P.M.-5:00 P.M.
Room 227, Second Level, Morial Convention Center

**REDUCING HARM: SAFER INJECTION AND OTHER STRATEGIES**

Chair: Curtis N. Adams, Jr., M.D.

Discussant: David A. Pollack, M.D.

1. Creating an Inclusive Drug Strategy: The Experience of Establishing Vancouver’s Supervised Injection Site
Liz Evans, B.S.N.

**SYMPOSIUM 49**
2:00 P.M.-5:00 P.M.
Rooms 228/229, Second Floor, Morial Convention Center

**ADVANCES IN THE TREATMENT OF BIPOLAR DISORDER**

Co-Chairs: Terence A. Ketter, M.D.
Po W. Wang, M.D.

1. Advances in Maintenance Treatment of Bipolar Disorder
Terence A. Ketter, M.D.
Po W. Wang, M.D.

2. Advances in the Treatment of Bipolar Depression
Po W. Wang, M.D.
Terence A. Ketter, M.D.

3. Treatment of Children and Adolescents With Bipolar Disorder
Kiki Chang, M.D.

4. Treatment of Pregnant Women With Bipolar Disorder
Myltiee Vemuri, M.D., M.B.A.

5. Management of Bipolar Disorders in Older Adults
John O. Brooks, M.D., Ph.D.

**SYMPOSIUM 50**
2:00 P.M.-5:00 P.M.
Room R01, Second Level, Morial Convention Center

**CHALLENGES IN PROVIDING MENTAL HEALTH CARE FOR COLLEGE AND UNIVERSITY STUDENTS**

APA Council on Children, Adolescents & Their Families

Co-Chairs: Jerald Kay, M.D.
Victor I. Schwartz, M.D.

Discussant: Beverly J. Fauman, Ph.D.

1. The Magnitude of Clinical Demands
Jerald Kay, M.D.

2. The Ethical and Legal Issues in Providing College Mental Health Care
Victor I. Schwartz, M.D.

3. Psychiatric Hospitalization and Follow-Up Care of the College Student
Rachel L. Glick, M.D.

4. Violence Assessment and Administrative Responses
Gregory T. Eells, Ph.D.

5. Managing the Suicidal College Student
Morton Silverman, M.D.

**SYMPOSIUM 51**
2:00 P.M.-5:00 P.M.
Rooms 333/334, Third Level, Morial Convention Center

**GERIATRIC PSYCHOPHARMACOLOGY OF LATE-LIFE MOOD DISORDERS: FOCUS ON THE USE OF BIOMARKERS AS PREDICTORS OF RESPONSE**

Chair: Helen Lavretsky, M.D., M.S.

1. Psychopharmacology of Geriatric Depression: The Use of Aging Biomarkers to Predict Treatment Response
Helen Lavretsky, M.D., M.S.

2. Geriatric Bipolar Disorder: Clinical Diagnosis and Treatment
Martha Sajatovic, M.D.

3. The Use of Structural MRI as Predictor of Antidepressant Response in Older Adults
Yvette Sheline, M.D.

4. Amygdala Activation to Emotional Faces in Geriatric Depression as a Marker of Treatment Response
Howard Aizenstein, M.D.

5. Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression
Gwenn Smith, Ph.D.
SYMPOSIUM 52
2:00 P.M.–5:00 P.M.
Rooms 338/339, Third Level, Morial Convention Center

INNOVATIONS IN INTEGRATED TREATMENT OF SUBSTANCE USE AND PSYCHIATRIC DISORDERS
National Institute on Drug Abuse

Co-Chairs:
Ivan D. Montoya, M.D., M.P.H.
Wilson M. Compton III, M.D.

Discussant:
Stanley Sacks, Ph.D.

1. Integrated Treatment of Depression and Substance Use Disorders in Adolescents
Paul Rohde, Ph.D.
Holly Waldron, Ph.D.
Charles Turner, Ph.D.
Janet Brody, Ph.D.
Jenel Jorgensen, M.A.

2. Posttraumatic Stress Disorder and Drug Abuse: Etiology and Treatment Linkages
Kathleen Brady, M.D., Ph.D.
Sudie Back, Ph.D.
Therese Killeen, Ph.D., R.N.

3. Integrated Group Therapy for Patients With Co-Occurring Bipolar Disorder and Substance Use Disorder
Roger D. Weiss, M.D.
Margaret L. Griffin, Ph.D.
William B. Jaffe, Ph.D.
Garrett M. Fitzmaurice, Ph.D.

4. Advances in Pharmacotherapy for Comorbid Depression and Addictions
Edward V. Nunes, M.D.

5. Treatment of Cannabis Use Disorder in Patients With Schizophrenia
Alan I. Green, M.D.

SYMPOSIUM 53
2:00 P.M.–5:00 P.M.
Rooms 340/341, Third Level, Morial Convention Center

GENOTYPES AND BIOMARKERS: THE NEW DECISION MAKERS FOR TAILORED TREATMENT

Co-Chairs:
Florian Holsboer, M.D.
Julio Licinio, M.D.

1. Genetic and Other Biomarkers of Antidepressant Outcome
Francis McMahon, M.D.

2. Individualized Antipsychotic Therapy for Schizophrenic Patients
Edwin J.C.G. van den Oord, Ph.D.

3. Gene Expression Profile in Persons Exposed to the Attack on the World Trade Center With and Without PTSD
Rachel Yehuda, Ph.D.

4. Genes x Environment Interactions Underlying Risk Versus Resilience for Stress-Related Disorders
Kerry Ressler, M.D., Ph.D.

5. Severity of Substance Use Disorders
Thomas J. Crowley, M.D.
Marc Auriacone, M.D.

SYMPOSIUM 54
2:00 P.M.–5:00 P.M.
Room 342, Third Level, Morial Convention Center

SUBSTANCE RELATED DISORDERS IN DSM-5: PROGRESS REPORT
National Institute on Drug Abuse

Co-Chairs:
Charles P. O’Brien, M.D., Ph.D.
Deborah S. Hasin, Ph.D.

1. The Search for Specific Criteria: A Report From the Criterion Subcommittee
Marc Schuckit, M.D.

2. Abuse and Dependence: Combining the Disorders Into a Single Category
Deborah S. Hasin, Ph.D.
Bridget F. Grant, Ph.D.
Guilherme Borges, Sc.D.
Kathleen Bucholz, Ph.D.
Tuishi Saha, Ph.D.
Katherine Keyes, M.P.H.
Arpana Agrawal, Ph.D.
Cheryl Besler, Ph.D.

3. Non-Substance Related Addictions: Their Place in DSM-5
Nancy M. Petry, Ph.D.
Eric Hollander, M.D.
Thomas Kosten, M.D.
Charles P. O’Brien, M.D.
Wim van de Brink, Ph.D.
Nora D. Volkow, M.D.

4. Terminology of Substance Use Disorders for DSM-5
Wilson M. Compton III, M.D.
Marc Auriacone, M.D.
Alan J. Budney, Ph.D.
Thomas J. Crowley, M.D.
Bridget F. Grant, Ph.D.
Deborah Hasin, Ph.D.
Walter Ling, M.D.
Charles P. O’Brien, M.D.
Nancy Petry, Ph.D.

5. Severity of Substance Use Disorders
Thomas J. Crowley, M.D.
Marc Auriacone, M.D.

SYMPOSIUM 55
2:00 P.M.–5:00 P.M.
Rooms 346/347, Third Level, Morial Convention Center

DSM-5 UPDATE SERIES, PART I: REPORTS FROM THE WORK GROUPS

Chair:
Darrel A. Regier, M.D., M.P.H.

1. Approaches to the Diagnosis and Classification of Eating Disorders in DSM-5
B. Timothy Walsh, M.D.

2. Key Recommendations From the DSM-5 Sexual and Gender Identity Disorders Workgroup
Kenneth J. Zucker, Ph.D.

3. Update From the Somatic Symptoms Workgroup
Joel E. Dimsdale, M.D.

4. Towards a Better, Practical Understanding of Sleep Disturbances in People Living With or At Risk for Mental Illness
Charles Reynolds, M.D.

5. Neurocognitive Disorders in DSM-5
Dilip V. Jeste, M.D.
Deborah Blacker, M.D.
Dan Blazer, M.D., Ph.D., M.P.H.
Mary Ganguli, M.D.
Igor Grant, M.D.
Jane Paulsen, Ph.D.
Ronald C. Petersen, M.D., Ph.D.
Perminer Sachdev, M.D.

SYMPOSIUM 56
2:00 P.M.–5:00 P.M.
Rooms 350/351, Third Level, Morial Convention Center

FOCAL BRAIN STIMULATION FOR PSYCHIATRIC DISORDERS: CLINICAL UPDATE

Chair:
Paul Holtzzheimer, M.D.

1. The Clinical Safety and Efficacy of Transcranial Magnetic Stimulation: Results From Recent Pivotal Clinical Trials
William M. McDonald, M.D.

2. Key Recommendations From the DSM-5 Sexual and Gender Identity Disorders Workgroup
Kenneth J. Zucker, Ph.D.

3. Update From the Somatic Symptoms Workgroup
Joel E. Dimsdale, M.D.

4. Towards a Better, Practical Understanding of Sleep Disturbances in People Living With or At Risk for Mental Illness
Charles Reynolds, M.D.

5. Neurocognitive Disorders in DSM-5
Dilip V. Jeste, M.D.
Deborah Blacker, M.D.
Dan Blazer, M.D., Ph.D., M.P.H.
Mary Ganguli, M.D.
Igor Grant, M.D.
Jane Paulsen, Ph.D.
Ronald C. Petersen, M.D., Ph.D.
Perminer Sachdev, M.D.

1. Approaches to the Diagnosis and Classification of Eating Disorders in DSM-5
B. Timothy Walsh, M.D.

2. Key Recommendations From the DSM-5 Sexual and Gender Identity Disorders Workgroup
Kenneth J. Zucker, Ph.D.

3. Update From the Somatic Symptoms Workgroup
Joel E. Dimsdale, M.D.

4. Towards a Better, Practical Understanding of Sleep Disturbances in People Living With or At Risk for Mental Illness
Charles Reynolds, M.D.

5. Neurocognitive Disorders in DSM-5
Dilip V. Jeste, M.D.
Deborah Blacker, M.D.
Dan Blazer, M.D., Ph.D., M.P.H.
Mary Ganguli, M.D.
Igor Grant, M.D.
Jane Paulsen, Ph.D.
Ronald C. Petersen, M.D., Ph.D.
Perminer Sachdev, M.D.

1. The Clinical Safety and Efficacy of Transcranial Magnetic Stimulation: Results From Recent Pivotal Clinical Trials
William M. McDonald, M.D.
2. Clinical Update on Magnetic Seizure Therapy (MST)
   Sarah H. Lisanby, M.D.

3. Clinical Update on Vagus Nerve Stimulation (VNS)
   Linda L. Carpenter, M.D.

4. The Promise of Direct Epidural Cortical Stimulation in Refractory MDD: The PROSPECT Experience and Future Directions
   Jerry L. Halverson, M.D.
   Brian Kopell, M.D.
   Douglas Kondziolka, M.D.
   Darin Dougherty, M.D.
   Robert Howland M.D.
   Harold Harsch, M.D.
   Emad Eskandar, M.D.
   Michael Thase, M.D.

5. Deep Brain Stimulation for Psychiatric Disorders: Clinical Update
   Paul Holtzheimer, M.D.

   Symposium 58
   2:00 P.M.-5:00 P.M.
   Rooms 356/357, Third Level, Morial Convention Center

   Neurobiology of Obesity: Why We Can Get Too Motivated to Eat
   National Institute on Drug Abuse

   Co-Chairs:
   Nora D. Volkow, M.D.
   Joseph Frascella, Ph.D.

1. Overeating and Obesity: Any End in Sight to Our “Addiction” to Food?
   David Kessler, M.D.

2. Central Control of Food Intake: Appetite Control and the Reward-Driven Brain
   Hans-Rudolf Berthoud, Ph.D.

3. Sweetness as a Super Reward: Comparison With Cocaine and Heroin
   Serge H. Ahmed, Ph.D.

4. Individual Differences in the Neurophysiology of Reward and the Obesity Epidemic
   Nora D. Volkow, M.D.

5. Neurocircuitry of Addiction and Obesity
   Nora D. Volkow, M.D.

Lecture 11
3:30 P.M.-5:00 P.M.
Rooms R02-R05, Second Level, Morial Convention Center

Solomon Carter Fuller: What Would He Say about Racial Politics in American Psychiatry Today?
Solomon Carter Fuller Award Lecture

Donna M. Norris, M.D.

BIO
Donna M. Norris, M.D., is a child, adolescent and forensic psychiatrist in private practice in Massachusetts and a member of the Program in Psychiatry and the Law at Beth Israel Deaconess Hospital, Harvard Medical School. She has written or cowritten articles on African-American children and loss, the impact of culture and race on the development of African Americans, countertransference, health care fraud, clergy sexual abuse, firearms and the roles of psychiatrists, and custody and parental fitness. Dr. Norris is a Distinguished Fellow of the American Psychiatric Association and has been the recipient of a number of awards, including the Women of Courage and Conviction Award of the National Council of Negro Women, Massachusetts Outstanding Psychiatrist Award for the Advancement of the Profession, and Special APA Presidential Commendations (2002 and 2008). She is a Fellow of the American College of Psychiatrists and is listed in both Who's Who Among Black Americans and Who's Who Among Women in America.
WORKSHOPS 86-87

WORKSHOP 86
3:30 P.M. - 5:00 P.M.
Room 235, Second Level,
Morial Convention Center

TEACHING PSYCHIATRY IN
NEW MEDICAL SCHOOLS

Chair:
Zebulon Taintor, M.D.

Presenters:
Kathleen S. Franco, M.D., M.S.
Daniel Castellanos, M.D.
David F. Briones, M.D.
Marcia L. Verduin, M.D.

WORKSHOP 87
3:30 P.M. - 5:00 P.M.
Room 335, Third Level,
Morial Convention Center

DEAFNESS, DISABILITY OR DIFFERENCE? THE CULTURAL
AND CLINICAL NEEDS OF DEAF PATIENTS
APA/SAMHSA
Minority Fellows

Co-Chairs:
Neil K. Aggarwal, M.D., M.B.A.
Christopher W. Tjoa, M.D., B.S.

Presenters:
Jason O. Mensah, D.O.
Deyadira Baez-Sierra, M.D.
Sosunmolu O. Shoyinka, M.B.B.S.
David R. Diaz, M.D.
Kimberly J. Roberts, M.D.
Sarah Anne Landsberger, M.D.

5:30 P.M.
CONVOCAION OF Distinguished Fellows
5:30 P.M. - 6:30 P.M.
Hall A, First Level,
Morial Convention Center

All Distinguished Life Fellows, Distinguished Fellows,
Life Fellows, International Fellows, APA Members, and
Registered Guests Are Invited to Attend.

Presiding:
Alan F. Schatzberg, M.D.
APA President

Grand Marshals:
Howard J. Osolfsky, M.D., Ph.D.
Daniel K. Winstead, M.D.

Marshals:
Edward F. Fouls, M.D.
Stephen M. Goldfinger, M.D.
Since her feature debut opposite Warren Beatty in “Shampoo” in 1975, Carrie Fisher has been a compelling force in the film industry. She attained international recognition as Princess Leia, a role that made her a cultural icon, in the box-office sensation “Star Wars” and the smash hit sequels “The Empire Strikes Back” and “Return of the Jedi.” Other acting credits include “The Blues Brothers,” “Garbo Talks,” “When Harry Met Sally,” and “Austin Powers” to name a few. Carrie became a sensation with the New York Times bestseller, Postcards From the Edge, for which she won the Los Angeles Pen Award for Best First Novel. Three additional best-selling novels, Surrender the Pink, Delusions of Grandma, and Wishful Drinking, followed. Fisher also wrote the screenplay based on Postcards from the Edge, which starred Meryl Streep and Shirley MacLaine. Ms. Fisher’s fourth novel, The Best Awful, received rave reviews and she is currently adapting it for Lifetime and Sony, with producers Bruce Cohen and Dan Jinks. Ms. Fisher completed a major run of her hit autobiographical one-woman show, Wishful Drinking at The Geffen Playhouse in Los Angeles in 2006 and most recently on Broadway at the Roundabout Theatre Company’s Studio 54. Carrie Fisher’s experience with mental illness and addiction has made her a popular speaker on the lecture circuit. She has appeared on the Senate floor urging state legislators to increase government funding for medication for people living with mental health issues. She has received dozens of awards for her courage and commitment to fighting mental illness and the stigmas associated with it.

1. Assessing Mood and Somatic Symptoms in the Medically-Ill Depressed Patient
   Gregory Simon, M.D., Ph.D.

2. Pathophysiology of Somatic Symptoms and Major Depressive Disorder in Medically-Ill Populations
   Janet Witte, M.D., M.P.H.

3. Managing Depression in the Medically-Ill: An Up-to-Date Evidence-Based Guide
   Bradley Gaynes, M.D.

4. Management of Treatment-Resistant Patients with Somatic Symptoms and Medical Illness
   Maurizio Fava, M.D.

---

BIO

Carrie Fisher

2010 APA Annual Meeting

ONLINE & DVD-ROM HIGHLIGHTS

Order yours during the meeting and save up to $500*

SALES BOOTHS:
- Lobby B1
- Exhibit Hall B2, Near the Registration Area

The American Board of Psychiatry and Neurology has reviewed FOCUS: The Journal of Lifelong Learning in Psychiatry and the FOCUS Self-Assessment Examination and has approved this program as part of a comprehensive lifelong learning and self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

ABPN approval is time limited to 3 years for each FOCUS CME course. Refer to APA’s CME website for ABPN approval status of each course.

The FOCUS Self-Assessment Program is approved for up to 20 hours of continuing professional development per year under Section 3 of the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Psychiatric Association designates the FOCUS educational program for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FOCUS is the best system for recertification, self-assessment, and lifelong learning. In one easy subscription, FOCUS provides a comprehensive review of current clinical practice based on the content outlined by the ABPN recertification exam. Each issue offers: Clinical Reviews, Patient Management Exercise, Seminal Articles, and a CME quiz with 20 hours of CME per year for the journal (20 additional hours can be earned through completion of the Self-Assessment Exam). All current and back issues are accessible online with available CME credits for your subscription year.

The FOCUS Self-Assessment Exam is an annual 100-question, multiple-choice supplement written by practicing psychiatrists and academic experts that allows you to earn 20 CME credits and the opportunity to anonymously compare your knowledge to that of your peers either online or on paper. Each question is similar to those used in board-type exams. The FOCUS Self-Assessment Exam is listed by the ABPN as an approved self-assessment activity that fulfills the requirement of psychiatrists applying for and taking the recertification examination.

FOCUS addresses the core content in psychiatry in four-year cycles. Each issue briefs you on new developments and reviews the current state of practice in that topic area through:

- Clinical synthesis articles and reviews
- Interactive Patient Management Exercise and “Ask-the-Expert” column
- Influential publications: reprints of new, and classic articles that influence practice

FOCUS updates you in core content areas:

- **Volume VI** (2008): Major Depressive Disorder and Suicide; Schizophrenia: Cognition and Outcomes; Child and Adolescent Psychiatry; Panic and Social Phobia
- **Volume VII** (2009): Geriatric Psychiatry; HIV AIDS Psychiatry and Psychosomatic Medicine; PTSD and Disaster Psychiatry; Sleep, Eating, and Sexual Disorders
- **Volume VIII** (2010): Psychotherapy; Personality Disorders and Temperament; Psychiatric Genetics and Genomics; Psychopharmacology
- **Volume IX** (2011): Addiction Psychiatry; Bipolar Disorder; Anxiety Disorders; Ethics and Professionalism

Visit the APPI Bookstore to purchase your subscription

**One-Year Prices:**
- U.S. APA Members: $296
- International Member: $375
- APA MIT (Online Only): $96
- U.S. Non-Member price: $476
- International Non-Members: $552
- **Conference Discount**
  - $246
  - $46

The First and Last Word in Psychiatry
Web: www.appi.org and focus.psychiatryonline.org
Email: appi@psych.org
Phone: 1-800-368-5777 | 703-907-7322 | Fax: 703-907-1091
When ordering, please reference priority code AH1022
TUESDAY
8:00 A.M. SESSIONS COURSES 65-68

1. An Evidence-Based Approach to the Use of Antipsychotic Medications in the Treatment of Mood and Anxiety Disorders
   Kristina Deligiannidis, M.D.

2. Antipsychotic Medication Use in Personality Disorders
   Kenneth R. Silk, M.D.

3. Use of Antipsychotic Medications in Schizophrenia and Schizoaffective Disorder
   Jayendra Patel, M.D.

4. Use of Antipsychotic Medications in the Medically Ill
   David Gitlin, M.D.

CASE CONFERENCES CASE CONFERENCE 2
9:00 A.M.-10:30 A.M.
Rooms 228-229, Second Floor, Morial Convention Center

This session is open to APA members only. Blue registration badge or APA membership card required for admittance.

DEATH OF A PHYSICIAN BY SUICIDE
Chair:
Michael F. Myers, M.D.

FORUMS FORUM 3
9:00 A.M.-10:30 A.M.
Room 224, Second Level, Morial Convention Center

Is a Game-Changing Psychotropic Too Much to Expect?
Chair:
Philip T. Ninan, M.D.

Presenters:
Philip Ninan, M.D.
Amir Kalali, M.D.
Jeffrey Lieberman, M.D.
Stephen Stahl, M.D., Ph.D.

LECTURES 12-13 LECTURE 12
9:00 A.M.-10:30 A.M.
Hall A, First Level, Morial Convention Center

ADDITION: CONFLICT BETWEEN BRAIN CIRCUITS
Frontiers of Science Lecture
National Institute on Drug Abuse

Nora D. Volkow, M.D.

Chair:
Herbert D. Kleber, M.D.
BIO

Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the aging brain. Dr. Volkow pioneered the use of brain imaging to investigate the health aspects of drug abuse and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the aging brain.

Francine M. Benes, M.D.

Chair: Sukriti Mittal, M.D.

SCIENTIFIC AND CLINICAL REPORTS
SCR 14

9:00 A.M.-10:30 A.M.
Room 227, Second Level, Morial Convention Center

ANXIETY DISORDERS

1. 40. The Long-Term Treatment of Obsessive Compulsive Disorder
   Afia Sadiq, M.D.
   Stepan Shannon, Ph.D.
   Eric D. Peselow, M.D.

41. Acute Treatment of Panic Disorder With Clonazepam or Paroxetine: A Randomized Naturalistic Open Study
   Antonio E Nardi, M.D., Ph.D.
   Alexandre M. Valença, M.D.
   Rafael C. Freire, M.D.
   Roman Amrein, M.D.
   Aline Sardinha, M.Sc.
   Michelle N. Levitan, Psy.D.
   Isabella Nascimento, M.D.
   Valfrido L. de Melo Neto, M.D.
   Anna L. King, M.Sc.
   Adriana Cardoso, Ph.D.
   Gastão L. Soares-Filho, M.D.
   Rafael T. da Costa, Psy.D.
   Marco A. Mezzasalma, M.D.
   Marcele R. de Carvalho, M.Sc.
   Ana C. de Cerqueira, M.D.
   Marcio Versiani, M.D.

42. Recurrence of Panic Attacks Following Medication Discontinuation
   Svetoslav Hristov, M.D.
   Shannon Stepan, Ph.D.
   Eric Peselow, M.D.

BIO

Dr. Benes is the William P. and Henry B. Test Professor of Psychiatric Neuroscience at Harvard Medical School and Director of the Program in Structural and Molecular Neuroscience and the Harvard Brain Tissue Resource Center, both located at McLean Hospital. She has served on the editorial boards or been a Section Editor of many neuroscience and psychiatry journals (i.e., *Biotechniques, Schizophrenia Bulletin, Development and Psychopathology, American Journal of Psychiatry, Neuropsychopharmacology, Schizophrenia Research, Current Opinion in Psychiatry, Neuroscience.Net and Clinical Schizophrenia and Related Psychoses*). She has also been invited to speak at many national and international meetings, including those sponsored by the NIH, the World Health Organization, the College de France, the National Academy of Sciences, Cold Spring Harbor Research Institute and the Nobel Committee in Stockholm.

Chair: Derya Iren Akbiyik, M.D.

Lecture 13

9:00 A.M.-10:30 A.M.
Rooms R02-R05, Second Level, Morial Convention Center

FROM CIRCUITS TO CELLS TO MOLECULAR REGULATION: IDENTIFYING NOVEL TARGETS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
Frontiers of Science Lecture

Francine M. Benes, M.D.

2. The Genetics of Autism
   Daniel Gerschwind, M.D.

3. A TOMM-40 Variable Length polyT Repeat Polymorphism, Inherited Through Evolution, Determines the Age of Onset Distribution of Late-Onset Alzheimer's Disease
   Allen Roses, M.D.

4. New Directions in the Genetics of Bipolar Disorder
   Pamela Sklar, M.D., Ph.D.

5. Progress in Schizophrenia Genetics
   Patrick Sullivan, M.D.

6. Genomics of Ethnic Minority Groups: Pharmacogenomics of Depression in Mexican-Americans
   Julio Licinio, M.D.

PRESIDENTIAL SYMPOSIUM 5

9:00 A.M.-NOON
Rooms 335-335, Third Level, Morial Convention Center

HEALTH REFORM AND PSYCHIATRY

Chair: Steven S. Sharfstein, M.D.

Discussant: James H. Scully, Jr., M.D.

1. What Will Be the Role of the Public Sector Following Health Reform?
   Howard H. Goldman, M.D.

2. The Impact of Health Reform on Inpatient and Outpatient Psychiatric Practice
   Steven S. Sharfstein, M.D.

3. Health Care Reform: An Academic Exercise?
   Anthony Lehman, M.D.

4. The Role of Managed Care in Health Care Reform
   Henry Harbin, M.D.
5. The Impact of Health Reform on Psychotherapy by Psychiatrists  
Eric M. Plakun, M.D.

<table>
<thead>
<tr>
<th>SYMPOSIA 60-68</th>
<th>SYMPOSUM 60</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 A.M.-NOON</td>
<td>Room 220/222, Second Level, Morial Convention Center</td>
</tr>
</tbody>
</table>

**THE POTENTIAL AND PITFALLS OF CREATING A BIPOLAR GENOMIC BIOBANK**

**Chair:**  
Mark Frye, M.D.

1. Mayo Clinic  
Individualized Medicine Biobank for Bipolar Disorder: Overview  
Joachim Benitez, M.D.

2. Antidepressant-Induced Mania: The Need for Rigorous Phenotypic Assessment  
Mark Frye, M.D.

3. Retrospective Pharmacogenomic Treatment Response  
Susan McElroy, M.D.

4. Advocacy Collaboration Into Biobanks  
Allen Daniels, Ed.D.

5. Biobanking: New Ethical Challenges?  
Barbara A. Koenig, Ph.D.

**SYMPOSIUM 61**  
9:00 A.M.-NOON  
Room 223, Second Level, Morial Convention Center

**PSYCHIATRISTS IN THE WORLD: ADVOCATING FOR LGBT MENTAL HEALTH**

**Chair:**  
Mary E. Barber, M.D.

**Discussants:**  
Annette B. Primm, M.D., M.P.H.  
Nada L. Stotland, M.D., M.P.H.

1. The Psychiatrist as Advocate: The Case of AGLP  
Mary E. Barber, M.D.  
Ubaldolo Leli, M.D.

2. The GAP Online Curriculum on LGBT Mental Health  
Vernon A. Rosario, M.D.  
Serena Y. Volpp, M.D.

3. A Picture’s Worth a Thousand Words: Using Film for Mental Health Advocacy and Activism  
Alicia J. Salzer, M.D.

4. Talking to the Media: Teaching Psychiatrists to Embrace the Sound Bite  
Jack Drescher, M.D.

**SYMPOSIUM 62**  
9:00 A.M.-NOON  
Room 225/226, Second Level, Morial Convention Center

**The Public Health and Clinical Interface Between HIV, STDs, and Mental Health**

**Chair:**  
Marshall Forstein, M.D.

1. The Public Health Interface Between HIV, Sexually Transmitted Diseases, and Mental Illness  
Marc A. Safran, M.D.

2. The Clinical Interface Between HIV, Sexually Transmitted Diseases, and Mental Illness  
Marshall Forstein, M.D.

3. The Impact of Neuropsychiatric Syndromes on the Course of Treatment in HIV  
Stephen J. Ferrando, M.D.

**SYMPOSIUM 63**  
9:00 A.M.-11:00 A.M.  
Rooms 238/239, Second Level, Morial Convention Center

**ADOLESCENT POTENTIAL: EXPLORING THE DEVELOPING BRAIN AND UNDERSTANDING PATHWAYS OF ADDICTION**

**National Institute on Drug Abuse**

**Co-Chairs:**  
Cheryl Anne Boyce, Ph.D.  
Joseph Frascella, Ph.D.

1. The Developing Brain, Adolescence and Alcohol/Drug Use: An Evolutionary Approach  
Linda Patia Spear, Ph.D.

2. The Teen Brain: Insights From Neuroimaging  
Jay N. Giedd, M.D.

3. Vulnerabilities in Adolescent Decision Making: Neuroimaging Evidence of Immaturities in Cognitive Control, Reward Processing, and Brain Connectivity  
Beatrix Luna, Ph.D.
SYMPOSIUM 64
9:00 A.M.-NOON
Rooms 343/345, Third Level, Morial Convention Center

The 2010 APA Task Force Report on the Practice of Electroconvulsive Therapy: Evidence Based Guidelines for the Practicing Clinician

Sponsored by: The APA Council on Research and Quality Care

Chair: William M. McDonald, M.D.

1. The History of the Classification of ECT and the Challenges for the Future
   Richard Weiner, M.D.

2. The Medical Evaluation and Consent Process for Patients Undergoing ECT
   Husain Mustafa, M.D.

3. Optimal Electrode Placement in the Administration of ECT
   Sarah H. Lisanby, M.D.

4. Emerging Data on the Importance of Pulse Width in ECT
   Joan Prudic, M.D.

5. Maintenance Treatment in ECT
   Charles H. Kellner, M.D.

SYMPOSIUM 65
9:00 A.M.-NOON
Rooms 346/347, Third Level, Morial Convention Center

DSM-5 EXAMINED: NOSOLOGY OF MOOD DISORDERS

Chair: S. Nassir Ghaemi, M.D., M.P.H.

Discussant: Michael B. First, M.D.

1. How Do We Classify the Mood Disorders?
   Michael A. Schwartz, M.D.

2. Depression: When Sadness is “Lost,” What Is Gained?
   Peter D. Kramer, M.D.

3. Pediatric Bipolar Disorder: More Than a Social Construction, Less than a Natural Kind
   Peter Zachar, Ph.D.

4. Major Depressive Disorder Deconstructed: Neurotic Depression and Mixed States
   S. Nassir Ghaemi, M.D., M.P.H.

5. An Update From the DSM-5 Workgroup on Mood Disorder: A Focus on Bipolar Symptoms
   Trisha Suppes, M.D.

SYMPOSIUM 66
9:00 A.M.-NOON
Rooms 348/349, Third Level, Morial Convention Center

DSM-5 UPDATE SERIES, PART II: REPORTS FROM THE WORK GROUPS

Chair: David J. Kupfer, M.D.

1. Balancing Conservation and Innovation in DSM-5: Update on Attention-Deficit Hyperactivity Disorder
   Xavier Castellano, M.D.

2. Reconsidering the Disruptive Behavior Disorders for DSM-5
   David Shaffer, M.D.
   Paul J. Frick, Ph.D.
   Terrie E. Moffitt, Ph.D.
   Prudence W. Fisher, Ph.D.
   Michelle L. Gallagher, M.A.

3. Developing a New Model of Personality Disorders for DSM-5
   Andrew E. Skodol, M.D.

SYMPOSIUM 67
9:00 A.M.-NOON
Rooms 350-351, Third Level, Morial Convention Center

REVISITING PHARMACOLOGICAL TREATMENTS TO PREVENT SUICIDE

Co-Chairs: Stephen Koslow, M.D.
   Paula J. Clayton, M.D.

Discussant: Joseph Calabrese, M.D.

1. The Evidence for and Potential Impact of Clozapine on Suicide Risk in Schizophrenia: So How Do We Get Psychiatrists to Prescribe It?
   Herbert Y. Meltzer, M.D.

   Kristian Wahlbeck, M.D.
   Jouko Lörenqvist, M.D., Ph.D.
   Timo Klaukka, M.D., Ph.D.
   Leo Niskanen, M.D.
   Antti Tanskanen, Ph.Lic.
   Jari Haukka, Ph.D.

3. Translating Suicide Endophenotypes Shared by Humans and Mice: Novel Strategies to Understand the Mechanism of Lithium’s Antisuicidal Efficacy
   Todd Gould, M.D.
   Colleen E. Kovacsics, B.S.
   Irving I. Gottesman, Ph.D.

4. Association Between Consistent Purchase of Anticonvulsants or Lithium and Suicide Risk: A Longitudinal Cohort Study From Denmark, 1995-2001
   Eric G. Smith, M.D.

SYMPOSIUM 68
9:00 A.M.-NOON
Room 352, Third Level, Morial Convention Center

REWARD NEUROCIRCUITRY IN SUBSTANCE DEPENDENCE AND OTHER PSYCHIATRIC DISORDERS: WHAT DOES BRAIN RESEARCH TELL US?
National Institute on Drug Abuse

Co-Chairs: Susan Volman, Ph.D.
   James M. Bjork, Ph.D.

1. Reward Neurocircuitry in Preclinical Models: Foundations and Alterations With Drug Use
   Susan R. Sesack, Ph.D.

2. Functional Neuroimaging of Neural Circuits Regulating Aversive Emotional Reactions and Expectations of Reward
   Mauricio Delgado, Ph.D.

3. Neuroimaging Studies of Reward Processing in Major Depressive Disorder
   Wayne C. Drevets, M.D.

4. Association of Nicotine Addiction and Nicotine’s Actions With Separate Cingulate Cortex Functional Circuits
   Elliot Hong, M.D.

5. PET Evaluation of Neurocircuitry Related to Etiology and Treatment of ADHD
WORKSHOPS 88-93

9:00 A.M.-10:30 A.M.
Room 210, Second Level, Morial Convention Center

AGING HEROICALLY IN AN URBAN SETTING: THE DIARY OF JESSIE SYLVESTER “THE BEAUTIFUL HILLS OF BROOKLYN”

Chair: David W. Preven, M.D.

WORKSHOP 88
9:00 A.M.-10:30 A.M.
Room 230, Second Level, Morial Convention Center

TRANSCRANIAL MAGNETIC STIMULATION (TMS) IN THE TREATMENT OF MAJOR DEPRESSION: A NEW THERAPEUTIC TOOL FOR PSYCHIATRY

Chair: John O’Reardon

Presenters: Amanda Helmer, R.N.

WORKSHOP 89
9:00 A.M.-10:30 A.M.
Room 333/334, Third Level, Morial Convention Center

PRACTICAL CHALLENGES FOR PSYCHIATRISTS IMPLEMENTING THE RECOVERY MODEL

Chair: Mark Ragins, M.D.

WORKSHOP 90
9:00 A.M.-10:30 A.M.
Rooms 340/341, Third Level, Morial Convention Center

COGNITIVE-BehaviorAL AND PSYCHODYNAMIC APPROACHES TO MEDICATION ADHERENCE IN SEVERE MENTAL ILLNESS

Co-Chairs: Jesse H. Wright, M.D., Ph.D. Glen O. Gabbard, M.D.

Presenters: Douglas Turkington, M.D. Allan Tasman, M.D. Sarah Johnson, M.D., M.S.C.

WORKSHOP 91
9:00 A.M.-10:30 A.M.
Rooms 333/334, Third Level, Morial Convention Center

BOUNDARY CROSSINGS AS BOUNDARY ACCOMMODATIONS: THE PHYSICIAN/PATIENT RELATIONSHIP WITH MEDICALLY ILL PATIENTS

Co-Chairs: James W. Lomax, M.D. Catherine C. Crone, M.D.

Presenters: Andreea Seritan, M.D. John Oldham, M.D., M.S.

COURSES 53, 69-74

9:00 A.M.-4:00 P.M.
Grand Ballroom E, Fifth Floor, Sheraton New Orleans

ADULT SEXUAL LOVE AND INFIDELITY

Director: Stephen B. Levine, M.D.

COURSE 69
9:00 A.M.-4:00 P.M.
Borgne Room, Third Floor, Sheraton New Orleans

PSYCHODYNAMIC PSYCHOPHARMACOLOGY:

APPLYING PRACTICAL PSYCHODYNAMICS TO IMPROVE PHARMACOLOGIC OUTCOMES WITH TREATMENT-RESISTANT PATIENTS

Director: David L. Mintz, M.D.

Faculty: Barri Belnap, M.D. Samar Habib, M.D. Anne Carter, M.D. David Flynn, M.D.

COURSE 70
9:00 A.M.-4:00 P.M.
Bayside Room C, Fourth Floor, Sheraton New Orleans

KUNDALINI YOGA MEDITATION TECHNIQUES FOR SCHIZOPHRENIA, THE PERSONALITY DISORDERS, AND AUTISM

Director: David Shannahoff-Khalsa, B.A.

COURSE 71
9:00 A.M.-4:00 P.M.
Gallier Rooms A/B, Fourth Floor, Sheraton New Orleans

COGNITIVE-BEHAVIORAL ANALYSIS SYSTEM OF PSYCHOThERAPY (CBASP): HOPE FOR CHRONIC DEPRESSION

Co-Directors: Paula Ravitz, M.D. Sian Rawkins, M.D.

Faculty: Melyn Leszcz, M.D.

COURSE 72
9:00 A.M.-4:00 P.M.
Nottoway Room, Fourth Floor, Sheraton New Orleans

NARRATIVE HYPNOSIS FOR PSYCHIATRY: EMPHASIS ON PAIN MANAGEMENT

Director: Lewis Mehl-Madrona, M.D., Ph.D.

Faculty: Ann Marie Chiasson, M.D., M.P.H.

COURSE 73
9:00 A.M.-4:00 P.M.
Grand Couteau Room, Fifth Floor, Sheraton New Orleans

TRAUMA-INFORMED CARE: PRINCIPLES AND IMPLEMENTATION

Director: Sylvia Atdjian, M.D.
Faculty:
Tonier Cain,
Joan Gillece, Ph.D.

**COURSE 74**
9:00 A.M.-4:00 P.M.
Cornet Room, Eighth Floor,
Sheraton New Orleans Hotel

**THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES**

**Director:**
David C. Jimerson, M.D.

**Faculty:**
Joel Yager, M.D.
Katherine Halmi, M.D.
Michael Devlin, M.D.
James Mitchell, M.D.

11:00 A.M.-12:30 P.M.
Room 217/219, Second Level,
Morial Convention Center

**AGING AND DEMENTIA: AN UPDATE ON NEUROSCIENCE AND BRAIN IMAGING**

**Chair:**
Anne L. Foundas, M.D.

11:00 A.M.-12:30 P.M.
Rooms 228/229, Second Level,
Morial Convention Center

---

**HELPING PARENTS OF A FIRST-EPIODE PSYCHOTIC PATIENT**

**Director:**
S. Charles Schulz, M.D.

**Presenters:**
Richelle Moen, Ph.D.
Michael O’Sullivan, M.D.

---

**LECTURES 14-15**
11:00 A.M.-12:30 P.M.
Rooms R02/R05, Second Level,
Morial Convention Center

**Co-MORBIDITY OF PSYCHIATRIC DISORDERS**

**Frontiers of Science Lecture**

**Chair:**
Richa Pathak, M.D.

---

**LECTURE 14**
11:00 A.M.-12:30 P.M.
Rooms R02/R05, Second Level,
Morial Convention Center

---

**LECTURE 15**
11:00 A.M.-12:30 P.M.
Rooms R06/R09, Second Level,
Morial Convention Center

**HIGHLIGHTS AND LESSONS FROM 40-PLUS YEARS IN PSYCHIATRY**

**International Guest Lecture**

**Eve C. Johnstone, M.D.**

---

**BIO**

Eve Johnstone was born and brought up in Scotland. She qualified MBChB (Glasgow) in 1967 and trained as a psychiatrist in Glasgow. She went to London in 1974 to work for the Medical Research Council in their Clinical Research Centre at Northwick Park. While there she conducted many studies of the course, treatment and biological basis of schizophrenia, including the first controlled study of cerebral ventricular size in schizophrenia using modern imaging published in the Lancet 1976. In 1989 she was appointed as Professor and Head of Department of Psychiatry in the University of Edinburgh. Since then she has been involved in family and cohort studies of psychotic illness, especially schizophrenia. She is the author of more than 300 journal articles, 9 books, and numerous other publications. Over her career she has won various prizes and awards and is involved in extensive committee work for the Medical Research Council and other governmental bodies.

---

**LECTURE 16**
11:00 A.M.-12:30 P.M.
Room 230, Second Level,
Morial Convention Center

**SIDE EFFECTS OF PSYCHOTROPIC MEDICATION**

**Chair:**
David W. Preven, M.D.

---

**SCIrr 15**
11:00 A.M.-12:30 P.M.
Room 227, Second Level,
Morial Convention Center

**INFORMATION TECHNOLOGY**

**Chair:**
Jerrold J. Block, M.D.

---

44. **Web-Based Access to Medicaid Data to Support the Implementation of Best Practices in Pharmacotherapy in a Large Scale Quality**

Matthew Perkins, M.D., M.P.H.
Edith Kealey, M.S.W.
Emily Leckman-Westin, Ph.D.

---

45. **International Telepsychiatry in Cross-Cultural Related Mental Health Care**

Davor Mucic, M.D.

---

46. **Risk of Low Bone Mineral Density Associated With Psychotropic Medications and Mental Disorders: A Population-Based Analysis**

James M. Bolton, B.S.C., M.D.
Laura E. Targownik, M.D.
Stella Leung, M.Sc.
Jitender Sareen, M.D.
William D. Leslie, M.Sc., M.D.

---

47. **Metabolic Syndrome in Psychiatric Inpatients: The Role of Valproate and Lithium**

Bonnie L. Szarek, R.N.,
John W. Goethe, M.D.

---

48. **A Novel, Patient-Rated Scale for Side Effects: Prospective Proof-of-Concept Study**

Rajnish Mago, M.D.
Angelica Kloos, D.O.
Constantine Daskalakis, Sc.D.
Michelle Shvarz, M.S. Ed.
Barry Rovner, M.D.
These sessions are limited to 50 participants on a first-come, first-served basis.

**SI 14**
11:00 A.M.-12:30 P.M.
Room 236, Second Level, Morial Convention Center

**MEET THE EDITORS:**
**PRINCIPLES AND PRACTICE OF CHILD AND ADOLESCENT FORENSIC MENTAL HEALTH**

Chair:
Elissa P. Benedek, M.D.

Presenters:
Peter Ash, M.D.
Charles L. Scott, M.D.

**SI 15**
11:00 A.M.-12:30 P.M.
Room 237, Second Level, Morial Convention Center

**ADDITION AND THE BRAIN**
National Institute on Drug Abuse

Chair:
Nora D. Volkow, M.D.

**SI 16**
11:00 A.M.-12:30 P.M.
Room 235, Second Level, Morial Convention Center

**ETHICAL ISSUES IN PSYCHIATRY**

Chair:
Paul S. Appelbaum, M.D.

**SI 17**
11:00 A.M.-12:30 P.M.
Room 336, Third Level, Morial Convention Center

**PSYCHIATRIC PHARMACOGENOMICS**

Chair:
David A. Mrazek, M.D.

**SI 18**
11:00 A.M.-12:30 P.M.
Room 337, Third Level, Morial Convention Center

**PSYCHIATRIC ISSUES RELATED TO RETURNING VETS FROM IRAQ AND AFGHANISTAN**

Chair:
Elspeth C. Ritchie, M.D., M.P.H.

**WORKSHOPS 94-99**

**WORKSHOP 94**
11:00 A.M.-12:30 P.M.
Room 210, Second Level, Morial Convention Center

**ETHICAL DILEMMAS IN PSYCHIATRIC PRACTICE**
Sponsored by: The Ethics Committee

Chair:
Wade Myers, M.D.

Presenters:
Burton V. Reifler, M.D.
Stephen Green, M.D., M.A.
Elissa Benedek, M.D.

**WORKSHOP 95**
11:00 A.M.-12:30 P.M.
Room 224, Second Level, Morial Convention Center

**CAM OR SCAM FOR MOOD DISORDERS: HERBALS AND BEYOND!**

Co-Chairs:
Vishal Madaan, M.D., M.B.B.S.
Diana S. Dinnantei, M.D.

Presenters:
Nalini V. Juthani, M.D.

**WORKSHOP 96**
11:00 A.M.-12:30 P.M.
Room 235, Second Level, Morial Convention Center

**A RESIDENT’S GUIDE TO BORDERLINE PERSONALITY DISORDER: FROM THE EXPERTS (PART II)**
(For Residents Only)

Chair:
John G. Gunderson, M.D.

Presenters:
Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.
John Oldham, M.D., M.S.
Brian Palmer, M.D., M.P.H.
James Hall, B.S.

**WORKSHOP 97**
11:00 A.M.-12:30 P.M.
Rooms 333/334, Third Level, Morial Convention Center

**PSYCHIATRIC PROFESSIONAL LIABILITY 2009: THE YEAR IN REVIEW**

Co-Chairs:
Donna Vanderpool, J.D., M.B.A.
Martin G. Tracy, J.D.

Presenters:
Jacqueline Melonas, J.D., R.N.

**WORKSHOP 98**
11:00 A.M.-12:30 P.M.
Rooms 340/341, Third Level, Morial Convention Center

**THE TRAIN HAS LEFT THE STATION: NATIONAL INCENTIVES AND DEVELOPMENTS IN ELECTRONIC HEALTH RECORDS**

Chair:
Laura J. Fochtmann, M.D.

Presenters:
Zebulon Taintor, M.D.
Robert Plownick, M.D., M.S.
Steven Daviss, M.D.
Marc Graff, M.D.

**WORKSHOP 99**
11:00 A.M.-12:30 P.M.
Room 342, Third Level, Morial Convention Center

**COGNITIVE THERAPY FOR PSYCHOSIS IN PRACTICE: BASIC TECHNIQUES FOR PSYCHIATRISTS**

Chair:
Shana Rathod, M.D.

Presenters:
Douglas Turkington, M.D.
David Kingdon, M.D.

**NEW RESEARCH/POSTER SESSION 4**
NOON-2:00 P.M.
La Loussiane C, First Level, Morial Convention Center

**For further information on New Research submissions, please refer to the New Research Program section of this book.**

**1:30 P.M. SESSIONS**

**ADVANCES IN MEDICINE 8**
1:30 P.M.-3:00 P.M.
Rooms 343/345, Third Level, Morial Convention Center

**MEDICAL MYSTERIES AND PRACTICAL MEDICAL PSYCHIATRIC UPDATES: IS IT MEDICAL, PSYCHIATRIC, OR A LITTLE OF BOTH?**

Chair:
Robert M. McCarron, D.O.

**COURSES 75-76**
1:00 P.M.-5:00 P.M.
Bayside Room A, Fourth Floor, Sheraton New Orleans Hotel
The Standard EEG in Psychiatric Practice

Directors:
Nash N. Boutros, M.D.
Silvana Riggio, M.D.

COURSE 76
1:00 P.M.-5:00 P.M.
Grand Ballroom B, Fifth Floor, Sheraton New Orleans Hotel

Evidence-Based Psychodynamic Therapy

Co-Chairs:
Richard F Summers, M.D.
Jacques P Barber, Ph.D.

LECTURE 16-17
LECTURE 16
1:30 P.M.-3:00 P.M.
Rooms R02-R05, Second Level, Morial Convention Center

New Directions in Drug Policy: President Obama’s National Demand Reduction Priorities
Special Guest Lecture National Institute on Drug Abuse

A. Thomas McLellan, Ph.D.
Deputy Director and Chief Scientist White House Office of National Drug Control Policy

Chair:
Charles O’Brien, M.D.

In 2009, A. Thomas McLellan, Ph.D., was sworn in as the Deputy Director of the Office of National Drug Control Policy. Dr. McLellan brings 35 years of addiction treatment research to the position, most recently at the Treatment Research Institute, and the University of Pennsylvania. He is the recipient of several distinguished awards including the Life Achievement Awards of the American and British Societies of Addiction Medicine (2001 & 2003); the Robert Wood Johnson Foundation Innovator Award (2005); and awards for Distinguished Contribution to Addiction Medicine from the Swedish and Italian Medical Associations (2002). In his career he has published over 400 articles and chapters on addiction research and served as editor-in-chief of the Journal of Substance Abuse Treatment. Dr. McLellan has contributed to the advancement of substance abuse research and the application of research findings to treatment systems and public policy. Dr. McLellan holds a B.A. from Colgate University and his Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University in England.

Toward a New Psychiatry: Valuing the Positive Emotions
Oskar Pfister Award Lecture

George E. Vaillant, M.D.

Co-Chairs:
James Lomax, M.D.
Clark Aist, Ph.D.

Dr. Vaillant is a Professor of Psychiatry at Harvard Medical School and the Department of Psychiatry, Brigham and Women’s Hospital. Dr. Vaillant has spent his research career charting adult development and the recovery process of schizophrenia, heroin addiction, alcoholism, and personality disorder. He has spent the last 35 years as Director of the Study of Adult Development at the Harvard University Health Service. The study has prospectively charted the lives of 824 men and women for almost 70 years. His published works include Adaptation to Life, 1977, The Wisdom of The Ego, 1993, The Natural History of Alcoholism-Revisited, 1995, and Aging Well, 2002. His most recent book on the positive emotions, Spiritual Evolution was published by Doubleday Broadway in 2008. Dr. Vaillant has received the Foundations Fund Prize for Research in Psychiatry from the American Psychiatric Association, the Strecker Award from The Institute of Pennsylvania Hospital, and the Jellinek Award for research in alcoholism. Most recently he received The Distinguished Service Award from the American Psychiatric Association.

Scientific and Clinical Reports: Sessions 17-19

1:30 P.M.-3:00 P.M.
Room 227, Second Level, Morial Convention Center

Weight Gain and Psychiatric Illness

Co-Chairs:
Jeffrey C. Fetter, M.D.
Saleem Ismail, M.D.

49. Biochemical Risk Factors for Development of Obesity in First-Episode Schizophrenia
Robert Bodén, M.D.
Arvo Haenni, M.D., Ph.D.
Leif Lindström, M.D., Ph.D.
Johan Sundström, M.D., Ph.D.

50. Relationship Between Cholesterol Levels and Cognitive Function in Patients with Schizophrenia Randomized to Clozapine, Olanzapine and Haloperidol
Menahem I. Krakowski, M.D., Ph.D.
Pal Czobor, Ph.D.

51. Oatmeal Versus Donuts: Treating metabolic Syndrome/Obesity Using CBT/DBT in an Inner City SPMI Population
Joanne Caring, M.D.

52. The Relationship Between Anxiety Disorders and Suicide Attempts: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions
James M. Bolton, B.S.C., M.D.
Josh Nepon M.D.
Shay Lee Belik M.Sc.
Jitender Sareen M.D.

53. Religion, Spirituality and Risk of Suicidal Ideation and Attempts: An Epidemiological Perspective
Daniel T. Rasic, B.S., M.D.
Jennifer Robinson, M.A.
Jitender Sareen, M.D.

54. A Multi-Site Review of Post-Discharge Suicides
Virginia L. Susman, M.D.
Fritz Engstrom, M.D.
Joseph Gold, M.D.
Theodore Mucha, M.D.
Robert Roca, M.D.
Lisa Shea, M.D.
Gail Tsimpria, Ph.D.
Sharon Chaput, R.N.
Barbara Charen, R.N.
Jud Giorigi-Cipriano, R.N.
Gail Nelson, R.N.
Mary Brimson, R.N.

55. Double-Blind, Placebo-Controlled Efficacy and Safety Study of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder

Chair: Meera Vaswani, M.D., Ph.D.

56. The Relationship Between Anxiety Disorders and Suicide Attempts: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions
James M. Bolton, B.S.C., M.D.
Josh Nepon M.D.
Shay Lee Belik M.Sc.
Jitender Sareen M.D.

57. Religion, Spirituality and Risk of Suicidal Ideation and Attempts: An Epidemiological Perspective
Daniel T. Rasic, B.S., M.D.
Jennifer Robinson, M.A.
Jitender Sareen, M.D.

58. A Multi-Site Review of Post-Discharge Suicides
Virginia L. Susman, M.D.
Fritz Engstrom, M.D.
Joseph Gold, M.D.
Theodore Mucha, M.D.
Robert Roca, M.D.
Lisa Shea, M.D.
Gail Tsimpria, Ph.D.
Sharon Chaput, R.N.
Barbara Charen, R.N.
Jud Giorigi-Cipriano, R.N.
Gail Nelson, R.N.
Mary Brimson, R.N.
Ann C. Childress, M.D.
Andrew J. Cutler, M.D.
Maria Gasior, M.D., Ph.D.
Mohamed Hamdani, M.S.
Celeste Ferreira-Cornwell, Ph.D.
Liza Squires, M.D.
Robert L. Findling, M.D.

56. Is Deficient Emotional Self-Regulation a Comorbid or Integral Feature of Attention-Deficit Hyperactivity Disorder in Adults? A Controlled Study
Craig B. Surman, M.D.
Joseph Biederman, M.D.
Thomas Spencer, M.D.
Carolyn A. Miller, B.A.
Stephen V. Farame, Ph.D.

57. Adjunctive Armodafinil for Major Depression Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo Controlled Study
Joseph R. Calabrese, M.D.
Terence A. Ketter, M.D.
James M. Youakim, M.D.
Jane Tiller, FRCPsych
Ronghua Yang, Ph.D.
Mark A. Frye, M.D.

WORKSHOPS
1:30 PM - 3:00 P.M.
Room 352, Third Level, Morial Convention Center

RESPONDING TO THE IMPACT OF SUICIDE ON CLINICIANS
Chair:
Eric M Plakun, M.D.

Presenters:
Jane Tillman, Ph.D.
Edward Shapiro, M.A., M.D.

2:00 P.M. SESSIONS
ADVANCES IN SERIES 7-8
2:00 P.M.-5:00 P.M.
Rooms 356/357, Third Level, Morial Convention Center

ADVANCES IN SUBSTANCE ABUSE TREATMENT
National Institute on Drug Abuse

Co-Chairs:
Marc Galanter, M.D.
Herbert D. Kleber, M.D.

1. The Treatment of Perinatal Addiction
Hendree Jones, M.D.

2. The Use of Buprenorphine in the Treatment of Opioid Dependence
John A. Renner, M.D.

3. Treatment of Anabolic-Androgenic Steroid Abuse
Harrison Pope, M.D.

4. Treatment of Marijuana Abuse and Dependence
Mark Gold, M.D.

5. Treatment of the Dually Diagnosed
Richard K. Ries, M.D.

ADVANCES IN PERSONALITY DISORDER

Co-Chairs:
John M. Oldham., M.D., M.S.
Andrew E. Skodol, M.D.

1. A Current Review of the Literature on Borderline Personality Disorder
John M. Oldham., M.D.

2. Behavioral Genetics of DSM-IV Personality Disorder
Ted Reichborn-Kjennerud, M.D.

3. Mentalization and Mentalization-Based Treatment for Antisocial Personality Disorder
Anthony W. Bateman, M.D.

4. Neuroimaging Social Behavior in Borderline Personality Disorder
Brooks King-Casas, M.D.

5. Personality Disorders in DSM-5: Emerging Perspectives
Andrew E. Skodol, M.D.

6. Psychodynamic Psychiatry of Obsessive-Compulsive Personality Disorder
Glen O. Gabbard, M.D.
2. Integrating Mentalization-Based Treatment With Other Evidence-Based Treatments for Borderline Personality Disorder: Lethal Cocktail or Super Therapy? Anthony W. Bateman, M.B.B.S. Peter Fonagy, Ph.D.

3. The Trials and Tribulations of Implementing Dialectical Behavior Therapy Joan Wheelis, M.D.

4. Dialectical Behavioral Therapy and Mentalization-Based Treatment: An Integration of Two Empirically Validated Treatments for BPD Lois W. Choi-Kain, M.D.

SYMPOSIUM 71
Withdrawn

SYMPOSIUM 72
2:00 P.M.-5:00 P.M.
Room 223, Second Level, Morial Convention Center

THE NUTS AND BOLTS OF THE PERINATAL PSYCHIATRIC CONSULTATION

Co-Chair:
Allison S. Baker, M.D.
Carolyn A. Broudy, M.D., M.S.

1. Evaluation of Mood and Anxiety Disorders During Pregnancy and the Postpartum Period
Ruta M. Nonacs, M.D.
Adele Viguera, M.D.
Margaret Spinelli, M.D.
Kristin Leight, M.D.
Elisabeth M. Fitelson, M.D.

2. Staying Informed and Afloat: How to Approach Evidence-Based Practice in the Psychiatric Treatment of Pregnant and Postpartum Patients
Elizabeth M. Fitelson, M.D.

3. Psychotherapy Treatments
Margaret Spinelli, M.D.
Jean Endicott Ph.D.

4. The Perinatal Psychiatric Consultation: Medication Treatment
Adele C. Viguera M.D.

5. Putting It All Together: The Last Movement of the Perinatal Psychiatric Consultation
Kristin Leight, M.D.

SYMPOSIUM 73
Withdrawn

SYMPOSIUM 74
2:00 P.M.-5:00 P.M.
Rooms 225/226, Second Level, Morial Convention Center

THE TREATMENT OF PSYCHIATRIC DISORDERS WITH rTMS: NEW RESEARCH AND CLINICAL FINDINGS

Chair:
Allan S. Kaplan, M.D.

1. Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations in Schizophrenia
Zafiris J. Daskalakis, M.D.

2. Transcranial Magnetic Stimulation (TMS) for Major Depression: Past, Present and Future Challenges
Yechiel Y.L. Levkovitz, M.D.
Abraham Zangen, Ph.D.

3. Can rTMS Help Obsessive-Compulsive Disorder?
Peggy Richter, M.D.
Zafiris J. Daskalakis, M.D.
Eliza Burroughs, B.A.
Melissa Daigle, B.A.

4. A Meta-Analytic Study Evaluating Brain Activation and Response to rTMS in Anorexia Nervosa
Allan S. Kaplan, M.D.
Kate Strasbury, M.D.
Paul B. Fitzgerald, M.B.B.S., Ph.D.
Angela R. Laird, Ph.D.
Jerome Maller, Ph.D.

SYMPOSIUM 75
2:00 P.M.-5:00 P.M.
Rooms 228/229, Second Floor, Morial Convention Center

THE TATTERED SAFETY NET: THE PUBLIC MENTAL HEALTH CRISIS IN AN ECONOMIC RECESSION

Sponsored by: The APA Council on Minority Mental Health & Health Disparities

Chair:
Russell F. Lim, M.D.

Discussant:
Jeffrey Geller, M.D., M.P.H

1. Who Cares? Can We Afford to Reduce Expenditures for Mental Health Services in Times of Need?
Anita S. Everett, M.D.

2. The Economic Downturn, Mental Health, Mental Illness: Prospects for Recovery
Kenneth Thompson, M.D.

3. Mental Health Consequences of the U.S. Economic Downturn: What Do We Know and What Can Be Done?

SYMPOSIUM 76
2:00 P.M.-5:00 P.M.
Rooms 238/239, Second Level, Morial Convention Center

LESSONS FROM HURRICANE KATRINA: RESPONSE, RECOVERY AND REBUILDING

Chair:
Howard J. Ososky, M.D., Ph.D.

Discussant:
James H. Scully, Jr., M.D.

1. Charting the Course of Recovery from Mental Disorders in Hurricane Katrina
Ronald C. Kessler, Ph.D.

2. The Federal Crisis Counseling Program: Lessons From New Orleans
Kenneth Thompson, M.D.

3. Louisiana Spirit: Catastrophic Impact and Psychological Recovery
Anthony Speier, Ph.D.

4. Mental Health and Recovery Following Hurricane Katrina
Howard J. Ososky, M.D., Ph.D.
Joy D. Ososky, Ph.D.

SYMPOSIUM 77
2:00 P.M.-5:00 P.M.
Room R01, Second Level, Morial Convention Center

TOWARD A NEW MODEL FOR MENTAL HEALTH SERVICES IN THE UNIVERSITY COMMUNITY

Sponsored by: The APA Council on Children, Adolescents & Their Families

Co-Chairs:
Jerald Kay, M.D.
Victor I. Schwartz, M.D.

Discussant:
Victor I. Schwartz, M.D.

Lisa M. Bates, S.M.
Kenneth S. Thompson, M.D.

5. Adding Insult to Injury: The Public Mental Health Crisis in Regions of Long-Term Economic Stagnation
Patrick S. Runnels, M.D.

6. An Action Plan for Public Mental Health During an Economic Recession
David A. Pollack, M.D.
1. The Need for a Community Mental Health Model  
Paul J. Barreira, M.D.

2. Contributions From the Public Health Orientation  
Laurie Davidson, M.A.

3. Integrating the Student’s Family Into College Mental Health  
Kristine A. Girard, M.D.

4. The Campus as Community: Working With Administration  
Lorraine D. Siggins, M.D.

5. Psychiatry Residents in the College Mental Health Service  
Jerald Kay, M.D.

**SYMPOSIUM 78**  
2:00 P.M.–5:00 P.M.  
Rooms 333/334, Third Level, Morial Convention Center

**DSM-5 UPDATE SERIES, PART III: REPORTS FROM THE WORK GROUPS**

Chair:  
Darrel A. Regier, M.D., M.P.H.

1. DSM-5 Update on Anxiety Disorders and Obsessive-Compulsive Spectrum Disorders  
Katharine A. Phillips, M.D.

Jan Fawcett, M.D.

3. Anticipating DSM-5: Schizophrenia and Related Psychoses  
William T. Carpenter, M.D.

4. Looking Towards DSM-5: PTSD and Dissociative Disorders  
Matthew J. Friedman, M.D.

5. Update from the Mood Disorders Workgroup, Bipolar Disorder Subcommittee  
Trisha Suppes, M.D.

**SYMPOSIUM 80**  
2:00 P.M.–5:00 P.M.  
Rooms 340/341, Third Level, Morial Convention Center

**SEX AND PSYCHODYNAMICS: CONTEMPORARY APPROACHES TO CLINICAL ISSUES THROUGH THE LIFECYCLE**  
Sponsored by: The American Academy of Psychoanalysis and Dynamic Psychiatry

Chair:  
Sherry P. Katz-Bearnot, M.D.

Discussant:  
Richard C. Friedman, M.D.

1. Breaking the Silence: Discussing Sex With Teens in Psychotherapy  
Eugene Beresin, M.D.

2. Psychodynamics of Hypersexuality in Children and Adolescents With Bipolar Disorder  
Stewart L. Adelson, M.D.

3. Driven Sexual Behavior in Adults With “Soft Bipolarity:” A Psychodynamic Perspective  
Jennifer I. Downey, M.D.

4. The Role of Sexual History-Taking in Improving Psychotherapeutic Treatment  
Matthew Neltner, M.D.

5. Menopause, Depression, and Decreased Sexual Desire: A Psychodynamic Contribution  
Laurie Davidson, M.D.

**SYMPOSIUM 79**  
2:00 P.M.–5:00 P.M.  
Rooms 338/339, Third Level, Morial Convention Center

**THE CHALLENGE OF COGNITIVE ENHANCERS IN MEDICINE**  
National Institute on Drug Abuse

Co-Chairs:  
Nora D. Volkow, M.D.  
Ruben D. Baler, Ph.D., M.S.C.

1. 5-HT Receptors as Targets for Cognitive Enhancement in Schizophrenia  
Herbert Y. Meltzer, M.D.

2. ADHD Treatment, Comorbidly With SUDs, and COGS Related Diversion  
Nora D. Volkow, M.D.

3. Modafinil’s Abuse Potential and Possible Role in Cocaine Dependence  
Charles Dackis, M.D.

James M. Ellison, M.D.

5. Pharmacological Cognitive Enhancement in Neuropsychiatric Disorders and in Healthy People  
Barbara Sahakian, M.D.  
Herbert Meltzer, M.D.

**SYMPOSIUM 81**  
2:00 P.M.–5:00 P.M.  
Room 342, Third Level, Morial Convention Center

**PROGRESS AND PROMISE: PREVENTING THE FIRST EPISODE OF PSYCHOSIS**

Chair:  
William R. McFarlane, M.D.

Carter S Cameron, M.D.  
Tara Niendam Ph.D.  
J. Daniel Ragland Ph.D.  
Andrea Author Ph.D.  
Barbara Cornblatt Ph.D.  
William Cook Ph.D.  
William McFarlane, M.D.

2. Pattern of Neurocognitive Deficits in Individuals at Clinical High Risk for Psychosis  
Barbara Cornblatt, Ph.D.  
Ricardo Carrión, Ph.D.  
Terry Goldberg, Ph.D.  
Danielle McLaughlin, M.A.  
Andrea Author, Ph.D.  
William Cook, Ph.D.  
William McFarlane, M.D.

3. Transitioning from First Episode to Prodrome: Learning from the EAST Program  
Robert Wolf, M.D.  
Tamara Sales, M.A.  
Roderick Calkins, Ph.D.  
Ryan Melton, L.P.C.

4. Portland Identification and Early Referral (PIER): Conversion and Incidence Outcomes in a Catchment Area-Wide Psychosis Prevention Program  
William R. McFarlane, M.D.  
William L. Cook, Ph.D.  
Donna Downing M.S., O.T.R./L  
Ezra Susser, M.D., Ph.D.

**SYMPOSIUM 82**  
2:00 P.M.–5:00 P.M.  
Rooms 346/347, Third Level, Morial Convention Center

**REPRODUCTIVE ISSUES AND WOMEN'S MENTAL HEALTH: HOW TO UNITE THE GORDIAN KNOT?**

Chair:  
Gisèle Apter, M.D., Ph.D.

Discussant:  
Carol Nadelson, M.D.

1. Why Psychiatry and Abortion?  
Nada L. Stotland, M.D.
2. Dilemmas Concerning Miscarriage and Genetic Terminations
Gail Erlick Robinson M.D., D.Psych, F.R.C.P. (C)

3. The Right to Health: The Need to Uphold Sexual and Reproductive Health to Promote Mental Health in Latin America
Marta B. Rondon, M.D.

4. What if Motherhood Cannot Chase All the Blues Away?
Gisèle Apter, M.D.

**SYMPOSIUM 82**
2:00 P.M.-5:00 P.M.
Rooms 348/349, Third Level, Morial Convention Center

**TREATMENT OF DEPRESSION WITH TMS: AN OVERVIEW OF FINDINGS FROM THE OPTIMIZATION OF TMS FOR THE TREATMENT OF DEPRESSION TRIAL (OPT-TMS)**

Co-Chairs:
William M. McDonald, M.D.
Mark S. George, M.D.

1. Introduction and State of the Current Practice and Knowledge
Mark S. George, M.D.

2. Clinical Results From the Randomized OPT-TMS Trial
Paul Holtzheimer, M.D.

3. How Do These Results Relate to Clinical Practice and How Do We Decide Who to Treat and for How Long?
William M. McDonald, M.D.

4. How Do You Create a TMS Sham?
Sarah H. Lisanby, M.D.

5. How Long Do the TMS Clinical Effects Last?
Antonio Montavani, M.D.

6. How Does Prefrontal TMS Work to Treat Depression?
Ziad H. Nahas, M.D.

**SYMPOSIUM 84**
2:00 P.M.-5:00 P.M.
Rooms 350/351, Third Level, Morial Convention Center

**MOOD, MEMORY AND MYTHS: WHAT REALLY HAPPENS AT MENOPAUSE?**

Co-Chairs:
C. Neill Epperson, M.D.
Ellen Freeman, Ph.D.

1. Depression and Other Symptoms: Risks in the Transition to Menopause
Ellen Freeman, Ph.D.

2. Hot Flashes and Sleep Disturbances During Menopause Transition: Exploring Effective Treatment Strategies
Claudio N. Soares, M.D.

3. Sexuality in Transition: Menopause and Aging
Anita H. Clayton, M.D.

4. Where Did I Put My Keys? The Ongoing Saga of Estrogen, Serotonin, Mood and Memory at Menopause
C. Neill Epperson, M.D.

**WORKSHOPS**
2:00 P.M.-5:00 P.M.
Rooms 208/209, Second Level, Morial Convention Center

**NOVEL PROGRAMS TO PROMOTE MENTAL WELLNESS IN MEDICAL STUDENTS**

Sponsored by: The American Foundation for Suicide Prevention

Co-Chairs:
Julie A Chilton, M.D.
Leah J. Dickstein, M.D., M.A.

Presidents:
Leah Dickstein, M.D., M.A.
Christine Moutier, M.D.
Julie Chilton, M.D.

**NEW RESEARCH/POSTER SESSION 5**
3:00 P.M.-5:00 P.M.
La Louisiane C, First Level, Morial Convention Center

**FORUM 4**
3:30 P.M.-5:00 P.M.
Rooms 334/345, Third Level, Morial Convention Center

**GLOBAL DISASTERS: LESSONS LEARNED FROM HAITI & NEW ORLEANS**

Sponsored by: The American Psychiatric Association, Pan American Health Organization/World Health Organization, World Psychiatric Association Conflict Management and Resolution Section

Chair:
Eliot Sorel, M.D.

**LEcTURES LECTURE 18**
3:30 P.M.- 5:00 P.M.
R02/R05 Second Level, Morial Convention Center

**PREVENTION INITIATIVES IN SCHIZOPHRENIA**

Research Award Lecture

**BIO**

Thomas H. McGlashan, M.D.

Chair:
Stuart C. Yudofsky, M.D.

He enjoys a national and international reputation for his work on the course and outcome of schizophrenia. Dr. McGlashan conducted the now classic Chestnut Lodge Follow-Up Study and his work examining suicide, gender differences, the predicting of outcomes in schizophrenia, as well as the phenomenology and natural history of negative symptoms, obsessive compulsive symptoms, and spontaneous dyskinesia has been especially productive. His nosologic investigations of schizophrenia subtypes has informed his participation on the APA’s workgroup to draft the DSM-IV diagnostic criteria for psychotic disorders and his being invited twice to be a member of the APA committee to draft the Practice Guidelines for Schizophrenia. Dr. McGlashan’s work has had a substantial impact on the way we describe, diagnose, track, treat, and think about schizophrenia and severe personality disorders.
The Association Between Pre-Admission Suicidality and Readmission is Modified by Patient Experiences, Feelings and Characteristics
Stephen B. Woolley, D.Sc., M.P.H.
John W. Goethe, M.D.
Bonnie L. Szarek, R.N.

Effectiveness of Peer Support in Reducing Readmissions Among People with Multiple Psychiatric Hospitalizations
William H. Sledge, M.D.
Martha Lawless
Dave Sells, Ph.D.
Melissa Wieland, Ph.D.
Maria O’Connell, Ph.D.
Larry Davidson, Ph.D.

Inpatients With Psychotic Versus Nonpsychotic MDD: Prevalence and Clinical Characteristics
John W. Goethe, M.D.
Bonnie L. Szarek, R.N.

Effectiveness of Peer Support in Reducing Readmissions Among People with Multiple Psychiatric Hospitalizations
William H. Sledge, M.D.
Martha Lawless
Dave Sells, Ph.D.
Melissa Wieland, Ph.D.
Maria O’Connell, Ph.D.
Larry Davidson, Ph.D.

Inpatients With Psychotic Versus Nonpsychotic MDD: Prevalence and Clinical Characteristics
John W. Goethe, M.D.
Bonnie L. Szarek, R.N.

Ethical Challenges in end-of-Life Care in the Hospitalized Elderly
Chair: Maria I. Lapid, M.D.
Presenters:
Jarrett Richardson, M.D.
Maria I. Lapid, M.D.
M. Caroline Burton, M.D.

Dynamic Therapy with Self-Destructive Borderline Patients: An Alliance-Based Intervention for Suicide
Co-Chairs:
Eric M. Plakun, M.D.
Edward Robert Shapiro, M.A., M.D.

Feasibility and Effectiveness of Using E-mail to Screen College Students for Depression
Irene Shyu, B.A.
Soo Jeong Youn, B.A.
Maurizio Fava, M.D.
Albert Yeung, M.D.

The Valuation of Impairment: Relative Values on the Psychiatric Impairment Rating (PIRS) Subscales
Gordon R. Davies, M.B., B.S.

Are Screening Scales for Bipolar Disorder Good Enough to be Used in Clinical Practice?
Mark Zimmerman, M.D.

WORKSHOPS 101-102

WORKSHOP 101
3:30 P.M.-5:00 P.M.
Room 235, Second Level,
Morial Convention Center

ETHICAL CHALLENGES IN END-OF-LIFE CARE IN THE HOSPITALIZED ELDERLY

WORKSHOP 102
3:30 P.M.-5:00 P.M.
Room 352, Third Level,
Morial Convention Center

DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS: AN ALLIANCE-BASED INTERVENTION FOR SUICIDE

4:00 P.M. SESSIONS
LECTURE 19
4:30 P.M.-5:30 P.M.
Grand Salon A, First Level,
Hilton New Orleans Riverside

DEPRESSION AND SUICIDAL BEHAVIOR IN LATINO POPULATIONS
Simon Bolivar Award Lecture
Maria Oquendo, M.D.
Chair: Andres Pumariega, M.D.

7:00 P.M. SESSIONS

WORKSHOPS MEDIA WORKSHOP 6
7:00 P.M.-10:00 P.M.
Grand Salon B, First Level,
Hilton New Orleans Riverside

BOY INTERRUPTED

Co-Chairs:
Nancy Rappaport, M.D.
Joanne Harpel, J.D.

Presenters:
Dana Perry

Maria A. Oquendo, M.D., is Professor of Clinical Psychiatry at Columbia University, Training Director for the Residency Program, and Vice-Chair for Education in the Department of Psychiatry at Columbia University and the New York State Psychiatric Institute (NYSPI). She is a Fellow of the American Psychiatric Association and the President of the American Society of Hispanic Psychiatrists. Her areas of expertise include the diagnosis, pharmacologic treatment, and neurobiology of bipolar disorder and major depression with a special emphasis on suicidal behavior, as well as Cross Cultural Psychiatry. Dr. Oquendo is the principal investigator on a NIMH-funded prospective study of suicidal behavior in patients with affective disorders and on a Conte Center project on candidate genes and HPA axis function in mood-disordered suicide attempters. She was recently awarded an R25 grant to create a research track in the residency-training program together with Drs. Gordon and Pincus. She has authored or co-authored over 200 peer-reviewed articles, chapters, and editorials.
WEDNESDAY
8:00 A.M. SESSIONS
MASTER COURSES
MASTER COURSE 5
8:00 A.M.-NOON
Grand Ballroom C, Fifth Floor, Sheraton New Orleans Hotel

NEUROPSYCHIATRY FOR VETERANS

Director(s):
Stuart C. Yudofsky, M.D.
Thomas Kosten, M.D., M.A.

Faculty:
Robin Hurley, M.D.
Thomas Kosten, M.D., M.A.
Thomas Newton, M.D.
Kimberly Arlinghaus, M.D.

9:00 A.M. SESSIONS
CASE CONFERENCES
CASE CONFERENCE 4
9:00 A.M.-NOON
Rooms 338/339, Third Level, Morial Convention Center

The Self-Defeating Patient

Chair:
Glen O. Gabbard, M.D.

Presenters:
Funmilayo Rachal, M.D.

COURSES COURSE 77
9:00 A.M.-4:00 P.M.
Grand Ballroom E, Fifth Floor, Sheraton New Orleans Hotel

KUNDALINI YOGA MEDITATION FOR ANXIETY DISORDERS INCLUDING OCD, DEPRESSION, ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, AND POST-TRAUMATIC STRESS DISORDER

Director:
David Shannahoff-Khalsa, B.A.

LECTURES LECTURE 20
9:00 A.M.-10:30 A.M.
Rooms R02-R05, Second Level, Morial Convention Center

SO YOU WANT TO BE A PHYSICIAN EXECUTIVE
Administrative Psychiatry Award Lecture

Arthur L. Lazarus, M.D., M.B.A.

Chair:
Barry K. Herman, M.D.

BIO

Arthur Lazarus, M.D., M.B.A., is senior director of clinical research for AstraZeneca Pharmaceuticals in Wilmington, Del. He is responsible for establishing AstraZeneca as the gold standard for medical research by developing and managing strategic clinical trials for pharmaceutical products and ensuring their successful utilization in the U.S. Dr. Lazarus has more than 20 years of experience in health care practice and administration. Previously, he served as director and medical research specialist for Pfizer, Inc. Earlier, he led quality management and care delivery programs at Humana, Prudential Health Care and Independence Blue Cross. Dr. Lazarus earned his medical and business degrees from Temple University in Philadelphia. He also has published over 100 articles in scientific and professional journals and cowrote or edited four books. He resides in Chadds Ford, Pa., with his wife and four children.

65. Psychiatric Phenotype in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
Andreea I. Seritan, M.D.
James A. Bourgeois, O.D., M.D.
E. Melina Casillas, B.A.
David Hessl, Ph.D.
Andrea Schneider, Ph.D.
Ying Yang, M.S.
Inderjeet Kaur, M.B.B.S.
Jennifer B. Cogswell, B.A.
Danh V. Nguyen, Ph.D.
Randi J. Hagerman, M.D.

66. Association of Seropositivity for Influenza and Coronavirus With History of Mood Disorders and Suicide Attempts
Olaoluwa O. Okusaga, M.D.
Robert H. Yolken, M.D.
Patricia Langenberg, Ph.D.
Manana Lapidus, M.D.
Timothy A. Arling, B.A.
Faith B. Dickerson, Ph.D.
Debra A. Scrandis, M.D.
Johanna A. Cabassa, M.D.
Theodora Balis, M.D.
Teodor T. Postolache, M.D.

67. Childhood and Adolescence Predictors of Psychosis in General Population in the Northern Finland 1986 Birth Cohort
Pirjo H. Maki, M.D., Ph.D.
Jouko Miettunen, Ph.D.
Irma Moilanen, M.D., Ph.D.
Marika Kaakin, M.Sc.
Anja Taanila, Ph.D.
Tuula Hurtig, Ph.D.
Graham Murray, M.D., Ph.D.
Peter B. Jones, M.D., Ph.D.
Matti Joukamaa, M.D., Ph.D.
Markus Heinimaa, M.D., Ph.D.
Sebastian Therman, M.Psych.
Juha Veijola, M.D., Ph.D.

The Use of Video Feedback to Improve the Mother-Infant Relationship in Women With Postnatal Depression
Anne Buist, M.D.
Justin Bilisz, Ph.D.
Nur Rusydina Zulkefli
Fandy Wang

Medical Comorbidity in Bipolar Children With Rapid Cycles: Is It Different Relative to Non-Rapid-Cycling Children?
Ruby C. Castilla-Puentes, M.D., D.P.H.
Wilma I. Castilla-Puentes, M.D.
Sandra R. Castilla-Puentes, M.D.
Carlos Sanchez-Russi, Ph.D.
Miguel E. Habeych, M.D.

**SCR 24**
9:00 A.M.-10:30 A.M.
Rooms 231/232, Second Level,
Morial Convention Center

**ANTIDEPRESSANT RESPONSE AND AUGMENTATION**

Chair:
Tana A. Grady-Weliky, M.D.

70. Quetiapine: Augmentation of Antidepressant Treatment in Elderly Depressed Patients
Yoram Barak, M.D., M.H.A.
Shelly Tadger, M.D.
Diana Paleacu, M.D.

71. Do Adjunctive Stimulants Destabilize Mood in Patients With Bipolar Disorders?
Findings From the STEP-BD
Joseph F. Goldberg, M.D.
John O. Brooks, III, M.D., Ph.D.
Terence A. Ketter, M.D.
Joseph R. Calabrese, M.D.
Michael E. Thase, M.D.

72. Difference Between Morning and Evening TRH Tests Could Predict Antidepressant Response
Fabrice Duval, M.D.
Marie-Claude Mokrani, Ph.D.
Felix Gonzalez Lopera, M.D.
Thanh Son Diep, M.D.
Hassen Rabia, M.D.
Said Fattah, M.D.

**SCR 25**
9:00 A.M.-10:30 A.M.
Room 335, Third Level,
Morial Convention Center

**PSYCHOPHARMACOLOGY**

Chair:
TBD

73. Tolerability of High-Dose Venlafaxine XL in Depressed Patients
Faouzi F.D. Alam, M.D., Psy.D.
Patrick Mbaya, M.B.B.S., M.R.C.Psych.
Krishna Soywnnya, M.B.B.S., M.R.C.Psych.
Javed Qaisar, M.B.B.S., M.R.C.Psych.

74. Twelve-Month Herbal Medicine Use for Mental Health From the National Comorbidity Survey: Replication (NCS-R)
Simha E. Ravven, M.D.
M. Bridge Zimmerman, Ph.D.
Susan K. Schultz, M.D.
Robert B. Wallace, M.D., M.S.

75. Relationship Between Serum Venlafaxine, Its Metabolite Levels (O-Desmethylvenlafaxine) and Treatment Response in Patients With Refractory Depression
Qaiser Q. Javed, M.B.B.S.
Alam F. M.R.C. Psych.
Geetha Jaganathan, M.D.

**SMALL INTERACTIVE SESSIONS 19-22**

These sessions are limited to 50 participants on a first-come, first-served basis.

**SI 19**
9:00 A.M.-10:30 A.M.
Room 236, Second Level,
Morial Convention Center

**ALTERNATIVE TREATMENTS IN PSYCHIATRY**

Chair:
David Mischoulon, M.D., Ph.D.

**SI 20**
9:00 A.M.-10:30 A.M.
Room 237, Second Level,
Morial Convention Center

**RESEARCH AND CLINICAL MANAGEMENT OF PATIENTS WITH TREATMENT-RESISTANT DEPRESSION**

Chair:
Carlos Zarate, M.D.

**SI 21**
9:00 A.M.-10:30 A.M.
Room 336, Second Level,
Morial Convention Center

**HOW TO GET YOUR PAPER PUBLISHED**

Chair:
Julio Licinio, M.D.

**SESSION TRACKS**

1. Affective Disorders (Mood and Anxiety)
2. Personality Disorders
3. Psychopharmacology
4. Psychotherapy
5. Schizophrenia and Other Psychotic Disorders
6. NIDA
7. DSM-5

**SYMPOSIA 85-98**

**SYMPOSIUM 85**
9:00 A.M.-NOON
Rooms 220/222, Second Level,
Morial Convention Center

**WOMEN’S MENTAL HEALTH IN LATIN AMERICA: PRESENT AND FUTURE RESEARCH**

Co-Chairs:
Wilma I. Castilla-Puentes, M.D.
Silvia Gaviria, M.D.

Discussant:
Maria Adelaida Rueda-Lara, M.D.

1. Depression Among Women With Cancer in Ecuador
Carlos León-Andrade, M.D.

2. Childhood Sexual and Physical Abuse History in a Gynecology Outpatient Clinic in Colombia: How Abuse Impacts Menopausal Symptoms
Ruby C. Castilla-Puentes, M.D.
Wilma I. Castilla-Puentes, M.D.
Sandra R. Castilla-Puentes, M.D.
Ivan Gomez, M.D.
Carlos Sanchez-Russi, Ph.D.
Miguel Habeych, M.D.

3. Improving the Treatment of Depression in Chilean Women
Enrique Jadresic, M.D.
Graciela Rojas, M.D.

4. Clinical Presentation and Treatment of Girls With Attention-Deficit/Hyperactivity Disorder in Chile and Argentina
Arturo P. Grau, M.D.
Roberto Yunes, M.D.

5. Women’s Mental Health in Latin America: Present and Future
Elvia Velásquez, M.D.
Silvia Gaviria, M.D.

6. Differences and Similarities in Mental Health Issues Between Men and Women in Latin America
Jorge Forero, M.D.
German Rueda, M.D.
Christian Munoz, M.D.
Castulo Casneros, M.D.
7. Suicidal Behavior and Substance Abuse Among Sexually Abused Girls in Ecuador
   Emma Saad, M.D.

**SYMPOSIUM 86**
9:00 A.M.-NOON
Room 224, Second Level, Morial Convention Center

**HOW DYSFUNCTION OF LEARNING AND MEMORY CIRCUITS CONTRIBUTE TO SUBSTANCE ABUSE AND OTHER PSYCHIATRIC DISORDERS**
National Institute on Drug Abuse

**Co-Chairs:**
Roger G. Sorensen, Ph.D., M.P.A.
Steven Grant, Ph.D.

1. Selective Impairments in Reward Versus Punishment Learning in Psychiatric Disorders
   Mark A. Gluck, Ph.D.

2. Addiction as Dysfunction in Learning- and Memory-Based Decision Systems: Multiple Potential Failure Points Leading to Multiple Addiction Endophenotypes
   A. David Redish, Ph.D.

3. Impaired Modulation of Learned Motivational Responses to Cues: Common Core Dysfunctions in Addiction—and in PTSD
   Anna Rose Childress, Ph.D.

4. Neuroplasticity in Prefrontal Regulation of the Basal Ganglia Underlies Vulnerability to Relapse
   Peter W. Kalivas, Ph.D.
   Haowei Shen, Ph.D.
   Khaled Moussawi, B.S.

5. Emotional Influences on Memory Circuits in Posttraumatic Stress Disorder and Healthy Adults
   Kevin S. LaBar, Ph.D.

**SYMPOSIUM 87**
9:00 A.M.-NOON
Rooms 225-226, Second Level, Morial Convention Center

**ADVANCES IN PSYCHIATRIC ETHICS: NEW APPROACHES THAT INFORM PSYCHIATRIC PRACTICE**

**Co-Chairs:**
Philip J. Candilis, M.D.
Jinger G. Hoop, M.D., M.F.A.

**Discussant:**
Laura W. Roberts, M.D.

1. Neuroethics: An Introduction for the Clinical Psychiatrist
   Jinger G. Hoop, M.D.
   Ryan Spelcey, Ph.D.

2. Ethical Considerations From Military Psychiatry
   Christopher H. Warner, M.D.
   George N. Appenzeller, M.D., LTC, MC, USA
   Thomas Grieger, M.D., CAPT (RET), MC, USN
   David M. Benedek, M.D., LTC, MC, USA
   Laura W. Roberts, M.D., M.A.

3. What Do Forensic Ethics Mean for General Psychiatry?
   Philip J. Candilis, M.D.

4. Research Ethics and the Practicing Psychiatrist: The Brave New World of Research in One’s Private Practice
   Donna T. Chen, M.D.
   Lois L. Shepherd, J.D.

5. Psychiatric Ethics Through the Prism of Geriatric Research
   Sahana Misra, M.D.

**SYMPOSIUM 88**
9:00 A.M.-NOON
Rooms 228/229 Second Level, Morial Convention Center

**ADHD FAQS: PRACTICAL ANSWERS FOR THE OFFICE-BASED PRACTITIONER**

**Chair:**
Gabriel Kaplan, M.D.

1. How Do I Identify and Treat Adult ADHD?
   Gabriel Kaplan M.D.

2. Cardiovascular Effects of Stimulants—Is There Cause for Concern?
   Donald Greydanus, M.D.

3. How Do I Approach the Bipolar Versus ADHD Issue?
   Christopher K. Varley, M.D.

4. How Do I Manage the ADHD/SUD Comorbidity?
   Atilla Turgay, M.D.

**SYMPOSIUM 89**
9:00 A.M.-NOON
Room 230, Second Level, Morial Convention Center

**AUTONOMY IN THE PROLONGATION AND CURTAILMENT OF LIFE**

**Co-Chairs:**
Norman B. Levy, M.D.
James J. Strain, M.D.

1. The Balance Between Suicide and Autonomy: End-of-Life Decisions: A Model Based on Chronic Kidney Disease and Dialysis
   Lewis M. Cohen, M.D.

2. Existential Resilience in Metastatic Breast Cancer: Choosing Life While Facing Death
   David Spiegel, M.D.
   Chin-Po Paul Yang, M.D., Ph.D., M.P.H.
   Michael Norden, M.D.
   Amitava Biswas, M.D.

3. Ethics and Judaism: Christian Views of Suicide and Life Extension
   Norman B. Levy, M.D.

4. Ethics in Suicide Not Associated With Psychiatric Illness
   James J. Strain, M.D.
   Rosamond Rhodes, Ph.D.

**SYMPOSIUM 90**
9:00 A.M.-NOON
Rooms 238/239, Second Level, Morial Convention Center

**NEW PERSPECTIVES ON INTERGENERATIONAL TRANSMISSION OF BPD**

**Chair:**
John G. Gunderson, M.D.

1. Genetic and Environmental Contributions to Borderline Personality Disorder
   John Livesley, M.D.

2. Familial Aggregation and Heritability of Borderline Personality Disorder and Its Component Traits
   Mary C. Zanarini, Ed.D.

3. Rejection Sensitivity as a Core Trait of Borderline Personality Disorder
   Lois W. Choi-Kain, M.D.
   John G. Gunderson, M.D.
   James Hudson, M.D.
   Mary Zanarini, Ed.D.

4. Familiality of Candidate Phenotypes
   John G. Gunderson, M.D.

5. Infantile Hypersensitivity to the Social Environment and Potential Developmental Failure in Affect Regulation, Effortful Control and Mentalization
   Peter Fonagy, Ph.D.
New CANMAT Guidelines for Depression and Bipolar Disorder: Combining Evidence with Clinical Practice

**Chair:** Roumen V. Milev, M.D., Ph.D.

1. CANMAT Clinical Guidelines for Mood & Anxiety Disorders—History and Development
   Sidney H. Kennedy, M.D.

2. CANMAT Clinical Guidelines for Management of Adults With Major Depressive Disorder
   Raymond W. Lam, M.D.

3. CANMAT Guidelines for Management of Bipolar Depression
   Lakshmi N. Yatham, M.B.B.S.

4. Combining Evidence-Based Psychiatry With Clinical Practice—CANMAT and Other Recent Guidelines
   Sagar Parikh, M.D.

Update on Cannabis Use Disorders

**Chair:** David A. Gorelick, M.D., Ph.D.

1. Marijuana Abuse and Dependence in the General Population: Risk Factors, Symptom Structure, and Axis I and Axis II Comorbidity Effects on Persistence
   Deborah S. Hasin, Ph.D.
   Efrat Aharonovich, Ph.D.
   Katherine Keyes, M.P.H.
   Timothy Geier, B.A.

2. Neurobiology and Brain Imaging of Cannabis Dependence
   Aviv Weinstein, B.S.C.

3. Advances in the Development of Behavioral Treatments for Cannabis Use Disorders
   Alan Budney, Ph.D.

4. Advances in the Development of Pharmacological Treatments for Cannabis Use Disorders
   Margaret Haney, Ph.D.

5. Medical and Psychiatric Effects Associated With Cannabis Use
   David A. Gorelick, M.D.

Cultural Adaptation of Cognitive-Behavior Therapy for Ethnic/Minority Patients

**Co-Chairs:**
Stephen M. Goldfinger, M.D.
Shanaya Rathod, M.D.

**Discussant:**
Toshiaki A. Furukawa, M.D., Ph.D.

1. Cognitive-Behavior Therapy Across Cultures
   David G. Kingdon, M.D.

2. Developing Culturally Sensitive Cognitive-Behavior Therapy for Psychosis: A United Kingdom-Based Study
   Shanaya Rathod, M.D.
   David G. Kingdon, M.D.
   Peter Phiri

3. Developing Culturally Sensitive CBT Project, Southampton: Adaptation of CBT for Depression in Pakistan
   Farooq Naeem, M.R.C.
   Mary Gobbi, M.D.
   Mohammed Ayub, M.B.B.S.
   David G. Kingdon, M.D.

4. Implementing CBT for Psychosis in the Treatment of Ethnic Minorities in the United States
   Michael Garrett, M.D.

Choosing the Right Treatment for Substance Abuse

**Chair:** Herbert D. Kleber, M.D.

1. Choosing the Right Treatment for Cocaine Dependence
   Adam Bisaga, M.D.

2. Choosing Treatments for Cannabis Dependence: What Are the Options?
   Frances R. Levin, M.D.

3. Principles of Combining Medications and Psychosocial Interventions in the Treatment of Substance Dependence
   Edward V. Nunes, M.D.

4. Pain and Addiction: Substance Use Disorders in the Context of Opioid Therapy
   Maria A. Sullivan, M.D.

should “Risk Syndrome of Psychosis” be included in DSM-5 as a Diagnosis? A Road Toward Preventive Psychiatry

**Chair:** Amresh Shrivastava, M.D., D.P.M.

**Discussant:**
William Carpenter, M.D.

1. Risk Syndrome of Psychosis as a Diagnosis in DSM-5: Is the Question Legitimate?
   Amresh Shrivastava, M.D.
   John John, M.D.
   Megan Johnston, M.A.

2. Inclusion of the Psychosis Risk Syndrome in DSM-5: An Argument for Placing It in the Appendix
   Cheryl Corcoran, M.D.

3. An Overview of the Current Status of Risk Syndrome for Psychosis
   Ming T. Tsuang, M.D.
   Larry J. Seidman, Ph.D.

4. Risk Syndrome for Psychosis: A Reliable and Valid Diagnosis
   Scott W. Woods, M.D.

5. Inclusion of the Psychosis At-Risk Category in DSM-5: Is It Premature?
   Barbara Cornblatt, Ph.D.

Synaptic Biology of Depression: G Proteins, Lipid Rafts, and the Search for a Biomarker

**Chair:** Mark H. Rapaport, M.D.

1. Synaptic Biology of Depression: G Proteins, Lipid Rafts, and the Search for a Biomarker
   Mark M. Rasenick, Ph.D.

2. Animal Models: Cell Cycle Regulators and Neurobehavioral Disorders
   Robert N. Pechnick, Ph.D.

3. Altered Brain Bioenergetics: A Reflection of Mitochondrial Dysfunction During the Treatment of Major Depressive Disorder
   Dan V. Iosifescu, M.D.
4. Neurogenesis Assays Prospectively Identify a Novel Clinically Efficacious Combination for the Treatment of Major Depressive Disorder
Carrolee Barlow, M.D.

SYMPOSIUM 97
9:00 A.M.-NOON
Rooms 333/334, Third Level, Morial Convention Center

THE SUPREME COURT AND PSYCHIATRY IN THE 21ST CENTURY

Chair:      Paul S. Appelbaum, M.D.

Discussant: Richard Bonnie, J.D.

1. Atkins v. Virginia: Mental Retardation and the Death Penalty
Paul S. Appelbaum, M.D.

2. Clark v. Arizona: The Supreme Court Considers the Insanity Defense and Psychiatric Testimony
Steven K. Hoge, M.D.

Howard V. Zonana, M.D.

4. Indiana v. Edwards: Competence to Represent Oneself
Debra Pinals, M.D., S. Kenneth Hoge, M.D., Richard Bonnie, L.L.B., Paul S. Appelbaum, M.D.

SYMPOSIUM 98
9:00 A.M.-NOON
Rooms 356/357, Third Level, Morial Convention Center

NOVEL TOOLS FOR PREVENTING AND TREATING SUBSTANCE USE AND COMORBIDITIES IN THE MILITARY AND RETURNING VETERANS
National Institute on Drug Abuse

Co-Chairs: Cecelia M. Spitznas, Ph.D., Eve E. Reider, Ph.D.

Discussant: Michael Kilpatrick, B.A., M.D.

1. Understanding Long-Term Tobacco and Alcohol Use and Comorbid Mental Health Symptoms in Military Service Members and Veterans: The Millennium Cohort Study
Tyler C. Smith, Ph.D.

2. Automated Interactive Voice Response as a Therapeutic Tool for Chronic Pain Reduction and Opioid Medication Use Decrease
Magdalena R. Naylor, M.D., Ph.D., Shelly Naud, Ph.D., Bart Brigidi, Ph.D., Michele Comette, B.A., Francis J. Keefe, Ph.D., John E. Helzer, M.D.

3. Virtual Reality and d-Cycloserine for Exposure-Based Therapy
Barbara Rothbaum, Ph.D.

4. The Video Doctor Approach: Potential Applications to Psychiatric Practices Serving Patients Impacted by War
Barbara Gerbert, Ph.D.

Kathleen M. Carroll, Ph.D., Samuel A. Ball, Ph.D., Steve Martino, Ph.D., Charla Nich, M.S., Bruce J. Rounsaville, M.D.

WORKSHOP 103-106
9:00 A.M.-10:30 A.M.
Room 210, Second Level, Morial Convention Center

MAKING YOUR PRESENTATION MORE INTERACTIVE: THE BETTER WAY!

Chair: Jon J.D. Davine, M.D.

WORKSHOP 104
9:00 A.M.-10:30 A.M.
Room 235, Second Level, Morial Convention Center

FIGHTING STIGMA: WHEN PSYCHIATRISTS WHO HAVE BEEN IN TREATMENT SPEAK OUT

Co-Chairs: Michael F. Myers, M.D., Leah J. Dickstein, M.D., M.A.

Presenters: Alphonse Osinski, M.D., Raymond Reyes, M.D., Suzanne E. Vogel-Scibilia, M.D., Francine Cournos, M.D.

WORKSHOP 105
9:00 A.M.-10:30 A.M.
Room 333/334 Third Level, Morial Convention Center

THE AWKWARD PROCESS OF RECRUITING YOUR OWN

Chair: Lewis Krain, M.D.

Presenters: Brandi Hawkins, Ph.D., Gregory Dalack, M.D., Michael Jibson, M.D., Ph.D., Molly Gathright, M.D.

WORKSHOP 106
9:00 A.M.-10:30 A.M.
Rooms 350/351, Third Level, Morial Convention Center

ASSessment of Capacity: Developments, Documentation and Defendability
Chair: Michael Jan Wise, M.B.B.S, M.S.C.

Presenters: Julian Beezhold, M.D.

MEDIA WORKSHOP 7
9:00 A.M.-NOON
Rooms 208/209, Second Level, Morial Convention Center

BUILDING BRIDGES: THE INTERSECTION BETWEEN FAITH AND MENTAL HEALTH

Co-Chairs: Asghar-Ali A. Ali, M.D., Cecil R. Webster, M.D.

Presenters: Toi Harris, B.A., M.D., Annelle Pimm, M.D., M.P.H., Valdesha Ball, M.D., Chanda Mayers-Elder, M.D.

11:00 A.M. SESSIONS

ADVANCES IN MEDICINE

11:00 A.M.-12:30 P.M.
Rooms 217/219, Second Level, Morial Convention Center

An Update on Gastroenterology and Hepatology for Psychiatrists and Mental Health Practitioners
Chair: Nathaniel S. Winstead, M.D., M.P.H.

LECTURES

11:00 A.M.-12:30 P.M.
Rooms R02-R05, Second Level, Morial Convention Center

SEEK and Treat for Optimal Prevention of HIV/AIDS-STOP HIV/AIDS Frontier of Science Lecture
National Institute on Drug Abuse
1. Julio Montaner, M.D.
   Chair: Annette M. Matthews, M.D.

   **BIO**
   Julio Montaner, M.D. received his M.D. with honors in 1979 at the University of Buenos Aires, Argentina. In 1981, he joined the University of British Columbia as a post-doctoral fellow, completed a residency in internal medicine and respiratory medicine and was chief resident for the Department of Medicine in 1986/1987. In 1987 Dr. Montaner joined the faculty at St. Paul’s Hospital/University of British Columbia (SPH/UBC) as the director of the AIDS Research Program and the Infectious Disease Clinic. He is the director of clinical activities at the BC Centre for Excellence in HIV/AIDS and a founding co-director of the Canadian HIV Trials Network. He held a National Aids Coordinating Committee Chair: Julio Montaner, M.D.

   **ISSUES IN MOOD DISORDERS**
   Chair: James Ellison, M.D.

   79. Minor Mixed Depression (Formerly Mixed Affective State): A Treatable Condition in Violent Court-Ordered Detention Patients With a Personality Disorder
   Carel C.V. De Blécourt, M.D., Ph.D.
   Tjoe I. Oei, M.D., Ph.D.

   80. Psychosocial Impairment Associated With Dysthymic Disorder in the NESARC Study
   David J. Hellerstein, M.D.
   Vito Agosti, C.S.W.
   Sarah Black, M.A.
   Monica Bosi, M.D.

   81. Increased Mortality and Hospital Readmissions in Patients Depressed at the Time of Discharge From Medical Wards
   Antonio Campayo, M.D.
   Antonio Bulbena, M.D., Ph.D.
   Joan DePablo, M.D., Ph.D.
   Josep Maria Farré, M.D., Ph.D.
   Eduardo García-Camba M.D., Ph.D.
   Javier García-Campayo, M.D., Ph.D.
   Manuel Girón, M.D., Ph.D.
   María Carlos Mingote, M.D., Ph.D.
   Luis Salvador-Carulla, M.D., Ph.D.
   F. Barcones, B.Sc.
   Javier Santabárbara, B.Sc.
   Pedro Saz, M.D., Ph.D.
   Aurora Sarasola, M.D., Ph.D.
   Antonio Lobo, M.D., Ph.D.

   82. Laboratory Evaluation of Psychiatric Patients in the Emergency Room
   Leslie Zun, M.D., M.B.A.
   Lavone Downey, Ph.D.

   83. STOP-BANG Sleep Apnea Screening Evinces a High Risk Among Patients Admitted to Psychiatric Units
   Sam Al-Saadi, M.D., M.S.
   Thomas Newmark M.D.
   Karl Doghramji, M.D.

   84. Schizotypal Personality Disorder in the United States: Prevalence and Correlates in a Representative General Population Sample
   Vanessa Lentz, M.S., B.S.
   Jennifer Robinson, B.A. (Hons)
   James M. Bolton, M.D.

   **SCW 27**
   11:00 A.M.-12:30 P.M.
   Room 227, Second Level,
   Morial Convention Center

   **WORKSHOPS 107-109**
   **WORKSHOP 107**
   11:00 A.M.-12:30 P.M.
   Room 235, Second Level,
   Morial Convention Center

   **TAI CHI EXERCISE, A CONTROLLABLE PHYSICAL INTERVENTION TO ENHANCE MINDFULNESS AND BEHAVIORAL ACTIVATION IN CBT GROUP TREATMENT FOR DEPRESSED PATIENTS**
   Co-Chairs:
   Jun Yang, M.D., Ph.D.
   Jennice Vilhauer, Ph.D.

   Presenters:
   Ernest Raszydi, M.D.

   **WORKSHOP 108**
   11:00 A.M.-12:30 P.M.
   Rooms 333/334, Third Level,
   Morial Convention Center

   **SCW 28**
   11:00 A.M.-12:30 P.M.
   Rooms 231/232, Second Level,
   Morial Convention Center

   **EPIDEMIOLOGY, SLEEP, AND MEDICAL SCREENING**
   Chair:
   Daniel Chapman, M.D.

   85. Overdiagnosis of Bipolar Disorder and Disability Payments
   Mark Zimmerman, M.D.
   Janine N. Galione, B.A.
   Camilo J. Ruggero, Ph.D.
   Iwona Chelminski, Ph.D.
   Diane Young, Ph.D.

   86. Can We Talk? Do Psychotherapists and Prescribing Psychiatrists Communicate With Each Other About Their Mutual Patients?
   Thomas P. Kalman, M.D., M.S.
   Jolie Avena, B.A.

   87. The Economic Impact of Medication-Access Problems Among Medicaid Psychiatric Patients in Ten States
   Joyce C. West, Ph.D., M.P.P.
   Donald S. Rae, M.S.
   Maritza Rubio-Stipe, Sc.D.
   Haiden Huskamp, Ph.D.
   Darrel A. Regier, M.D., M.P.H.

   **SCW 29**
   11:00 A.M.-12:30 P.M.
   Room 335, Third Level,
   Morial Convention Center

   **IMPORTANT BUT INFREQUENTLY ADDRESSED TOPICS**
   Chair:
   Elias K. Shaya, M.D.

   **SCW 30**
   11:00 A.M.-12:30 P.M.
   Room 333, Third Level,
   Morial Convention Center

   **SCW 31**
   11:00 A.M.-12:30 P.M.
   Room 332, Third Level,
   Morial Convention Center

   **SCW 32**
   11:00 A.M.-12:30 P.M.
   Room 331, Third Level,
   Morial Convention Center

   **SCW 33**
   11:00 A.M.-12:30 P.M.
   Room 329, Third Level,
   Morial Convention Center
USING THE DSM-IV-TR OUTLINE FOR CULTURAL FORMULATION FOR CULTURALLY APPROPRIATE ASSESSMENT: A SKILLS-BASED APPROACH WITH DVD CASES

**Chair:**
Russell F. Lim, M.D.

**WORKSHOP 109**
11:00 A.M.-12:30 P.M.
Rooms 350/351, Third Level, Morial Convention Center

**CHILDREN OF PSYCHIATRISTS**

**Co-Chairs:**
Michelle B. Riba, M.D., M.S.
Leah J. Dickstein, M.D., M.A.

**Presenters:**
Evon Moffic
Erica Riba
Stacia Goldstein, B.S., M.Ed.

1:00 P.M. SESSIONS
NEW RESEARCH/POSTER SESSION 6
NOON-2:00 P.M.
La Louisiane C, First Level, Morial Convention Center

---

For further information on New Research submissions, please refer to the New Research Program section of this book.

---

1:00 P.M. SESSIONS
SEMINAR 7
1:00 P.M.-5:00 P.M.
Room 223, Second Level, Morial Convention Center

**PRACTICAL GUIDE TO THE PERFORMANCE OF THE MENTAL STATUS EXAMINATION**

**Chair:**
Stephen I. Deutsch, M.D., Ph.D.

**Presenters:**
Richard B. Rosse, M.D.
Stephen I. Deutsch, M.D., Ph.D.

**WORKSHOPS 110-112**
1:30 P.M.-3:00 P.M.
Room 235, Second Level, Morial Convention Center

**GAMES PEOPLE PLAY: WHAT EVERY PSYCHIATRIST NEEDS TO KNOW ABOUT VIDEO GAMES**

---

**Co-Chairs:**
Deidre E. Williams, M.D., M.Ed.
Faye Chao, M.D.

**Presenters:**
Jason Caplan, M.D.

**WORKSHOP 111**
1:30 P.M.-3:00 P.M.
Room 335, Third Level, Morial Convention Center

**HOW TO IMPLEMENT CARDIO-METABOLIC MONITORING ACROSS LARGE PUBLIC HEALTH SYSTEMS**

**Co-Chairs:**
Laura K. Kent, M.D.
Christina V. Mangurian, M.D.

**Presenters:**
Gregory Miller, M.D., M.B.A.
Aaron Chapman, M.D.

**WORKSHOP 112**
1:30 P.M.-3:00 P.M.
Rooms 334/345, Third Level, Morial Convention Center

**FEEDBACK ON CRITERIA AND TERMINOLOGY IN DSM-5**

**Co-Chairs:**
David J. Kupfer, M.D.
Darrel A. Regier, M.D.

**Presenters:**
Faye Chao, M.D.
Deidre E. Williams, M.D., M.Ed.

**SESSIONS SYMPOSIA 99-105**
2:00 P.M.-5:00 P.M.
Rooms 333/334, Third Level, Morial Convention Center

**HOT TOPICS IN AFRICAN-AMERICAN MENTAL HEALTH: IMPACT OF PAST AND CURRENT PREJUDICES; WOMEN’S MENTAL HEALTH; HIV; AND UNIQUE PSYCHOPHARMACOLOGICAL FINDINGS**

**Chair:**
David W. Smith, M.D.

**1. History of Racism in Mental Health: Seeds of Distrust**
Harriet A. Washington

**2. Pseudoscientific Literature Promotes Racial Prejudice Among Physicians**
Zack Z. Cernovsky, Ph.D.

**3. Black Women and Depression: The Role of Stigma as a Barrier to Treatment**
Janet E. Taylor, M.D.

**4. HIV and African-American Mental Health**
David W. Smith, M.D.

---

**SYMPOSIUM 100**
2:00 P.M.-5:00 P.M.
Rooms 340/341, Third Level, Morial Convention Center

**DYSCONNECTION IN MENTALIZATION OR METACOGNITION IN PERSONALITY DISORDERS: EMPIRICAL EVIDENCE AND IMPLICATIONS FOR PATHOLOGY, TREATMENT AND RESEARCH**

**Chair:**
Giuseppe Nicolo, M.D.

**Discussants:**
Giancarlo Dimaggio, M.D.
Cesare Maffei, M.D., Ph.D.

1. **Impaired Metacognition and Correlations With Symptoms, Social Functioning, and Overall Personality Disorder Severity**
Giuseppe Nicolo, M.D.
Antonino Carcione, M.D.
Michele Proacci, M.D.
Antonio Semerari M.D.
Giuseppe Giancarlo Dimaggio M.D.
Stefania D’Angelo Ph.D.
Raffaele Popolo M.D.

2. **Improving Mentalization in Borderline Patients in Transference-Focused Psychotherapy (TFP)**
John F. Clarkin, Ph.D.

3. **Verbal Elaboration of Distinct Affect Categories in BPD**
Serge Lecours, Ph.D.
Marc-André Bouchard, Ph.D.

**SYMPOSIUM 101**
Withdrawn

**SYMPOSIUM 102**
2:00 P.M.-5:00 P.M.
Rooms 346/347, Third Level, Morial Convention Center

**TREATING BORDERLINE PERSONALITY DISORDER: CURRENT PSYCHODYNAMIC PERSPECTIVES**

**Chair:**
Eve Caligor, M.D.

**Discussant:**
Peter Fonagy, Ph.D.

1. **Key Clinical Interventions of Mentalization-Based Treatment**
Anthony W. Bateman, M.D.
Peter Fonagy M.D.

2. **Transference-Focused Psychotherapy in Theory and in Practice**
Frank E. Yeomans, M.D.
3. Overview of Expressive Supportive Psychotherapy
John G. Gunderson, M.D.

4. An Overview of Integrated Psychotherapy for BPD
Glen O. Gabbard, M.D.

SYMPOSIUM 103
2:00 P.M. - 5:00 P.M.
Rooms 348/349, Third Level,
Morial Convention Center

COMPREHENSIVE HIV PSYCHIATRY UPDATE

Chair: Karl Goodkin, M.D., Ph.D.

1. HIV/AIDS Medical Update
David Mushatt, M.D.

2. Neuropsychiatric Overview
Mordecai Potash, M.D.

3. Neurocognitive Decline
Karl Goodkin, M.D.

4. Psychopharmacology
Francisco Fernandez, M.D.

SYMPOSIUM 104
2:00 P.M. - 5:00 P.M.
Rooms 350/351, Third Level,
Morial Convention Center

UNDERSTANDING COMORBIDITY OF HEART DISEASE WITH DEPRESSION AND ANXIETY DISORDERS

Co-Chairs:
Ruby C. Castilla-Puentes, M.D., D.P.H.
Maria A. Oquendo, M.D.

Discussant:
Carlos Leon-Andrade, M.D.

1. Depression-Anxiety Comorbidity: Clinical Aspects
Jose Luis Ayuso, M.D.

2. Treatment of Anxiety Disorders Is Associated With a Significantly Lower Prevalence of Secondary Depression
Leo Russo, Ph.D.

3. Neurobiological Mechanisms in Anxiety/Depression and the Impact on Coronary Heart Disease
Jorge Tellez-Vargas, M.D.

4. Understanding Comorbidity of Heart Disease With Depression and Anxiety Disorders
Ricardo Secin, M.D.

5. Depression and Panic Disorders Significantly Increase the Risk for Heart Disease: One More Piece of Evidence
Ruby C. Castilla-Puentes, M.D.

Andres Gomez-Caminero, Ph.D.
William A. Blumentals, Ph.D.
Leo J. Russo, Ph.D.

6. Association Study Between Blood Pressure and Personality, Anxiety and Depression
Jorge Osipa, M.D.

7. Strategies for Optimizing Treatment of Depression and Panic Disorder: What to Do When SSRIs Fail?
Carolina Remed, M.D.
Carlos A. Soria, M.D.

THE ETHICS OF INNOVATIVE INTERVENTIONS IN PSYCHIATRY

Co-Chairs:
Paul S. Appelbaum, M.D.
Laura B. Dunn, M.D.

Discussant:
Scott Kim, M.D., Ph.D.

1. Ethical Issues in DBS Research for Psychiatric Disorders
Laura B. Dunn, M.D.
Paul E. Holtzheimer III, M.D.
Jinger G. Hoop, M.D., M.F.A.
Helen Mayberg, M.D.
Laura W. Roberts, M.D., M.A.
Paul S. Appelbaum, M.D.

2. The Ethics of Genetic Screening for Psychiatric Disorders
Paul S. Appelbaum, M.D.

3. Ethical Issues Related to the Use of Transcranial Magnetic Stimulation and Vagus Nerve Stimulation in Psychiatry
Paul E. Holtzheimer, M.D.

4. Ethical Issues in Pharmacologic Enhancement
Jinger G. Hoop, M.D.
Ryan Spellecy, Ph.D.

WORKSHOPS MEDIA WORKSHOP 8
2:00 P.M. - 5:00 P.M.
Rooms 208/209, Second Level,
Morial Convention Center

RACHEL IS GETTING MARRIED, KYM IS GETTING SOBER, EVERYONE IS LOSING IT

Sponsored by: The American Academy of Addiction Psychiatry

Chair: Petros Levounis, M.D., M.A.

Presenters:
Richard Rosenthal, M.D.
Hunter McQuistion, M.D.
Andrew Anson, M.D.
Stephen Ross, M.D.
Kimberly Roberts, M.D.

3:00 P.M. SESSIONS
NEW RESEARCH/POSTER SESSION 7
3:00 P.M. - 5:00 P.M.
La Louisiane C, First Level,
Morial Convention Center

For further information on New Research submissions, please refer to the New Research Program section of this book.

3:30 P.M. SESSIONS
WORKSHOPS 113-115
WORKSHOP 113
3:30 P.M. - 5:00 P.M.
Room 227, Second Level,
Morial Convention Center

MAINTENANCE OF CERTIFICATION FOR DIPLOMATES OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Chair: Larry R. Faulkner, M.D.

Presenters:
Beth Ann Brooks, M.D., M.S.
Victor Reus, M.D.
David Mrazek, M.D.

WORKSHOP 114
3:30 P.M. - 5:00 P.M.
Room 235, Second Level,
Morial Convention Center

SUICIDE BOMBERS: PSYCHOLOGY, PSYCHOPATHOLOGY AND CULTURAL VIEWS

Co-Chairs:
Mostafa K. Ismail, M.D., M.R.C.
Afaf H. Khalil, M.D., M.R.C.

Presenters:
Ahmed El-Shafei, M.D.
Mohamed Ghanem, M.D., M.R.C.
Yasser Elsayed, M.D., M.S.
Nashwa Zarif, M.S., M.D.

WORKSHOP 115
3:30 P.M. - 5:00 P.M.
(Repeat of Workshop 112)
Rooms 343/345, Third Level,
Morial Convention Center

FEEDBACK ON CRITERIA AND TERMINOLOGY IN DSM-5

Co-Chairs:
David J. Kupfer, M.D.
Darrel A. Regier, M.D.
ADDICTION PSYCHIATRY
ADVANCES IN
7 Advances in Substance Abuse Treatment

COURSES
44 Street Drugs and Mental Disorders: Overview and Treatment of Dual Diagnosis Patients
68 Office-based Buprenorphine Treatment of Opioid-Dependent Patients

LECTURES
12 Addiction: Conflict between Brain Circuits
16 New Directions in Drug Policy: President Obama's National Demand Reduction Priorities

MEDIA WORKSHOP
8 Rachel is Getting Married, Kym is Getting Sober, Everyone is Losing it

SCIENTIFIC AND CLINICAL REPORTS
1 Addiction Psychiatry
13 Addictive Behavior

SMALL INTERACTIVE SESSION
15 Addiction and the Brain

SYMPOSIA
3 Smoking and Psychiatric Disorders: Clues About Causal Pathways and Innovative Treatment Approaches
29 Executive Function as a Brain System for Self-Control: The Neurocircuity of Psychiatric Disorders and Addiction
30 Addiction Research, Prevention and Treatment in the U.S. and France: Vive la Difference!
35 Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes
36 Treating Chronic Pain and Co-Occurring Addiction in Substance Abuse Patients
42 Update on Medications Development: Promising New Treatments for Drug Addiction
48 Reducing Harm: Safer Injection and Other Strategies
52 Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders
54 Substance Related Disorders in DSM-5: Progress Report
59 Neurobiology of Obesity: Why We Can Get Too Motivated to Eat
63 Adolescent Potential: Exploring the Developing Brain and Understanding Pathways of Addiction
67 Revisiting Pharmacological Treatments to Prevent Suicide
68 Reward Neurocircuitry in Substance Dependence and Other Psychiatric Disorders: What Does Brain Research Tell Us?
70 The Challenge of Cognitive Enhancers in Medicine
86 How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders

GUIDE TO USING THE TOPIC INDEX
You can use this index to find sessions of interest to you. Listed below are all of the topic areas contained in the scientific program. Listed under each topic you will find the title of the individual session listed by number. The listing will also show the page number where the session appears in this book. Look up the page number for further details about the session.

92 Update on Cannabis Use Disorders
94 Choosing the Right Treatment for Substance Abuse Symposium
98 Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans

WORKSHOP
56 Maintenance Treatment for Opiate Dependence: Terminable or Interminable?

AIDS AND HIV
LEcTURES
21 Seek and Treat for Optimal Prevention of HIV/AIDS: STOP HIV/AIDS

SYMPOSIA
103 Comprehensive HIV Psychiatry Update
62 The Public Health and Clinical Interface Between HIV, STDs, and Mental Health

WORKSHOP
30 From Outreach to Assertive Community Treatment: Transferring Research to Practice in Comprehensive Care for Underserved People Living With HIV/AIDS

ANXIETY DISORDERS
CASE CONFERENCE
1 PTSD and the American Soldier Today

COURSE
7 Complementary and Integrative Treatments for Stress, Depression, Anxiety, PTSD, Mass Trauma, Cognitive Function, ADD, and Schizophrenia

SCIENTIFIC AND CLINICAL REPORT
14 Anxiety Disorders

SYMPOSIA
1 PTSD in Military Populations: Translating Research Into Practice
12 Anxiety Treatment: New Research Findings for the Clinician
24 Prevention of PTSD: Recent Israeli Practices

WORKSHOP
65 Guided Self-Help: A new Intervention to Overcome Anxiety Complaints

SCHroTEN RED 3UR SPECTRUM DISORDERs
COURSE
19 Essentials of Assessing and Treating Attention Deficit Hyperactivity Disorder in Adults and Children
62 Advanced Assessment and Treatment of Attention Deficit Hyperactivity Disorder

SCIENTIFIC AND CLINICAL REPORT
19 Attention Deficits and Psychostimulants

SYMPOSIUM
88 ADHD FAQs: Practical Answers for the Office-Based Practitioner
## TOPIC INDEX

### BEHAVIOR AND COGNITIVE THERAPIES COURSES

<table>
<thead>
<tr>
<th>Course</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motivational Interviewing for Routine Psychiatric Practice</td>
<td>76</td>
</tr>
<tr>
<td>Cognitive Behavioral Therapy for Insomnia Co-morbid with Depression and Anxiety Disorders</td>
<td>76</td>
</tr>
<tr>
<td>Cognitive-Behavior Therapy for Severe Mental Illness</td>
<td>90</td>
</tr>
<tr>
<td>A Primer on Acceptance and Commitment Therapy</td>
<td>94</td>
</tr>
<tr>
<td>Cognitive-Behavioral Analysis Systems of Psychotherapy (CBASP): Hope for Chronic Depression</td>
<td>108</td>
</tr>
</tbody>
</table>

### MASTER COURSE

| 4 Practical Cognitive-Behavior Therapy                                  | 79   |

### SCIENTIFIC AND CLINICAL REPORTS

| 7 Borderline Personality Disorder and Emotion                          | 87   |

### SEMINAR

| 2 Evidence Based Psychotherapy for Chronic Major Depression            | 62   |

### WORKSHOPS

| 8 Cognitive Therapy for Personality Disorders                          | 63   |
| 36 Meditation and Psychiatry                                           | 72   |
| 40 Cognitive-Behavioral Therapy: Troubleshooting Common Challenges      | 73   |
| 99 Cognitive Therapy for Psychosis in Practice: Basic Techniques for Psychiatrists | 110  |
| 107 Tai Chi Exercise, a Controllable Physical Intervention to Enhance Mindfulness and Behavioral Activation in CBT Group Treatment for Depressed Patients | 123  |

### BIOLOGICAL, PSYCHIATRY AND NEUROSCIENCE COURSES

| 9 Neuroanatomy of Behavior: An Introduction                            | 68   |
| 33 Neuroanatomy of Emotions                                            | 80   |

### LECTURE

| 13 From Circuits to Cells to Molecular Regulation: Identifying Novel Targets for the Treatment of Psychotic Disorders | 105  |

### PRESIDENTIAL SYMPOSIUM

| 3 Can Basic and Translational Neuroscience Improve Treatment in Psychiatry? | 95   |

### SYMPOSIAS

| 19 Pathophysiology of Psychotic and Mood Disorders: Do We Have any Solid Evidence of Interest to Clinicians? | 70   |
| 29 Executive Function as a Brain System for Self-Control: The Neurocircuitry of Psychiatric Disorders and Addiction Genotypes and Biomarkers: The New Decision Makers for Tailored Treatment | 72   |
| 70 The Challenge of Cognitive Enhancers in Medicine                    | 98   |
| 86 How Dysfunction of Learning and Memory Circuits Contribute to Substance Abuse and Other Psychiatric Disorders | 114  |
| 96 Basic Science in Psychiatry: A Move Toward Translational Medicine   | 120  |

### WORKSHOP

| 3 A Medicinal Cannabis Update for 2010: Use, Abuse, New Research, New Forensic and New Political Realities | 63   |

### CHILD AND ADOLESCENT PSYCHIATRY COURSES

| 6 Child and Adolescent Psychiatry for the General Psychiatrist          | 66   |
| 19 Essentials of Assessing and Treating Attention Deficit Hyperactivity Disorder in Adults and Children | 78   |
| 31 Autism Spectrum Disorders: Diagnostic Classification, Neurobiology, Biopsychosocial Interventions and Pharmacologic Management | 79   |

### MASTER COURSE

| 1 Update on Pediatric Psychopharmacology                               | 66   |

### SCIENTIFIC AND CLINICAL REPORTS

| 2 Mood Disorders                                                       | 81   |
| 19 Attention Deficits and Psychostimulants                            | 111  |

### SMALL INTERACTIVE SESSIONS

| 7 Child Psychopharmacology: SSRIs, Stimulants and Safety Issues         | 92   |
| 10 What's New in Child and Adolescent Psychiatry?                      | 106  |
| 14 Meet the Editors: Principles and Practice of Child and Adolescent Forensic Mental Health | 110  |

### SYMPOSIAS

| 6 Update on Treatments for Child and Adolescent Eating Disorders       | 64   |
| 7 Neurodevelopment Disorders in DSM-5: An Update from the Work Group  | 64   |
| 31 Understanding Personality Disorders in Children and Adolescents: Current Status and Future Directions | 77   |
| 57 Depression, Metabolic Syndrome and Obesity                         | 99   |
| 63 Adolescent Potential: Exploring the Developing Brain and Understanding Pathways of Addiction | 106  |

### WORKSHOPS

| 21 Lost in Translation: Generational Issues and Mental Health         | 67   |
| 25 Adult Pervasive Developmental Disorder: For Better Understanding and Treatment | 68   |
| 26 Bridging the Cultural Divide: Challenges of First Generation Immigrants With Children With Mental Illness | 68   |
| 64 Treating the Aggressive Child and Teen: Integrated Techniques for Management and Intervention | 88   |
| 66 Preventing Late Life Sequelae Resulting from Early Life Trauma      | 88   |
| 81 Telepsychiatry and the Changing Face of Access for Rural America's Children and Adolescents | 93   |
| 109 Children of Psychiatrists                                         | 124  |

### COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, ETC.)

### ADVANCES IN MEDICINE

| 1 Delirium: Neurobiology, Prevention and Treatment Approaches         | 86   |
| 4 Aging and Dementia: An Update on Neuroscience and Brain Imaging     | 109  |

### COURSE

| 52 Traumatic Brain Injury: Neuropsychiatric Assessment                | 90   |

### SCIENTIFIC AND CLINICAL REPORT

| 10 Cognitive Disorders                                               | 94   |

### SMALL INTERACTIVE SESSIONS

| 2 Successful Cognitive and Emotional Aging: How Can We Get There?     | 88   |
| 8 Delirium Assessment and Management                                | 92   |

### WORKSHOP

| 67 Behavioral Complications of Dementia: A Comprehensive Multi-Disciplinary Treatment Approach | 88   |

### COMBINED PHARMACOTHERAPY & PSYCHOTHERAPY COURSE

| 69 Psychodynamic Psychopharmacology: Applying Practical Psychodynamics to Improve Pharmacologic Outcomes with Treatment Resistant Patients | 108  |

### WORKSHOPS

| 33 Making the Most of Your Twenty-minute Hour: Maximizing the Therapeutic Experience | 72   |
| 92 Cognitive-Behavioral and Psychodynamic Approaches to Medication Adherence in Severe Mental Illness | 108  |
### TOPIC INDEX

#### COMPUTERS, TECHNOLOGY, INTERNET & RELATED COURSES

- 20 How to Blog, Tweet, Friend, Wiki, and not get Addicted: 21st Century Internet Technologies for Beginners
- 42 Exploring Technologies in Psychiatry

#### SCIENTIFIC AND CLINICAL REPORT

- 15 Information Technology

#### SMALL INTERACTIVE SESSION

- 21 How to get Your Paper Published

#### SYMPOSIUM

- 40 Privacy in Electronic Medical Records

#### WORKSHOPS

- 16 Telepsychiatry for Education and Psychotherapy: Teaching to the Near and Far Ends
- 63 The Explosion of Social Media: Why, Where, When and How can Psychiatrists Catch up with the Trend?
- 81 Telepsychiatry and the Changing Face of Access for Rural America’s Children and Adolescents
- 86 Teaching Psychiatry in New Medical Schools
- 98 The Train has Left the Station: National Incentives and Developments in Electronic Health Records
- 110 Games People Play: What Every Psychiatrist Needs to Know About Video Games

#### COUPLE AND FAMILY THERAPIES

- Advances in
  - 5 Family Assessment and Intervention for Psychiatrists

#### COURSE

- 53 Adult Sexual Love and Infidelity

#### SEMINAR

- 4 Infidelity and Marital Relationships: Death Knell or Wake-up Call?

#### CREATIVITY AND THE ARTS

- COURSE
  - 58 Chopin Psychiatry

#### FORUM

- 1 Chopin at 200: His Mind and His Music

#### MEDIA WORKSHOP

- 1 Is It All Horror Psychological? Horror Film Director George Romero and Steve Schlozman, MD Discuss Polanski’s Classic Film “Repulsion”

#### WORKSHOPS

- 4 Unconscious Projections: The Portrayal of Psychiatry in Recent American Film
- 41 After a Parent’s Suicide: Children’s Grief and Healing
- 37 Publishing Books for the General Public

#### CROSS-CULTURAL AND MINORITY ISSUES

- COURSE
  - 48 Culturally Appropriate Assessment Made Incredibly Clear: A Skills-Based Course With Hands-On Experiences

#### LECTURES

- 11 Solomon Carter Fuller: What Would He Say About Racial Politics in American Psychiatry Today?
- 19 Depression and Suicidal Behavior in Latino Populations

#### MEDIA WORKSHOP

- 7 Building Bridges: The Intersection Between Faith and Mental Health

#### SYMPOSIUM

- 11 Culturally Sensitive Assessment of Psychologically Distressed Ethnic and Non-English Speaking Populations
- 22 Culture and Psychiatric Diagnosis: Implications for the International Impact of DSM-5
- 26 Transcultural Psychiatry for Mental Health in a Changing World
- 30 Addiction Research, Prevention and Treatment in the U.S. and France: Vive la Difference!
- 32 Treatment of Depression in Ethnic Minorities
- 37 Culturally Sensitive Treatment of Psychologically Distressed Ethnic and Non-English Speaking Populations
- 85 Women’s Mental Health in Latin America: Present and Future Research
- 93 Cultural Adaptation of Cognitive Behaviour Therapy for Ethnic/Minority Patients
- 99 Hot Topics in Afro-American Mental Health: Impact of Past and Current Prejudices; Women’s Mental Health; HIV; Unique Psychopharmacological Findings

#### WORKSHOPS

- 2 The Deadly Years: Preventing Suicide in Asian-American College Students
- 9 The IMG Journey: Snapshots Across the Professional Lifespan
- 17 Preparing IMG (International Medical Graduate) Psychiatry Residents for a Career in Academic Psychiatry
- 26 Bridging the Cultural Divide: Challenges of First Generation Immigrants With Children With Mental Illness
- 85 The Psychiatrist’s Role in Integrating Primary Care and Behavioral Health Care: Friend or Foe?
- 87 Deafness - Disability or Difference?
- 108 Using the DSM-IV-TR Outline for Cultural Formulation for Culturally Appropriate Assessment: A Skills Based Approach with DVD Cases
- 114 Suicide Bombers: Psychology, Psychopathology and Cultural Views

#### DIAGNOSTIC ISSUES

- ADVANCES IN MEDICINE
  - 5 Medical Mysteries and Practical Medical Psychiatric Updates: Is it Medical, Psychiatric, or a Little of Both?

#### COURSES

- 26 Understanding the Person Behind the Illness: An Approach to Psychodynamic Formulation
- 48 Culturally Appropriate Assessment Made Incredibly Clear: A Skills-Based Course With Hands-On Experiences

#### FORUM

- 2 DSM-5: Progress in Research and Development

#### SCIENTIFIC AND CLINICAL REPORTS

- 11 Diagnostic Issues and DSM-5
- 21 Scales and Screening Measures

#### SEMINAR

- 7 Practical Guide to the Performance of the Mental Status Examination

#### SMALL INTERACTIVE SESSION

- 9 Neuropsychiatric Assessment for General Psychiatrists

#### SYMPOSIUM

- 7 Neurodevelopmental Disorders in DSM-5: An Update from the Work Group
- 44 An Examination of CNS Trial Methodologies
- 54 Substance Related Disorders in DSM-5: Progress Report
- 55 DSM-5 Update Series, Part I: Reports from the Work Groups
- 65 DSM-5 Examined: Nosology of Mood Disorders
- 66 DSM-5 Update Series, Part II: Reports from the Work Groups
- 78 DSM-5 Update Series, Part III: Reports from the Work Groups

#### WORKSHOPS

- 79 The Use of Research Measures in Clinical Practice

128 www.psych.org
# TOPIC INDEX

## COURSES
16 Mood Disorders in Later Life
43 Psychiatric Consultation in Long-term Care: Advanced Course
57 Pain and Palliative Care in Psychogeriatrics

## SCIENTIFIC AND CLINICAL REPORTS
10 Cognitive Disorders
24 Antidepressant Response and Augmentation

## SMALL INTERACTIVE SESSION
13 Psychiatric Issues in Palliative Care

## SYMPOSIA
14 Examining the Outcome Continuum of Schizophrenia Into Later Life
51 Geriatric Psychopharmacology of Late-Life Mood Disorders: Focus on the use of Biomarkers as Predictors of Response
8 Aggressive Behaviors in Geropsychiatric Patients: Neurobiology, Assessment and Management

## WORKSHOPS
5 Psychiatric Care at the End of Life
67 Behavioral Complications of Dementia: A Comprehensive Multi-Disciplinary Treatment Approach
74 To File or Not to File: Guardianship for Older Adults with Dementia
82 Guardianship and Powers of Attorney: Issues in Geriatric Psychiatry
88 Aging Heroically in an Urban Setting: The Diary of Jessie Sylvester “The Beautiful Hills of Brooklyn”
101 Ethical Challenges in End of Life Care in the Hospitalized Elderly

## GROUP THERAPY

### SCIENTIFIC AND CLINICAL REPORT
2 Mood Disorders

### SYMPOSIUM
69 Implementing the STEPPS* Program for Borderline Personality Disorder (*Systems Training for Emotional Predictability and Problem Solving)

### WORKSHOPS
11 A Program of Psychotherapy for Combatants’ Dependents - The Effect on Recall Rates: “They Are Not Going for Three Weeks and the Fighting Has Begun!”
107 Tai Chi Exercise, a Controllable Physical Intervention to Enhance Mindfulness and Behavioral Activation in CBT Group Treatment for Depressed Patients

## HEALTH SERVICES RESEARCH

### PRESIDENTIAL SYMPOSIUM
2 Comparative Effectiveness of Psychotropic Drugs: What can We Learn From Practical Clinical Trials?

### SCIENTIFIC AND CLINICAL REPORTS
3 Psychopharmacology
15 Information Technology
29 Important but Infrequently Addressed Topics

### SYMPOSIUM
1 PTSD in Military Populations: Translating Research Into Practice Ensuring a Public Health Impact: Partnering with Consumers and Community Stakeholders to Improve Access and Quality of Care for Mental Disorders
76 Lessons from Hurricane Katrina: Response, Recovery and Rebuilding
80 Sex and Psychodynamics: Contemporary Approaches to Clinical Issues Through the Lifecycle

### WORKSHOPS
6 Enhancing Risk-Assessment Across Services in Mental Health
46 Changing Paradigms of Psychiatric Practice in an Era of Health Care Reform
78 Integrating Complementary Alternative Medicine (CAM) in Psychiatric Care: New Paradigms and Perspectives

## HISTORICAL QUESTIONS

### COURSE

## SCIENTIFIC AND CLINICAL REPORTS
11 Diagnostic Issues and DSM-5
12 Psychosomatics and Cardiac Vulnerability

## WORKSHOP
75 The Vicissitudes of the Doctor-Patient Relationship in Modern Medicine: Endurance, Erosion or Transformation

## IMPULSE CONTROL DISORDERS

### COURSE
20 How to Blog, Tweet, Friend, Wiki, and not get Addicted: 21st Century Internet Technologies for Beginners

### SCIENTIFIC AND CLINICAL REPORT
27 Issues in Mood Disorders

## INDIVIDUAL PSYCHOTHERAPIES

### ADVANCES IN
4 Advances in Psychotherapeutic Treatments

## COURSES
10 Time-Limited Dynamic Psychotherapy: An Attachment-based/Relational/Experiential Approach
29 Transference-Focused Psychotherapy for Borderline Personality
30 Advanced Interviewing Techniques
37 Interpersonal Psychotherapy (IPT)
41 Short-Term Psychodynamic Supportive Psychotherapy for Depression
54 A Psychodynamic Approach to Treatment Resistant Mood Disorders: Breaking Through Complex Comorbid Treatment Resistance by Focusing on Axis I
55 Improving Psychotherapy Effectiveness: Making Therapeutic use of Countertransference and Mentalizing
56 Davanloo’s Intensive Short-Term Dynamic Psychotherapy in Clinical Practice
71 Cognitive Behavioural Analysis Systems of Psychotherapy (CBASP): Hope for Chronic Depression
72 Narrative Hypnosis for Psychiatry: Emphasis on Pain Management
76 Evidence-Based Psychodynamic Therapy

## MASTER COURSE
3 Psychodynamic Psychotherapy

## SCIENTIFIC AND CLINICAL REPORT
6 Psychotherapy and Depression

## SYMPOSIUM
5 New Developments in Interpersonal Psychotherapy (IPT)

### WORKSHOPS
77 The “Negative Outcome” in Psychotherapy: Who Is Responsible and How?
93 Boundary Crossings as Boundary Accommodations: The Physician/Patient Relationship with Medically Ill Patients
102 Dynamic Therapy With Self-Destructive Boundaries: An Alliance Based Intervention for Suicide

## LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

### MEDIA WORKSHOP
3 Patrik, Age 1.5: A Swedish Film About Unexpected and Gay Adoption

### SYMPOSIUM
61 Psychiatrists in the World: Advocating for LGBT Mental Health
<table>
<thead>
<tr>
<th>PAGE</th>
<th>WORKSHOP</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Sexual Minority Youth: Clinical Competencies and Training Needs for the 21st Century</td>
<td>69</td>
</tr>
<tr>
<td>63</td>
<td>Current Procedural Terminology Coding and Documentation</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Health Reform and Psychiatry</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>The Crisis of Access to Psychiatrists in an Era of Health Reform</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Health and Mental Health Around the World? Are all Systems go?</td>
<td>89</td>
</tr>
<tr>
<td>75</td>
<td>The Tattered Safety Net: The Public Mental Health Crisis in an Economic Recession</td>
<td>113</td>
</tr>
<tr>
<td>90</td>
<td>Understanding CPT Coding and How Fees are Calculated</td>
<td>108</td>
</tr>
<tr>
<td>16</td>
<td>Mood Disorders in Later Life</td>
<td>76</td>
</tr>
<tr>
<td>34</td>
<td>Management of Psychiatric Disorders in Pregnant and Postpartum Women</td>
<td>80</td>
</tr>
<tr>
<td>37</td>
<td>Interpersonal Psychotherapy (IPT)</td>
<td>81</td>
</tr>
<tr>
<td>39</td>
<td>Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders</td>
<td>81</td>
</tr>
<tr>
<td>41</td>
<td>Short-Term Psychodynamic Supportive Psychotherapy for Depression</td>
<td>86</td>
</tr>
<tr>
<td>54</td>
<td>A Psychodynamic Approach to Treatment Resistant Mood Disorders: Breaking Through Complex Comorbid Treatment Resistance by Focusing on Axis I</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Psychopharmacologic, ECT and Psychotherapeutic Treatment of Psychotic (Delusional) Depression</td>
<td>90</td>
</tr>
<tr>
<td>67</td>
<td>ECT Practice Update for the General Psychiatrist</td>
<td>104</td>
</tr>
<tr>
<td>2</td>
<td>Novel Approaches to Assessing and Treating Depression</td>
<td>101</td>
</tr>
<tr>
<td>2</td>
<td>The Future of Depression Research</td>
<td>66</td>
</tr>
<tr>
<td>7</td>
<td>Neuroimaging Clue to the Causes of Bipolar Disorder: Where We Are and Where We're Going</td>
<td>91</td>
</tr>
<tr>
<td>14</td>
<td>Co-Morbidity of Psychiatric Disorders</td>
<td>109</td>
</tr>
<tr>
<td>19</td>
<td>Depression and Suicidal Behavior in Latino Populations</td>
<td>116</td>
</tr>
<tr>
<td>6</td>
<td>Boy Interrupted</td>
<td>116</td>
</tr>
<tr>
<td>4</td>
<td>Child and Adolescent Psychiatry</td>
<td>83</td>
</tr>
<tr>
<td>6</td>
<td>Psychotherapy and Depression</td>
<td>87</td>
</tr>
<tr>
<td>20</td>
<td>Inpatient Psychiatry: Admissions and Readmissions</td>
<td>115</td>
</tr>
<tr>
<td>21</td>
<td>Scales and Screening Measures</td>
<td>116</td>
</tr>
<tr>
<td>22</td>
<td>Genetics</td>
<td>118</td>
</tr>
<tr>
<td>24</td>
<td>Antidepressant Response and Augmentation</td>
<td>119</td>
</tr>
<tr>
<td>25</td>
<td>Psychopharmacology</td>
<td>119</td>
</tr>
<tr>
<td>2</td>
<td>Evidence Based Psychotherapy for Chronic Major Depression</td>
<td>62</td>
</tr>
<tr>
<td>1</td>
<td>Diagnosis and Evidence-Based Treatment of Bipolar Disorder</td>
<td>88</td>
</tr>
<tr>
<td>20</td>
<td>Research and Clinical Management of Patients with Treatment-Resistant Depression</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Treatment of Complex Mood Disorders</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SYMPOSIA</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>New Developments in Interpersonal Psychotherapy (IPT)</td>
<td>64</td>
</tr>
<tr>
<td>9</td>
<td>Advances in the Management of Treatment-Resistant Depression</td>
<td>65</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Trends in Bipolar Disorders</td>
<td>65</td>
</tr>
<tr>
<td>19</td>
<td>Pathophysiology of Psychotic and Mood Disorders: Do We Have any Solid Evidence of Interest to Clinicians?</td>
<td>70</td>
</tr>
<tr>
<td>38</td>
<td>Neuroendocrine and Neuroimmunological Correlates of Bipolar Disorder in Women</td>
<td>83</td>
</tr>
<tr>
<td>45</td>
<td>Interpersonal and Social Rhythm Therapy (IPSRT) for Bipolar Disorder: New Applications, New Populations, and New Evidence</td>
<td>96</td>
</tr>
<tr>
<td>49</td>
<td>Advances in the Treatment of Bipolar Disorder</td>
<td>97</td>
</tr>
<tr>
<td>51</td>
<td>Geriatric Psychopharmacology of Late-Life Mood Disorders: Focus on the use of Biomarkers as Predictors of Response</td>
<td>97</td>
</tr>
<tr>
<td>60</td>
<td>The Potential and Pitfalls of Creating a Bipolar Genomic Biobank</td>
<td>106</td>
</tr>
<tr>
<td>65</td>
<td>DSM-5 Examined: Nosology of Mood Disorders</td>
<td>107</td>
</tr>
<tr>
<td>91</td>
<td>New CANMAT Guidelines for Depression and Bipolar Disorder: Combining Evidence with Clinical Practice</td>
<td>121</td>
</tr>
<tr>
<td>12</td>
<td>New APA Practice Guideline for the Treatment of Patients with Major Depressive Disorder</td>
<td>63</td>
</tr>
<tr>
<td>39</td>
<td>Where Science and Social Justice Meet: The Example of Smoking in Persons With Bipolar Disorder</td>
<td>72</td>
</tr>
<tr>
<td>73</td>
<td>Transcranial Magnetic Stimulation in Clinical Practice: A Pragmatic Approach to a New Psychiatric Procedure</td>
<td>92</td>
</tr>
<tr>
<td>83</td>
<td>Practical Pharmacotherapy of Mood Disorders</td>
<td>93</td>
</tr>
<tr>
<td>89</td>
<td>Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A New Therapeutic Tool for Psychiatry</td>
<td>108</td>
</tr>
<tr>
<td>95</td>
<td>CAM or sCAM for Mood Disorders: Herbs and Beyond!</td>
<td>110</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>NEUROPSYCHIATRY ADVANCES IN MEDICINE</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Movement Disorders in Psychiatric Patients</td>
<td>104</td>
</tr>
<tr>
<td>1</td>
<td>Neuropsychiatric Masquerades: Medical and Neurological Disorders That Present With Psychiatric Symptoms</td>
<td>62</td>
</tr>
<tr>
<td>46</td>
<td>Advances in Neuropsychiatry: The Neuropsychiatry of Emotion and Its Disorders</td>
<td>86</td>
</tr>
<tr>
<td>52</td>
<td>Traumatic Brain Injury: Neuropsychiatric Assessment</td>
<td>90</td>
</tr>
<tr>
<td>75</td>
<td>The Standard EEG in Psychiatric Practice</td>
<td>110</td>
</tr>
<tr>
<td>12</td>
<td>Addiction: Conflict between Brain Circuits</td>
<td>104</td>
</tr>
<tr>
<td>5</td>
<td>Neuropsychiatry for Veterans</td>
<td>118</td>
</tr>
<tr>
<td>9</td>
<td>Neuropsychiatric Assessment for General Psychiatrists</td>
<td>106</td>
</tr>
<tr>
<td>15</td>
<td>Addiction and the Brain</td>
<td>110</td>
</tr>
<tr>
<td>8</td>
<td>Aggressive Behaviors in Geropsychiatric Patients: Neurobiology, Assessment and Management</td>
<td>65</td>
</tr>
<tr>
<td>13</td>
<td>Challenges and Opportunities in Teaching Neurology to Psychiatry Residents</td>
<td>67</td>
</tr>
<tr>
<td>22</td>
<td>Diagnosis and Treatment of Psychogenic Nonepileptic Seizures: What Does a Psychiatrist Do Once the Diagnosis Is Made?</td>
<td>67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>LECTURE</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>Boy Interrupted</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>Evidence Based Psychotherapy for Chronic Major Depression</td>
<td></td>
</tr>
<tr>
<td>91</td>
<td>Advances in the Management of Treatment-Resistant Depression</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Scales and Screening Measures</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Antidepressant Response and Augmentation</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Psychopharmacology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>WORKSHOPS</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Challenges and Opportunities in Teaching Neurology to Psychiatry Residents</td>
<td>67</td>
</tr>
<tr>
<td>21</td>
<td>EEG Feedback in Psychiatry: Clinical Applications</td>
<td>78</td>
</tr>
<tr>
<td>38</td>
<td>Internal Medicine Update: What Psychiatrists Need to Know</td>
<td>81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SCIENTIFIC AND CLINICAL REPORTS</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>87</td>
<td>Evidence Based Psychotherapy for Chronic Major Depression</td>
<td>62</td>
</tr>
<tr>
<td>88</td>
<td>Advances in the Management of Treatment-Resistant Depression</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Scales and Screening Measures</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Antidepressant Response and Augmentation</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Psychopharmacology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SYMPOSIUM</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Aggressive Behaviors in Geropsychiatric Patients: Neurobiology, Assessment and Management</td>
<td>65</td>
</tr>
<tr>
<td>13</td>
<td>Challenges and Opportunities in Teaching Neurology to Psychiatry Residents</td>
<td>67</td>
</tr>
<tr>
<td>22</td>
<td>Diagnosis and Treatment of Psychogenic Nonepileptic Seizures: What Does a Psychiatrist Do Once the Diagnosis Is Made?</td>
<td>67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>MASTER COURSE</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Neuropsychiatry for Veterans</td>
<td>118</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SMALL INTERACTIVE SESSIONS</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Neuropsychiatric Assessment for General Psychiatrists</td>
<td>106</td>
</tr>
<tr>
<td>15</td>
<td>Addiction and the Brain</td>
<td>110</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SEMINAR</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>Evidence Based Psychotherapy for Chronic Major Depression</td>
<td>62</td>
</tr>
<tr>
<td>87</td>
<td>Advances in the Management of Treatment-Resistant Depression</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Scales and Screening Measures</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Antidepressant Response and Augmentation</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Psychopharmacology</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAGE</th>
<th>SMALL INTERACTIVE SESSIONS</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Top 10 Medical Articles of 2009: A Comprehensive and Practical Review of What We Need to Know</td>
<td>91</td>
</tr>
<tr>
<td>21</td>
<td>EEG Feedback in Psychiatry: Clinical Applications</td>
<td>78</td>
</tr>
<tr>
<td>38</td>
<td>Internal Medicine Update: What Psychiatrists Need to Know</td>
<td>81</td>
</tr>
</tbody>
</table>

163rd Annual Meeting
## TOPIC INDEX

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS ADVANCES IN</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Advances in Personality Disorders</td>
</tr>
<tr>
<td>112</td>
<td></td>
</tr>
</tbody>
</table>

## COURSES:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS COURSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Time-Limited Dynamic Psychotherapy: An Attachment-based/Relational/Experiential Approach</td>
</tr>
<tr>
<td>68</td>
<td>Transference-Focused Psychotherapy for Borderline Personality</td>
</tr>
<tr>
<td>79</td>
<td>Mentalization Based Treatment (MBT) for Borderline Personality</td>
</tr>
<tr>
<td>81</td>
<td>Personality Disorder (BPD): Introduction to Clinical Practice</td>
</tr>
</tbody>
</table>

## MEDIA WORKSHOP:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS MEDIA WORKSHOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Rachel is Getting Married, Kym is Getting Sober, Everyone is Losing it</td>
</tr>
<tr>
<td>125</td>
<td></td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORT:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS SCIENTIFIC AND CLINICAL REPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Borderline Personality Disorder and Emotion</td>
</tr>
<tr>
<td>8</td>
<td>Borderline Personality Disorder</td>
</tr>
<tr>
<td>9</td>
<td>Child Abuse</td>
</tr>
<tr>
<td>87</td>
<td></td>
</tr>
<tr>
<td>91</td>
<td></td>
</tr>
<tr>
<td>92</td>
<td></td>
</tr>
</tbody>
</table>

## SYMPOSIA:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Family and Behavioral Genetic Studies of BPD</td>
</tr>
<tr>
<td>20</td>
<td>Updating the APA Guidelines for the Treatment of Borderline Personality Disorder</td>
</tr>
<tr>
<td>31</td>
<td>Understanding Personality Disorders in Children and Adolescents: Current Status and Future Directions</td>
</tr>
<tr>
<td>34</td>
<td>Diagnosing and Treating the Narcissistic Personality Disorder: Awaiting DSM-5</td>
</tr>
<tr>
<td>69</td>
<td>Implementing the STEPPS* Program for Borderline Personality Disorder (‘Systems Training for Emotional Predictability and Problem Solving’)</td>
</tr>
<tr>
<td>70</td>
<td>Evidence-based Treatments (EBT) for Borderline Personality Disorder: Empirical Clarity Meets Clinical Reality</td>
</tr>
<tr>
<td>92</td>
<td>New Perspectives on Intergenerational Transmission of BPD</td>
</tr>
<tr>
<td>90</td>
<td>Dysfunctions in Mentalization or Metacognition in Personality Disorders: Empirical Evidence and Implications for Pathology, Treatment and Research</td>
</tr>
<tr>
<td>102</td>
<td>Treating Borderline Personality Disorder: Current Psychodynamic Perspectives</td>
</tr>
<tr>
<td>111</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
</tr>
<tr>
<td>124</td>
<td></td>
</tr>
</tbody>
</table>

## WORKSHOPS:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS WORKSHOPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Cognitive Therapy for Personality Disorders</td>
</tr>
<tr>
<td>63</td>
<td>A Resident’s Guide to Borderline Personality Disorder From the Experts: Part I</td>
</tr>
<tr>
<td>70</td>
<td>A Resident’s Guide to Borderline Personality Disorder: From the Experts (Part II)</td>
</tr>
<tr>
<td>89</td>
<td></td>
</tr>
</tbody>
</table>

## POLITICAL QUESTIONS:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS POLITICAL QUESTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Health Reform and Psychiatry</td>
</tr>
<tr>
<td>105</td>
<td></td>
</tr>
</tbody>
</table>

## LECTURE:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS LECTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>New Directions in Drug Policy: President Obama’s National Demand Reduction Priorities</td>
</tr>
<tr>
<td>111</td>
<td></td>
</tr>
</tbody>
</table>

## SYMPOSIA:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>The Medical Home: Is There a Place for Psychiatry in It?</td>
</tr>
<tr>
<td>41</td>
<td>Health and Mental Health Around the World? Are all Systems go?</td>
</tr>
<tr>
<td>83</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td></td>
</tr>
</tbody>
</table>

## WORKSHOPS:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS WORKSHOPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>Where Science and Social Justice Meet: The Example of Smoking in Persons With Bipolar Disorder</td>
</tr>
<tr>
<td>53</td>
<td>Scope of Practice Challenges: Experiences, Successes, and Tribulations From Across the Country</td>
</tr>
<tr>
<td>72</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
</tr>
</tbody>
</table>

## PRACTICE MANAGEMENT COURSE:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS PRACTICE MANAGEMENT COURSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>Current Procedural Terminology Coding and Documentation</td>
</tr>
<tr>
<td>94</td>
<td></td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORT:

<table>
<thead>
<tr>
<th>PAGE</th>
<th>PERSONALITY DISORDERS SCIENTIFIC AND CLINICAL REPORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Psychopharmacology</td>
</tr>
<tr>
<td>81</td>
<td></td>
</tr>
</tbody>
</table>
PSYCHOPHARMACOLOGY

ADVANCES IN
6 Advances in the Use of Antipsychotic Medications

COURSES
24 Treatment of Schizophrenia
36 Fostering Adherence to Psychotropic Medications: A Practical Resource for Clinicians

FORUM
3 Is a Game Changing Psychotropic Too Much to Expect?

LECTURE
8 The Audacity Principle in Science?

MASTER COURSE
2 Essential Psychopharmacology

PRESIDENTIAL SYMPOSIUM
2 Comparative Effectiveness of Psychotropic Drugs: What can We Learn From Practical Clinical Trials?

SCIENTIFIC AND CLINICAL REPORT
16 Side Effects of Psychotropic Medication

SMALL INTERACTIVE SESSIONS
19 Alternative Treatments in Psychiatry
5 Antipsychotic Polypharmacy: An Evidence-based Perspective

SYMPOSIUM
18 Translating the Psychopharmacology Evidence Base Into Practice: A Sampler From the American Society of Clinical Psychopharmacology

WORKSHOPS
10 A Discussion About Weight Gain During Medication Treatment for Schizophrenia: How Much and What to do about it
58 Pharmacological Approaches to Autism Spectrum Disorders for Clinicians
80 “Taking It Personal”: Integrating Pharmacogenetics into the Management of Depression
95 CAM or sCAM for Mood Disorders: Herbs and Beyond!

SCIENTIFIC AND CLINICAL REPORTS
14 Anxiety Disorders
17 Weight Gain and Psychiatric Illness
25 Psychopharmacology
29 Important but Infrequently Addressed Topics

SYMPOSIUM
42 Update on Medications Development: Promising New Treatments for Drug Addiction
49 Advances in the Treatment of Bipolar Disorder

WORKSHOPS
19 Transplant Psychiatry Update
78 Integrating Complementary Alternative Medicine (CAM) in Psychiatric Care: New Paradigms and Perspectives

SYMPOSIUM
80 Sex and Psychodynamics: Contemporary Approaches to Clinical Issues Through the Lifecycle

WORKSHOP
83 Practical Pharmacotherapy of Mood Disorders

PSYCHOSOMATIC MEDICINE

ADVANCES IN
2 Advances in Psychosomatic Medicine

COURSES
18 Research and Publishing on a Shoe-String Budget
26 The Future of Depression Research

LECTURES
89 Highlights and Lessons from 40 Years in Psychiatry
105 Advances in Research

RESEARCH ISSUES
ADVANCES IN RESEARCH
18 Research and Publishing on a Shoe-String Budget
26 The Future of Depression Research

### Topic Index

#### Presidential Symposia
1. The Emerging Neurobiology of Antidepressant Treatment Response
2. Recent Advances in Psychiatric Genetics: From Fundamental Discovery to Clinical Implication

#### Symposia
1. An Examination of CNS Trial Methodologies
2. New Studies to Appear in the June Issue of the American Journal of Psychiatry: Presentations by the Authors and Editors
3. Treatment of Depression with TMS: An Overview from the Optimization of TMS for the Treatment of Depression Trial (Opt-TMS)
4. The Ethics of Innovative Interventions in Psychiatry

#### Resident & Medical Student Concerns
1. Novel Programs to Promote Mental Wellness in Medical Students

#### Symposium
1. Toward a New Model for Mental Health Services in the University Community

#### Workshops
1. The IMG Journey: Snapshots Across the Professional Lifespan
2. Oral Boards Boot Camp 2010: Focus on Diagnostic Interviewing
3. Making the Most of Your Twenty-minute Hour: Maximizing the Therapeutic Experience
4. Patient Suicide During Psychiatry Residency: A Workshop Discussion
5. Making the Most of Your Chief Year: Chief Residents’ Forum, Part I
6. Promoting International Medical Graduates Psychosocial Support During Residency Training
7. Making the Most of Your Chief Year: Chief Residents’ Forum, Part II
10. “If a Patient Googles Me, What Will They Find?” – The Information Age and Its Impact on Residency Training
11. American Board of Psychiatry and Neurology Update: Certification in Psychiatry and Its Subspecialties
12. A Resident’s Guide to Borderline Personality Disorder: From the Experts (Part II)

#### Schizophrenia & Other Psychotic Disorders
1. Helping Parents of a First Episode Psychotic Patient
2. Treatment of Schizophrenia

#### Industry Supported Symposium
1. New Developments in Schizophrenia Research and Practice: From the Pipeline to the Clinic

#### Lectures
1. Translational Research in Schizophrenia: Challenges and Promises
2. The Simple Truth About the Genetic Complexity of Schizophrenia
3. From Circuits to Cells to Molecular Regulation: Identifying Novel Targets for the Treatment of Psychotic Disorders
4. Prevention Initiatives in Schizophrenia

#### Scientific and Clinical Reports
1. Psychosomatic Medicine and Health Services
2. Weight Gain and Psychiatric Illness
3. Issues in Child and Adolescent Psychiatry
4. Psychosis

#### Symposia
1. Examining the Outcome Continuum of Schizophrenia Into Later Life
2. Non-Psychotic Issues of Schizophrenic Patients

#### Sleep Disorders
1. An Overview of Sleep Medicine for the Mental Health Provider
2. Cognitive Behavioral Therapy for Insomnia Co-morbid With Depressive and Anxiety Disorders
3. Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders

#### Workshops
1. Evaluation and Management of Patients with Excessive Daytime Sleepiness in Psychiatric Practice
2. Update on Parasomnias: A Review for Psychiatric Practice

#### Social & Community Psychiatry Course
1. Emergency Psychiatry: Theory to Practice

#### Forum
1. Global Disasters Forum: Lessons Learned from Chile, Haiti & New Orleans

#### Scientific and Clinical Report
1. Epidemiology, Sleep, and Medical Screening

#### Seminar
1. Overview of Recovery for Psychiatrists

#### Symposia
1. Recent Changes to Acute Psychiatric Care: An International Perspective
2. Treatment of Depression in Ethnic Minorities
3. Psychiatrists in the World: Advocating for LGBT Mental Health
4. Lessons from Hurricane Katrina: Response, Recovery and Rebuilding

#### Workshops
1. Enhancing Risk-Assessment Across Services in Mental Health
2. The Behavioral Health Action Network: Reorganizing the Behavioral Health Delivery System in Post-Katrina New Orleans
3. When Adults with Pervasive Developmental Disorders Present in a Community Mental Health Setting
4. Street to Home: Shame in Homelessness
5. I’m Violent, Admit Me if you Dare: How and Where to Manage Potentially Violent Individuals With Unclear Diagnoses Presenting to Emergency Services
6. Practical Challenges for Psychiatrists Implementing the Recovery Model

#### Somatoform Disorders
1. Assessment of Capacity: Developments, Documentation & Defendability
2. Diagnosis and Treatment of Psychogenic Nonepileptic Seizures: What Does a Psychiatrist Do Once the Diagnosis Is Made?
**TOPIC INDEX**

### STIGMA/ADVOCACY

**MEDIA WORKSHOPS**

1. Is It All Horror Psychological? Horror Film Director George Romero and Steve Scholzman, MD Discuss Polanski's Classic Film "Repulsion"
2. Novel Programs to Promote Mental Wellness in Medical Students

**WORKSHOPS**

104. Fighting Stigma: When Psychiatrists Who Have Been in Treatment Speak Out
20. When Disorder Hits Home: Dealing With Serious Psychiatric Disorders in Our Own Families
48. Street to Home: Shame in Homelessness
63. The Explosion of Social Media: Why, Where, When and How can Psychiatrists Catch up with the Trend?

### STRESS

**CASE CONFERENCE**

1. PTSD and the American Soldier Today

**COURSES**

27. Mindfulness: Practical Applications for Psychiatry
28. Yoga of the East and West: Integrating Breath Work and Meditation Into Clinical Practice

**SYMPOSIA**

24. Prevention of PTSD: Recent Israeli Practices
98. Novel Tools for Preventing and Treating Substance Use and Comorbidities in the Military and Returning Veterans

**WORKSHOPS**

28. Vulnerability and Resilience: Katrina's Widespread Impact on First Responders, Clinicians, Youth and Relocated Survivors
42. From Narrative and Theory to Evidence-based Support for Psychiatrists Working Under Extreme Stress
62. Disaster Preparedness, Evacuation and Rebuilding: Lessons Learned from Katrina Applied to Gustav and Ike

### TREATMENT TECHNIQUES & OUTCOME STUDIES

**ADVANCES IN**

4. Advances in Psychotherapeutic Treatments

**COURSES**

3. Examining Professional Boundaries: Weighing Risks Versus Opportunities
36. Fostering Adherence to Psychotropic Medications: A Practical Resource for Clinicians
65. How to Practice Evidence Based Psychiatry: Principles and Case Studies
69. Psychodynamic Psychopharmacology: Applying Practical Psychodynamics to Improve Pharmacologic Outcomes with Treatment Resistant Patients
73. Trauma-Informed Care: Principles and Implementation

**SYMPOSIA**

4. Shared Decision Making in Mental Health Care: a Recovery and Person-centered Approach
20. Updating the APA Guidelines for the Treatment of Borderline Personality Disorder
52. Innovations in Integrated Treatment of Substance Use and Psychiatric Disorders
64. The 2010 APA Task Force Report on the Practice of Electroconvulsive Therapy: Evidence-based Guidelines for the Practicing Clinician
70. Evidence-based Treatments (EBT) for Borderline Personality Disorder: Empirical Clarity Meets Clinical Reality
74. The Treatment of Psychiatric Disorders with rTMS: New Research and Clinical Findings
93. Cultural Adaptation of Cognitive Behaviour Therapy for Ethnic/Minority Patients
100. Dysfunctions in Mentalization or Metacognition in Personality Disorders: Empirical Evidence and Implications for Pathology, Treatment and Research

### VIOLENCE, TRAUMA & VICTIMIZATION

**COURSES**

56. Maintenance Treatment for Opiate Dependence: Terminable or Interminable?
60. Interviewing Patients Who Hate or Fear Psychiatrists
64. Treating the Aggressive Child and Teen: Integrated Techniques for Management and Intervention
65. Guided Self-Help: A new Intervention to Overcome Anxiety Complaints

### VIOLENCE, TRAUMA & VICTIMIZATION

**WORKSHOPS**

66. Risk Assessment for Violence
73. Trauma-Informed Care: Principles and Implementation

**FORUM**

4. Global Disasters Forum: Lessons Learned from Chile, Haiti & New Orleans

**LECTURE**

3. Patient Violence Against Mental Health Clinicians: Safety Assessment and Prevention

**MEDIA WORKSHOP**

4. National Disasters: Developing a Road Map for Preparedness and Interventions

### SCIENTIFIC AND CLINICAL REPORT

9. Child Abuse

### SMALL INTERACTIVE SESSION

18. Psychiatric Issues Related to Returning Vets From Iraq and Afghanistan

**WORKSHOPS**

28. Vulnerability and Resilience: Katrina's Widespread Impact on First Responders, Clinicians, Youth and Relocated Survivors
49. I'm Violent, Admit Me if you Dare: How and Where to Manage Potentially Violent Individuals With Unclear Diagnoses Presenting to Emergency Services
59. Psychological Aspects of Biologic, Chemical, and Nuclear Terrorism
114. Suicide Bombers: Psychology, Psychopathology and Cultural Views

### WOMEN'S HEALTH ISSUES

**COURSES**

34. Management of Psychiatric Disorders in Pregnant and Postpartum Women

**SYMPOSIA**

35. Sex/Gender Differences and Women-Specific Issues in Drug Abuse: Predicting and Improving Treatment Outcomes
38. Neuroendocrine and Neuroimmunological Correlates of Bipolar Disorder in Women
72. The Nuts and Bolts of the Perinatal Psychiatric Consultation
82. Reproductive Issues and Women's Mental Health: How to Untie the Gordian Knot?
84. Mood, Memory and Myths: What Really Happens at Menopause?
85. Women's Mental Health in Latin America: Present and Future Research

**WORKSHOPS**

44. Mood Disorders in Women of Reproductive Age
45. Cognitive Behavioral Strategies for Weight Loss
77. Neonicotide: Phenomenology and Prevention

---

136 www.psych.org

The First and Last Word in Psychiatry

Visit the APPI Bookstore at the 2010 APA Annual Meeting

APPI Bookstore Hours
Saturday 10:00 am – 4:00 pm
Sunday 10:00 am – 4:00 pm
Monday 10:00 am – 4:00 pm
Tuesday 10:00 am – 4:00 pm

Extra Special Discount for Members!
15% Discount for APA Members
30% Discount for APA Members-in-Training

Author Signings

Sunday, May 23
11:00am – 12:00pm
Alan F. Schatzberg, M.D.
Manual of Clinical Psychopharmacology,
Seventh Edition

11:00am – 12:00pm
Charles B. Nemeroff, M.D., Ph.D.

11:00am – 12:00pm
Terence A. Ketter, M.D.
Handbook of Diagnosis and Treatment of Bipolar Disorders

Monday, May 24
11:00am – 12:00pm
Glen O. Gabbard, M.D.
Long-Term Psychodynamic Psychotherapy: A Basic Text, Second Edition

Tuesday, May 25
11:00am – 12:00pm
Mina K. Dulcan, M.D.
Dulcan’s Textbook of Child and Adolescent Psychiatry

11:00am – 12:00pm
Jesse H. Wright, M.D., Ph.D.
High-Yield Cognitive-Behavior Therapy for Brief Sessions: An Illustrated Guide
PsychiatryOnline.com

Online access to a premier collection of psychiatric resources

Visit the APPI Bookstore for a demo!

PsychiatryOnline.com is a powerful website that features _DSM-IV-TR®_ and _The American Journal of Psychiatry_ as the cornerstones of an unsurpassed collection of psychiatric references, including books, journals, and self-assessment tools. Much more than simply books and journals presented online, PsychiatryOnline.com features sophisticated searching and indexing tools that enable you to quickly target all the information you need.

Whether your needs are clinical, learning, or research, PsychiatryOnline.com provides access to the information critical to your work and everyday practice with convenient features such as:

- Search and linking tools that let you find relevant book chapters and journal articles quickly.
- Unlimited downloads to PDA so you can take book sections with you wherever you go.
- Copy and paste functions for easy creation of tables and presentations.
- Citation exports to most reference manager formats.
- Printer-friendly views that mean no reformatting when you need a hard copy.
- Saved searches and bookmarked chapters to make it easy to return to topics of interest.
- Email page feature that allows you to share the information with colleagues.

Interested in an institutional subscription? Please contact us at: 1-703-907-8538, ext. 8538 or institutions@psych.org.

Also Sample APPI Content on Four Different E-Book Readers!

- iPad
- Kindle
- Edge
- Nook

APPI Bookstore Hours

Saturday, May 22 to Tuesday, May 25

10:00 am – 4:00 pm
New Research

CONTENTS

Monday Posters ................................................................. 138
Tuesday Posters ............................................................... 150
Wednesday Posters ......................................................... 159
Topic Index ....................................................................... 165
NR1-1
Mediation as Treatment Modality in Active Duty Service Members Participating in Residential Substance Abuse Rehabilitation
Amy Canuso, D.O.
Lyn Waelde, Ph.D.
Robert Mcelay, M.D., Ph.D.
Mary Rusher, M.D.
Chris Johnson, Ph.D.
Scott Johnston, Ph.D.

NR1-2
STRAWs: Scheduled Taper Recommended for Alcohol Withdrawal Syndrome
Cheryl Graber, M.D.
Anthony Tobia, M.D.
Shannon Parks, D.O.

NR1-3
Correlation Between Chronic Cocaine Use and Hypoglycemia in Patients Admitted to the Hospital
Faiz A. Cheema, M.D.
Ferhana Nadeem, M.D.
Summer Jaffrey, M.D.
Ghalam Baija, M.D.
David Chiapaiko, B.S.
Yoshie Umemura, B.S.
Amal Badr, M.D.
Joan Wynn, M.B.A.
Javed Iqbal, M.D.

NR1-4
Safety and Efficacy of Varenicline in Schizophrenia: Preliminary Data
Johanna Nino, M.D.
A. Eden Evans, M.D., M.P.H.

NR1-5
Clinical Correlates of Attrition in Residential Substance Abuse Therapeutic Community Program
Jonathan C. Lee, M.D.
Douglas M. Burgess, M.D.
Karen Kelley.
Kevin McDonald
Kathleen S. Peindl, Ph.D.
Julie L. Adams M.D.
Ashwin Patkar, M.D.

NR1-6
Collectivistic and Sosiotropic Tendency of Patients with Alcohol Dependence in Korea
Jungwon Min, M.D.
Jung-Ho Shin, M.D.
Min-Hyuk Kim, M.D.

NR1-7
Sexual Dysfunction in Patients Diagnosed with Substance Use Disorder
Nesilhan Akkisi Kumsar, M.D.
Nesrin Dildar

NR1-8
Substance Use and Trauma: A Retrospective Chart Review of Trauma Patients in the Urban South
Rachel A. Houchins, M.D.
Kristin Arthur, M.D.
Mark A. Jones, M.D.

NR1-9
The Contributing Factors on the Problem Drinking of Workers
Sang Kye Lee, M.D.
Hong-Soek Lee, M.D., Ph.D.

NR1-10
Comparison of Behavioral, Psychological Characteristic Features and Severity Between Gamblers in Legal and Illegal Gambling Places
Sang Kye Lee, M.D.
Hong-Seok Lee, M.D. Ph.D.

NR1-11
Psychiatry Residents’ Attitudes on Substance Abuse: Changes in Attitudes Post-SBIRT Training
Victoria Balkoski, M.D.
Tavi Thongdy, M.D.

NR1-12
Withdrawal and Abstinence-Related Psychiatric Symptoms in Abstinent Methamphetamine-Dependent Subjects
Todd Zorick, M.D., Ph.D.
Karen Miotto, M.D.
Gerhard Hellemann, Ph.D.
Catherine Sugar, Ph.D.
Rick Rawson, Ph.D.
Edythe London, Ph.D.

NR1-13
Association Study Between Panic Disorder and 5-HT1A Gene C(-1019)G Polymorphism
Choi Wonseok, B.A.
Yong-Ku Kim, M.D., Ph.D.
Bum-Hee Yu, M.D., Ph.D.
Ho-Kyoung Yoon, M.D., Ph.D.

NR1-14
Association Study Between Panic Disorder and -874 A/T Interferon-Gamma Gene Polymorphism
Choi Wonseok, B.A.
Ho-Kyoung Yoon, M.D., Ph.D.
Yong-Ku Kin, M.D., Ph.D.

NR1-15
Comparison of Anxiety-Related Traits Between Early and Late-Onset Panic Disorder
Eun Jin Kim, M.D.
Ju-Won Ha, M.D.
Se-Won Lim, M.D.
Kang-Seob Oh, M.D., Ph.D.

NR1-16
The Effect of Temperament and Character on the Treatment Outcome after 24-Week Pharmacotherapy with Escitalopram in Patients with Panic Disorder
Hae-Ran Na, M.D.
Yoon-Jae Song, M.D.
Eun-Ho Kang, M.D.
Bum-Hee Yu, M.D., Ph.D.

NR1-17
Brain Glucose Metabolism and Temperament and Character in Patients with Panic Disorder: An [18]FDG-PET Study
Hae-Ran Na, M.D.
Sang-Wook Kim, M.D.
Eun-Ho Kang, M.D.
Bum-Hee Yu, M.D., Ph.D.

NR1-18
Efficacy of Korean-Type Cognitive-Behavioral Group Therapy for Social Anxiety Disorder
Ju-Won Ha, M.D.
Eun-Jin Kim, M.D.
Se-Won Lim, M.D.
Kang-Seob Oh, M.D.

NR1-19
Association of the C-1019G Polymorphism of Serotonin 1A Receptor Gene and Abnormal Eating Behavior in Korean Female Adolescents
Ju-Won Ha, M.D.
Eun-Jin Kim, M.D.
Se-Won Lim, M.D.
Kye-Hyun Kim, M.D.

NR1-20
An Open-Label, Rater Blinded 6-Week Pilot Trial of Escitalopram for GAD Among Patients with HIV
Manmohandeep Sohi, M.D.
Haresh Tharwani, M.D.
Chi-Un Pae, M.D.
Prakash Masand, M.D.
Meera Narasimhan, M.D.
Ashwin A Patkar, M.D.

New Research :: Monday, May 24
NR1-38
Contrasting Patterns of Deficits in Visuospatial Memory and Executive Function in Patients with Major Depression, with and without ECT Referral
Eirini Theochari, M.D.
Stamatina Kalogerakou, M.Sc.
Vassiliki-Maria Papakosta, B.Sc.
Dimitrios Kontis, M.D., Ph.D.
Marina Kaukouni, B.Sc.
Eleni Anylandi, B.Sc.
Ioannis Michopoulos, M.D., Ph.D.
Evangelos Karapoulou, M.D.
George Papadimitriou, M.D., Ph.D.
Panagiotis Oulis, M.D., Ph.D.
Eleftheria Tsaltas, Ph.D.

NR1-39
A Clinical Comparison Between Early (< 15 years) and Late-Onset Patients with Bipolar Disorder
Farah S. Hassan, M.D.
Elizabeth C. Penick, Ph.D.
Ekkehart Othmer, M.D., Ph.D.
Elizabeth J. Nickel, M.A.
Cherylne DeSouza, M.D.
E. N. Hunter, Ph.D.
William F. Gabrielli, M.D., Ph.D.

NR1-40
Depressive Symptoms in Anxiety Disorders and MDD
Hyunjoo Yang, M.D.
Hong Yang
Yan Ren

NR1-41
A Comparison of Medical Comorbidities in Elderly Versus Younger Bipolar Patients
Illyse Rosenberg, D.O., B.S.
J. Proser, M.D.
K. Shah, M.D.
I. Galynker, M.D.
L. Cohen, Ph.D.
M. Lantz, M.D.

NR1-42
Feasibility and Effectiveness of Using E-mail to Screen College Students for Depression
Irene Shyu, B.A.,
Soo Jeong Youn, B.A.
Maurizio Fava, M.D.
Albert Yeung, M.D., Sc.D.

NR1-43
Seasonal Variation of Mood and Behavior in Bipolar I and Bipolar II Disorders
Jungmi Choi, M.D.
Jihae Noh, M.A.,
Ji Hyun Baek, M.D.
Ji Sun Kim, M.D.
Ji Sun Choi, RN-BSN
Hee Jung Nam, M.D.
Dong soo Lee, M.D., Ph.D.
Kyung Sue Hong, M.D., Ph.D.

NR1-44
Comorbid Anxiety and Mood Disorders in a Tertiary Care Outpatient Setting
Kavi K. Devulapalli, B.A.
Keming Gao, M.D., Ph.D.

NR1-45
Diagnostic Stability of First-Episode Psychoses Retrospectively Assessed after Recurrence of Psychotic Episodes
Ji Sun Kim, M.D.
Ji Sun Choi
Kyung Sue Hong, M.D., Ph.D.

NR1-46
ATR as a Predictor of Response to Reboxetine
Marissa Caudill, M.D., Ph.D.
Ian A. Cook, M.D.
Aimee M. Hunter, Ph.D.
Andrew F. Leuchter, M.D.

NR1-47
Genetic Association of the Interaction Between the BDNF and GSK3B Genes and MDD in a Chinese Population
Ning Sun, B.S.C.
Chunxia Yang, M.Sc.
Yong Xu, M.Sc.
Hong Yang, M.Sc.
Jinli Liu, M.Sc.
Kerang Zhang, M.D.
Qi Xu, Ph.D.
Yan Shen, M.Sc.

NR1-48
How to Use Adverse Events Listed in the PDR for Antidepressants?
Srimasparayana Marella, M.B.B.S.
Rajnish Mago, M.D.

NR1-49
Stephanie Gerard, Pharm.D.
Chantal Henry, M.D.
Amandine Luquèns, M.D.
Christophe Lancon, M.D., Ph.D.
Hélène Sapin, Elena Perrin, M.D.
Bruno Failllard, M.D., Ph.D.
Stephanie Gerard, Pharm.D.
Michael Lukastewitz, M.D., Ph.D.

NR1-50
Resting-State Spontaneous Neural Activities in Patients with a First-Episode of MDD and Their First-Degree Relatives
Xiaohua Cao, Ph.D.
Zhifen Liu, M.Sc.
Bing Zhao, M.Sc.
Cheng Xu, B.M.
Lijian Bai, M.Sc.
Chongxi Du, B.M.
Kerang Zhang, M.D.

NR1-51
Decreased Regional Homogeneity in Insula and Cerebellum: A Resting-State fMRI Study in Patients with Depression and Subjects at Risk for Depression
Zhifen Liu, B.S.C.
Chong-Xi Du

NR1-52
Does Gender Impact the Relationship Between Parental Maltreatment and Personality Pathology in Adulthood?
Aarti Nanda, M.D.
Michelle Foster
Winter Halmi
Cristina Nesci
Igor Galynker, M.D.
Lisa J. Cohen, Ph.D.

NR1-53
Risk Factors for Obesity in Patients with BPD Over 10 Years of Prospective Follow-Up
Jolie Weingeroff, M.A.
Frances R. Frankenbueg, M.D.
Garrett Fitzmaurice, Sc.D.
Mary C. Zanarini, Ed.D.

NR1-54
Prevalence of Personality Disorders in Adult Gay, Lesbian, Bisexual, and Transgender Patients in an Inpatient Chemical Dependency Treatment Program
Meredith B. Flynn, M.D.
Winter Halmi
Aarti Naanda, M.D.
Cristina Nesci
Igor Galynker, M.D.
Lisa J. Cohen, Ph.D.

NR1-55
Reduction of Typical Gender Differences Among Psychiatric Outpatients with ASPD
Micaela P. Wexler, D.O.
Mary C. Zanarini, Ed.D.
Igor Galynker, M.D.
Cristina Nesci
Winter Halmi
Aarti Naanda, M.D.
Kavi K. Devulapalli, B.A.

APA 2010 ANNUAL MEETING ONLINE:
• Special onsite pricing
• Earn CME credit for top lectures and symposia online
For more information: <psych.org/amlibrary>
NR1-56  Withdrawn

NR1-57  Quality of Care and Crime Rates Among Patients with Schizophrenia: A Nationwide Population-Based Follow-Up Study
Charlotte Pedersen,
Merete Nordenstav, Ph.D.
Søren Pauske Johnsen, Ph.D.
Jan Mainz, Ph.D.

NR1-58  The Efficacy of Low-Frequency Repetitive Transcranial Magnetic Stimulation Treatment for Auditory Verbal Hallucinations May Be Low
Christina C. Slotema, M.D., D.Phil.
Jan Dirk Blom, Ph.D.
Hans W. Hoek, M.D., Ph.D.
René S. Kahn, M.D., Ph.D.
Iris E.C. Sommer, M.D., Ph.D.

NR1-59  Metabolic and Cardiovascular Risk in Psychotic Patients Treated with Atypical Antipsychotics
Clara Franck Pato
Juan I. Franch Valderde, Ph.D.
Gema Medina Ojeda, Ph.D.
Ana I. Ledo Rubio, M.D.

NR1-60  “How Long Should I Take This Medicine?” A Literature Review of the Duration of Maintenance Treatment in Schizophrenia
Durga Bestha, M.B.B.S.
Vishal Madaan, M.D.
Babuji Gandra, M.B.B.S.

NR1-61  Beyond Smoking Cessation: Varenicline in Schizophrenia?
Durga Bestha, M.B.B.S.
Vishal Madaan, M.D.
Namita Dhiman, M.B.B.S.

NR1-62  Facial Emotion Recognition in Chinese with First-Episode Schizophrenia: Emotion Specific Deficit and Error Pattern
Joey Shuk Yan Leung, M.B.B.S.

NR1-63  Previous Offending Among First Episode Psychosis Patients: Prevalence and Clinical Correlates
Laila Asmal, M.D., M.Med.
Robin A. Ensley, MB.Ch.B, M.Med, M.D.
Piet Oosthuizen, MB.Ch.B, M.Med, M.D.
Bonginkosi Chitiza, MB.Ch.C.

NR1-64  Antipsychotics and Long-Term Outcome in Schizophrenia: Milan-Stanford Collaborative Project
Massimiliano Buoli, M.D.
Filippo Dragona, M.D.
Massimo Carlo Mauri, M.D.
Giobbio Gian Marco, M.D.
Beneda Dell’Osso, M.D.
Carlo Altamura, M.D.
Ira D. Glick, M.D.

NR1-65  Exacerbation of Psychosis in Relation to Menstrual Cycle in Women: Role of Estrogen
Michelle Thorpe, M.D.
Sadia Ghaffar, M.D.
Anuradha Seshadri, B.S.
Amel Badr, M.D.
Joan Wynn, MBA
Javed Iqbal, M.D.

NR1-66  Delusions, Delusional Conviction and Metacognitive Impairments in Patients with Schizophrenia
Nicolás Bruno, M.D.
Nadia Sachs, Ph.D.
Nicolás Franck, M.D., Ph.D.
Elisabeth Pacherie, Ph.D.

NR1-67  Predictors of Functional Disability and Number of Hospitalizations in Schizophrenia: Relations with Neurocognition, Symptoms, and Premorbid Adjustment
Javier Peña, Ph.D.
Pedro Manuel Sánchez, M.D.
Natalia Ojeda, Ph.D.
Edorta Elizagarate, M.D.
Jesus Ezcurre, M.D.
Miguel Gutiérrez, M.D.

NR1-68  Comparative Analysis of Involuntary Admission and Voluntary Admission in Schizophrenia: A Three-Year Follow-Up
Seung-Ho Jung, M.D.
Young-Su Lee, M.D.
Chul-Jin Shin, M.D., Ph.D.

NR1-69  Carbon Dioxide-Induced Panic in Schizophrenia with Auditory Hallucinations
Tara A. Kahn
Jeffrey P. Kahn, M.D.
Adam Savitz, M.D., Ph.D.

NR1-70  Three Dimensional Electroencephalographic Mapping with eLORETA During Sleep Onset Period
Chul-Jin Shin, M.D., Ph.D.
Jae Young Park, M.D.
Doo-Heun Park M.D.

NR1-71  Study Comparing PSG Data in Insomnia Patients with HIV Versus Matched Controls with Insomnia
Younghi Yh. Low, B.S.C.
Toma Omonuwa, M.D.
Jack Edinger, Ph.D.
Harold Goforth, M.D.
Xavier Prud’hon, M.D.
Colleen Carney, Ph.D.
Andrew Krystal, M.D.

NR1-72  Decreases in Soluble CD40 Ligand are Associated with Improvements in Severity of Insomnia in HIV-Infected Patients: A Pilot Study
Younghi Yh. Low, B.S.C.
Edward C. Suarez, Ph.D.
Harold Goforth, M.D.
Toma Omonuwa, M.D.
Andrew Krystal, M.D.

NR1-73  Perceived Stress and Psychopathology in Schizophrenia
Anders Jorgensen, M.D.
Anders Fink-Jensen, M.D., DMSci
Henrik Enghusen Poulsen, M.D., DMSci
Martin Balslev Jorgensen, M.D., DMSci

12:30 P.M.-2:00 P.M.
YOUNG INVESTIGATORS’ POSTER SESSION 2
LA LOUISIANE C, MORIAL CONVENTION CENTER

Moderator:
Barton Blinder, M.D.

NR2-1  Exploring the Relationship Between Sleep and an Anxiety-Related Endophenotype: Active Avoidance Learning Increases REM Sleep
Frank A. Fetterolf, B.S.
Helene S. Porte, Ph.D.

NR2-2  The Second Digit to the Fourth Digit Length Ratio and Its Personality and Temperament Characteristic
Hyun Young Oh, M.D.
Hwang Lyong Kim, M.D.
Hyun Joo Yang, M.D.
Suk Hyun Kim, M.D., Ph.D.
Yong Chan Park, M.D., Ph.D.
NR2-3
Loss of Heart Rate Complexity in Men with Depression
Samuel Leistedt, M.D.
Paul Linkowski, M.D., Ph.D.
Jean-Pol Languart, Ph.D.
Chung-Kang Peng, Ph.D.
Joseph E. Mietus, Ph.D.
Ary L. Goldberger, M.D.
Madalena D. Costa, Ph.D.

NR2-4
Neurobiologic Correlates of Low Plan/Impulsive Suicide Attempt: A Review
Sarah Berkson, B.A.
Lauren M. Klayman, B.A.
Lance M. Rappaport
Lisa J. Cohen, Ph.D.
Serena J. Fox, M.D.
Igor I. Galynker, M.D., Ph.D.

NR2-5
Up-Regulation in Serum Tropomyosin-Related Kinase B Protein Level in Acute Stage of Major Depression
Tiao-Lai Huang, M.D.
Yi-Yung Hung, M.D.
Chia-Ju Lin

NR2-6
Association Study of Personality and Brain Evoked Potentials in Healthy Chinese
Yan Ren, B.S.C.
Hong Yang
Kerang Zhang
Huirun Duan

NR2-7
Structural Volumes of the Cerebellar Vermis in a Pediatric Bipolar Population with Comorbid ADHD
Amy Shah, M.D.
David E. Fleck, Ph.D.
Melissa P. DelBello, M.D.
Neil P. Mills, B.S.

NR2-8
Neural Representation of Visual Processing of Attachment Figures in Young Adult Women Using fMRI
Curren E. Katz, Ed.M.
Joy Hirsh Ph.D.
Steve Dashnaw
Leo Bierman B.A.
Gillian Jennings, B.A.
Amie Sanders B.A.
Cristina Nesci, M.S.
Hellen Mayberg, M.D.
Arnold Winston, M.D.
Igor Galynker, M.D., Ph.D.

NR2-9
A Comparison Study Between Visual Interpretation and Statistical Parametric Mapping (SPM) Analysis of SPECT Images in Patients with Traumatic Brain Injury
Hwang Lyong Kim, M.D.

NR2-10
Relationship Between rCBF and Neuropsychiatric Symptoms in Traumatic Brain Injury at the Chronic Stage: A SPECT Study with SPM Analysis
Hwang Lyong Kim, M.D.
Hyun Joo Yang, M.D.
Hyun Young Kim, M.D.
Yong Chon Park, M.D., Ph.D.
Dong Hoon Oh, M.D.

NR2-11
The Link Between Tourette’s Syndrome and Bipolar Disorder: A Closer Look
Atif Waseem, B.S.
Gulam A Noorani, M.D., M.P.H.
Javed Iqbal, M.D.

NR2-12
Improvement in Multiple Symptom Domains in Youth Following 12 Weeks of Atypical Antipsychotic Treatment for Irritability and Aggression
Cara Fosdick, B.A.
Ginger Nicol, M.D.
Michael Yingling, B.S.
John Newcomer, M.D.

NR2-13
Ziprasidone-Induced Galactorrhea in an Adolescent Female: A Case Report
Fasiha Haq, M.D.
Shakeel Raza, M.D.

NR2-14
Intelligence and Neurocognitive Functioning by KPI-C Profile Type in Children with ADHD
Han Kyal Park, M.D.
Wanseok Seo, M.D., Ph.D.
Bon-Hoon Koo, M.D., Ph.D.
Kwangheun Lee, M.D., Ph.D.
Kyung-Keun Kim, M.D.

NR2-15
Chronic Depression in an 11-Year-Old Asthmatic Male: A Case Report and Literature Review
Matthew Lowe, D.O., M.S.
Leanne Strack, D.O.
Amy Hotsington-Stabile, M.D.

NR2-16
Well-Being and Psychiatric Status of Parents of Children with Mental Retardation in Pakistan
Muhammad Waqar Azeem, M.D.
Intiaz Dogar, M.D.
Imran Haider, M.D.
Marianne Wudarsky, M.D., Ph.D.
Alia Asmat, M.Sc.
Madeeha Akbar, M.Sc.
Sumitra Kousar, M.Sc.

NR2-17
Repetitive Transcranial Magnetic Stimulation and Olanzapine Versus Olanzapine Alone in the Treatment of Adolescents with Bipolar Mania
Ram Jeewan Bisnoh, D.P.M.
Venu Gopal Jhanwar, M.D.

NR2-18
Neurofeedback: An Effective and Safe Treatment Option for Chronic Tension Type Headaches
Ram Jeewan Bisnoh, D.P.M.

NR2-19
Prevalence of Mental Illness and Substance Abuse Among Child and Adolescent Suicide Victims
Yilmaz Yildirim, M.D.
Umnuhan Yesil-Dagli, Ph.D.
Richard Bloch, Ph.D.

NR2-20
The Joker: A Dark Night for Depictions of Mental Illness
Cecil R. Webster, M.D.
John Coverdale, M.D.

NR2-21
Migration Psychiatric Disorders at an Acute Psychiatric Unit
Eva Roman Mazaeco, M.D.
Jesus J. Marin-Lazano, M.D.
Ainoa Muñoz S. Jose, M.D.
David Lopez Gomez, M.D.
Belén Bardón Rivera, M.D.
Mª Pé Bravo Ortiz, M.D., Ph.D.

NR2-22
Is She Bipolar? Considering Contributions of a Cultural Background from a Spanish-Speaking Patient and Bilingual Mental Health Treatment Team
Kristine Munoz, M.D.
Jason Bennett, M.D.

NR2-23
The Impact of Race, Ethnicity, and Culture on the Diagnosis of Bipolar Disorder: A Review
Sophia Haeri, B.A.
J. Williams, B.A.
A. Newmark, B.A.
I. Kopeykin, B.A.
L. Cohen, Ph.D.
I. Galynker, M.D. Ph.D.
<table>
<thead>
<tr>
<th>Page Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| NR2-24      | Clinical and Demographical Characteristics Among Psychiatric Patients in an Emergency Service | Ainoa Muñoz San José, M.D.  
Jesús J. Marin, M.D.  
Mª Eva Román, M.D.  
Mª Victoria Bonan, M.D.  
David López, M.D.  
Marífe Bravo, Ph.D. |
| NR2-25      | Familial Relation of Obsessive-Compulsive and Schizoid/Schizotypal Traits in Autism Traits in Pediatric OCD | Hannah E. Reed, B.A.  
Kelley Anderson, B.A.  
Sarah Davarya, B.A.  
Ariana Tirt-Zelvin  
Kathryn Mills  
Pedro Alvarez  
Marco Grados, M.D., M.P.H. |
| NR2-26      | Outpatient Psychotherapy Use Prevalence, Correlates and Expenditures: A Systematic Review | Paula Silva, M.D.  
Sergio L. Blay, M.D., Ph.D. |
| NR2-27      | Can Economic Crises Turn Deadly? Mental Health Emergencies in Times of Economic Crisis in a General Hospital in Madrid | Susana S. Cebolla, M.D.  
Juan J. De Frutos, M.D.  
Belén Bardón, M.D.  
Maria F. Bravo, Ph.D. |
| NR2-28      | Mental Health Change in Flooded District Citizen: Two Years Follow-Up | Young Ju Cho, M.D.  
Seongho Min, M.D., Ph.D.  
Min-Hyuk Kim, M.D. |
| NR2-29      | Too Many Duties, Too Few Rights: Ethical Dilemmas in Psychiatrist’s Rights Vis-à-Vis Patients Rights: Proposal for an International Consensus | Mohamed Nasr, M.D.  
Hani Hamed, M.D.  
Dalal Amer, M.D.  
Nahed Khairy, M.D. |
| NR2-30      | Frequency of Third Party Notification Following a Threat in an Inpatient State Psychiatric Hospital Population | Delaney Smith, M.D.  
Tara Mayes, M.D. |
| NR2-31      | Neurobiological Characteristics Co-Vary with Personality Traits: Forensic Psychiatric Findings Replicated in the General Population | Sara Bromander, M.D.  
Thomas Nilsson, Ph.D.  
Rolf Ankarsäter, M.D.  
Marianne Kristiansson, M.D., Ph.D.  
Anders Forsman, M.D., Ph.D.  
Kaj Blennow, M.D., Ph.D.  
Henrik Zetterberg, M.D., Ph.D.  
Henrik Ankarsäter, M.D., Ph.D.  
Caroline Wiss, Ph.D. |
| NR2-32      | T3111C CLOCK SNP and Mood Disorders: A Systematic Review | Enrique Gaspar, M.D.  
Raffaella Calati, Ph.D.  
Carlos S. Cruz-Fuentes, Ph.D.  
Diana De Ronchi, M.D., Ph.D.  
Alessandro Serretti, M.D., Ph.D. |
| NR2-33      | Neuropsychological and Psychiatric Alterations Caused by Mutations of the Mitochondrial DNA | Gabriella Incezedy-Farkas, M.D.  
Agnes Meszaros  
Monika Andrejkovics  
Aniko Gal, Ph.D.  
Viktoria Renenyi  
Maria Judit Molnar, M.D., Ph.D. |
| NR2-34      | Dental Care and Associated Factors Among Older Adults with Schizophrenia | Thulasiram Janardhanan, M.D.  
Stanley Kim, D.D.S.  
Jean-Claude Desrosiers, M.D.  
Nikhil Palekar, M.D.  
Susan Pugliese, D.D.S.  
Jasvir Singh, M.D.  
Batool F Rizvi, D.D.S.  
Paul Ramirez, Ph.D.  
Carl I Cohen, M.D. |
| NR2-35      | Barriers in Metabolic Screening for People with Severe Mental Illnesses in Community Behavioral Health Clinics in San Francisco and New York City | Charlene Chang, B.A.  
Sharat Parameswaran, M.D.  
Karimi Mailauth, M.D., M.P.H.  
Lisa Dixon, M.D., M.P.H.  
Christina Mangurian, M.D. |
| NR2-36      | Improving Follow Up After Inpatient Care: Staff Perspectives | Jane N. Kogan, Ph.D.  
Shari L. Hutchison, M.S.  
Emily A. Magee, B.A.  
Bradley D. Stein, M.D., Ph.D. |
| NR2-37      | Pilot of Measurement-Based Care for Depression in an HIV Outpatient Clinic | Julie Adams, M.D.  
R. Scott Pollard, L.C.S.W.  
Kristen G. Shirey, M.D.  
Brian W. Pence, Ph.D. |
| NR2-38      | Triaging Psychiatric Patients in the Emergency Department: Effectiveness of a Brief Screening Tool | Kathleen C. Diller, M.D.  
Olga Achilli, M.D.  
William R. Dubin, M.D. |
| NR2-39      | The Chronic Pain Patient in 5D: Better Care through Understanding of Five Core Complicating Issues in the Treatment of Chronic Pain Patients | Mitchell J.M. Cohen, M.D.  
Muhammed A. Abbas, M.D. |
| NR2-40      | Variations in Cancer Care and Outcomes in Older Adults with Mental Illness: Results from the Health and Retirement Study | Simha E. Ravven, M.D.  
Susan K. Schultz, M.D.  
Robert B. Wallace, M.D., M.S. |
| NR2-41      | Language, Communication and Psychiatric Disorders: A Case for Psycholinguistics and Psychiatric Literacy: The Effects of Ethnicity and Education | Swapnil Gupta, M.D.  
Jatinder Mohan Chawla, M.D.  
Harshvardhan Reddy, M.D. |
| NR2-42      | Combating Stigma in Mental Health: The Effects of Ethnicity and Education on Mental Health Literacy | Christian Reusche, M.D.  
Cheryl Ann Kennedy, M.D.  
Jeffrey Borckardt, Ph.D. |
| NR2-43      | Meta-Analysis of 123I-MIBG Cardiac Scintigraphy for the Diagnosis of A-Synucleinopathies | Alisha E. King, M.D.  
A-Synucleinopathies |
PHANTOM LIMB AND PHANTOM PAIN SYNDROME IN COLOMBIAN MILITARY PERSONNEL AMPUTED BY LANDMINES
Juliana Acosta-Uribe, Ligia Eugenia Uribe, M.D. Francisco Lopera, M.D.

FIREARMS USE, PSYCHIATRIC ILLNESS, AND NEUROPSYCHOLOGICAL FUNCTION
Kári A. Stenback, M.D. Robert McLaughlin, M.D. Ph.D. Heather Kurera, D.O.
Massoud Nikkhoy, M.P.H.

RELATIONSHIPS BETWEEN MULTIPLE SCLEROSIS AND DEPRESSION
Nancy Byatt, D.O., M.B.A.
Anthony J. Rothschild, M.D.
Peter Riskind, M.D., Ph.D.
Carolina Ionete, M.D., Ph.D.
Anne Hunt, Sc.D.

THE RETROSPECTIVE STUDY OF THE EFFECT OF EEG BIOFEEDBACK IN CHILD AND ADOLESCENT PATIENTS WITH PSYCHIATRIC DISORDERS
Bon-Hoon Koo, M.D., Ph.D.
Wanseok Seo, M.D., Ph.D.
Kwangheun Lee, M.D., Ph.D.
Kyung-Kun Kim, M.D.
Han Kyul Park, M.D.

EARLY FAMILY FACTORS AND RISK OF ATTEMPTED SUICIDES OR SUICIDES IN OFFSPRING: THE NORTHERN FINLAND 1966 BIRTH COHORT STUDY
Antti Alaräisänen, M.D.
Jouko Miettinen, Ph.D.
Ameli Pouta, M.D., Ph.D.
Matti Boisanni, M.D., Ph.D.
Pirkko Räisänen, M.D., Ph.D.
Pirjo Mäki, M.D., Ph.D.

THE SUICIDE TRIGGER SCALE (STS-3): PRELIMINARY RESULTS FROM A PROSPECTIVE STUDY OF SUICIDAL PATIENTS IN THE ER
Zimri Yaseen, M.D.
Lance M. Rappaport
Dragos Serseni, M.D.
Lisa J. Cohen, Ph.D.
Igor Galynker, M.D., Ph.D.

INCREASING THE USE OF RISPERDAL CONSTA AS A TREATMENT REGIMEN: A QUALITY IMPROVEMENT PROJECT
Abderrahmane Richane, M.D.
Carolina Mercader, D.O.
Michelle Thorpe, M.D.
Harpreet Kaur
Amel Badr, M.D.
J. Iqbal, M.D.

ASSESSING CURRENT PHYSICAL RESTRAINT PROTOCOLS AND THEIR USE ON PSYCHIATRIC PATIENTS
Amin Shamal, M.D.
Deepa Hasija, M.D.
Melissa Oliver
Su tupa Dubu
Amel Badr, M.D.
J. Iqbal, M.D.

A QUALITY IMPROVEMENT PROJECT TO ASSESS THE IMPORTANCE OF SCREENING VARIABLES IN PATIENTS BEING TREATED WITH LITHIUM
Asad Amir, M.D.
Gulam Noorani, M.D., M.P.H.
Radha Agepati, M.D.
Ayme Frometa, M.D.
Deepa Hasija, M.D.
Joan Wynn, M.D.
A. Hassain, M.D.
Amel Badr, M.D.
Javed Iqbal, M.D.

ASSESSMENT OF THE IMPORTANCE OF SCREENING VARIABLES IN PATIENTS BEING TREATED WITH VALPROATE
Ayme Frometa, M.D.
Asad Amir, M.D.
Gulam A Noorani M.D.
Radha Agepati, M.D.
Deepa Hasija, M.D.
Jonathan Chan, B.A.
Vandana Parvatam, B.S.
Johan Murugaser, B.A.
Joan Wynn, M.B.A.
Amel Badr, M.D.
Javed Iqbal, M.D.

IMPLEMENTATION OF TWO POLICIES REDUCES PATIENT WAIT TIME IN THE EMERGENCY DEPARTMENT
Bushra F. Mirza, M.B.B.S. B.S.
Ir nute Usiene, M.D.
Ferhana Nadeem, M.D.
David Chaipakeo
Lulua Mambuwala
Amel Badr, M.D.
Joan Wynn, M.B.A.
Javed Iqbal, M.D.

ASSESSMENT OF APPROPRIATE PRESCRIBING PRACTICES OF SECOND-GENERATION ANTIPSYCHOTICS FOR PSYCHIATRIC PATIENTS WITH COMORBID DIABETES MELLITUS
Jonathan K. Chan, B.A.
Vandana Parvatam, B.S.
Gulam Noorani, M.D., M.P.H.
Asghar Hassain, M.D.
Javed M. Iqbal, M.D.

CHOICE OF BRAND NAME VERSUS GENERIC MEDICATIONS PRESCRIBED BY PSYCHIATRIST IN THE OUTPATIENT CLINICAL SETTING
Yakir K. Vaks, M.D.
Bushra Mirza, M.D.
Ferhana Nadeem, M.D.
Lindi Zhuta
Philip Silva
Amel Badr, M.D.
Joan Wynn, M.B.A.
Javed Iqbal, M.D.

THERAPY BITES: PROMOTING COMPETENCY IN PSYCHOTHERAPY THROUGH AN EXPLORATION OF POPULAR FICTION
Ashley B. Jones, M.D.
Leslie E. Frinks, M.D.
Nioaka N. Campbell, M.D.

UNDERUTILIZATION OF NONPHARMACOLOGIC INTERVENTIONS FOR INSOMNIA BY HEALTHCARE PROVIDERS
Meghan L. Rieu-Werden, B.S.
Kelly M. Sutton-Skinner, B.A.
Sarah A. Romeo, B.A.
John A. Fromson, M.D.
Robert J. Birnbaum, M.D., Ph.D.

POST PEDS PORTAL PROJECT: GENERATING WORKFORCE IN CHILD AND ADOLESCENT PSYCHIATRY
Robert Ellis, M.D.
Amy Kathryn Anderson, M.D.
Vishal Madaan, M.D.
Jamie Snyder, M.D.

MENTAL HEALTH PROVIDERS’ RESPONSES TO A CLINICAL CASE VIGNETTE: TRANSCULTURAL DIAGNOSTIC AND TREATMENT DIFFERENCES
Sarah A. Romeo, B.A.
Hongyu Tang, M.D.
Ronghuan Jiang, M.D.
Xin Yu, M.D.
Hong Ma, M.D.
Yangjing Guo, M.D.
Fanbo Li, M.D.
Hongyu Tang, M.D.
Robert J. Birnbaum, M.D., Ph.D.

STUTTERING-ONSET ASSOCIATED WITH STREPTOCOCCAL INFECTION: A CASE SUGGESTING STUTTERING AS PANDAS
Scott M. Summers, Ph.D.
Gerald A. Maguire, M.D.
Steven N. Viele, M.D.
Sanjay Agarwal, M.D.
Elliot Handler
David Franklin, Psy.D.
The Role of Acetaldehyde in Human Psychomotor Function: A Double-Blind Placebo-Controlled Crossover Study
Bae Kyung Yeol, M.D.
Sung-Wan Kim, M.D., Ph.D.
Hee-Young Shin, M.D., Ph.D.
Jae-Min Kim, M.D., Ph.D.
Il-Seon Shin, M.D., Ph.D.
Tak Youn, M.D., Ph.D.
Jin Kim, Ph.D.
Jong-Keun Kim, M.D., Ph.D.
Jin-Sang Yoon, M.D., Ph.D.

The Association Between Obesity, Suicide, Brain-Derived Neurotrophic Factor and Tyrosine Kinase B Receptor Protein Levels in Major Depression
Chin-Chuen Lin, M.D.
Tiao-Lai Huang, M.D.

Biochemical and Polysomnographic Study of Patients with MDD and Somatofom Pain Disorders
Samah Affii, M.D., Ph.D.
Timothy Roehrs, Ph.D.
Nash Boutros, M.D.
Gamal Shamma, M.D.
Tarek Asaad, M.D.
Aisha Abdullatif, M.D.
Tarek Asaad, M.D.

Plasma Serotonin Level of Korean Vietnam War Veterans with PTSD and Symptom Severity
Moon Young Chung, M.D., Ph.D.
Suk-Hoon Kang, M.D.

A Correlation Among Plasma Aβ42, Depressive Symptom, and Cognitive Function in the Korean Elderly
Suk-Hoon Kang, M.D.
Do Hoon Kim, M.D., Ph.D.

Evidence for Interaction Between BDNF Pathway Genes and Personality in Chinese Han Population
Yang Hong, B.S.C.
Xuemei Liao, M.Sc.
Fei Yu, M.Sc.
Qiankun Yao, M.Sc.
Kerang Zhang, M.D.
Juyi Peng

Diffusion Tensor Imaging in Studying White Matter Complexity: A Gap Junction Hypothesis
Chadi Abdallah, M.D.
Jeremy D. Coplan, M.D.
Cheuk Y. Tang, Ph.D.
Sanjay J. Mathew, M.D.
Jose Martinez, M.A.
Patrick R. Hof, M.D., Ph.D.
Eric L.P. Smith, Ph.D.
Andrew J. Dwork, M.D.
Tarique D. Perera, M.D.
Leonard A. Rosenblum, Ph.D.
Dikoma C. Shungu, Ph.D.
Joel Gelernter, M.D.
Arie Kaffman, M.D., Ph.D.
Andrea Jackowski, Ph.D.
Joan Kaufman, M.D.
Amjad Hindi, M.D.
Jack M. Gorman, M.D.

Correlations Between Mood and Brain Gamma-Aminobutyric Acid Levels after Yoga and Walking
Chris C. Streeter, M.D.
Theodore Hatch Whitfield, Sc.D.
Tasha Reit, B.A.
Domenic A. Ciraulo, M.D.
Perry F. Renshaw, M.D., Ph.D.
J. Eric Jensen, Ph.D.

Players of First Person Shooter Games Show Increased Activity in Frontal Brain in Default-Mode Network as Shown by fMRI
Gregor R Szych, Ph.D.
Bahram Mohammadi, M.D.
Thomas F Münte, M.D.
Amir Samii, M.D.
Wolfgang Dillo, M.D.
Ber T te Wildt, M.D.

Nature or Nurture? Personality Dimensions and fMRI Neural Representation of Attachment
Igor Galyenker, M.D., Ph.D.
Joy Hirsh, Ph.D.
Steve Dashnaw
Leo Bierman, B.A.
Gillian Jennings, B.A.
Janine Samuel, B.A.
Christina Nesci, M.S.
Hellen Mayberg, M.D.
Arnold Winston, M.D.
Curren Katz, Ed.M.

PET-Measured Occupancy of the D2 Receptor: A Comparison of Quetiapine Fumarate Immediate- and Extended-Release Formulations in Healthy Subjects
Svante Nyberg, M.D.
NR3-21
Patient and Staff Perceptions of the Implementation of an Enhanced Discharge Process for Inpatient Psychiatric Settings
Bradley D. Stein, M.D., Ph.D.
Jane N. Kogan, Ph.D.
Shari L. Hutchison, M.S.
Emily A. Magee, B.A.

NR3-22
Successful Implementation of a Glucose Monitoring Program in a Community Mental Health Setting
Ginger E. Nicol, M.D.
Elaine H. Morrato, Dr.P.H.
Mark C. Johnson, M.D.
John W. Newcomer, M.D.

NR3-23
Treatment Adherence and Persistence with Branded Antidepressants Among Patients with MDD and Painful Chronic Diseases
Junling Wang, Ph.D., M.S.
Xiaochen Liu, M.D., Ph.D.
C. Daniel Mullins, Ph.D.

NR3-24
Is “Home Treatment” for the Acutely Mentally Ill in a Rural Southern German Area as Effective as the Usual Inpatient Treatment?
Karel J. Frasch, M.D.
Miriam Ott Henriette John, M.D.
Annett Rauscher
Christoph Piesbergen, Ph.D.
Markus Jaeger, M.D.
Thomas Becker, M.D.
Reinhold Kilian, Ph.D.
Isolde Munz

NR3-25
Frequency and Duration of Physical Restraints in Generalized Versus Specialized Emergency Room Settings
Natalie A. Lester, M.D.
Ali Kazim, M.D.

NR3-26
A Drug Interaction Study of Dextromethorphan/Quinidine: An Investigational Agent for Pseudobulbar Affect and Paroxetine
Kerr Schoedel, Ph.D.
Laura E. Pope, Ph.D.
Randall Kaye, M.D.
Adrian Hepner, M.D.
Edward M. Sellers, M.D., Ph.D.

NR3-27
A Study of Potential Pharmacokinetic (PK) and Pharmacodynamic (PD) Interactions Between Dextromethorphan/Quinidine and Memantine
Laura Pope, Ph.D.
Randall Kaye, M.D.
Adrian Hepner, M.D.
Kerri A. Schoedel, Ph.D.
Cynthia Bartlett, M.Math
Edward M. Sellers, M.D., Ph.D.

NR3-28
Employee Perspectives on Patient Safety Inside a Behavioral Health Clinic: A Case Study
Colleen S. Lewy, Ph.D.
Celina Oliver, Ph.D.
Holly Fussell, Ph.D.
Bentson McFarland, M.D., Ph.D.

NR3-29
Predictive Validity of the Reasons for Living Inventory in Colombian Psychiatry Patients with Suicide Risk
German E. Rueda-Jaines, M.D.
Andres M. Rangel-Martinez-Villalba, M.D.
Paul A. Camacho-Lopez, M.Sc.

NR3-30
The Role of Perceived Social Support as a Risk Factor for Adolescent Suicide Attempts: A Systematic Review
Lance M. Rappaport
Igor I. Galynerk, M.D., Ph.D.
Serena J. Fox, M.D.

NR3-31
Liaison Opportunities for Psychiatry: Challenges in the Neonatal Intensive Care Unit
Joshua Friedman, M.D., Ph.D.
Susan Hatters Friedman, M.D.
Marc Collin, M.D.
Richard Martin, M.D.

NR3-32
Improving Efficiency and Access to Mental Health Care: Integrating Mental Health and Primary Care Services at McGuire Veterans Affairs Medical Center
Cheryl W. Jones, M.D.
Steven Carter, F.N.P.
Antony Fernandez, M.D.

NR3-33
Clinical Indices of Institutional Stress in Relocating to a New Hospital
Jeffry R. Nurenberg, M.D.
Janet J. Monroe, R.N., M.A.S.
David I. Mayerhoff, M.D.
Steven J. Schleifer, M.D.

NR3-34
Is There a Difference in Transportation of Psychiatric Patients to the Emergency Department?
Leslie Zun, M.D., M.B.A.
Lavonne Downey, Ph.D.

NR3-35
Physician Compliance with Required Testing on Psychiatric Patients in the Emergency Department
Leslie Zun, M.D., M.B.A.
Lavonne Downey, Ph.D.

NR3-36
Acute Care Model: A Novel Way of Service Provision in Adult Psychiatric Services
Sowmya Krishna, M.D., Psy.D.
Faouzi Alam, M.D.
Geetha Jaganathan, M.D.
Quaiser Javed, M.D.

NR3-37
Predictors of Psychiatric Disorders During PEG-Interferon and Ribavirin Therapy in Patients with Chronic Hepatitis HCV-Correlated Hepatitis
Bernardo Delfosso, M.D.
Massimiliano Buoli, M.D.
Mariacarolotta Palazzo M.D.
Marta Serati, M.D.
Gianmaria Prati, M.D.
Alessio Aghemo, M.D.
Roberta D’Ambrosio, M.D.
Maria Grazia Rumi, M.D.
Massimo Colombo, M.D.
A. Carlo Altamura, M.D.

NR3-38
Childhood Sexual Abuse by Parents and Others Caregivers: Intra-Familial Characteristics and Biomarkers of Immune Response
Vivian Uemura, M.D.
Juliana Brum Moraes, M.D.
Sandra Oddebrecht Vargas Nunes, M.D. Ph.D.
Renato Moriya, M.D.
Edna Maria Vissoci Reiche, Ph.D.
Helena K. Morimoto, M.S.
Maria Angélica Watanabe, Ph.D.
Tiemi Matsuo, Ph.D.

NR3-39
Hypersensitivity Pneumonitis Secondary to Clozapine Therapy: A Case Report
Arif Shahabuddin, M.D.
Gregory Stepanets, M.D.
Beatrice Kovačzay, M.D.
Victoria Balkosi, M.D.
NR3-40 Translational Pharmacology of Quetiapine and Norquetiapine: Preclinical Findings Support Multifunctional Psychotropic Properties
Daniel Widowski, Ph.D.
Svante Nyberg

NR3-41 Predictors of Post-Discharge Adherence to Atypical Antipsychotic Medications in Adolescent Psychiatric Patients
David L. Pogue, Ph.D.
John Stakes, Ph.D.
Philip D. Harvey, Ph.D.

NR3-42 The Impact of Patients’ Expectations on Clinical Response: Re-Analysis of Data from the Hypericum Depression Trial Study Group
David Mischoulon, M.D., Ph.D.
Justin Chen, M.D.
George I. Papakostas, M.D.
Soo Jeong Youn, B.A.
Lee Baer, Ph.D.
Alisabet J. Clain, M.S.
Maurizio Fava, M.D.
David Mischoulon, M.D., Ph.D.

NR3-43 Simplifying Antipsychotic Polypharmacy Regimens for Patients with Chronic Mental Illness
Galina J. Georgieva, M.D.
Stephan Shannon, Ph.D.
Eric D. Peselow, M.D.
Andrew J. Kolodny, M.D.

NR3-44 Effectiveness of Switching from Aripiprazole to Ziprasidone in Patients with Schizophrenia
Jin-Sang Yoon, M.D.
Sung-Wan Kim, M.D., Ph.D.
Il-Seon Shin, M.D., Ph.D.
Jae-Min Kim, M.D., Ph.D.
Kyung-Yeol Bae, M.D.
Su-Jin Yang, M.D., Ph.D.

NR3-45 Drug Use Among Social Network Members of Patients with Co-Occurring Substance Use Dependence and Bipolar Disorder
Margaret L. Griffin, Ph.D.

NR3-46 L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode
Lawrence D. Ginsberg, M.D.
Alondra Y. Oubre, Ph.D.
Yahya A. Daoud

NR3-47 Response and Symptomatic Remission with Open-Label Co-Administration of Guanfacine Extended Release and Stimulants for ADHD
Lawrence D. Ginsberg, M.D.
Rakesh Jain, M.D.
William Rory Murphy, M.D., M.P.H.
Jonathan Rubin, M.D.

NR3-48 Effect of Age on Armodafinil Pharmacokinetics in Healthy Subjects
Mary Kirby, M.S., M.B.A.
Mona Darwish, Ph.D.
Edward T. Hellriegel, Ph.D.
Ronghua Yang, Ph.D.
Philmore Robertson, Jr., Ph.D.

NR3-49 An Open-Label, Eight-Week, Flexible Dose Trial of Escitalopram in Comorbid Major Depression with Multiple Sclerosis
Meera Narasimhan, M.D.
Suzanne Hardeman, APRN-BC
David Mrelashvili, M.D.
Kimberly Rudd, M.D.
Shilpa Srinivasan, M.D.
Ashwin Patkar, M.D.
Kathi Peindl, Ph.D.

NR3-50 Effect of Armodafinil on Quetiapine Pharmacokinetics in Patients with Schizophrenia
Mona Darwish, Ph.D.
Mary Kirby, M.S.
Edward T. Hellriegel, Ph.D.
Ronghua Yang, Ph.D.
Philmore Robertson, Jr., Ph.D.

NR3-51 Betahistine Safely Mitigates Olanzapine Adverse: Role of Histamine Receptors in Weight Gain and Somnolence
Nir Barak, M.D.

NR3-52 An In-Depth Cardiovascular Study of Longer-Term Lisdexamfetamine (LDX) Treatment in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Paul G. Hammerness, M.D.

NR3-53 Point of Care Lithium Monitoring: Quantitative Detection of Lithium Using Microchip Capillary Electrophoresis
Pieternel Kolling, M.D.
Ralph W. Kapka, Ph.D., M.D.
Arjan Floris, M.Sc.
Steven S. Staal, M.D.
Albert van den Berg, Prof.

NR3-54 The Maintenance Rate of Aripiprazole Among Schizophrenic Patients with Different Illness Duration and Experience of Neuroleptics During Six Months
Sae-Heon Jang, M.D.
Young-Myo Jae, M.D., Ph.D.
Dae-Su Lee M.D.

NR3-55 Influence of Antipsychotics Augmentation on Treatment Adherence in Treatment of MDD with Antidepressants
Sae-Heon Jang, M.D.
Young-Myo Jae, M.D., Ph.D.
Dae-Su Lee, M.D.
Jin-Hyug Choi, M.D.

NR3-56 Panax Ginseng Augmentation of Subsyndromal Depressive Symptoms (SSD) in Schizophrenia: A Multi-Site RCT Study
Simon Chiu, M.D., Ph.D.
Zack Cernovsky, Ph.D.
Mariwan Husni, M.D., MRC
John Copen M.D, M.Sc.
Robbie Campbell Jr., M.D.
Jason Carr, Ph.D.

NR3-57 Long-Term Weight Loss Effect of Adjunctive Zonisamide in Psychiatric Patients: A Retrospective Chart Review
Young-Hoon Ko, M.D., Ph.D.
Jaebyoung Lim, M.D.
Sook-Haeng Joe, M.D., Ph.D.
Changsu Han, M.D., Ph.D.
Ho-Kyoung Yoon, M.D., Ph.D.
Hwa-Young Lee, M.D., Ph.D.

NR3-58 Mental Status in NMS
Varadaraj Velamoor, M.D.
Ronald Herrera M.D.
Zack Z. Cernovsky, Ph.D.

NR3-59 Women’s and Men’s Depressive Symptoms and Functional Recovery Following Coronary Artery Graft (CAG) Surgery
James D. Mendenonca, Ph.D.
Ronald R. Holden, Ph.D.
Zack Z. Cernovsky, Ph.D.

NR3-60
Psychological Distress in Women with Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Nancy C. Maruyama, M.D.
Khyati Shah, M.D.

NR3-61
Does a Self-Report Measure (RSQ) and the AAI Evaluate the Same Dimension of Secure Adult Attachment?
Gillian Jennings, B.A.
Curren Katz, M.Ed.
Leo Bierman
Elizabeth Menaker, B.A.
Lisa J Cohen, Ph.D.
Arnold Winston, M.D.
Igor Galynker, M.D., Ph.D.

NR3-62
Economy and Suicide in Colombia: Relationship Between Macroeconomic Variables and Suicide Rate
Edwin Herazo, M.D., M.S.C.
Andrea C. Acevedo
Adalberto Campo-Arias, M.D., M.Sc.

NR3-63
From Windy Storm to Total Darkness: The Effect of a Community-Wide Blackout on ED Visits and Psychiatric Admissions to an Urban University Hospital
Jeffrey M. Turell, M.D., M.P.H.
Parikshit Deshmukh, M.D.
Joseph Calabrese, M.D.

NR3-64
Withdrawn

NR3-65
A Comparison of Rapid Titration Quetiapine and Haloperidol in Agitated Adults in an Emergency Setting
George Simpson, M.D.
Akikur Reza Mohammad
Syed Fauzia
Marius Campaneau
Eugene Laska
Rebecca Ninah
Joseph Wanderling
George Simpson

NR3-66
Use of a Predictive Algorithm and an Automated Telephone Screener Tool in Identifying Misdiagnosed Bipolar Disorder Patients
Keith Isenberg, M.D.
C. Fang
E. Tafesse
S. A. Kamat

NR3-67
Methodologic Approaches to the Naturalistic Assessment of Clinical Utilization and Outcome of a Device-Based Treatment in Clinical Practice
Mark Demitrack, M.D.

NR3-68
Medication Adherence and Persistence and Psychiatric Hospitalization in Patients with MDD
Xianchen Liu, M.D., Ph.D.
Ping Tepper, M.D., Ph.D.
Peter Watson, M.P.H.
Steven Able, Ph.D.
Michael Happich, Ph.D.

NR3-69
Nicotine Dependence, Adaptive Functioning, and Psychopathology Among Psychiatric Inpatients
Mariwan Husni, M.D.
Zach Cernovsky, Ph.D.
Simon Chiu, M.D.

NR3-70
Complementary Use of Tai Chi Improves Resilience, Quality of Life, and Cognitive Function in Depressed Older Adults
Helen Lavretsky, M.D., M.S.
Michael Irwin, M.D.

NR3-71
Aripiprazole and Haloperidol in the Treatment of Delirium and Its Subtypes
Soenke Boettger, M.D.
William Breitbart, M.D.
Steven Passik, Ph.D.

NR3-72
Factors Associated with Low Delirium Resolution Rates
Soenke Boettger, M.D.
Steven Passik, Ph.D.
William Breitbart, M.D.

NR3-73
Meta-Analysis of Placebo Response in Antipsychotic Trials
Ofer Agid, M.D.
Steven Potkin, M.D.
Gary Remington, M.D.
Shitij Kapur, M.D., Ph.D.
Eric Watsky, M.D.
Douglas Vanderburg, M.D., M.P.H.
Cynthia Siu, Ph.D.
NOON-2:00 P.M.
POSTER SESSION 4:
MOOD DISORDERS
LA LOUISIANE C,
MORIAL CONVENTION CENTER

Moderator:
David A. Baron, M.S.Ed., D.O.

NR4-1
Evaluation of the Efficacy of Extended Release Quetiapine Fumarate for the Treatment of Patients with MDD
Amir H. Kaldali, M.D.
Stuart Montgomery, M.D.
Willie Earley, M.D.
Johan Szamosi, M.Sc., Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-2
Efficacy and Tolerability of Vila done, a Dual-Acting Serotonergic Antidepressant, in the Treatment of Patients with MDD
Arif Khan, M.D.
Andrew J. Cutler, M.D.
Daniel Kajdasz, Ph.D.
Maria Athanasiou, Ph.D.
Heidi Whalen, M.H.S.
Carol R. Reed, M.D.

NR4-3
A Six-Week Randomized, Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State
Ashwin A. Patkar, M.D.
William Gilmer, M.D.
Mannohandaep Sohi, M.D.
Elizabeth Whitham, B.A.
Sairah Thommi, B.S.
Anthony Loebel, M.D.
Prakash Masand, M.D.
S. Nassir Ghaemi, M.D., M.P.H.
Chi-un Pae, M.D., Ph.D.

NR4-4
Effect of Childhood Trauma on the Course of Bipolar Disorder
Asli Funda Kalkay, M.D.
Evrin Ertcn, M.D.
Omer Saltcioglu, M.D.
Tunmcn Oral, M.D.
Duran Catmak, M.D.

NR4-5
Osteoporosis Risk Burden in Depressed Mid-Life Outpatients
Barbara L. Gracious, M.D.
Melissa N. Parkhurst, B.S.
Teresa L. Finucane, M.S.

NR4-6
Extended Release Quetiapine Fumarate as Adjunct to Antidepressants in MDD: Pooled Analysis in Patients with Low and High Levels of Baseline Anxiety
Borwin Bandelow, M.D.
Eduard Vieta, M.D.
Nizar El-Khalili, M.D.
Mattias Uld, M.Sc.
Urban Gustafsson, Ph.D.
Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-7
The Impact of Stress Factors on HPA Function in Patients with Depression and Neurosis: A Study with the Use of DST
Bozena Spila, M.D.
Halina Dubas-SlepM, M.D.
Helena Donica, Ph.D.
Beata Wojszisak-Duma, Ph.D.
Anna Urbanska

NR4-8
Expectancy Effects and Treatment of Depression: Cognitive and Neural Mechanisms
Bret R. Rutherford, M.D.
Steven P. Roose, M.D.
Joel Sneed, Ph.D.
Dev Devanand, M.D.

NR4-9
Improvements in Cognitive Functioning During Inpatient Hospitalization for Unipolar and Bipolar Depression with and without Psychotic Features
Caleb J. Siefert, Ph.D.
John Matthews, M.D.
Adrienne van Nieuwenhuizen, B.A.
Rita Seabrook, B.A.
Lauren House, M.A.
Kaloynan Taney, M.D.
David Abramson, M.D.
Maurizio Fava, M.D.

NR4-10
Comparison of Safety, Efficacy, and Tolerability of Modified and Immediate Release Escitalopram and Placebo in Adults with MDD
Carl Gommoll, M.S.
William M. Greenberg, M.D.
Kaloyan Tanev, M.D.
Lauren House, M.A.
Peter Werner, Ph.D.

NR4-11
Genotypic and Phenotypic CYP2D6 Poor Metabolizer Status Among Outpatients with Depression Treated with Venlafaxine
Cecelia Kane, M.D.
Alice Nichols, Ph.D.
Vatsali Chhaya
Gina Buckley, M.T., M.S.
Christine J. Guico-Pabia, M.D., M.B.A., M.P.H.

NR4-12
Analysis of the Effect of Ziprasidone on Agitation in Acute Bipolar Mania Using Clinician-Rated PANSS and SADS-C Proxy Measures
Cedric O’Gorman, M.D.
Steven Potkin, M.D.
Francine Mandel, Ph.D.
Douglas Vanderburg, M.D.

NR4-13
Treatment Outcomes-Based on Disease Severity for Subjects with Bipolar I Disorder Treated with Ziprasidone Plus a Mood Stabilizer
Charles Bowden, M.D.
Balarama Gundapaneni, M.S.
Cedric O’Gorman, M.D.
Elizabeth Pappadopulos, Ph.D.
Jeffrey Schwartz, Ph.D.
Rodger Kobs, M.D.
Onur Karayal, M.D.

NR4-14
Significant Bipolar Risk Factors in Patients Presenting a Current Major Depressive Episode
Charles Bowden, M.D.
J. Angst, Ph.D.
J. M. Azorin, Ph.D.
G. Perugi, M.D.
E. Vieta, Ph.D.
Allan H. Young, Ph.D.

NR4-15
Pooled Analysis of the Efficacy of Desvenlafaxine 50 mg Compared with Placebo in the Patients with Moderate or Severe MDD
Christine J. Guico-Pabia, M.D., M.B.A.
Jeff Musgnug, M.S.
Ben Wang

NR4-16
Rurality, Suicide and the Availability of Mental Health Providers
Dale D’Mello, M.D.

NR4-17
The Prevalence and Clinical Consequences of Concurrent Hypertension in Patients with Bipolar Disorder
Dale D’Mello, M.D.

NR4-18
Efficacy of Adjunctive Aripiprazole in MDD: A Pooled Response Quartile Analysis (CN138-139, CN138-163 and CN138-165)
Daniel E. Casey, M.D.
Kimberly Laubmeier, Ph.D.
Ross A. Baker, Ph.D., M.B.A.
Sabrina Marler, M.S.
Robert A. Forbes, Ph.D.
Randall Owen, M.D.
NR4-19
Duloxetine 60 Mg/Day for the Prevention of Depressive Recurrences: Post-hoc Analyses from a Recurrence Prevention Study
David Perahia, M.D., M.R.C.
Michael Berk, M.D., Ph.D.
Melissa Spann, Ph.D.
Doron Sagman, M.D.
Joel Raskin, M.D.
Daniel Walker, Ph.D.
Katarina Kelin, M.D.

NR4-20
Clinical Correlates of Eating Disorders Comorbidity in Women with Bipolar Disorder Type 1
Elisa Brietzke, M.D.
Camila Moreira
Ricardo Alexandre Tonio, M.D.
Benny Lafer, M.D., Ph.D.

NR4-21
Efficacy of Duloxetine on Functional Impairment in Patients with MDD
David V. Sheehan, M.D., M.B.A.
Adam L. Meyers, M.S.
Jonna Ahl, Ph.D.
Apurva Prakash, B.A.
Tina Marie Myers Oakes, Ph.D.

NR4-22
Effects of Extended Release Quetiapine Fumarate on Long-Term Functioning and Sleep Quality in Patients with GAD
David V. Sheehan, M.D., M.B.A.
Henrik Svedsäter, Ph.D.
Julie Locklear, Pharm.D., M.B.A.
Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-23
A One-Year Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with MDD
Donald Robinson, M.D.
Daniel Kajdasz, Ph.D.
Susan Gallipoli, R.N.
Heidi Whalen, M.H.S.
Art Wamit, M.D., Ph.D.
Carol R. Reed, M.D.

NR4-24
Attributes of Response in Depressed Patients Switched to Duloxetine Treatment
Doron Sagman, M.D.
Diane McIntosh, M.D.
Min Soo Lee, M.D.
Huichun Li, M.D.
Sandra Ruschel, M.D.
Nadia Hussain, B.Sc.
Renee Granger, Ph.D.
Arier Lee, Ph.D.
Joel Raskin, M.D.

NR4-25
The Correlation Between White Matter Tract Integrity of Anterior Cingulate and Thyroid Function in Patients with Major Depression
Dong Hyun Han, D.P.H.
Doo Byung Park, Psy.D.
Joon Mo Kang, M.D.
Beom Wo Nam, M.D., Psy.D.
Churl Na, Psy.D.

NR4-26
Clinical Correlates of Eating Disorders Comorbidity in Women with Bipolar Disorder Type 1
Elisa Brietzke, M.D.
Camila Moreira
Ricardo Alexandre Tonio, M.D.
Benny Lafer, M.D., Ph.D.

NR4-27
Efficacy of Adjunctive Aripiprazole in Patients with MDD with Minimal or Partial Response to Antidepressant Therapy
Elizabeth Bellocchio, Ph.D.
Ross A. Baker, Ph.D., M.B.A.
Linda M. Rollin, Ph.D.
Robert D. McQuade, Ph.D.
Ronald N. Marcus, M.D.
Robert M. Berman, M.D.
J. Craig Nelson, M.D.

NR4-28
Efficacy of Adjunctive Aripiprazole in Patients with MDD with Minimal or Partial Response to Antidepressant Therapy
Elizabeth Bellocchio, Ph.D.
Ross A. Baker, Ph.D., M.B.A.
Linda M. Rollin, Ph.D.
Robert D. McQuade, Ph.D.
Ronald N. Marcus, M.D.
Robert M. Berman, M.D.
J. Craig Nelson, M.D.

NR4-29
Efficacy of Adjunctive Aripiprazole in Patients with MDD with Minimal or Partial Response to Antidepressant Therapy
Elizabeth Bellocchio, Ph.D.
Ross A. Baker, Ph.D., M.B.A.
Linda M. Rollin, Ph.D.
Robert D. McQuade, Ph.D.
Ronald N. Marcus, M.D.
Robert M. Berman, M.D.
J. Craig Nelson, M.D.

NR4-30
Quality of Life in Subgroups of Bipolar I Patients Who Had Childhood Trauma
Evrin Erten, M.D.
Ashl Funda Kalkay, M.D.
Omer Sautcioglu, M.D.
Duran Çakmak, M.D.

NR4-31
HPA Axis Dysfunction in Remitted Bipolar Patients
Fabrice Duval, M.D.
Marie-Claude Mokrani, Ph.D.
Hassen Rabia, M.D.
Felix Gonzalez, M.D.
Claudia Alexa, M.D.
Said Fattah, M.D.

NR4-32
Extended Release Quetiapine Fumarate in Patients with MDD Stratified by Baseline Anxiety Level: Pooled Analysis of Data from Two Monotherapy Studies
Hans Eriksson, M.D., Ph.D.
Koen Demyttenaere, M.D., Ph.D.
Michael E. Thase, M.D.
Mattias Udd, M.Sc.
Urban Gustafsson, Ph.D.

NR4-33
Vilazodone Pharmacokinetics in Subjects with Mild to Moderate Renal Impairment
Harry Alcorn, Pharm.D.

NR4-34
Treatment-Emergent Sexual Dysfunction in Outpatients with MDD: Six-Month Treatment and Functional Outcomes
Hector J. Duenas, M.D.
Saiyed Abdulrazak, M.D.
Arier Lee, Ph.D.
Amanda Lowry, Ph.D.
Joel Raskin, M.D.
Adam Meyers, M.A.
Alan Brunnic, M.A.
Martin Dossenbach, M.D.

NR4-35
Long-Term Safety, Tolerability and Efficacy of Extended Release Carbamazepine in a Large Clinical Practice: A Chart Review Study
Lawrence D. Ginsberg, M.D.
Herbert W. Harris, M.D., Ph.D.

NR4-36
Association of the Serotonin Transporter Intronic VNTR Polymorphism with Treatment Response to Mirtazapine in Patients with MDD
Min-Soo Lee, M.D., Ph.D.
Sang-Woo Hahn, M.D., Ph.D.
Hwa-Young Lee, M.D., Ph.D.
Hun Soo Chang, Ph.D.
Byung-Joo Ham, M.D., Ph.D.
Jong-Woo Paik, M.D., Ph.D.
Moon-Soo Lee, M.D., Ph.D.
Chang-su Han, M.D., Ph.D.
Young-Hoon Ko, M.D., Ph.D.
Focus: The Journal of Lifelong Learning in Psychiatry
Tel: 800-368-5777

NR4-37
Vilazodone Pharmacokinetics in Subjects with Mild to Moderate Hepatic Impairment
James Longstreth, Ph.D.
Harry Alcorn, Jr., Pharm.D.
Marijke H. Adams, Pharm.D., Ph.D.
Carol R. Reed, M.D.

NR4-38
Long-Term Outcome of First Manic Episodes: A Retrospective Review of 354 Inpatient Patients
Javad Moamai, M.D., M.S.C.
Jacques Seguin, M.D., Ph.D.

NR4-39
Placebo Response in Trials of Antidepressants in Patients with MDD
Jeff Musgnung, M.S.
Christine J. Guico-Pabia, M.D., M.B.A., M.P.H.
Ron Pedersen, M.S.
Philip T. Ninan, M.D.

NR4-40
Incidence of Headache, Nausea, and Myalgia after ECT in Adolescents and Adults: Relation to Treatment Number and Patient Age
John L. Olsen, M.D.
Howard Weeks, M.D.
Lowry Bushnell, M.D.
Kelly W. Smith, M.D.

NR4-41
High Levels of Comorbid Personality Disorder Predict Non-response to Methylphenidate for Adults with ADHD
John L. Olsen, M.D.
Barrie K. Marchant, M.S.
Robert E. Strong, D.O.
Reid J. Robison, M.D.
Fred W. Reimherr, M.D.

NR4-42
Asenapine as Adjunctive Treatment for Bipolar Mania: Results of a Placebo-Controlled 12-Week Study and 40-Week Extension
Joseph Calabrese, M.D.
Let Stet, Ph.D.
Himanshu Kotari, Ph.D.
Jun Zhao, Ph.D.
Alex Kousasi, Ph.D.
Armin Szegedi, M.D., Ph.D.
John Panagides, Ph.D.

NR4-43
Higher Scores on Motor Impulsivity and Lower Scores on Cooperativeness are Associated with History of Suicide Attempts in Brazilian Outpatients with Bipolar Disorder
Karla Almeida, M.D., L.N.
Abreu, M.D.
B. Lafer, M.D., Ph.D.

NR4-44
Comparison Between Clinical Characteristics of Suicide Attempters and Non-A attempters in a Sample of Bipolar Disorder Patients with Mania as First Episode
Lena Abreu, M.D.
Fabião G. Nery, M.D., Ph.D.
Elisa Brieztke, M.D.
Pedro V.S. Magalhaes, M.D.
Flavio Kacpezinski, M.D., Ph.D.
Beny Lafer, M.D., Ph.D.

NR4-45
Association of Medication Adherence with Therapeutic Alliance in Individuals with Bipolar Disorder
Louisa G. Sylvia, Ph.D.
Aleena C. Hay, B.A.
Andrew A. Nierenberg, M.D.
Michael J. Ostacher, M.D., M.P.H.
Thilo Deckersbach, Ph.D.
David J. Miklowitz, Ph.D.
Michael E. Thase, M.D.
Gary S. Sachs, M.D.
Roy H. Perlis, M.D., M.Sc.

NR4-46
Correlation Between Functionality and Subjective Well-Being in Unipolar Depressive Patients in Remission
Luis G. Herbst, M.D.
Laura Lorenzo, M.D.
Eduardo Leidernan, M.D.
Anibal Goldberg, M.D.
Pedro Gargoloff, M.D.
Damian Gargoloff, M.D.

NR4-47
Comparison of Hospitalizations and Costs Among Bipolar Patients Who Switched to Extended-Release Quetiapine from Immediate-Release Quetiapine
Mariam Hassan, Pharm.D.
Elise Pelletier, M.S.
Daniel Smith, M.A.
Berhanu Alemayehu
Jennifer Kim, Pharm.D.

NR4-48
A Web-Based System for Measuring Outcome in the Treatment of Depression: Reliability, Validity, and Patient Acceptance
Mark Zimmerman, M.D.
Janine Gallione, B.S.

NR4-49
Depressed Patients Perspectives of Two Measures of Outcome: The Quick Inventory of Depressive Symptomatology & Remission from Depression Questionnaire
Mark Zimmerman, M.D.
Janine Gallione, B.S.
Naureen Attiullah, M.D.
Michael Friedman, M.D.
Cristina Toba, M.D.
Daniela Boerscun, M.D.
Moataz Ragheb, M.D.

NR4-50
The Relationship Between Continued Use of Antidepressants and Acute Psychiatric Events Among Patients with Manic or Mixed Bipolar Disorder Episodes
Matthew Sussman, B.S.
M. Friedman
J.R. Korn
M. Hassan
J. Kim
J. Menzin

NR4-51
Efficacy of Aripiprazole in the Treatment of Irritability in Pediatric Patients (6–17 years) with Autistic Disorder: Results from a 52-Week Study
Meeta Patel, Pharm.D.
Randall Owen, M.D.
Patricia K. Corey-Lisle, Ph.D.
Raymond Mankoski, M.D., Ph.D.
Lisa Kamen, M.H.A.
George Manos, Ph.D.
Robert D. McQuade, Ph.D.
William H. Carson, M.D.
Ronald N. Marcus, M.D.

NR4-52
Association of Age of Onset and Mood in Bipolar Disorder: Comparing Sub-Groups Identified by Cluster Analysis and Clinical Observation
Michael Bauer, M.D., Ph.D.
Tasha Glenn, Ph.D.
Natalie Rason, M.D.
Wendy Marsh, M.D.
Kemal Sagduyu, M.D.
Rodrigo Munoz, M.D.
Peter C Whybrow, M.D.

NR4-53
Effects of Adjunctive Extended Release Quetiapine Fumarate on Sleep Disturbance and Quality in Patients with MDD: A Pooled Analysis
Michael Bauer, M.D., Ph.D.
Roger S. McIntyre, M.D.
Johan Szamosi, M.S.
Hans Eriksson, M.D.
NR4-59
Efficacy of Adjunctive Aripiprazole to Lithium or Valproate in the Long-Term Treatment of Mania in Subjects with Bipolar I Disorder (CN138-189)
Randall Owen, M.D.
Linda Rollin, Ph.D.
Arif Khan, M.D.
Raymond Sanchez, M.D.
William Carson, M.D.
Beth Morris, B.A.
Karen Tinko, B.S., M.B.A.
Ronald Marcus, M.D.

NR4-60
Development of In Vitro Diagnostic Test for Lithium-Sensitive Bipolar Disorder
Sairah Thommi, B.S.
Elizabeth Whitham, B.A.
Hanady Gouta, M.D.
Hussain Khrad, M.S.
Sang Kil Lee, Ph.D.
Connie Maddox, L.P.N.
Suephy C. Chen, M.D.
P. Michael Iwune, Ph.D.
S. Nassir Ghaemi, M.D.
Chaki Fukuhara, Ph.D.

NR4-61
Association Between Median Family Income and Self-Reported Mood in Bipolar Disorder
Tasha Glenn, Ph.D.
Michael Bauer, M.D.
Natalie Raasgon, M.D.
Wendy Marsh, M.D.
Kemal Sagduyu, M.D.
Rodrigo Manoza, M.D.
Peter C. Whybrow, M.D.

NR4-62
Anxiety as Predictor or Moderator for Effect of Ziprasidone Combined with Mood Stabilizer in Maintenance Treatment of Bipolar I Disorder
Terence A. Ketter, M.D.
Douglas Vanderburg, M.D., M.P.H.
Cynthia O. Siu, Ph.D.
Elizabeth A. Pappadopulos, Ph.D.
Onur Karayal, M.D., M.P.H.

NR4-63
The Effects of Quetiapine XR Monotherapy on Sleep Disturbance: Pooled Data from Four Acute Studies in Patients with MDD
Willie W. Earley, M.D.
Eliyahu Simon, M.D.
Koen Demyttenaere, M.D., Ph.D.
George Papakostas, M.D.
Madhukar Trivedi, M.D.
D. Johan Szamosi, M.Sc.
Hans Eriksson, M.D., Ph.D., M.B.A.

NR4-64
A Large-Scale DTI Study in MDD: Utility of Legacy Data
Wouter S. Hoogenboom, M.S.
Roy H. Perlis, M.D.
Jordan W. Smoller, M.D., Sc.D.
Qing Zeng-Treitler, Ph.D.
Vivian S. Gainer, M.S.
Shawn N. Murphy, M.D., Ph.D.
Susanne E. Churchill, Ph.D.
Isaac Kohane, M.D., Ph.D.
Susan E. Churchill, Ph.D.
Daniel V. Iosifescu, M.D., M.S.

NR4-65
Baseline Characteristics of Patients with MDD from the Clinical Outcomes in Measurement-Based Treatment (COMET) Study
Yonghua Jing, Ph.D.
Elizabeth A. Pappadopulos, Ph.D.
Terence A. Ketter, M.D.
Mark T. Bauer, L.I.C.S.W.
Kathleen A. Poppe, R.N.
Simon Kung, M.D.
Vivian S. Gainer, M.S.
Qing Zeng-Treitler, Ph.D.
Jordan W. Smoller, M.D., Sc.D.
Roy H. Perl, M.D.
Wouter S. Hoogenboom, M.S.

NR4-74
Attributes of Response in Depressed Patients Switched to Duloxetine Treatment
Doron Sagman, M.D.
Diane McIntosh, M.D.
Min Soo Lee, M.D.
Hui-chun Li, M.D.
Sandra Ruschel, M.D.
Nadja Hussain, B.Sc.
Renee Granger, Ph.D.
Ariel Lee, Ph.D.
Joel Raskin, M.D.

NR4-75
Characteristics of Emotional Response and Its Relationship with Early-Life Stress and Resilience in MDD
Seok Jeong-Ho, M.D., Ph.D.

NR4-76
Relationship of Psychopathology with Early-Life Stress and Resilience in a Young Adulthood Population
Seok Jeong-Ho, M.D., Ph.D.

NR4-77
Close Correlation of the PHQ-9 and BDI-II for Depression Measurement in the Mood Disorders Outpatient and Inpatient Settings
Simon Kang, M.D.
Renato D. Alarcon, M.D., M.P.H.
Kathleen A. Poppe, R.N.
Mary Jo Moore, R.N.
Grant T. Bauer, L.I.C.S.W.
Mark D. Williams, M.D.
Mark A. Frye, M.D.

NR4-78
Efficacy of Levomilnacipran in Improving Symptoms and Functional Impairment Associated with MDD
Stuart A. Montgomery, M.D.
Yves Lecrubier, M.D.
Lucillli Mansuy, M.D.
Daniel Ventura, Ph.D.
Dayong Li, Ph.D.
Peter Werner, Ph.D.

NR4-79
NR4-80
NR4-81
NR4-82
NR4-83
NR4-84
NR4-85
NR5-16
The Application of a Comparative Effectiveness Trial Criteria to a Commercially-Insured Population of Children with ADHD
Safiya Abouzaid, Pharm.D.
Joan Busner
Michael Durkin
Garu Schneider

NR5-17
Psychopathology and Temperament in Parents of Children and Adolescents with ADHD: A Controlled Study
Sermin Kesebir, M.D.
Y. Bilge Sair, M.D.
I. Ferhan Dereboy, M.D.

NR5-18
Mental Status of Caregivers and Treatment Adherence: Comparison of Caregivers of Bipolar and Schizophrenic Patients
Sermin Kesebir, M.D.
Enver Demirel Yilmaz, M.D.
Ali Görkem Gencer, M.D.
Mehmet Fatih Üstündag, M.D.
Mustafa Biliç, M.D.

NR5-19
Effect of OROS Methylphenidate Treatment on Reading Performance in Children with ADHD
Sharon Wigal, Ph.D.
Tim Wigal, Ph.D.
Sabrina Schuck, Ph.D.
David Williamson, Ph.D.
Robert B. Armstrong, M.D.
Matthew Brams, M.D.
C.V. Damaraju, Ph.D.
Steve Asher, Ph.D.
H. Lynn Starr, M.D.

NR5-20
Visual Memory as an Endophenotype in ADHD: Evidence from the Cambridge Neuropsychological Test Battery
Susan Shar-Fen Gau, M.D., Ph.D.
Chi-Yung Shang, M.D.

NR5-21
Clinical Utility of ADHD Symptom Thresholds to Assess Normalization of Executive Function with Lisdexamfetamine Dimesylate Treatment
Thomas E. Brown, Ph.D.
Matthew Brams, M.D.
Maria Gasior, M.D.
Ben Adeyi, M.S.
Bryan Dirks, M.D.
Thomas Babcock, D.O.
Brian Schechick, Pharm.D.
Robert Lasser, M.D.
Timothy Wigal, Ph.D.

NR5-22
What Predicts Substance Abuse in ADHD Youth? A 10-Year Follow-Up Study
Timothy E. Wilens, M.D.
MaryKate Martelon, M.P.H.
Michael C. Monuteaux, Sc.D.
Eric Mick, Sc.D.
Maggie Evans, B.A.
Clancy Bateman, B.A.
Joseph B. Biederman, M.D.

NR5-23
Changes of Sleep Parameters After Taking Methylphenidate in Children with ADHD
Wan Seok Seo, M.D., Ph.D.
Bon Hoon Koo, M.D.
Kwang-Hun Lee, M.D.
Kyun-Keun Kim, M.D.
Han-Kyul Park, M.D.

NR5-24
Effects of Long-Term Open-Label Co-Administration of Guanfacine Extended Release and Stimulants on Core Symptoms of ADHD
Bradley Vine, D.O.
Floyd R. Sallee, M.D., Ph.D.
Sharon Youcha, M.D.

NR5-25
Changes in Parental Stress with Guanfacine Extended Release in Children with ADHD and Oppositional Symptoms
Daniel F. Connor, M.D.
Floyd R. Sallee, M.D., Ph.D.
Sharon Youcha, M.D.

NR5-26
School-Based Intervention for K-Second Graders Presenting with Disruptive Behavior
Jacobs Venter, M.D.
Linda Wiskerchen, M.S.W.
Melissa Shaw, M.A.
Alicia Ledges, M.A.
Sara DeSimone, M.S.W.
Anne Marie Cardinal, M.S.W.

NR5-27
Clinical Predictors of Cardiometabolic Risk in Children Treated with Antipsychotic Medications
John W. Newcomer, M.D.
G. E. Nicol, M.D.
M. D. Yingling, B.S.

NR5-28
Continuity of Depressive Disorders from Childhood and Adolescence to Adulthood: A Naturalistic Study at Community Mental Health Centers in Madrid, Spain
Juan J. Carballo, M.D., Ph.D.
Laura Muñoz-Lorenzo, L, Psy.D., Hilario Blasco-Fontecilla, M.D., Ph.D.
Jorge Lopez-Castroman, M.D., Ph.D.
Mercades Perez-Rodriguez, M.D.
Ph.D., Kanita Dervic, M.D.
Maria A. Oquendo, M.D.

NR5-29
Paliperidone for Irritability in Adolescents and Young Adults with Autistic Disorder
Kimberly A. Tsigler, M.D.
Craig A. Erickson, M.D.
David J. Posey, M.D., M.S.
Jennifer E. Mullett, R.N., C.C.R.P.
Jon T. Diener, B.S.
Arlene E. Kohn, B.A.
Christopher J. McDougle, M.D.

NR5-30
Polypharmacy Reduction Leads to Positive Effects on both Treatment Outcome and Healthcare Cost: Analyses from a Residential Treatment Center
Pieter Joost van Wattum, M.D., M.A.
Caroline Fabius, M.S.
Tod John, L.C.S.W.
Cheryl Smith, L.C.S.W.
Daniel Lyga, L.C.S.W.

NR5-31
Extended-Release Dexamethasone 30 Mg Improves Late-Day ADHD Symptom Control in Children with ADHD: A Randomized, Double-Blind, Crossover Study
Rafael Muniz, M.D.
Linda Pestreich
Kevin McCague, Ph.D.
Americo Padilla, M.D.
Matt Brams, M.D.
Ann Childress, M.D.

NR5-32
Deficient Emotional Self-Regulation is a Core Deficit that Predicts Adaptive Impairments in Adults with ADHD
Russel A. Barkley, Ph.D.
Kevin R. Murphy, Ph.D.
NR5-54  Correlation of White Matter Changes with Behavioral and Psychological Symptoms and Cognition in Alzheimer’s Disease Patients
Shin Gyeom Kim, M.D.
Han-Yong Jung M.D., Ph.D.
Sooyoung Irene Lee, M.D., Ph.D.
Hee Yeun Jung M.D., Ph.D.
Eun Young Shin, M.D.
Wooyul Jung, M.D.
Mihee Park, M.D.

NR5-55  The Effect of Extended-Release Memantine on Behavioral Domains in Patients with Moderate to Severe Alzheimer’s Disease
Stephen M. Graham, Ph.D.
Michael Tocco, Ph.D.
Hai-an Hsu, Ph.D.
Lei Xie, Ph.D.
James L. Perhach, Ph.D.

NR5-56  Synergistic Effects of Depression and Apolipoprotein E4 on the Incidence of Dementia
Yong-Hwan Kim, M.D.
Jae-Min Kim, M.D., Ph.D.
Robert Stewart, M.D., Ph.D.
Sun-Wan Kim, M.D., Ph.D.
Kyung-Yeol Bae, M.D.
Sun-Young Kim, M.D.
Su-Jin Yang, M.D., Ph.D.
Il-Seon Shin, M.D., Ph.D.
Jin-Sang Yoon, M.D., Ph.D.

NR5-57  TSH, Cognitive Impairment, and Depression in an Older Korean Population
Young-Heon Song, M.D.
Jae-Min Kim, M.D., Ph.D.
Robert Stewart, M.D., Ph.D.
Kyung-Yeol Bae, M.D.
Sun-Wan Kim, M.D., Ph.D.
Su-Jin Yang, M.D., Ph.D.
Ho-Chel Kang, M.D., Ph.D.
Il-Seon Shin, M.D., Ph.D.
Jin-Sang Yoon, M.D., Ph.D.

NR5-58  Witchcraft or Mental Illness?
Beatriz Quintanilla, M.D., Ph.D.

NR5-59  Social Support and Acculturation: Predictors of Psychological Health of International Medical Graduates Pursuing Psychiatric Residencies
Ashutosh Atri, M.S., M.D.

NR5-60  Changes in Empathy During Korean Medical College and Medical School Education: 1-Year Follow Up
Minha Hong, M.D.
Duk Soo Moon, M.D.
Geon Ho Bahn, M.D., Ph.D.
Won Hye Lee, Ph.D.

NR5-61  Empathy in Korean Psychiatric Residents
Minha Hong, M.D.
Geon Ho Bahn, M.D., Ph.D.
Won Hye Lee, Ph.D.
Min Young Lee, B.A.

NR5-62  Volume of Orbitofrontal Cortex and Clinical Symptoms in Patients with PTSD after a Traffic Accident
Jun Won Kim, M.D.
Han-Doug Hyun, M.D., Ph.D.
Beom Woa Nam, Ph.D.
Churl Na, Ph.D.
Doo Byung Park, Ph.D.

NR5-63  Antidepressant Medications in Pregnancy and Postpartum: Adherence Versus Decline
Diana Carter, M.D.
Shaila Misri, M.D.
Deirdre Ryan, M.D.
Jasmin Abizadeh, B.A.
Arjun Nanda

NR5-64  An Open-Label Trial of Escitalopram in Postpartum Women with Mood and Anxiety Disorders
Shaila Misri, M.D.
Karen Joe, B.Sc. (Hon.)
Jasmin Abizadeh, B.A.

NR5-65  Withdrawn

164th ANNUAL MEETING
HAWAII
HONOLULU, MAY 14-18, 2011

American Psychiatric Association
Transforming Mental Health Through Leadership, Discovery and Collaboration
The Cardiovascular Safety of Inhaled Loxapine (AZ-004)
Daniel A. Spyker, Ph.D., M.D.
Mildred D. Gottwald, Pharm.D.
Robert S. Fishman, M.D.
James V. Cassella, Ph.D.

Dose-Associated Changes in Safety and Efficacy Parameters Observed in a 24-Week Maintenance Trial of Olanzapine Long-Acting Injection in Patients with Schizophrenia
Angela Gulliver, Pharm.D.
Bin Sun, Ph.D.
Jami L. Karagianis, M.D.
Fangyi Zhao, Ph.D.
Susan B. Watson, Ph.D.
David P. McDonnell, M.B.

Efficacy of Paliperidone Palmitate: A One-Year, Open-Label Study in Patients with Schizophrenia
Danielle Coppola, M.D.
Yannig Liu, M.S.
Sriri Gopal, M.D.
Bart Remmery
Mahesh Samtani, Ph.D.
Gahan Pandina, Ph.D.
David Hough, M.D.
Isaac Nuamah, Ph.D.
Ahmad Hatim Sulaiman, M.D.

Increased Maternal Age at Birth Hampers Reversal Learning in Schizophrenia
Dimitrios Kontis, M.D., Ph.D.
Eirini Theochari, M.D.
Spiros Kleisias, M.D.
Stamatina Kalogerakou, M.Sc.
Angeliki Andreopoulou, M.Sc.
Charalambos Karouzos, M.D.
Eleftheria Tsaltas, Ph.D.

Paliperidone Extended Release as Monotherapy or Adjunctive Therapy to Mood Stabilizers/ Antidepressants in Subjects with Schizophrenia: Summary of Results from the Clinical Development Program
Antony Loebel, M.D.
Amir Kalali, M.D.
Doreen Simonelli, Ph.D.
Debra Phillips, B.A.
Masaaki Ogasa, M.S.
Robert Silva, Ph.D.
Josephine Cucchiaro, Ph.D.
Herbert Y. Meltzer, M.D.

Emotional Musical Recognition Deficits in Paranoid Schizophrenic Patients
Eric E. Constant, M.D., Ph.D.
Severine Samson, Ph.D.
Pierre Philippot, Ph.D.
Catherine De Graeuwe D'Aoust, Psy.
Aline De Jaegere, M.P.H.
Vincent Meert, M.D.
Benoit Delatte, M.D.
Benoit Gilliain, M.D.
Xavier De Longueville, M.D.
Jean Delbeke, M.D.
Isabelle Peretz, Ph.D.

A Randomized, Double-Blind, Comparative Study of Paliperidone Palmitate and Risperidone Long-Acting Therapy in Patients with Schizophrenia
Gahan Pandina, Ph.D.
R. Lane, M.A.S.
S. Gopal, M.D., M.H.S.
C. Gassmann-Mayer, Ph.D.
D. Hough, M.D.
B. Remmery,
G. Simpson, M.D.

Glutamate Quantification in the Associative Striatum of Patients with Schizophrenia Before and After Antipsychotic Treatment
Camilo de la Fuente, M.D., M.S.
Rafael Pavila, M.Sc.
Pablo León-Ortiz, M.D.
Leonardo Díaz-Galvis, M.D.
Carmen Amezcuia, M.D.
Sylvana Stephano, M.D.
Ariel Graff-Guerrero, M.D., Ph.D.

Efficacy of Adjunctive Antidepressants to Mood Stabilizers/ or Adjunctive Therapy Release as Monotherapy
Paliperidone Extended

Onset of Efficacy with Paliperidone Palmitate in Patients with Acutely Exacerbated Schizophrenia
Cynthia Bossie, Ph.D.
J. Thomas Haskins, Ph.D.
Jennifer Kern Silva, Pharm.D.
Yi-Wen Ma, Ph.D.
Larry Alphs, M.D., Ph.D.

Obtain your Certificate of Attendance for the 2010 APA Annual Meeting at <www.psych.org/AnnualMeetingCME>
NR6-16
Efficacy, Safety, and Tolerability of Paliperidone Extended Release in Adolescent Patients with Schizophrenia
Jaskaran Singh, M.D.
Ujjwala Vijapurkar, Ph.D.
Adelaide Robb, M.D.
Isaac Naaam, Ph.D.
David Hough, M.D.

NR6-17
Effects of Paliperidone Palmitate Treatment in Schizophrenia Patients Previously Treated with Oral Risperidone
Jennifer Kern Sliwa, Pharm.D.
Cynthia A. Bossie, Ph.D.
Yi-Wen Ma, Ph.D.
Larry Alphs, M.D., Ph.D.
J. Thomas Haskins, Ph.D.

NR6-18
Hematological Clozapine Monitoring with a Point-of-Care Device
Jimmi Nielsen, M.D.
Christoph U. Correll, M.D.

NR6-19
Differential Metabolic Profiles of Lurasidone and Olanzapine: Data from a Six-Week, Double-Blind, Placebo-Controlled Schizophrenia Trial
Jonathan M. Meyer, M.D.
Josephine Cucchiara, Ph.D.
Andrei Pikalov, M.D., Ph.D.
Jay Hsu, Ph.D.
Antony Loebel, M.D.

NR6-20
Safety of Lurasidone: Pooled Analysis of Five Placebo-Controlled Trials in Patients with Schizophrenia
Josephine Cucchiara, Ph.D.
Andrei Pikalov, M.D., Ph.D.
Masaaki Ogasa, M.S.
Robert Silva, Ph.D.
Jay Hsu, Ph.D.
Jane Xu, Ph.D.
Antony Loebel, M.D.

NR6-21
Tolerability of Paliperidone Palmitate Initiation Doses in Subjects with Recently Diagnosed Schizophrenia
Larry D. Alphs, M.D.
Cynthia Bossie, Ph.D.
Jennifer Kern Sliwa, Pharm.D.
Yi-Wen Ma, Ph.D.
J. Thomas Haskins, Ph.D.

NR6-22
Gamma Oscillation and Serum Nitric Oxide Metabolites in the Chronic Schizophrenic Patients
Masatomo Suetsugi, M.D., Ph.D.
Yasushi Mizuki, M.D., Ph.D.
Kumiko Hara, B.S.
Yoshifumi Watanabe, M.D., Ph.D.

NR6-23
Change in Appetite as a Predictor of Weight Change During Olanzapine Treatment
Michael G. Case, M.S.
Jamie Karagianis, M.D.
Tamas Treurer, M.D.
Vicki Poole-Hoffmann, Pharm.D.

NR6-24
Strategy for Selection of Various Switching Doses for Olanzapine Long-Acting Injection
Michael M. Witte, Ph.D.
Holland Detke, Ph.D.
Fangyi Zhao, Ph.D.
Prajakti Kathare, Ph.D.
Parag Garhyan, Ph.D.
Janice Carlson, Ph.D.
David McDonnell, MRCPsych

NR6-25
Cost-Effectiveness of Paliperidone Palmitate Versus Oral Atypicals and a Conventional Depot Formulation in the U.S.
Mirko Sikirica, Pharm.D.
Concetta Crivera, Pharm.D., M.P.H.
Riad Dirani, Ph.D.

NR6-26
Effects of Paliperidone Palmitate in Acutely Ill Subjects with a Marked-to-Severe Exacerbation of Schizophrenia
Norris Turner, Ph.D., Pharm.D.
Cynthia A. Bossie, Ph.D.
J. Thomas Haskins, Ph.D.
Jennifer Kern Sliwa, Pharm.D.
Yi-Wen Ma, Ph.D.
Larry Alphs, M.D., Ph.D.

NR6-27
Withdrawn

NR6-28
A Three Arm Dose Finding Study of Lurasidone: Efficacy and Tolerability Data
Philip D. Harvey, Ph.D.
Mitsukuni Murasaki, M.D.
Masaaki Ogasa, M.D.
Josephine Cucchiara, Ph.D.
Antony Loebel, M.D.

NR6-29
Long-Term Efficacy of Asenapine in People with Persistent Negative Symptoms of Schizophrenia
Pilar Cazorla, Ph.D.
John Panagides, Ph.D.
Jun Zhao, Ph.D.
Phillip Phiri, Ph.D.
Larry Alphs, M.D., Ph.D.
Nina Schooler, Ph.D.
Armin Szegedi, M.D., Ph.D.
Robert W. Buchanan, M.D.

NR6-30
Preliminary Results about Caregivers’ Quality of Life of First-Episode Psychosis Patients in Brazil
Rita Jorge, M.D.
Ana Cristina Chaves, Ph.D.

NR6-31
Caregivers Ego Defense Mechanisms in First-Episode Psychosis
Rita Jorge, M.D.
Ana Cristina Chaves, Ph.D.

NR6-32
The Selective NK3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia
Robert E. Litman, M.D.
Mark Smith, M.D., Ph.D.
Dhaval Desai, M.D.
Thomas Simpson, Ph.D.
Stephen Kanes, M.D., Ph.D.

NR6-33
Treating Agitation with Inhaled Loxapine (AZ-004): Efficacy Analyses in Patients with Schizophrenia or Bipolar Disorder
Robert S. Fishman, M.D.
Daniel A. Spyker, Ph.D., M.D.
James V. Cassella, Ph.D.

NR6-34
Efficacy of Long-Acting Risperidone in Patients with Schizophrenia: A Six-Month Follow-Up from the e-STAR Database in Latin America
Rogelio Aipiquian, M.D., Ph.D.
Rodrigo Córdoba, M.D.
Mario Souza, M.D.
Carlos Castillejos, M.D.
Carmen Amezua, M.D.
Leonardo Díaz, M.D.

NR6-35
Personality Differences in First Episode Schizophrenia and Bipolar Disorder
Ronald J. Guerrera, M.D.
Toni Mahowald, B.A.
Dean Salisbury, Ph.D.
New Diagnostic Criteria for NMS Using the Delphi Consensus Technique and an International Expert Panel
Ronald J. Gurrera, M.D.
Stanley N. Caroff, M.D.
Abigail Cohen, Ph.D.

Long-Term Safety and Efficacy of Asenapine Versus Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
Schoemaker Joep, M.S.C.
Let Stott, Ph.D.
Dieter Nöber, M.D., Ph.D.
John Panagides, Ph.D.
Robin Emsley, M.D., Ph.D.

Time to Negative Symptoms Remission and Psychosocial Functioning in Schizophrenia: A 196-Week Double-Blind Study of Ziprasidone versus Haloperidol
Stephen Stahl, M.D., Ph.D.
Ashok Malla, M.D.
John W. Newcomer, M.D.
Steven G. Potkin, M.D.
Peter J. Weiden, M.D.
Philip D. Harvey, Ph.D.
Antony Loebel, M.D.
Eric Watsky, M.D.
Cynthia O. Siu, Ph.D.
Steve Romano, M.D.

Short-Term Tolerability, Safety, and Pharmacokinetic Profile of Asenapine in Older Patients with Psychosis
Steven Dubovsky, M.D.
Colleen Frobose, Ph.D.
Phillip Phiri, Ph.D.
John Panagides, Ph.D.

Comparative Receptor Binding Profile of Lurasidone and Other First and Second Generation Antipsychotics
Takeo Ishiyama, Ph.D.
Antony Loebel, M.D.
Josephine Cucchiara, Ph.D.
Tomoko Horisawa, B.S.
Kumiko Tokuda, B.S.
Maasaki Ogasa, M.S.
Tadashi Ishibashi, Ph.D.
Steven M. Stahl, M.D., Ph.D.

Reduction of Hospitalization in Patients Initiated on Risperidone Long-Acting Injection in the U.S., Spain, Australia, and Belgium
Timothy Lambert, M.D., B.S., Ph.D.
J.M. Olivares, M.D., Ph.D.
J. Peuskens, M.D., Ph.D.
Cherylyn DeSouza, M.D.

Efficacy and Safety of Quetiapine for Depressive Symptoms in Patients with Schizophrenia
Tae-Youn Jun,
Yang-Whan Jeon
Hae-Kook Lee
Kyoung-Uk Lee

Rates of Leukopenia and Agranulocytosis Associated with Clozaril Treatment during 19 Years of Blood Monitoring by the Clozaril National Registry
Vinod Kumar, M.D.
Jonathan J. Salem

Gender Specific Effects of Premature Birth on the Risk for Alcoholism Greater in Males Than Females: A 45-Year Danish Birth Cohort Study
Ann Manzardo, Ph.D.
Elizabeth C. Penick, Ph.D.
Joachim Knop, M.D.
Wendy Madarasz, M.P.E.
Erik Lykke Mortensen, Cand. Psych.
Holger J. Sorensen, M.D., Ph.D.
Ulrik Becker, M.D.
Elizabeth J. Nickel, M.S.
William F. Gabrielli Jr., M.D., Ph.D.

Diagnostic Aspects of Pathological Internet Use: A Prospective Study of Psychiatric Phenomenology and Comorbidity of Internet Dependence
Bert T. te Wildt, M.D.
I. Putzig, M.D.
M. Drevs, M.D.
F. Wedegaertner, M.D., M.P.H.
G. R. Szyck, Ph.D.

Characteristics, Persistence, and Outcomes of Insured Patients Treated with Extended-Release Naltrexone (XR-NTX) or Oral Medications
David R. Gastfriend, M.D.
Henry R. Kranzler, M.D.
Leslie Montejano, Ph.D.
Tami Mark, Ph.D.
Mady Chalk, Ph.D.
David R. Gastfriend, M.D.

Misidentified Content and Contaminants: Further Risks of Underground Anabolic Steroid Use
Dwight Smith, M.D.
Troy Pulas, M.D.
John Renner, M.D.

An Update on Testing for Drugs of Abuse: Scientific Background and Practical Clinical Concerns
Dwight Smith, M.D.
Ashish Anand, M.D.
Ronald Bugaon, M.D.
John Renner, M.D.

Efficacy and Safety of Extended-Release Injectable Naltrexone (XR-NTX) for the Treatment of Opioid Dependence
Evgeny Krupitsky
Ari Illeperuma, M.S.
David R. Gastfriend, M.D.
Bernard L. Silverman, M.D.

Longitudinal Associations Between Early Emotional Problems, Behavioural Problems, and Substance Use: 20 Year Follow-Up of a Finnish Birth Cohort
Jouko Miettunen, Ph.D.
Graham K. Murray, M.R.C.Psych.
Jouko Miettunen, Ph.D.

Characteristics, Persistence, and Outcomes of Insured Patients Treated with Extended-Release Naltrexone (XR-NTX) or Oral Medications
Mady Chalk, Ph.D.
Leslie Montejano, Ph.D.
Tami Mark, Ph.D.
Henry R. Kranzler, M.D.
Irmak Mustafan, M.D., Ph.D.

163rd Annual Meeting 161
NR7-9
Withdrawn

NR7-10
Withdrawn

NR7-11
The Diagnostic and Abstention Supervision with Markers of Alcohol Dependency
Matej Kravos, M.D., Ph.D.
Ivan Malešić

NR7-12
Preliminary Evaluation of Extended-Release Naltrexone (XR-NTX) in Michigan and Missouri Drug Courts
Michael W. Finigan, Ph.D.
Tamara Perkins, Ph.D.
Phyllis Zold-Kilbourn, Ph.D.

NR7-13
Alcohol Use and Addition of Low Dose Naltrexone in Opioid Detoxification
Paolo Mannelli, M.D.
Kathleen Peindl, Ph.D.
Ashwin A. Patkar, M.D.
Haresh Tharwani, M.D.
Li-Tzy Wu, Sc.D.

NR7-14
Withdrawn

NR7-15
An Analysis of Co-Ocurring Tobacco Smokers, Depression, and Substance Use
Sandra Odebrecht Vargas Nunes, M.D., Ph.D.
Juliana Brum Moraes, M.D.
Vivian Uemura, M.D.
Márcia Regina Pizzo de Castro, M.S.
Tiem Matsu, Ph.D.
Heber Odebrecht Vargas, M.D.

NR7-16
Extended-Release Injectable Naltrexone (XR-NTX) Reduces Brain Response to Alcohol Cues in Alcohol-dependent Volunteers: A BOLD fMRI Study
Scott E. Lukas, Ph.D.
Steven Lowen, Ph.D.
David M. Penetar, Ph.D.
Nina Conn
Wendy Tartarini, M.A.
John Rodolico, Ph.D.
Gopi Mallya, M.D.
Christopher Palmer, M.D.
Bernard L. Silverman, M.D.
David R. Gastfriend, M.D.

NR7-17
Treatment of Chronic Pain in a Veteran with Traumatic Brain Injury
Shipta Sachdeva, M.D.
Adekola Alao, M.D.

NR7-18
Mortality Following Treatment for Cannabis, Cocaine, Amphetamine, Ecstasy, and Opioid Use Disorders: A Nationwide Follow-Up Study from Denmark
Signe Jensen, M.S.C.
Mikkel Arendt, MS,Psych, Ph.D.
Povl Munk-Jørgensen, M.D.
Dr.Med.Sc, Leo Sher, M.D.

NR7-19
Translational Development of Novel Pharmacotherapeutic Strategies for Psychostimulant Dependence
Steven T. Szabo, M.D., Ph.D.
Ashwin Patkar, M.D.
Barry Mangum, Pharm. D.
Wayne F. Beyer, Ph.D.
F. Joseph McClernon, Ph.D.
Bruce K. Burnett, Ph.D.
Tong H. Lee, M.D., Ph.D.

NR7-20
Substance Intoxication Significantly Reduces Serum Thyrotropin (TSH) Levels in Acute Psychiatric Patients: Preliminary Results
Trevor Wells M.D.
Elana Miller M.D., Ph.D.
Cheryl Vigen Ph.D.
Osama A. Abulseoud M.D.

NR7-21
Brain Mechanisms of Decision Making During Recovery from Methamphetamine Dependence
William F. Hoffman, M.D., Ph.D.
D. Schwartz, B.A.
A. Mitchell, B.A.
D. Lahna, B.A.
H. Luber, B.A.
S. Mitchell, Ph.D.
M. Huckans, Ph.D.

NR7-22
A Review of Panic Disorder/Attacks and Suicidal Attempts in the Absence of Mood Disorders
Anne Ruminjo, M.D.
Sadie Shin, B.A.
Igor Galynker, M.D., Ph.D.
Lisa J. Cohen, Ph.D.

NR7-23
Does Early Improvement Predict Endpoint Response in GAD Patients Treated with Pregabalin or Venlafaxine-XR?
David Baldwin, D.M.
Edward Schweizer, M.D.
Yikang Xu, Ph.D.
Gavin Lyndon, M.D.
Sean Donevan, Ph.D.

NR7-24
Efficacy of Pregabalin in Generalized Social Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled, Fixed-Dose Study
Douglas Feltner, M.D.
Robert Bielski, M.D.
Maria Liu-Dumaw, M.S.

NR7-25
Functional and Health-related Quality of Life Outcomes in Patients with OCD: Relationship to Treatment Response and Symptom
Eric Hollandier, M.D.
Dan I. Stein, M.D.
Naomi A. Fineberg, M.D.
M. Marteau, Ph.D.
Mark Legault, M.D.

NR7-26
Switching from Long-term Benzodiazepine Therapy to Pregabalin in Patients with GAD: A Double-Blind, Placebo-Controlled Trial
Francine Mandel, Ph.D.
Sean Donevan, Ph.D.
Edward Schweizer, M.D.

NR7-27
Efficacy of Pregabalin in Preventing Relapse in Generalized Social Anxiety Disorder: Results of a Double-Blind, Placebo-Controlled 26-Week Study
John Greist, M.D.
Maria Liu-Dumaw, M.S.
Douglas Feltner, M.D.

NR7-28
The Use of the Internet by Social Phobics to Seek Health Information
Michael Van Ameringen, M.D.
Catherine Mancini, M.D., F.R.C.P.C.
William Simpson, B.Sc.
Beth Patterson, B.Sc., B.Ed.

NR7-29
Harm Avoidance and Incompleteness in a Clinical Sample of OCD
Nicholas J. Sibrava, Ph.D.
Jane L. Eisen, M.D.
Maria C. Mancebo, Ph.D.
Steven A. Rasmussen, M.D.

NR7-30
Insomnia and GAD: Clinical Presentation and Differential Response to Three Drug Classes
Sean Donevan, Ph.D.
Edward Schweizer, M.D.
Yikang Xu, Ph.D.
Gavin Lyndon, M.D.
Beck Depression Inventory (BDI) as a Screening Inventory for Depression: A Population-Based Finnish Cohort Study
Jussi K. Seppala, M.D., Mauno Vanhala, M.D., Prof. Hannu Kautiainen, Ph.D. Salme Jarvenpaa, M.Sc. Johan Eriksson, M.D., Ph.D. Olli Kampman, M.D., Ph.D. Yrjo Ovaskainen, M.D. Merja Viikki, M.D., Ph.D. Hannu Koponen, M.D., Prof.

Effectiveness of Eating Disorder Treatment in Real World Settings: Comprehen sive Assessment and Outcome

Withdrawn

Tests of the Koob-Kelly-Gold-Volkow-Kessler Hypothesis of BMI Increases in the U.S.
Jennifer Cavender, B.A. Yulia Dementieva, Ph.D. Marc A. Lindberg, Ph.D.

Psychotropic Drug Use in Older People and Risk of Death During Heat Waves: A French Population-Based Case-Control Study
Clementine Nordon, M.D., M.S.C. Karin Martin-Latry, Ph.D. Laurence de Roquefeuil, Ms.C. Philippe Latry, Ms.C. Bernard Begaud, Ph.D. Bruno Fallissard, Ph.D. Frederic Rouillon, Ph.D. Helene Verdoux, Ph.D.
There are significant direct consequences to the invasion of HIV into the nervous system that may present as neurological, neuropsychiatric, and/or psychiatric syndromes and disorders. These may arise acutely and require rapid evaluation and intervention, or they may be chronic and subtle and be accompanied by physical complaints.

Know how to respond.
To learn more contact the APA Office of HIV Psychiatry.
We can help with your training and resource needs.

American Psychiatric Association • Office of HIV Psychiatry
703.907.8668 • aids@psych.org • www.psych.org/aids

OMG! DYK HIV FX CNS?
NEW RESEARCH: TOPIC INDEX

Addiction Psychiatry/Substance Use Disorders
NR1-1 to NR1-12, NR3-28, NR3-45, NR3-69, NR7-1 to NR7-8, NR7-11 to NR7-13, NR7-15 to NR7-21, NR7-36

AIDS & HIV
NR2-37

Anxiety Disorders
NR1-13 to NR1-18, NR1-20 to NR1-22, NR1-69, NR2-1, NR4-21, NR7-21 to NR7-30

Attention Spectrum Disorders
NR2-77, NR4-41, NR5-1 to NR5-17, NR5-19 to NR5-23, NR5-32

Behavior & Cognitive Therapies
NR2-18, NR3-1 to NR3-3

Biological Psychiatry & Neuroscience
NR1-70, NR2-1 to NR2-6, NR2-8, NR2-33, NR3-4 to NR3-7, NR3-9, NR3-10, NR3-12, NR4-8, NR4-31, NR6-6, NR6-33

Brain Imaging
NR1-50, NR1-51, NR2-7 to NR2-10, NR3-10 to NR3-15, NR4-24, NR4-58, NR4-73, NR4-84, NR5-62, NR6-3, NR7-16

Child & Adolescent Psychiatry
NR1-23, NR2-7, NR2-11 to NR2-17, NR2-19, NR2-48, NR2-63, NR3-30, NR3-41, NR3-47, NR4-35, NR5-1, NR5-5, NR5-7, NR5-13, NR5-24 to NR5-34, NR5-40

Cognitive Disorders (Delirium, Dementia, etc.)
NR1-24 of NR1-26, NR3-71, NR3-72, NR4-9, NR7-31

Computers, Technology, Internet & Related
NR2-46, NR4-49, NR5-34

Couple & Family Therapies
NR5-35

Creativity & the Arts
NR2-20, NR2-58

Cross-Cultural & Minority Issues
NR2-21 to NR2-23, NR2-79, NR5-36 to NR5-38, NR7-34

Diagnostic Issues
NR1-15, NR1-27 to NR1-30, NR1-35, NR3-58, NR4-14, NR4-48, NR4-87, NR5-6, NR6-36, NR7-11, NR7-32 to NR7-34

Eating Disorders
NR1-19, NR1-31, NR1-53, NR3-57, NR4-25, NR7-35, NR7-36

Epidemiology
NR1-8, NR1-44, NR1-57, NR2-24 to NR2-28, NR2-49, NR3-62, NR3-63, NR4-16, NR4-38, NR4-59, NR5-2, NR7-32, NR7-37 to NR7-43, NR7-54

Ethics & Human Rights
NR2-29, NR5-39, NR5-42

Forensic Psychiatry
NR1-63, NR2-30, NR2-31, NR5-39 to NR5-45

Gender Issues
NR1-34, NR1-55, NR4-72, NR5-58, NR7-1, NR7-15

Genetics
NR1-13, NR1-14, NR1-19, NR2-32, NR2-33, NR2-67, NR3-16 to NR3-20, NR4-11, NR4-36

Geriatric Psychiatry
NR1-24, NR1-41, NR2-34, NR2-40, NR2-43, NR2-64, NR2-70, NR3-8, NR3-70, NR5-46 to NR5-57, NR7-31, NR7-37

Group Therapy
NR1-18, NR5-26

Health Services Research
NR2-35 to NR2-40, NR2-75, NR3-21 to NR3-25, NR4-78, NR5-38, NR7-35

Historical Questions
NR2-41, NR5-58

Impulse Control Disorders
NR1-10, NR1-32, NR5-43, NR7-2, NR7-21, NR7-44

Lesbian/Gay/Bisexual/Transgender Issues
NR1-54

Managed Care & Health Care Financing
NR5-18

Men's Health Issues
NR2-42

Mood Disorders
NR1-27, NR1-33 to NR1-51, NR2-3, NR2-5, NR2-23, NR2-32, NR2-47, NR2-76, NR3-5, NR3-16, NR3-18, NR3-42, NR3-49, NR3-55, NR3-67, NR3-67, NR3-68, NR3-70, NR4-1 to NR4-86, NR5-28, NR7-7, NR7-9

Neuropsychiatry
NR1-21, NR2-41, NR2-43 to NR2-47, NR2-73, NR3-26, NR3-27, NR5-20, NR5-55, NR6-12, NR6-24, NR7-20

Other Somatic Therapies
NR2-17, NR2-48, NR4-66, NR7-45, NR7-46

Pain Management
NR5-46, NR7-47 to NR7-49

Patient Safety & Suicide
NR1-23, NR2-49, NR2-50, NR3-28 to NR3-30, NR7-22

Personality Disorders
NR1-52 to NR1-55, NR3-13, NR4-41, NR6-35, NR7-50 to NR7-52

Practice Management
NR2-51 to NR2-57, NR3-32, NR3-53

163rd Annual Meeting 165
NEW RESEARCH: TOPIC INDEX

**Professional & Personal Issues**
NR2-29, NR3-31

**Psychiatric Administration & Services:**
Public, Private & University
NR3-22, NR3-32 to NR3-34, NR3-36

**Psychiatric Education**
NR1-59, NR2-58 to NR2-61, NR2-74, NR5-60

**Psychoanalysis**
NR2-22, NR6-31

**Psychoimmunology**
NR2-62, NR3-37, NR3-38, NR4-64, NR4-75

**Psychopharmacology**
NR1-26, NR1-60, NR1-61, NR2-12, NR2-63 to NR2-70, NR3-19, NR3-39 to NR3-44, NR3-46, NR3-48 to NR3-58, NR4-10, NR4-42, NR4-80, NR5-9, NR5-23, NR6-27, NR5-30, NR6-1, NR6-2, NR6-5, NR6-7, NR6-8, NR6-15, NR6-16, NR6-18 to NR6-21, NR6-28, NR6-29, NR6-34, NR6-3

**Psychosomatic Medicine**
NR1-2, NR1-22, NR2-15, NR2-71 to NR2-73, NR3-31, NR3-59, NR3-60, NR4-5

**Religion, Spirituality, & Psychiatry**
NR1-1

**Research Issues**
NR3-15, NR3-61, NR4-15, NR4-39

**Resident & Medical Student Concerns**
NR2-74, NR5-36, NR5-59 to NR5-61

**Schizophrenia & Other Psychotic Disorders**
NR1-4, NR1-30, NR1-57 to NR1-69, NR1-73, NR2-36, NR2-66, NR2-69, NR3-39, NR3-44, NR3-51, NR3-54, NR3-56, NR3-73, NR6-1 to NR6-43

**Sleep Disorders**
NR1-70 to NR1-73, NR3-6, NR4-61, NR7-53, NR7-54

**Social & Community Psychiatry**
NR1-9, NR3-24, NR3-35, NR3-62, NR3-63, NR5-51, NR7-41

**Somatoform Disorders**
NR4-88

**Stigma/Advocacy**
NR1-11, NR2-20

**Stress**
NR1-73, NR3-11, NR3-33 NR4-7, NR4-77, NR4-78, NR7-55

**Treatment Techniques & Outcome Studies**
NR1-58, NR2-18, NR2-75 to NR2-77, NR3-25, NR3-37, NR3-65 to NR3-68, NR4-43, NR4-74, NR5-35, NR6-13, NR6-14, NR7-55

**Violence, Trauma & Victimization**
NR1-52, NR2-45, NR2-78, NR3-38, NR4-56, NR5-45, NR5-62

**Women’s Health Issues**
NR1-48, NR2-78, NR2-79, NR5-63, NR5-64

---

VISIT THE EXHIBITS

Publishers Book Fair and APA Member Center
Open Saturday 10 am – 4:00 pm

All Exhibits Open
Sunday 10:00 am – 4:00 pm
Monday 10:00 am – 4:00 pm
Tuesday 10:00 am – 4:00 pm

Exhibit Hall Reception
Monday 12:30 – 1:30 pm

NOTE: Final closing of exhibits is Tuesday at 4:00 pm
American Psychiatric Association
164th ANNUAL MEETING
HONOLULU, HAWAII • May 14-18, 2011
Transforming Mental Health Through
Leadership, Discovery and Collaboration

Visit our website on June 15th for further information regarding submissions. www.psych.org

CALL FOR ABSTRACTS
Don’t miss the opportunity to submit your proposed presentation for a: symposium, workshop, course, iss and/or other scientific sessions.

Visit our website on June 15th for further information regarding submissions. www.psych.org

For more information about the APA Annual Meeting visit our website at: www.psych.org
Moving Forward Together

SZ Magazine is a trusted resource, providing the essential information on treatment options and lifestyle enhancements necessary to move forward together.

Visit Booth #1931 to receive your complimentary copy of SZ Magazine and learn about the special subscription offer available exclusively to APA members.

www.szmagazine.com

Ask us how you can receive the new digital version of

Conquering Depression

or visit www.anchormag.com to learn more.

Member of:
Have you ever wondered about the decision-making process used to determine which studies are published by The American Journal of Psychiatry?

At APA’s 2010 annual meeting in New Orleans, you’ll get some insight into the answer in a symposium led by AJP Editor Robert Freedman, M.D. He will use the upcoming June issue to explain how submission decisions are made as he highlights important research reported in that issue to be released the following week. Authors of papers that will be appearing in the June issue will also be on hand to present overviews of their findings.

Be a part of this exciting event in New Orleans!

Symposium 47: New Studies to Appear in the June Issue of The American Journal of Psychiatry: Presentations by the Authors and Editors
Chair: Robert Freedman, M.D.
Monday, May 24: 2:00 p.m.-5:00 p.m.
Rooms 225/226, Second Level, Morial Convention Center

Among the presenters:

- **David Spiegel**, discussing evidence for a dissociative subtype of PTSD
- **Mary Zanarini**, discussing recovery from borderline personality disorder and its stability
- **Alexandre Dombrovski**, discussing reward/punishment reversal learning in older suicide attempters
- **David Gardner**, discussing an international consensus study of antipsychotic dosing

Other articles of note in the June issue:
- A Double-Blind, Placebo-Controlled Trial That Combines Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence
- Life-Threatening Danger Suppresses Attention Bias to Threat
The NEW www.appi.org just debuted!

The new www.appi.org offers:

- Special Discounts for American Psychiatric Association Members and Members-in-Training
- Detailed descriptions on more than 700 titles + subscription products
- My Account history with order and tracking information.
- Fast and easy navigation
- Enhanced search engine

APPI Bookstore Hours
Saturday, May 22 to Tuesday, May 25
10:00 am – 4:00 pm

Extra Special Discount for Members at the APPI Bookstore!
15% Discount for APA Members
30% Discount for APA Members-in-Training

Priority Code AH1020

The First and Last Word in Psychiatry
1-800-368-5777 or 703-907-7322
appi@psych.org
Find us on Facebook and Twitter.
PSYCHIATRISTS,
YOUR PROFESSIONAL LIABILITY INSURER MAY NO LONGER BE SAFE OR SOUND.

MAKE SURE YOUR PROFESSIONAL LIABILITY INSURANCE IS PROVIDED BY A COMPANY WITH AN “EXCELLENT” RATING. AND DON’T SETTLE FOR ANYTHING LESS.

Darwin National Assurance Company
Darwin is rated “Excellent” by A.M. Best Co. and anticipates a further upgrade in its rating very soon not a downgrade.

Discounts
• 50% for Part-time
• 10% Claims free
• 50% as a New Graduate

(Disabled 1-800-421-6694 for complete details on these discounts.)

95 Broadway, Amityville, NY 11701
1-800-421-6694
www.americanprofessional.com

MAKE SURE YOUR PROFESSIONAL LIABILITY INSURANCE IS PROVIDED BY A COMPANY WITH AN “EXCELLENT” RATING. AND DON’T SETTLE FOR ANYTHING LESS.

American Psychiatric Association

2010 APA Annual Meeting
ONLINE & DVD-ROM HIGHLIGHTS
Order yours during the meeting and save up to $500*

SALES BOOTHs:
• Lobby B1
• Exhibit Hall B2, Near the Registration Area

The APA Exhibits Program is an integral component of the overall Annual Meeting and provides an excellent opportunity for meeting registrants to obtain the latest information on products and services related to the psychiatric profession.

Please allow adequate time in your daily schedule to visit the exhibits, which are located in Exhibit Halls B-D, First Level of the Morial Convention Center. At the exhibits you participate in interactive computer programs and speak with the representatives of companies who provide services and products related directly to psychiatrists’ professional and personal interests.

To assist in locating a particular company or product, a floor plan of the Exhibit Hall is included in the exhibits section of The Guide, along with a list of: 1) exhibitors with product/service description; 2) exhibitors by product/service listing; and 3) exhibitors listed alphabetically with booth numbers.

ENDORSEMENTS

Products and services displayed in the Exhibit Hall occur by the contractual arrangement between the American Psychiatric Association and participating companies. This arrangement does not constitute or imply an endorsement by the American Psychiatric Association of these products or services.

EXHIBIT DATES AND HOURS

Publisher’s Book Fair (only):

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SATURDAY, MAY 22</td>
<td>10:00 A.M. – 4:00 P.M.</td>
</tr>
</tbody>
</table>

All Exhibits:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUNDAY, MAY 23</td>
<td>10:00 A.M. – 4:00 P.M.</td>
</tr>
<tr>
<td>MONDAY, MAY 24</td>
<td>10:00 A.M. – 4:00 P.M.</td>
</tr>
<tr>
<td>TUESDAY, MAY 25</td>
<td>10:00 A.M. – 4:00 P.M.</td>
</tr>
<tr>
<td>WEDNESDAY, MAY 26</td>
<td>10:00 A.M. – 4:00 P.M.</td>
</tr>
</tbody>
</table>

BADGE COLOR CODES

<table>
<thead>
<tr>
<th>Color</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLUE</td>
<td>Members</td>
</tr>
<tr>
<td>YELLOW</td>
<td>Nonmembers</td>
</tr>
<tr>
<td>RED</td>
<td>Exhibitors</td>
</tr>
<tr>
<td>GREEN</td>
<td>APA Staff</td>
</tr>
<tr>
<td>SILVER</td>
<td>Press</td>
</tr>
<tr>
<td>BLACK</td>
<td>Temporary Staff</td>
</tr>
</tbody>
</table>

NEW THIS YEAR!

Exhibit Hall Reception
Open to All Registrants

MONDAY, MAY 24, 2010
12:30-1:30 PM

Join us for fun and food. Meet colleagues and visit the exhibits.
Practice Management for Early Career Psychiatrists: A Reference Guide

Created by the American Psychiatric Association's Office of Healthcare Systems and Financing, this handbook provides APA members with an overview of many of the things they need to be aware of as a psychiatrist. Although specifically designed to meet the needs of Residents and Early Career Psychiatrists (ECPs), the information it contains may also be of value to those who have been in practice for years. Contents include:

I. STARTING OUT
   1. Conducting an Effective Job or Practice Search
   2. Negotiating an Employment Contract
   3. Licensing and Board Certification
   4. Practice Options

II. ESTABLISHING YOUR PRACTICE
   5. Incorporation Options
   6. Buying or Leasing Office Space and Equipment
   7. Medical Professional Liability Insurance
   8. Hiring and Managing Administrative Staff
   9. Selecting Computer Applications and Software
  10. Marketing Your Practice Effectively
  11. Putting Your Practice on a Budget

III. MAINTAINING YOUR PRACTICE
  12. Managing Relationships with Other Clinicians
  13. Managing Appointment Scheduling
  15. Verifying Benefit Coverage Accurately and Efficiently
  16. Coordinating Benefits for Patients with More than One Source of Insurance Coverage
  17. Implementing Electronic Billing Capabilities
  18. Increasing the Success Rate of Collections Efforts
  19. Avoiding Common Procedure Coding Problems

IV. PATIENT CARE ISSUES
  20. Confidentiality
  21. Duty to Warn
  22. Informed Consent
  23. Civil Commitment
  24. Medical Records
  25. Conducting a Patient Satisfaction Survey

V. MANAGED CARE ISSUES
  26. Defining Managed Care
  27. Getting on Managed Care Panels
  28. Reviewing and Negotiating Contracts
  29. Appealing Reimbursement Denials
  30. Getting Paid
  31. Maintaining Confidentiality in the Era of Managed Care
  32. Handling Medical Record Reviews
  33. Avoiding Deselection
  34. Managed Care Resources

VI. PROFESSIONAL ISSUES
  35. Principles of Medical Ethics
  36. Opinions of the Ethics Committee
  37. Managing Relationships with Patients
  38. Reducing Malpractice Risk
  39. Practice Guidelines

VII. LEGAL ISSUES
  40. Medicare and Medicaid
  40a. How to Appeal Decisions by Medicare Carriers
  40b. Compliance Programs
  41. Fraud and Abuse
  41a. HIPAA
  42. ERISA
  43. An Overview of Antitrust Laws Affecting Physicians
  44. The National Practitioner Data Bank

Access this valuable member benefit at www.psych.org in the “Members Corner”
CHANTIX is indicated as an aid to smoking cessation treatment in adults 18 and over. Patients may benefit from behavioral modification and support during their quit attempt. Patients should be encouraged to continue to attempt to quit if they have early lapses after quit day.

IMPORTANT SAFETY INFORMATION

All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide have been reported in some patients attempting to quit smoking while taking CHANTIX in the post-marketing experience.

These events have occurred in patients with and without pre-existing psychiatric disease. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the pre-marketing studies of CHANTIX and the safety and efficacy of CHANTIX in such patients has not been established.

Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after discontinuation of CHANTIX was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.

CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.

Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.

The most common adverse reactions include nausea (30%), sleep disturbance, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.

Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.

Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.

www.pfizerpro.com/chantix
Please see accompanying brief summary of Prescribing Information.
Brief summary of full Prescribing Information.
CHANTIX®

(varenicline) Tablets
WARNING:
Serious neuropsychiatric events, including, but not limited to depression, suicidal ideation, suicide attempt and completed suicide
have been reported in patients taking CHANTIX. Some reported cases may have been complicated by the symptoms of nicotine
withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely
including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt without medication. However,
some of these symptoms have occurred in patients taking CHANTIX who continued to smoke.
All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well
as worsening of pre-existing psychiatric illness and completed suicide have been reported in some patients attempting to quit
smoking while taking CHANTIX in the post-marketing experience. When symptoms were reported, most were during CHANTIX
treatment, but some were following discontinuation of CHANTIX therapy.
These events have occurred in patients with and without pre-existing psychiatric disease. Patients with serious psychiatric illness
such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the pre-marketing studies of CHANTIX
and the safety and efficacy of CHANTIX in such patients has not been established.
Advise patients and caregivers that the patient should stop taking CHANTIX and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed,
or if the patient develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after
discontinuation of CHANTIX was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and
supportive care should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use. CHANTIX has been demonstrated to increase the likelihood
of abstinence from smoking for as long as one year compared to treatment with placebo. The health benefits of quitting smoking
are immediate and substantial.
(See WARNINGS/Neuropsychiatric Symptoms and Suicidality, PRECAUTIONS/Information for Patients, and ADVERSE
REACTIONS/Post-Marketing Experience)
INDICATIONS AND USAGE
CHANTIX is indicated as an aid to smoking cessation treatment.
WARNINGS
Neuropsychiatric Symptoms and Suicidality
Serious neuropsychiatric symptoms have been reported in patients being treated with CHANTIX (See Boxed Warning, PRECAUTIONS/
Information for patients, and ADVERSE REACTIONS/Post-Marketing Experience). These post-marketing reports have included
changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation,
anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Some reported cases may have been
complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine
withdrawal. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt
without medication. However, some of these symptoms have occurred in patients taking CHANTIX who continued to smoke. When
symptoms were reported, most were during CHANTIX treatment, but some were following discontinuation of CHANTIX therapy.
These events have occurred in patients with and without pre-existing psychiatric disease; some patients have experienced worsening
of their psychiatric illnesses. All patients being treated with CHANTIX should be observed for neuropsychiatric symptoms or worsening
of pre-existing psychiatric illness. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive
disorder did not participate in the pre-marketing studies of CHANTIX and the safety and efficacy of CHANTIX in such patients has not
been established.
Advise patients and caregivers that the patient should stop taking CHANTIX and contact a health care provider immediately
if agitation, depressed mood, changes in behavior or thinking that are not typical for the patient are observed, or if the patient
develops suicidal ideation or suicidal behavior. In many post-marketing cases, resolution of symptoms after discontinuation
of CHANTIX was reported, although in some cases the symptoms persisted, therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of CHANTIX should be weighed against the benefits of its use. CHANTIX has been demonstrated to increase the likelihood of
abstinence from smoking for as long as one year compared to treatment with placebo. The health benefits of quitting smoking are
immediate and substantial.
Angioedema and Hypersensitivity Reactions.
There have been post-marketing reports of hypersensitivity reactions including angioedema in patients treated with CHANTIX (See
ADVERSE REACTIONS/Post-Marketing Experience). Clinical signs included swelling of the face, mouth (tongue, lips, and gums),
extremities, and neck (throat and larynx). There were infrequent reports of life-threatening angioedema requiring emergent medical
attention due to respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if
they experience these symptoms.
Serious Skin Reactions
There have been post-marketing reports of rare but serious skin reactions, including Stevens-Johnson Syndrome and Erythema
Multiforme in patients using CHANTIX (See ADVERSE REACTIONS/Post-Marketing Experience) As these skin reactions can be lifethreatening, patients should be instructed to stop taking CHANTIX and contact their healthcare provider immediately at the first
appearance of a skin rash with mucosal lesions or any other signs of hypersensitivity.
PRECAUTIONS
General Nausea was the most common adverse event associated with CHANTIX treatment. Nausea was generally described as mild
or moderate and often transient; however, for some subjects, it was persistent over several months. The incidence of nausea was
dose-dependent. Initial dose-titration was beneficial in reducing the occurrence of nausea. Nausea was reported by approximately
30% of patients treated with CHANTIX 1 mg BID after an initial week of dose titration. In patients taking CHANTIX 0.5 mg BID, the
incidence of nausea was 16% following initial titration. Approximately 3% of subjects treated with CHANTIX 1 mg BID in studies
involving 12 weeks of treatment discontinued treatment prematurely because of nausea. For patients with intolerable nausea, dose
reduction should be considered.
Accidental Injury There have been post-marketing reports of traffic accidents, near-miss incidents in traffic, or other accidental
injuries in patients taking CHANTIX. In some cases, the patients reported somnolence, dizziness, loss of consciousness or difficulty
concentrating that resulted in impairment, or concern about potential impairment, in driving or operating machinery. Patients should be
advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX
may affect them.
Effect of smoking cessation: Physiological changes resulting from smoking cessation, with or without treatment with CHANTIX, may alter
the pharmacokinetics or pharmacodynamics of some drugs, for which dosage adjustment may be necessary (examples include
theophylline, warfarin and insulin).
Drug Interactions Based on varenicline characteristics and clinical experience to date, CHANTIX has no clinically meaningful
pharmacokinetic drug interactions (See Full Prescribing Information, CLINICAL PHARMACOLOGY, Drug-Drug Interactions).
Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis. Lifetime carcinogenicity studies were performed in CD-1 mice
and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at
doses up to 20 mg/kg/day (47 times the maximum recommended human daily exposure based on AUC). Rats were administered varenicline
(1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma (tumor of the
brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the maximum recommended human daily exposure based on
AUC) and maximum dose (2 tumors, 15 mg/kg/day, 67 times the maximum recommended human daily exposure based on AUC). The
clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats.
Mutagenesis. Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay;
mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations in vivo in rat bone marrow and in vitro in human lymphocytes.
Impairment of fertility. There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered
varenicline succinate up to 15 mg/kg/day (67 and 36 times, respectively, the maximum recommended human daily exposure based on AUC
at 1 mg BID). However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenicline succinate at
an oral dose of 15 mg/kg/day (36 times the maximum recommended human daily exposure based on AUC at 1 mg BID). This decrease in
fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the maximum recommended human
daily exposure based on AUC at 1 mg BID).
Pregnancy Pregnancy Category C. Varenicline succinate was not teratogenic in rats and rabbits at oral doses up to 15 and
30 mg/kg/day, respectively (36 and 50-times the maximum recommended human daily exposure based on AUC at 1 mg BID,
respectively). Nonteratogenic effects Varenicline succinate has been shown to have an adverse effect on the fetus in animal reproduction
studies. Administration of varenicline succinate to pregnant rabbits resulted in reduced fetal weights at an oral dose of 30 mg/kg/day
(50 times the human AUC at 1 mg BID); this reduction was not evident following treatment with 10 mg/kg/day (23 times the maximum
recommended daily human exposure based on AUC). In addition, in the offspring of pregnant rats treated with varenicline succinate there
were decreases in fertility and increases in auditory startle response at an oral dose of 15 mg/kg/day (36 times the maximum recommended
human daily exposure based on AUC at 1 mg BID). There are no adequate and well-controlled studies in pregnant women. CHANTIX should
be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mothers Although it is not known
whether this drug is excreted in human milk, animal studies have demonstrated that varenicline can be transferred to nursing pups.
Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from
CHANTIX, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the
drug to the mother. Labor and delivery The potential effects of CHANTIX on labor and delivery are not known. Pediatric Use Safety and

174

www.psych.org

effectiveness of CHANTIX in pediatric patients have not been established; therefore, CHANTIX is not recommended for use in patients under
18 years of age. Geriatric Use A combined single and multiple-dose pharmacokinetic study demonstrated that the pharmacokinetics of
1 mg varenicline given QD or BID to 16 healthy elderly male and female smokers (aged 65-75 yrs) for 7 consecutive days was similar to
that of younger subjects. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and
other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater
sensitivity of some older individuals cannot be ruled out. Varenicline is known to be substantially excreted by the kidney, and the risk of
toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have
decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND
ADMINISTRATION, Special Populations, Patients with impaired renal function). No dosage adjustment is recommended for elderly
patients (see DOSAGE AND ADMINISTRATION, Special Populations).
Information for Patients:
• Patients should be instructed to set a date to quit smoking and to initiate CHANTIX treatment one week before the quit date.
• Patients should be advised that CHANTIX should be taken after eating, and with a full glass of water.
• Patients should be instructed how to titrate CHANTIX, beginning at a dose of 0.5 mg/day. Prescribers should explain that one 0.5 mg
tablet should be taken daily for the first three days, and that for the next four days, one 0.5 mg tablet should be taken in the morning
and one 0.5 mg tablet should be taken in the evening.
• Patients should be advised that, after the first seven days, the dose should be increased to one 1 mg tablet in the morning and one
1 mg tablet in the evening.
• Patients should be encouraged to continue to attempt to quit if they have early lapses after quit day.
• Patients should also be provided with educational materials and necessary counseling to support an attempt at quitting smoking.
• Patients should be informed that nausea and insomnia are side effects of CHANTIX and are usually transient; however, patients should
be advised that if they are persistently troubled by these symptoms, they should notify the prescribing physician so that a dose
reduction can be considered.
• Patients should be informed that they may experience vivid, unusual or strange dreams during treatment with CHANTIX.
• Patients should be informed that quitting smoking, with or without CHANTIX, may be associated with nicotine withdrawal symptoms
(including depression or agitation) or exacerbation of pre-existing psychiatric illness. Furthermore, some patients have experienced
changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression,
anxiety, and panic, as well as suicidal ideation and suicide when attempting to quit smoking while taking CHANTIX. If patients develop
agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for them, or if patients develop suicidal
ideation or behavior, they should be urged to discontinue CHANTIX and report these symptoms to their healthcare provider immediately.
• Patients should be encouraged to reveal any history of psychiatric illness prior to initiating treatment.
• Patients should be informed that some medications may require dose adjustment after quitting smoking.
• Patients intending to become pregnant or planning to breast-feed an infant should be advised of the risks of smoking and risks and
benefits of smoking cessation with CHANTIX.
• Patients should be advised to use caution driving or operating machinery until they know how quitting smoking with varenicline may
affect them.
• Patients should be informed that there have been reports of angioedema, with swelling of the face, mouth (lip, gum, tongue) and neck
(larynx and pharynx) that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX
and immediately seek medical care if they experience these symptoms.
• Patients should be informed that serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme, were reported
by some patients taking CHANTIX. They should be advised to stop taking CHANTIX at the first sign of rash with mucosal lesions or skin
reaction and contact a health care provider immediately.
ADVERSE REACTIONS
During the premarketing development of CHANTIX, over 4500 individuals were exposed to CHANTIX, with over 450 treated for at least
24 weeks and approximately 100 for a year. Most study participants were treated for 12 weeks or less. In Phase 2 and 3 placebocontrolled studies, the treatment discontinuation rate due to adverse events in patients dosed with 1 mg BID was 12% for CHANTIX
compared to 10% for placebo in studies of three months’ treatment. In this group, the discontinuation rates for the most common
adverse events in CHANTIX treated patients were as follows: nausea (3% vs. 0.5% for placebo), headache (0.6% vs. 0.9% for placebo),
insomnia (1.2% vs. 1.1% for placebo), and abnormal dreams (0.3% vs. 0.2% for placebo). Adverse Events were categorized using the
Medical Dictionary for Regulatory Activities (MedDRA, Version 7.1).
The most common adverse events associated with CHANTIX (>5% and twice the rate seen in placebo-treated patients) were nausea,
sleep disturbance, constipation, flatulence, and vomiting. Smoking cessation, with or without treatment, is associated with nicotine
withdrawal symptoms.
The most common adverse event associated with CHANTIX treatment is nausea. For patients treated to the maximum recommended
dose of 1 mg BID following initial dosage titration, the incidence of nausea was 30% compared with 10% in patients taking a
comparable placebo regimen. In patients taking CHANTIX 0.5 mg BID following initial titration, the incidence was 16% compared with
11% for placebo. Nausea was generally described as mild or moderate and often transient; however, for some subjects, it was
persistent throughout the treatment period.
Table 3 shows the adverse events for CHANTIX and placebo in the 12 week fixed dose studies with titration in the first week (Studies
2 (titrated arm only), 4, and 5). MedDRA High Level Group Terms (HLGT) reported in ≥ 5% of patients in the CHANTIX 1 mg BID dose
group, and more commonly than in the placebo group, are listed, along with subordinate Preferred Terms (PT) reported in ≥ 1% of
CHANTIX patients (and at least 0.5% more frequent than placebo). Closely related Preferred Terms such as ‘Insomnia’, ‘Initial
insomnia’, ‘Middle insomnia’, ‘Early morning awakening’ were grouped, but individual patients reporting two or more grouped events
are only counted once.
Table 3: Common Treatment Emergent AEs (%) in the Fixed-Dose, Placebo-Controlled Studies (≥ 1% in the
1 mg BID CHANTIX Group, and 1 mg BID CHANTIX at least 0.5% more than Placebo)
SYSTEM ORGAN CLASS
High Level Group Term
Preferred Term
GASTROINTESTINAL
GI Signs and Symptoms
Nausea
Abdominal Pain*
Flatulence
Dyspepsia
Vomiting
GI Motility/Defecation Conditions
Constipation
Gastroesophageal reflux disease
Salivary Gland Conditions
Dry mouth
PSYCHIATRIC DISORDERS
Sleep Disorders/Disturbances
Insomnia**
Abnormal dreams
Sleep disorder
Nightmare
NERVOUS SYSTEM
Headaches
Headache
Neurological Disorders NEC
Dysgeusia
Somnolence
Lethargy
GENERAL DISORDERS
General Disorders NEC
Fatigue/Malaise/Asthenia
RESPIR/THORACIC/MEDIAST
Respiratory Disorders NEC
Rhinorrhea
Dyspnoea
Upper Respiratory Tract Disorder
SKIN/SUBCUTANEOUS TISSUE
Epidermal and Dermal Conditions
Rash
Pruritis
METABOLISM & NUTRITION
Appetite/General Nutrit. Disorders
Increased appetite
Decreased appetite/Anorexia

CHANTIX
0.5 mg BID
N=129

CHANTIX
1mg BID
N=821

Placebo

16
5
9
5
1

30
7
6
5
5

10
5
3
3
2

5
1

8
1

3
0

4

6

4

N=805

19
9
2
2

18
13
5
1

13
5
3
0

19

15

13

8
3
2

5
3
1

4
2
0

4

7

6

0
2
7

1
1
5

0
1
4

1
0

3
1

2
1

4
1

3
2

2
1

* Includes PTs Abdominal (pain, pain upper, pain lower, discomfort, tenderness, distension) and Stomach discomfort
** Includes PTs Insomnia/Initial insomnia/Middle insomnia/Early morning awakening
The overall pattern, and the frequency of adverse events during the longer-term trials was very similar to that described in Table 3,


fewer than 1 out of 1000 patients reported euphoria.

**DISORDERS**

- Drug hypersensitivity.
- Metabolic effects:
  - Diabetes mellitus, Hyperlipidemia, Hypokalemia.
- Myositis.
- Abnormal, Muscle enzyme increased, Urine analysis abnormal.

**HEPATOBILIARY DISORDERS**

- Infrequent: Gall bladder disorder.
- Rare: Gallstone, Jaundice.
- Very rare: Hemolytic anemia.

**EAR AND LABYRINTH DISORDERS**

- Infrequent: Asthma.
- Rare: Vertigo.

**BLOOD AND LYMPHATIC SYSTEM DISORDERS**

- Rare: Uremia.

**RESPRATORY, THORACIC AND MEDIASTINAL DISORDERS**

- Infrequent: Angina pectoris, Pericarditis.
- Very rare: Pneumothorax.

**RESPIRATORY DISORDERS**

- Rare: Bronchitis, Dry cough, Dyspnea, Hemoptysis, Hoarseness.
- Very rare: Paroxysmal nocturnal dyspnea.

**SKIN DISORDERS**

- Infrequent: Conjunctivitis, Dry eye, Eye irritation, Vision blurred, Visual disturbance, Eye pain.
- Rare: Acquired night blindness, Blindness transient, Glaucoma subluxation, Ophthalmia, Uveitis.

**GASTROINTESTINAL DISORDERS**

- Frequent: Abdominal cramp.
- Infrequent: Anorexia, Nausea.
- Rare: Appetite decreased, Gastroenteritis.
- Very rare: Constipation.

**GENERAL DISORDERS AND ADMINISTRATION CONDITIONS**

- Frequent: Headache.

**POST-Marketing Experience**

The following adverse events have been reported during post-approval use of CHANTIX. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

There have been reports of depression, mania, psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completions, suicide attempt in patients attempting to stop smoking while taking CHANTIX, and smoking while taking CHANTIX. Patients may consider smoking to be a more pleasurable activity than other activities such as exercise or socializing with friends. The possibility of increased risk of suicide should be considered when prescribing CHANTIX for smoking cessation.

There have been reports of hypersensitivity reactions, including angioedema (See WARNINGS). There have been reports of anemia, neutropenia, thrombocytopenia, leukopenia, and agranulocytosis. There have been reports of liver function test abnormalities, including transaminase elevations, elevations in alkaline phosphatase, and elevations in gamma-glutamyltransferase.

There have been reports of a hyperglycemic crisis in patients with diabetes mellitus.

**Drug Abuse and Dependence**

Centrally-Related Substance Class

Varenicline is a centrally-acting agent. Fewer than 1 out of 1000 patients reported euphoria in clinical trials with CHANTIX. At higher doses (greater than 2 mg), CHANTIX produced more frequent reports of gastrointestinal disturbances such as nausea and vomiting. There is no evidence of abuse/dependence to maintain therapeutic effects in clinical studies, which suggest that abuse potential does not exceed the potential of placebo. Abnormal withdrawal of CHANTIX was associated with an increase in irritability and sleep disturbances in up to 2% of patients. This suggests that, in some patients, varenicline may produce mild physical dependence which is not associated with abstinence. In a human laboratory abuse liability study, a single dose of 5 mg varenicline produced no significant positive or negative subjective responses in non-smokers. In smokers, 5 mg varenicline produced an increase in some positive subjective effects, but this was accompanied by an increase in negative adverse effects, especially nausea. A single oral dose of 3 mg varenicline uniformly produced unpleasant subjective responses in both smokers and non-smokers.

**OVERDOSAGE**

In case of overtreatment, standard supportive measures should be instituted as required. Varenicline has been shown to be devoid of clinical effects in patients with end-stage renal disease (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations). Patients on regular hemodialysis who received a 10 mg dose of CHANTIX had a 5-fold increase in the systemic exposure of varenicline over a 24-hour period. There have been reports of varenicline being detected in post-mortem analyses of patients receiving therapeutic dosages of CHANTIX. In rats, varenicline has produced no evidence of abuse potential or physical dependence. The human laboratory abuse liability study included 180 patients (aged 18–55 years) who received a single oral dose of 1 mg varenicline. Varenicline produced no indication of abuse potential or physical dependence.

**DOSAGE AND ADMINISTRATION**

**Drug Interactions**

Patients who are taking CHANTIX and who are at risk for CHF should be monitored closely for evidence of CHF.

**Special Populations**

- Patients with impaired renal function: No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment (creatinine clearance of 10–19 mL/min), CHANTIX should be started at a dose of 0.5 mg once daily. At lower doses, CHANTIX produced more frequent reports of gastrointestinal disturbances (nausea, vomiting). At a dose of 2 mg once daily, CHANTIX produced more frequent reports of gastrointestinal disturbances (nausea, vomiting). At higher doses (greater than 2 mg), CHANTIX produced more frequent reports of gastrointestinal disturbances (nausea, vomiting).

- Patients with hepatic impairment: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, monitoring, and dosage adjustment.

- Patients with severe renal impairment: The recommended starting dose of CHANTIX is 0.5 mg once daily. Patients may then titrate as tolerated.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Hot flash, Hypersensitivity, Periorbital edema, Thrombophlebitis.

There have been reports of suicidal ideation, suicide attempt, and completions, suicide attempt in patients attempting to stop smoking while taking CHANTIX. Patients may consider smoking to be a more pleasurable activity than other activities such as exercise or socializing with friends. The possibility of increased risk of suicide should be considered when prescribing CHANTIX for smoking cessation.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.

- Infrequent: Acne, Cervicitis, Eye irritation, Pruritus, Urticaria.
- Rare: Photosensitivity reaction.
Being the market leader of behavioral healthcare hospital services allows Psychiatric Solutions, Inc. to boast a wide variety of partnerships and practice opportunities with our medical staffs. With more than 90 plus locations across the U.S., Puerto Rico and U.S. Virgin Islands, we offer flexibility that is unrivaled in the industry. Whether you are just completing your residency or currently have a successful practice, Psychiatric Solutions, Inc. welcomes the opportunity to explore ways to bring your expertise and leadership to one of our facilities.

Come visit us at **BOOTH #1832** to explore the possibilities we can offer.
Product Theaters will again be held this year during the Annual Meeting. These infomercials are being held as an extension of the exhibit hall. Seating is limited to 200, and is on a first-come basis. They feature promotional programs supported by our exhibitors. CME credit is not provided for these sessions. The 30-minute sessions will be held in Room 231, Level Two of the Morial Convention Center. Sessions will be on Sunday, Monday, and Tuesday with three sessions each day at 8:30 a.m., 9:30 a.m., and 4:00 p.m. Light refreshments will be available. Topics may include treatment management, disease updates, and issues of interest to the supporting company. Supporters of the sessions include Alkermes, Boehringer Ingelheim, Janssen, Merck, Shire US, and Wyeth Legacy. Look for signs announcing the presenters and topics in the Convention Center, exhibit hall, and outside Room 231 and plan to attend.

SUNDAY, MAY 23
SESSIONS

8:30 A.M.
Supported by Shire US Inc.

MANAGING ADHD IN ADULTS BEYOND THE WORKDAY: INSIGHTS AND PERSPECTIVE FROM A LEADING EXPERT

Speaker:
Gregory W. Mattingly, M.D.
Associate Clinical Professor,
Department of Psychiatry Washington University School of Medicine

MONDAY, MAY 24
SESSIONS

8:30 A.M.
Supported by Alkermes

EVIDENCE-BASED MEDICINE FOR THE TREATMENT OF ALCOHOL DEPENDENCE: ASSUMPTIONS VS. REALITIES

Speaker:
Hugh Myrick, M.D.
Associate Professor of Psychiatry,
Service Chief, Center for Drug and Alcohol Programs, Medical University of South Carolina

TUESDAY, MAY 25
SESSIONS

8:30 A.M.
Supported by Wyeth Legacy

DISCUSSIONS IN DEPRESSION: HELPING PATIENTS TOWARD THEIR TREATMENT GOALS

Speaker:
To be announced

9:30 A.M.
Supported by Janssen®,
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

INVEGA SUSTENNA PRODUCT THEATER: RETHINKING SCHIZOPHRENIA MANAGEMENT: A ONCE-MONTHLY MEDICATION OPTION FOR SCHIZOPHRENIA

Speaker:
Henry A. Nasrallah, M.D.
Professor of Psychiatry and Neuroscience,
University of Cincinnati College of Medicine, Cincinnati, Ohio

4:00 P.M.
Supported by Merck

IMPORTANT CLINICAL INFORMATION ABOUT SCHIZOPHRENIA

Speaker:
Steven G. Potkin, M.D.
Professor of Psychiatry and Human Behavior Director of Research, Robert R. Sprague Endowed Chair in Brain Imaging, Director of UCI Brain Imaging Center, University of California

It’s Time to Talk: Recognizing Female Sexual Dysfunction and Diagnosing Hypoactive Sexual Desire Disorder

Speaker:
Raymond C. Rosen, Ph.D.,
Professor, Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, University of Medicine and Dentistry

9:30 AM
Supported by Boehringer-Ingelheim

ABOUT SCHIZOPHRENIA

Speaker:
Raymond C. Rosen, Ph.D.,
Professor, Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, University of Medicine and Dentistry

9:30 AM
Supported by Janssen®,
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

INVEGA SUSTENNA PRODUCT THEATER: RETHINKING SCHIZOPHRENIA MANAGEMENT: A ONCE-MONTHLY MEDICATION OPTION FOR SCHIZOPHRENIA

Speaker:
Henry A. Nasrallah, M.D.
Professor of Psychiatry and Neuroscience,
University of Cincinnati College of Medicine, Cincinnati, Ohio

4:00 PM
Supported by Merck

IMPORTANT CLINICAL INFORMATION ABOUT SCHIZOPHRENIA

Speaker:
Steven G. Potkin, M.D.
Professor of Psychiatry and Human Behavior Director of Research, Robert R. Sprague Endowed Chair in Brain Imaging, Director of UCI Brain Imaging Center, University of California

The First and Last Word in Psychiatry

Visit the APPI Bookstore at the 2010 APA Annual Meeting

Be sure to stop by the APPI bookstore and check out APPI’s latest selections, from the newest textbooks, clinical manuals, journals, and electronic products.

APPI Bookstore Hours
Saturday 10:00 am – 4:00 pm
Sunday 10:00 am – 4:00 pm
Monday 10:00 am – 4:00 pm
Tuesday 10:00 am – 4:00 pm

Extra Special Discount for Members!
15% Discount for APA Members
30% Discount for APA Members-in-Training

Manual of Clinical Psychopharmacology, Seventh Edition
Alan F. Schatzberg, M.D., Jonathan O. Cole, M.D., and Charles DeBattista, D.M.H., M.D.
2010 • 704 pages • ISBN 978-1-58562-377-8
Paperback • $92.00 • Item #62377

Essentials of Neuropsychiatry and Behavioral Neurosciences, Second Edition
Edited by Stuart C. Yudofsky, M.D., and Robert E. Hales, M.D., M.B.A.
2010 • 640 pages • ISBN 978-1-58562-376-1
Paperback • $129.00 • Item #62376

Dulcan’s Textbook of Child and Adolescent Psychiatry
Edited by Mina K. Dulcan, M.D.
Hardcover • $239.00 • Item #62233

Textbook of Anxiety Disorders, Second Edition
Edited by Dan J. Stein, M.D., Ph.D., Eric Holland, M.D., and Barbara O. Rothbaum, Ph.D., A.B.P.P.
Hardcover • $125.00 • Item #62254

Long-Term Psychodynamic Psychotherapy
A Basic Text, Second Edition
Core Competencies in Psychotherapy
Glen O. Gabbard, M.D.
2010 • 233 pages • ISBN 978-1-58562-385-3
Paperback • $65.00 • Item #62385

High-Yield Cognitive-Behavior Therapy for Brief Sessions
An Illustrated Guide
Jesse H. Wright, M.D., Ph.D., Donna M. Sudak, M.D., Douglas Turkington, M.D., and Michael E. Thase, M.D.
2010 • 432 pages • ISBN 978-1-58562-362-4
Paperback • $74.00 • Item #62362

Edited by Robert I. Simon, M.D., and Liza H. Gold, M.D.
Hardcover • $120.00 • Item #62378

Textbook of Pediatric Psychosomatic Medicine
Edited by Richard J. Shaw, M.B., B.S., and David R. DeMasco, M.D.
2010 • 551 pages • ISBN 978-1-58562-350-1
Hardcover • $125.00 • Item #62350

American Psychiatric Publishing, Inc. • www.appi.org
Phone: 1-800-368-5777 • Email: appi@psych.org

Priority code AH1015 } Find us on }
Candidates and Employers Connect through the APA Job Bank

- Visit APA Job Bank booth during the APA Annual Meeting to search the most comprehensive online listing of psychiatric positions and other career resources.

- Use APA Job Bank Conference Connection Tool to connect with prospective employers at the meeting.

- Visit psych.org/jobbank today and get your job posted in time for the meeting.

- Sign up for the Conference Connection and get a chance to win $100 gift card.

- Ask APA Job Bank representatives for a demonstration of the redesigned and enhanced web site features.

- Visit the APA Job Bank today to find the ideal position!
Leadership in Discovery and Service: 21st Century Psychiatry

62nd Institute on Psychiatric Services
October 14–17, 2010

This four-day event will feature more than 200 expertly-led educational sessions on a variety of topics, popular networking events, and exhibits that complement the educational program. Further information can be found on the Web at www.psych.org/IPS.

Who Should Attend?
- All APA members, including early career psychiatrists and psychiatric residents (only $75 for advance registration)
- International psychiatrists
- Physicians
- Mental health professionals from all disciplines

Why Should You Attend?
- To earn CME credit (CEs have also been applied for)
- To improve patient care
- To learn about clinically-focused topics that offer specific skill sets
- To network with colleagues and obtain solutions for the challenges you face
- Because your return on investment will reap both personal and professional rewards

The IPS Has Gone “GREEN”
The Preliminary Program, which includes registration, housing, travel, and detailed program information is available online only at www.psych.org/IPS.

For more information, please contact:
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/IPS

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Institute of Bisexuality, Inc. (AIB) encourages, supports and assists research and education about bisexuality, through programs likely to make a material difference and enhance public knowledge and awareness.

www.bisexual.org

ICANotes
The EMR for The Behavioral Health Profession

Learn How ICANotes Creates, Organizes and Stores Initial Evals, Progress Notes, Treatment Plans and Discharge Summaries With little or no Typing

Thinks Like a Psychiatrist

Runs Like a Dream!

Free Test Drives
Booth 1736

www.icanotes.com
866-847-3590

GLOBAL DISASTERS FORUM
Lessons Learned From Chile, Haiti, and New Orleans

APA’s 2010 ANNUAL MEETING
NEW ORLEANS
Tuesday, May 25th, 2010
3:30 p.m. - 5:30 p.m.

Morial Convention Center
Third Level 343/344/345

Chairs: Eliot Sorel, M.D., and Karen DeSalvo, M.D.

Presentors: General Russel L. Honoré (Ret.), Jean Luc Poncelet, M.D., Ben Sppringate, M.D.

The Global Disasters Forum at the annual APA meeting in New Orleans, an APA, WPA, PAHO/WHO collaborative, addresses the multidimensional aspects of disasters’ response including: preparedness & mitigation, logistics/coordinaton, search and recovery, complex emergencies responses; systemic integration of surgical/medical, mental health, public health interventions; the continued assistance toward infrastructure revival, recovery and resumed societal functioning across systems. Field presentations with a focus on Chile, Haiti & New Orleans illustrate the challenges and opportunities for systemic responses and effective models of primary care, mental health & public health integration. The Forum will provide a robust dialogue between and among the audience and the panelists following the panelists' stimulus presentations.

www.psych.org
# Alphabetical List of Exhibitors

**Exhibitors as of April 16, 2010**

## A

<table>
<thead>
<tr>
<th>Company/Association</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>15th World Congress of Psychiatry</td>
<td>14</td>
</tr>
<tr>
<td>ACIGI Relaxation/Fujiiryoki</td>
<td>2302</td>
</tr>
<tr>
<td>Alcoholics Anonymous</td>
<td>1234</td>
</tr>
<tr>
<td>Alkermes, Inc.</td>
<td>1815, 2214</td>
</tr>
<tr>
<td>All Star Recruiting</td>
<td>2001</td>
</tr>
<tr>
<td>Allina Hospitals and Clinics</td>
<td>2009</td>
</tr>
<tr>
<td>American Academy of Psychiatry and the Law</td>
<td>922</td>
</tr>
<tr>
<td>American Association for Geriatric Psychiatry</td>
<td>227</td>
</tr>
<tr>
<td>American Association of Community Psychiatrists</td>
<td>1021</td>
</tr>
<tr>
<td>American Board of Psychiatry and Neurology, Inc.</td>
<td>919</td>
</tr>
<tr>
<td>American College of Psychiatrists</td>
<td>917</td>
</tr>
<tr>
<td>American Express® OPEN</td>
<td>737</td>
</tr>
<tr>
<td>American Physician Institute for Advanced Professional Studies</td>
<td>824</td>
</tr>
<tr>
<td>American Professional Agency, Inc.</td>
<td>2412</td>
</tr>
<tr>
<td>American Psychological Association</td>
<td>1636</td>
</tr>
<tr>
<td>ANT - Advanced Neuro Technology</td>
<td>2335</td>
</tr>
<tr>
<td>Army Healthcare Recruiting</td>
<td>2012</td>
</tr>
<tr>
<td>ASPMD, Inc.</td>
<td>2403</td>
</tr>
<tr>
<td>Association of Gay and Lesbian Psychiatrists</td>
<td>932</td>
</tr>
<tr>
<td>Association of Women Psychiatrists</td>
<td>1023</td>
</tr>
<tr>
<td>AssureRx Health</td>
<td>2332</td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals</td>
<td>416</td>
</tr>
<tr>
<td>Atlantic Coastal Supply, Inc.</td>
<td>1835</td>
</tr>
<tr>
<td>Austen Riggs Center</td>
<td>1722</td>
</tr>
<tr>
<td>Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail</td>
<td>2212</td>
</tr>
<tr>
<td>Avanir Pharmaceuticals, Inc.</td>
<td>538</td>
</tr>
</tbody>
</table>

## B

<table>
<thead>
<tr>
<th>Company/Association</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bassett Healthcare Network - Bassett Medical Center</td>
<td>1904</td>
</tr>
<tr>
<td>BHR Corporation</td>
<td>1806</td>
</tr>
<tr>
<td>BioBehavioral Diagnostics Company</td>
<td>2413</td>
</tr>
<tr>
<td>BioMed Central</td>
<td>1538</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>818</td>
</tr>
<tr>
<td>Borgess Health</td>
<td>2002</td>
</tr>
<tr>
<td>bp Magazine/esperanza</td>
<td>2134</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company/ Otsuka America Pharmaceutical, Inc.</td>
<td>1032</td>
</tr>
</tbody>
</table>

## C

<table>
<thead>
<tr>
<th>Company/Association</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambridge University Press</td>
<td>1533</td>
</tr>
<tr>
<td>Cannon Design</td>
<td>328</td>
</tr>
<tr>
<td>CareerStaff Unlimited</td>
<td>215</td>
</tr>
<tr>
<td>CBR Youth Connect</td>
<td>326</td>
</tr>
<tr>
<td>The Center for Eating Disorders at Sheppard Pratt</td>
<td>1717</td>
</tr>
<tr>
<td>Center for Family Guidance (CFG) Health Network</td>
<td>2006</td>
</tr>
<tr>
<td>Christian Medical Association, Psychiatry Section</td>
<td>936</td>
</tr>
<tr>
<td>Clinical Psychiatry News</td>
<td>720</td>
</tr>
<tr>
<td>CNS Response, Inc.</td>
<td>1825</td>
</tr>
<tr>
<td>CNS Vital Signs</td>
<td>827</td>
</tr>
<tr>
<td>CompHealth</td>
<td>2109</td>
</tr>
<tr>
<td>Correctional Medical Services</td>
<td>2304</td>
</tr>
<tr>
<td>Current Psychiatry/Quadrant Healthcom</td>
<td>1620</td>
</tr>
</tbody>
</table>

## D

<table>
<thead>
<tr>
<th>Company/Association</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSP/Sepracor Inc.</td>
<td>2102</td>
</tr>
<tr>
<td>Defense Centers of Excellence (DCOE) for Psychological Health and Traumatic Brain Injury</td>
<td>2405</td>
</tr>
</tbody>
</table>

163rd Annual Meeting 183
## ALPHABETICAL LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>Exhibit Order</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1804</td>
<td>Department of Veterans Affairs</td>
</tr>
<tr>
<td>2210</td>
<td>Dey Pharma, L.P.</td>
</tr>
<tr>
<td>2312</td>
<td>Doctors Behavioral Health Center</td>
</tr>
<tr>
<td>2011</td>
<td>Duluth Clinic</td>
</tr>
<tr>
<td>12</td>
<td>ECNP Congress - European College of Neuropsychopharmacology</td>
</tr>
<tr>
<td>815</td>
<td>Electromedical Products International, Inc.</td>
</tr>
<tr>
<td>1429</td>
<td>Elsevier</td>
</tr>
<tr>
<td>2313</td>
<td>EMR-BEAR, LLC</td>
</tr>
<tr>
<td>2233</td>
<td>EXHIBITCHEK</td>
</tr>
<tr>
<td>2113</td>
<td>Favorite Physicians</td>
</tr>
<tr>
<td>2136</td>
<td>FDA/Division of Drug Marketing, Advertising, and Communications</td>
</tr>
<tr>
<td>1238</td>
<td>Fisher Wallace Laboratories</td>
</tr>
<tr>
<td>1905</td>
<td>Floyd Behavioral Health Center</td>
</tr>
<tr>
<td>2103</td>
<td>Forefront Behavioral Telecare</td>
</tr>
<tr>
<td>434</td>
<td>Forest Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>1837</td>
<td>Genesis Healthcare System</td>
</tr>
<tr>
<td>1810</td>
<td>Global Medical Staffing</td>
</tr>
<tr>
<td>1933</td>
<td>Gould Farm</td>
</tr>
<tr>
<td>2311</td>
<td>Group Health Permanente</td>
</tr>
<tr>
<td>1534</td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>2105</td>
<td>Haven Behavioral Healthcare</td>
</tr>
<tr>
<td>1902</td>
<td>Health Match BC</td>
</tr>
<tr>
<td>1912</td>
<td>HealthForceOntario Marketing and Recruitment Agency</td>
</tr>
<tr>
<td>1650</td>
<td>Hogrefe Publishing</td>
</tr>
<tr>
<td>2010</td>
<td>Hospital Corporation of America (HCA)</td>
</tr>
<tr>
<td>1736</td>
<td>ICANotes</td>
</tr>
<tr>
<td>1435</td>
<td>Intellisphere, LLC</td>
</tr>
<tr>
<td>1823</td>
<td>INTERIM PHYSICIANS</td>
</tr>
<tr>
<td>1910</td>
<td>INTERNATIONAL MEDICAL RECRUITMENT</td>
</tr>
<tr>
<td>826</td>
<td>INTERNATIONAL PSYCHOGERIATRIC ASSOCIATION (IPA)</td>
</tr>
<tr>
<td>1802</td>
<td>JACKSON &amp; COKER</td>
</tr>
<tr>
<td>733</td>
<td>JANSSEN, DIVISION OF ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.</td>
</tr>
<tr>
<td>1430</td>
<td>Johns Hopkins University Press</td>
</tr>
<tr>
<td>1629</td>
<td>JONES &amp; BARTLETT</td>
</tr>
<tr>
<td>2005</td>
<td>Kaiser Permanente</td>
</tr>
<tr>
<td>1726</td>
<td>Karger Publishers</td>
</tr>
<tr>
<td>2306</td>
<td>KIWIS STAT</td>
</tr>
<tr>
<td>634</td>
<td>The Litebook Company Ltd.</td>
</tr>
<tr>
<td>1729</td>
<td>LocumTenens.com</td>
</tr>
<tr>
<td>425</td>
<td>LA LETTRE DU PSYCHIATRE</td>
</tr>
<tr>
<td>828</td>
<td>Lexicor Medical Technology, LLC</td>
</tr>
<tr>
<td>734</td>
<td>Lilly USA, LLC</td>
</tr>
<tr>
<td>1616</td>
<td>Lippincott Williams &amp; Wilkins, Wolters-Kluwer</td>
</tr>
<tr>
<td>634</td>
<td>THE LITEBOOK COMPANY LTD.</td>
</tr>
<tr>
<td>2411</td>
<td>Little Hill – Alina Lodge</td>
</tr>
<tr>
<td>2206</td>
<td>LA AMISTAD FOUNDATION, INC., LAKEWOOD CENTER</td>
</tr>
<tr>
<td>425</td>
<td>Lexicor Medical Technology, LLC</td>
</tr>
<tr>
<td>1616</td>
<td>Lippincott Williams &amp; Wilkins, Wolters-Kluwer</td>
</tr>
<tr>
<td>2411</td>
<td>Little Hill – Alina Lodge</td>
</tr>
<tr>
<td>1729</td>
<td>LocumTenens.com</td>
</tr>
</tbody>
</table>
M

The Magstim Company Limited ........................................ 726
MagVenture A/S .............................................................. 2138
Massachusetts General Hospital Academy ................................ 2310
Maxim Physician Resources ............................................. 419
Mayo Clinic ................................................................. 925
MBL Communications, Inc ................................................ 1730
McLean Hospital ............................................................ 1735
MECTA Corporation ....................................................... 716
Medical Associates Clinic ............................................... 1901
Medical Billing Professionals .......................................... 1337
Medical Doctor Associates .............................................. 1738
MedNet Technologies, Inc ............................................... 320
The Menninger Clinic .................................................... 2235
MentalNote ................................................................. 633
Merck .............................................................................. 2216, 2314
Merrill Lynch ................................................................. 2237
MHM Services, Inc ........................................................ 1236
Ministry Health Care ...................................................... 1814

N

NARSAD and NARSAD Artworks .................................... 938
National Death Index ..................................................... 534
National Institute of Mental Health ................................ 1025
National Institute on Alcohol Abuse and Alcoholism (NIAAA) ........................................................................ 1031
National Institute on Drug Abuse (NIDA) .......................... 1033
Nature Publishing Group ............................................... 1331
Netsmart Technologies .................................................. 2303
Neuronetics, Inc ............................................................ 224
NewYork-Presbyterian Hospital ...................................... 316
The New York Times ...................................................... 1632
North Carolina Office of Rural Health .............................. 1911

P

Northern Light Technologies ........................................... 816
Novartis Pharmaceuticals .............................................. 638, 1716, 2101, 2301

Q

Oregon State Hospital .................................................... 1906
Oxford University Press ................................................ 1330

R

Pamlab, LLC .................................................................... 415
Pfizer, Inc. ......................................................................... 1816
Philips Consumer Lifestyle ............................................ 1838
Physician Finders .......................................................... 2429
Physicians for a National Health Program ..................... 923
Pikes Peak Behavioral Health Group .............................. 2404
Pine Rest Christian Mental Health Services .................... 2013
PracticeFusion .............................................................. 217
PracticeLink.com ........................................................... 1913
Psychiatric Solutions, Inc .............................................. 1832
Psychiatric Times .......................................................... 1821
Psychiatrists Only, LLC .................................................. 915
The Psychiatrists’ Program .......................................... 916
QTC Medical Services .................................................. 825
Rapid Psychler Press ...................................................... 1336
The Reading Hospital and Medical Center ........................ 2309
Reckitt Benckiser Pharmaceuticals .................................. 2330
Registry of Physician Specialists .................................. 1724
RiverValley Behavioral Health ....................................... 819
Robert Young Center for Community Mental Health ........ 2003
Rosenrance Health Network .......................................... 636
Routledge ....................................................................... 1438
Routledge Journals ............................................................. 1434
Royal College of Psychiatrists ......................................... 1530
RVJ International LLC / Happy Feet, Inc. ......................... 324

Secure TeleHealth ......................................................... 223
Sepracor Inc. ................................................................. 2110
Sheppard Pratt Health System ........................................ 1715
Shire Pharmaceuticals .................................................... 216
Singing River Hospital
Behavioral Health Services ............................................. 1909
Skyland Trail ................................................................. 724
Social Security Administration ........................................ 2204
Sociedad Espanola de
Patologia Dual (SEPDA) ................................................ 11 (in lobby)
Somatics LLC ................................................................. 728
SOS Programs & Parents Press ........................................ 1633
Spartanburg Regional ...................................................... 2004
Staff Care, Inc. ............................................................... 924
Substance Abuse and Mental Health Services Administration (SAMHSA) ........................................... 926
SuiteMed, LLC ............................................................... 2305
SZ Magazine ................................................................. 1931

TEVA Pharmaceuticals ................................................... 1723
TheraManager LLC ....................................................... 1719
The TOVA Company .................................................... 221

U.S. Army Civilian Corps ............................................... 1903
U.S. Department of State, Office of Medical Services ..................................................... 1812
U.S. Navy Recruiting ....................................................... 2202
U.S. Public Health Service ............................................ 2409
Uplift Technologies Inc. .................................................. 423

VA Northwest Health Network ....................................... 2111
Valant Medical Solutions .............................................. 823
Validus Pharmaceuticals, LLC ........................................ 2230
VISTA Staffing Solutions, Inc. ......................................... 1232

W.W. Norton ................................................................. 1529
Wiley - Blackwell ......................................................... 1624
World Association for Social Psychiatry ................................ 13 (in lobby)
To gain your free access, register your details at the Cambridge University Press stand.

*this offer is available to a limited number of recipients

---

**New from Routledge**

American Psychiatric Association 2010 Annual Meeting

**Get the Diagnosis Right**

by Jerome S. Blackman

978-0-415-80155-3 - 265 pp.

“This book is an excellent addition to Dr. Blackman’s previous 101 Defenses. Get the Diagnosis Right is characterized by a broad knowledge of the psychoanalytic literature, extensive references, and an exceptional capacity to convey difficult concepts on the dynamic understanding of psychopathology and therapeutic approaches with ease and a touch of humor.” - Cecilio Paniagua, MD, ScD, Madrid

---

Routledge Mental Health is pleased to offer a 20% discount and free shipping to attendees at our booth, #1438!

For more information on this and all of our titles, visit www.routledgementalhealth.com

---

The Johns Hopkins University Press

**Addiction and Art**

edited by Patricia B. Santoro, Margaret L. Dowell, and Jack E. Henningfield

$29.95 hardcover

**The Yipping Tiger and Other Tales from the Neuropsychiatric Clinic**

Perminder Sachdev, M.D.

$24.95 hardcover

**Developmental Disabilities from Childhood to Adulthood**

What Works for Psychiatrists in Community and Institutional Settings

edited by Roxanne C. Dryden-Edwards, M.D., and Lee Combrinck-Graham, M.D.

$65.00 hardcover

**Practical Plans for Difficult Conversations in Medicine**

Strategies That Work in Breaking Bad News

Robert Buckman, M.D., Ph.D.

$30.00 paperback

**Trouble in Mind**

An Unorthodox Introduction to Psychiatry

Dean F. MacKinnon, M.D.

$25.00 paperback

**Psychiatric Consultation in Long-Term Care**

A Guide for Health Care Professionals

Abhijit K. Desai, M.D., FAPA, and George T. Grossberg, M.D.

$70.00 hardcover

**Happy Pills in America**

From Miltown to Prozac

David Herzberg

$30.00 paperback

---

We are pleased to announce that PROFESSOR SIR MICHAEL RUTTER is the 2010 recipient of the C. CHARLES BURLINGAME, M.D. AWARD for his outstanding contributions to psychiatry.

Past Recipients

1988 Robert Keller, M.D., Ph.D.
1989 William T. Carpenter, Jr., M.D.
1990 Dennis P. Cantwell, M.D.
1991 George E. Vaillant, M.D.
1992 A. John Rush, M.D.
1993 John C. Nemiah, M.D.
1994 Maurice J. Martin, M.D.
1995 Otto F. Kernberg, M.D.
1996 Charles P. O’Brien, M.D., Ph.D.
1997 Glen O. Gabbard, M.D.
1998 Lissy F. Jarvik, M.D., Ph.D.
1999 Nancy C. Andreasen, M.D., Ph.D.
2000 Lewis L. Judd, M.D.
2001 Paul S. Appelbaum, M.D.
2002 Charles B. Nemeroff, M.D., Ph.D.
2003 Dipil V. Jose, M.D.
2004 David H. Barlow, Ph.D.
2005 Herbert D. Kleber, M.D.
2006 Daniel N. Stern, M.D.
2007 Jerrold F. Rosenbaum, M.D.
2008 K. Ranga Rama Krishnan, M.D.
2009 David J. Kupfer, M.D.

---

200 Retreat Avenue
Hartford, CT 06106
1-800-673-2411
NewYork-Presbyterian Psychiatry provides a full continuum of expert diagnosis and treatment services for adults, adolescents and children with psychiatric, behavioral and emotional problems.

Accomplished specialists in psychiatry, psychopharmacology, clinical psychology and neurology work together to provide the highest quality of care, incorporating the most recent clinical and scientific advances. With proper diagnosis and treatment, every mental health condition can be effectively addressed.

The psychiatric services of NewYork-Presbyterian Hospital are ranked among the nation’s best by U.S. News & World Report®.

To make a referral or for further information, please call:
Columbia Psychiatry (212) 305-6001
Weill Cornell Psychiatry (888) 694-5700

Visit us at Booth #316

www.nyppsychiatry.org
The 15th World Congress of Psychiatry will take place on September 18-22, 2011 in Buenos Aires, Argentina. For more information go to our website: <www.wpa-argentina2011.com.ar>

ACIGI RELAXATION/FUJIIRYOKI
4399 Ingot Street
Fremont, CA 94538
(Booth 2302)

With over 55 years in the Medical Cyber Relax Massage Chair industry, Fujiiryoki developed professional techniques that remove accumulated strain even in your brain. The extreme mechanisms exquisite comfort approaches the deep, powerful, and pliant touch of real hands. Fuji helps massage and squeeze away tension, pain, and stress.

ALCOHOLICS ANONYMOUS
475 Riverside Drive, 11th Floor
New York, NY 10115
(Booth 1234)

Alcoholics Anonymous is a fellowship of men and women who have found a solution to their drinking problem. The only requirement for membership is a desire to stop drinking. There are no dues or fees; A.A. is supported by voluntary contributions of its members, neither seeking nor accepting outside funding. Our members observe personal anonymity at the public level.

ALKERMES, INC.
852 Winter Street
Cambridge, MA 02139
(Booths 1815, 2214)

Alkermes, Inc., is a fully integrated biotechnology company that uses proprietary technologies and know-how to create innovative medicines designed to yield better therapeutic outcomes for patients with serious disease, including alcohol dependence and other CNS disorders. For more information about Alkermes, please visit: <www.alkermes.com>. Please visit us at booths #1815 and #2214.

AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
One Regency Drive
Bloomfield, CT 06002
(Booth 922)

The American Academy of Psychiatry and the Law (APPL) is the association for members of the APA who are interested in the interface of psychiatry and the law. The purpose of this exhibit is to introduce attendees to the Academy and acquaint them with the advantage of membership.

AMERICAN ASSOCIATION FOR GERIATRIC PSYCHIATRY
7910 Woodmont Avenue, Suite 1050
Bethesda, MD 20814
(Booth 227)

AGP is dedicated to serving its membership of geriatric psychiatrists and mental health professionals who work to improve the quality of life for older people with mental disorders. Members of AAGP's Board of Directors will be staffing our booth so stop by to meet our elected officials and learn about AAGP's services, products, and conferences. Join us at AAGP's 2011 Annual Meeting in San Antonio, TX.
AAMERICAN ASSOCIATION OF COMMUNITY PSYCHIATRISTS
P.O. Box 570218
Dallas, TX 75357
(Booth 1021)

The American Association of Community Psychiatrists (AACP) exhibit will present information for members and prospective members, including educational materials pertaining to the field of community psychiatry.

AAMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.
2150 E. Lake Cook Road, Suite 900
Buffalo Grove, IL 60089
(Booth 919)

The American Board of Psychiatry and Neurology (ABPN) serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and maintenance of certification processes for psychiatry, addiction psychiatry, child and adolescent psychiatry, forensic psychiatry, geriatric psychiatry, hospice and palliative medicine, pain medicine, psychosomatic medicine, and sleep medicine. Please visit the ABPN booth for answers to your questions.

AAMERICAN COLLEGE OF PSYCHIATRISTS
122 South Michigan Avenue, Suite 1360
Chicago, IL 60603
(Booth 917)

The American College of Psychiatrists is an honorary psychiatric association. The College develops and administers PRITE (for psychiatry residents) and PIPE, an online preparatory tool for recertification that also fulfills ABPN's self-assessment requirement.

AAMERICAN EXPRESS® OPEN
200 Vessey Street
New York, NY 10285
(Booth 737)

American Express® Business Cards give you automatic access to the tools and resources that American Express OPEN has to offer, including benefits that can help you save money, gain control over your practice expenses, earn valuable rewards and much more.

AAMERICAN PHYSICIAN INSTITUTE FOR ADVANCED PROFESSIONAL STUDIES
125 Windsor Drive, Suite 111
Oak Brook, IL 60523
(Booth 824)

The American Physician Institute provides comprehensive, guaranteed board preparation and medical education courses. For free study materials and for complete course listings and information, visit our website: <www.AmericanPhysician.com>.

AAMERICAN PROFESSIONAL AGENCY, INC.
95 Broadway
Amityville, NY 11701
(Booth 2412)

Please visit the American Professional Agency, Inc., exhibit for more information about their products and services that will be of interest to you.

AAMERICAN PSYCHOLOGICAL ASSOCIATION
750 First Street, N.E.
Washington, DC 20002
(Booth 1636)

American Psychological Association (APA) is the premier source for information in psychology. APA delivers this information through their expansive collection of books, journals, newsletters, electronic products, and on their website at <www.apa.org>.

AANT - ADVANCED NEURO TECHNOLOGY
Colosseum 22
7521 PT Enschede, The Netherlands
(Booth 2335)

ANT- Advanced Neuro Technology is introducing Cognitrace, a comprehensive system for recording, analysis, and reporting of EEG and cognitive evoked potentials. It integrates high-quality data recording, online analysis, and reporting. Cognitrace provides EEG, AEP, VER P300, CNV, and other protocols that may be used with psychiatric disorders like schizophrenia, memory deficit, depressions, attention deficit, and alcoholism.

AARMY HEALTHCARE RECRUITING
Building 1307, 1307 Third Avenue
Fort Knox, KY 40121
(Booth 2012)

The U.S. Army Medical Corps has a variety of dynamic opportunities available for talented doctors to serve their country. Visit the Army Medical Corps booth to learn more about full-time positions in the Army or part-time positions in the Army Reserves.

AASPMD, INC.
229 Third Street
Cambridge, MA 02142
(Booth 2403)

Developers of AMOS – totally web-based practice management and EHR, with no upfront costs and lower monthly fees than our competitors, AMOS offers more for less. AMOS + Stimulus = EHR in your office, and $35,000 cash in your pocket. AMOS was designed by a physician, for a physician.

AASSOCIATION OF GAY AND LESBIAN PSYCHIATRISTS
4514 Chester Avenue
Philadelphia, PA 19143
(Booth 932)

The Association of Gay and Lesbian Psychiatrists (AGLP) is a professional organization of psychiatrists, psychologists in training, and other mental health professionals, which
serves as a voice for the concerns of lesbian, gay, bisexual, and transgendered (LBT) people within the psychiatric community. The Association is committed to fostering a more accurate understanding of sexual orientation and gender identity, opposing discriminatory practices against LBT people, and promoting supportive, well informed mental health treatment for LBT patients. The organization provides opportunities for affiliation and collaboration among people who share these concerns. Please visit the AGLP exhibit booth #932 to learn more about our mission, advocacy, and membership opportunities.

ASSOCIATION OF WOMEN PSYCHIATRISTS
P.O. Box 570218
Dallas, TX 75357-0218
(Booth 1023)

The Association of Women Psychiatrists (AWP) is a national organization of women psychiatrists working to: 1) form a national and international network of women psychiatrists; 2) improve communication and provide support to women psychiatrists; 3) promote women psychiatrists into leadership positions in all aspects of health care; 4) encourage and support activities and research in women's mental health issues; 5) advocate for just legislation for women; 6) encourage women psychiatrists to actively participate in the APA, both locally and nationally; and 7) influence the policy and procedures of the APA so it meets the needs of women. AWP maintains active liaison relationships with the Committee on Women under the APA Council on National Affairs and the APA Women's Caucus, providing representation in the APA Assembly.

ASSURERX HEALTH
(Booth 2332)

Please visit the AssureRx Health exhibit for more information about their products and services that will be of interest to you.

ASTRAZENECA PHARMACEUTICALS
1800 Concord Pike
Wilmington, DE 19850
(Booth 416)

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology, and neuroscience products. Please stop by exhibit booth #416 for further information.

ATLANTIC COASTAL SUPPLY, INC.
4539 U.S. Highway 13
Greenville, NC 27834
(Booth 1835)

The Versi-Shower is a risk reducing addition to your facility and will pay for itself in water savings in just a few years and reduces the risk of suicide which will help reduce liability issues for your facility. Please visit the Atlantic Coastal Supply, Inc. exhibit for more information on the Suicide Resistant In Line Shower Unit.

AUSTEN RIGGS CENTER
25 Main Street, P.O. Box 962
Stockbridge, MA 01262
(Booth 1722)

The Austen Riggs Center is a nonprofit, hospital-based continuum of care center offering intensive psychotherapy in a fully open therapeutic community setting. The Austen Riggs Center is a national referral center for treatment of refractory patients and is located on Main Street in Stockbridge, Massachusetts, two and one-half hours from Boston and three hours from New York City.

AUSTIN LAKES HOSPITAL
TEXAS NEURO REHAB AND HICKORY TRAIL
1025 East 32nd Street
Austin, TX 78705
(Booth 2212)

Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail are part of the psychiatric solutions family of hospitals. These three facilities are located in Central and North Texas and provide comprehensive psychiatric services for children, adolescents, adults and older adults. The Texas Neuro Rehab campus also houses a neurobehavioral program as well as chemical dependency treatment.

AVANIR PHARMACEUTICALS, INC.
101 Enterprise, Suite 300
Aliso Viego, CA 92656
(Booth 538)

Please visit the Avanir Pharmaceuticals, Inc. exhibit for more information about their products and services that will be of interest to you.
BHR Corporation
5674 Stoneridge Drive, Suite 116
Pleasanton, CA 94588
(Booth 1806)

BHR Corporation is an 11-year old behavioral healthcare management company. We provide psychiatric medication management and therapy services to medical groups, hospitals, county and state facilities, and commercial health care companies nationwide. Our services also include physician recruitment and management, clinical consultation, billing, intake, utilization management, appeals writing, strategic management, and mental health training. Visit and submit your CV through <www.bhrcorp.org>.

BioBehavioral Diagnostics Company
239 Littleton Road, Suite 6A
Westford, MA 01886
(Booth 2413)

BioBehavioral Diagnostics Company is the developer of the Quotient™ ADHD system which measures motion and attention state to given an objective, clear picture of ADHD.

BioMed Central
Floor 6, 236 Gray’s Inn Road
London, WC1X 8HL, United Kingdom
(Booth 1538)

BioMed Central is the open access publisher committed to the free widespread dissemination of scientific research. BioMed Central publishes over 200 peer-reviewed, open access journals, including a range of psychiatry journals. All original research articles published are immediately and permanently available online without charge or any other barriers to access. Visit our booth to learn more about the journals and the benefits of open access publishing.

Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield, CT 06877
(Booth 818)

Boehringer Ingelheim Pharmaceuticals, Inc., the U.S. subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 47 countries with approximately 39,800 employees. The company is committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

bp Magazine/esperanza
374 Delaware Avenue, #302
Buffalo, NY 14202
(Booth 2134)

bp Magazine/esperanza are quarterly publications tailored to the unique interests and needs of people living with bipolar disorder, anxiety, and/or depression. Both magazines deliver cutting-edge research and news and are packed with in-depth features and real-life profiles to serve up as inspiration to consumers and their extended communities. bp Magazine/esperanza are distributed to psychiatrists' offices, consumer associations, and individual and bulk subscribers.

Borgess Health
1521 Gull Road
Kalamazoo, MI 49048
(Booth 2002)

Borgess Medical Center is a 424-bed teaching hospital and Level 1 trauma center providing nationally recognized cardiac and neuro care with advanced capabilities in multiple specialties. Located in Kalamazoo, Michigan, Borgess offers a complete continuum of services to 1.1 million people living in 11 counties in southwest and south central Michigan.

Bristol-Myers Squibb Company/Onsuka America Pharmaceutical, Inc.
777 Scudders Mill Road
Plainboro, NJ 08536
(Booth 1032)

Bristol-Myers Squibb welcomes you to New Orleans. We invite you to visit our exhibit and welcome you the opportunity to meet our representatives to discuss the products and services we have to offer.

Cannon Design
2170 Whitehaven Road
Grand Island, NY 14072
(Booth 328)

Cannon Design is ranked among the leading international firms in planning and design for healthcare science and technology, education, sports and recreation, and government clients. At present, the firm employs a staff of over 1,000, delivering services in 17 offices throughout North America, as well as abroad in Shanghai, China, and Mumbai, India.

CareerStaff Unlimited
6191 North State Highway 161, Suite 650
Irving, TX 75038
(Booth 215)

CareerStaff is one of the nation's leading providers of temporary and permanent healthcare staff, combining the resources of a national staffing service with the personal
touch of a local agency. CareerStaff offers rewarding career opportunities for healthcare professionals who want to combine exciting travel, personal growth, and professional excellence. Locum tenens or a long-term placement, CareerStaff can help you meet your career and lifestyle goals.

**CBR YOUTH CONNECT**
28071 Highway 109
LaJunta, CO 81050
(Booth 326)

CBR YouthConnect (CBRYC) is a national residential treatment facility that provides mental health services and education to at-risk boys, ages 10 to 21. Located on 340-acres, CBRYC serves youth who have coexisting psychiatric, behavioral, and educational problems that prevent them from successfully functioning at home. CBRYC’s mission is to achieve excellence in providing troubled youth with the means to become hopeful and productive citizens.

**THE CENTER FOR EATING DISORDERS AT SHEPPARD PRATT**
(Booth 1717)

The Center for Eating Disorders at Sheppard Pratt offers a comprehensive continuum of treatment services for adults, adolescents, and children with complex eating disorders. The continuum provides inpatient, day hospital, intensive outpatient services, and ongoing outpatient treatment, and boasts a team of more than 20 multi-disciplinary professionals with specialized experience. The program is designed to respond to both the psychiatric and medical aspects of eating disorders, with a comprehensive array of mental health and consultative medical reports.

**CENTER FOR FAMILY GUIDANCE (CFG) HEALTH NETWORK**
765 East Route 70, Suite A100
Marlton, NJ 08053
(Booth 2006)

CFG Health System, LLC, is a comprehensive, physician-owned and operated, broad-based organization dedicated to providing quality, state-of-the-art, mental health services. These services are based upon a set of core beliefs: dignity, respect, and value of the individuals placed in our care. CFG recognizes the importance of multidisciplinary, multimodal treatment which addresses the physical, emotional and social needs of the individual. Please visit with us and learn of our innovation approach in patient care.

**CHRISTIAN MEDICAL ASSOCIATION, PSYCHIATRY SECTION**
P.O. Box 33795
Decatur, GA 30033
(Booth 936)

The Christian Medical Association is part of the larger Christian Medical and Dental Associations (CMDA), a 15,000 member organization providing resources, networking, education, and a public voice for Christian healthcare professionals and students. The Psychiatry Section offers a forum for the interface of psychiatric practice and the Christian faith. APA participants are welcome to attend our concurrent programs. Visit <www.cmda.org/psychiatry> for more information.

**CLINICAL PSYCHIATRY NEWS**
60-B Columbia Road
Morristown, NJ 07960
(Booth 720)

Clinical Psychiatry News is an independent newspaper that provides the practicing psychiatrist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician’s practice.

**CNS RESPONSE, INC.**
85 Enterprise, Suite 410
Aliso Viejo, CA 92656
(Booth 1825)

CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient’s brain waves and compare the results to an extensive patient outcomes database. The process produces an rEEG* report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient’s own brain physiology. To read more about the benefits this patented technology provides physicians, patients, and insurers, please visit the CNS Response website, <www.cnsresponse.com>.

**CNS VITAL SIGNS**
1829 Franklin Street
Chapel Hill, NC 27514
(Booth 827)

CNS Vital Signs is a world leader in the design and development of neurocognitive assessment tools. CNS Vital Signs gives practicing clinicians and researchers assessment platforms that provide the ability to detect subtle cognitive deficits while creating a baseline of cognitive function (measure) and track subtle cognitive changes (monitor).

**COMPHEALTH**
6440 South Millrock Dr., Suite 175
Salt Lake City, UT 84121
(Booth 2109)

CompHealth is one of the largest providers of healthcare staffing and recruiting services. For 30 years, we have offered physicians more locum tenens and permanent placement opportunities in more locations nationwide. Contact us about opportunities in your specialty. Call (800) 453-3030 or visit <www.comphealth.com/physician>.

**CORRECTIONAL MEDICAL SERVICES**
(Booth 2304)

Please visit the Correctional Medical Services exhibit for more information about their products and services that will be of interest to you.

**CURRENT PSYCHIATRY/QUADRANT HEALTH.COM**
7 Century Drive, Suite 302
Parsippany, NJ 07054
(Booth 1620)

Sign up for a complimentary subscription to Current Psychiatry and learn more about the publication. Edited by Henry A. Nasrallah, M.D., Current Psychiatry provides peer-
reviewed, up-to-date practical advice by leading authorities emphasizing solutions to commonly seen clinical problems. In just eight years, this publication has become one of the leading journals among psychiatric practitioners. Published as an educational partnership with the University of Cincinnati, Department of Psychiatry, this journal is free to psychiatric practitioners who provide patient care, as well as residents and faculty members (U.S. only). Please visit <www.CurrentPsychiatry.com> for additional information.

DSP/SEPRACOR INC
84 Waterford Drive
Marlborough, MA 01752
(Booth 2102)

Dainippon Sumitomo Pharma Co., Ltd., (DSP) is a multi-billion dollar Japanese company with a diverse portfolio of pharmaceuticals, animal health, food, and specialty products. In 2009, Sepracor Inc. became an indirect, wholly-owned U.S. subsidiary of DSP. Sepracor has several marketed products, including Lunesta® brand eszopiclone. The DSP-Sepracor U.S. pharmaceutical candidate pipeline is focused principally in the central nervous system and respiratory areas. Visit <www.sepracor.com>.

DEFENSE CENTERS OF EXCELLENCE (DCOE) FOR PSYCHOLOGICAL HEALTH AND TRAUMATIC BRAIN INJURY
1401 Wilson Boulevard, Suite 400
Arlington, VA 22209
(Booth 2405)

Please visit the Defense Centers of Excellence (DCOE) exhibit for more information about their products and services that will be of interest to you.

DEPARTMENT OF VETERANS AFFAIRS (HRRO)
1555 Poydras Street, Suite 1971
New Orleans, LA 70112
(Booth 1804)

The Department of Veterans Affairs (HRRO) is focused on recruiting healthcare professionals and students throughout the U.S. to provide the best care for our nation’s veterans. Promoting a diverse workforce and offering a wide array of employment benefits, scholarships and retention initiatives, the VA truly is a leader in our nation’s health care industry. Join VA - Best Care - Best Careers.

DEY PHARMA, L.P.
110 Allen Road, 4th Floor
Basking Ridge, NJ 07920
(Booth 2210)

Dey Pharma, L.P., a subsidiary of Mylan, Inc., (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing, and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions, and psychiatric disorders. The company puts patients first and facilitates effective partnerships with customers.

DOCTORS BEHAVIORAL HEALTH CENTER
(Booth 2312)

Please visit the Doctors Behavioral Health Center exhibit for more information about their products and services that will be of interest to you.

DULUTH CLINIC
400 East Third Street
Duluth, MN 55805
(Booth 2011)

We are searching for an adult and child/adolescent psychiatrist for the Duluth Clinic, part of the SMDC Health System, with 400+ physicians, a multi-specialty group, with 17 locations and 5 hospitals caring for over 460,000 people. An inpatient unit is adjacent to the clinic. The clinic offers Norman Rockwell living; four seasons of outdoor adventure on the shores of Lake Superior in the upper Midwest. Visit the Duluth Clinic exhibit for more information.

ECNP CONGRESS - EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY
P.O. Box 85410
3508 AK Utrecht, The Netherlands
(Booth 12 – Exhibit Hall Lobby)

The 23rd ECNP Congress will be held August 28-September 1, 2010, in Amsterdam, The Netherlands. Please visit the ECNP Congress exhibit for more information about this meeting.

ELECTROMEDICAL PRODUCTS INTERNATIONAL, INC.
2201 Garrett Morris Parkway
Mineral Wells, TX 76067
(Booth 815)

Since 1981, Alpha-Stim® cranial electrotherapy stimulation technology has proven safe and efficacious in the treatment of anxiety, insomnia, and depressions. Supported by more scientific research than any therapeutic device, there are over 55 studies abstracted at <www.alpha-stim.com>. The company offers free clinical support at (940) 328-0788 and a 60-day loan option for psychiatrists who would like to try it in their practice (first time customers only).

ELSEVIER
1600 John F. Kennedy Boulevard, Suite 1800
Philadelphia, PA 19103
(Booth 1429)

Please visit the Elsevier exhibit for more information about their products and services that will be of interest to you.
EXHIBITORS WITH PRODUCT/SERVICE DESCRIPTIONS

EMR-BEAR, LLC
15 Calle Esperanza
Santa Fe, NM 87507
(Booth 2313)

EMR-Bear is a web-based electronic health record designed by and for behavioral health professionals. Come by our booth for a tour of the product and its features, such as clinical notes, assessments, and treatment plans, scheduling, electronic prescriptions, and much more. We will show you how easy and affordable it can be to take your private group practice, community mental health organization, or private practice paperless.

EXHIBITCHEK
20351 East LaSalle Place
Aurora, CO, 80013
(Booth 2233)

EXHIBITCHEK is a specialized market research program designed to measure and enhance the educational value of exhibits at this meeting. We invite you to complete a brief survey, which will lead to more informative exhibits at future meetings.

FAVORITE PHYSICIANS
7255 West 98th Terrace, Building 5, Suite 150
Overland Park, KS, 66212
(Booth 2113)

Favorite Physicians, a locum tenens company, provides our clients and physicians a full service consultant, and we have on-site staff 24/7/365 to cover your requests. We specialize in family practice, hospitalists, internal medicine and psychiatry, and provide coverage from one week to one year.

FDA/ DIVISION OF DRUG MARKETING, ADVERTISING, AND COMMUNICATIONS
10903 New Hampshire Avenue
Silver Spring, MD 20993
(Booth 2136)

The purpose of this booth is to educate healthcare practitioners about prescription drug advertising regulations, how to identify misleading drug promotion, and what course of action to take if misleading drug promotion is observed. The booth will be staffed by the Division of Drug Marketing, Advertising, and Communications.

FISHER WALLACE LABORATORIES
515 Madison Avenue, Suite SW
New York, NY 10022
(Booth 1238)

Fresh off a successful study at Harvard Medical School, Fisher Wallace Laboratories continues to pioneer the drug-free treatment of depression, insomnia, anxiety and stress. In addition to Harvard, our technology recently completed a successful pilot program at Phoenix House, the largest non-profit drug and alcohol rehab center in the U.S. Please visit our booth to speak to our President, Chip Fisher.

FLOYD BEHAVIORAL HEALTH CENTER
306 Shorter Avenue
Rome, GA 30165
(Booth 1905)

Floyd Behavioral Health Center is a 53-bed, voluntary receiving adult behavioral health center with psychiatry, chemical dependency, and geriatric programs. Located in Northwest Georgia, within an hour of Atlanta, Rome is a unique small city with a flourishing health care community of more than 350 practicing physicians. We are searching for a hospital-based psychiatrist and an office-based psychiatrist to join our team. To learn more, visit <www.floyd.org>.

FOREFRONT BEHAVIORAL TELECARE
2200 Powell Street, Suite 840
Emeryville, CA 94608
(Booth 2103)

Forefront Behavioral Telecare's telehealth network of independent psychiatrists provides behavioral health services to rural SNFs, health clinics, youth homes, and county jails where resources are scarce. Members can use their home/office PCs to use Forefront's live video conferencing service. Members set their telehealth hours weekly to take appointments in their specialties from networked facilities all over their state(s) of licensure. See <www.forefrontbt.com> for more details.

FOREST PHARMACEUTICALS, INC.
13600 Shoreline Drive
St. Louis, MO 63045
(Booth 434)

Forest Pharmaceuticals, Inc., welcomes you to New Orleans! We invite you to visit our exhibit where our professional representatives will welcome the opportunity to discuss and answer any questions regarding our products Lexapro® (escitalopram oxalate) and Namenda® (memantine HCl). Please visit our website at <www.forestpharm.com>.

GENESIS HEALTHCARE SYSTEM
2951 Maple Avenue
Zanesville, OH 43701
(Booth 1837)

Genesis Healthcare System, Zanesville, OH, is now recruiting psychiatrists for a facility of 24 adult beds, and 14 child/adolescent beds. A dedicated nursing team provides individualized treatments for each patient. Wide range of services offered include art/music therapy, group-family therapy, occupational therapy, therapeutic recreation, stress management and wellness education, alcohol/substance abuse assessment and groups, and partial hospitalization.
Life enriching experiences through International and U.S. Locum Tenens! Being a locum tenens physician is a life-changing experience—whether you want a change of scenery or a change of pace, and whether you stay in your own back yard or travel the world. Global Medical and its staff pioneered the international locum tenens staffing industry and we are the benchmark for all other international staffing groups. Nearly 3,000 physicians have chosen us for their life-enriching locum experience in Australia, New Zealand, the U.S. and beyond— and we can make it a reality for you now. The world is your practice. Where do you want to go? For more information call (800) 760-3174 or visit <www.gmedical.com>.

Founded in 1913, Gould Farm is the first residential, therapeutic community in the Nation dedicated to helping adults living with mental illness move toward recovery, health, and greater independence through community living, meaningful work, and clinical support. Within this safe, family-like community, all members are accepted, respected, and celebrated as individuals.

Please visit the Group Health Permanente exhibit for more information about their products and services that will be of interest to you.

New titles from Guilford Publications include: Barkley, Taking Charge of Adult ADHD; Miklowitz, Understanding Bipolar Disorder; Salekin, Handbook of Child and Adolescent Psychopathy; Leiblum, Treating Sexual Desire Disorders; Blaustein, Treating Traumatic Stress in Children and Adolescents; Millon, Contemporary Directions in Psychopathology; Maroda, Psychodynamic Techniques; Klonoff, Psychotherapy After Brain Injury; Butler, Cognitive-Behavioral Therapy for Anxiety Disorders; and Clark/Beck, Cognitive Therapy of Anxiety Disorders.
ICANOTES, LLC
1600 St. Margarets Road
Annapolis, MD 21409
(Booth 1736)

Over two million notes created and counting. ICANOTES is the most widely used Electronic Health Software (EHR, EMR) for psychiatrists and other mental health professionals. ICANOTES requires little or no typing and is available to any clinician with an internet connection. ICANOTES is by psychiatrists as well as nurses, social workers, counselors, etc., in both inpatient and outpatient settings.

INTELLISHERE, LLC
666 Plainsboro Road
Plainboro, NJ 08536
(Booth 1435)

Connecting more than 200,000 physicians and specialists to current and emerging healthcare technology trends, hundreds of online resources, and the latest breakthroughs affecting their medical practice, the MDNG series of publications and custom publishing products offer the best healthcare and technology news and information for physicians, patients and their caregivers.

INTERIM PHYSICIANS
1040 Crown Pointe Parkway, Suite 120
Atlanta, GA 30338
(Booth 1823)

Interim Physicians has been serving physicians in all major specialties since 1979. Our dedicated team of professional consultants has over 35 years of combined experience placing psychiatrists in positions throughout the U.S. Stop by our booth and allow one of our consultants to tell you about the exciting opportunities we have open today, or call us at (800) 226-6347 anytime!

INTERNATIONAL MEDICAL RECRUITMENT
Level 6, West Tower, 608 St. Kilda Road
Melbourne, Victoria, Australia 3004
(Booth 1910)

Choose Australia’s largest and most experienced medical recruitment company when it comes to securing your new career and life in Australia or New Zealand with: 1) a dedicated specialist psychiatry division; 2) access to hundreds of unadvertised jobs; 3) unlimited free advice on employment opportunities; 4) free registration and immigration processing; and 5) $500 cash gift to all doctors taking jobs through us. Visit us at Booth #1910 for a confidential discussion about your individual needs. International: phone: +61 3 8506 0185, fax: +61 3 8648 6846, psychiatry@IMRmedical.com, <www.IMRpsychiatry.com or www.IMRmedical.com>.

INTERNATIONAL PSYCHogeriatric Association (IPA)
550 Frontage Road, Suite 3759
Northfield, IL 60093
(Booth 826)

With a mission to “improve mental health for older people,” the International Psychogeriatric Association (IPA) is a multidisciplinary professional healthcare association, with members from over 60 countries: psychiatrists, neurologists, geriatricians, psychologists, primary care physicians, scientists, nurses, social workers, and occupational therapists. IPA promotes research, offers education, advocates for better care, facilitates an international exchange of ideas, and fosters cross-cultural understanding of the latest developments in the field.

J

JACKSON & COKER
2655 Northwinds Parkway
Alpharetta, GA 30009
(Booth 1802)

Jackson & Coker (J&C) is among the most recognized physician recruitment firms in the nation, providing temporary (locum tenens) and permanent placement services to government and commercial hospitals, clinics, and other medical facilities. J&C has the unique distinction of being awarded certification from the National Committee for Quality Assurance (NCQA) in ten out of ten credentialing services, and from The Joint Commission as a “Gold Star” Certified Health Care Staffing Service.

JANSSEN, DIVISION OF ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
1125 Trenton-Harbourton Road
Titusville, NJ 08560
(Booth 733)

Please visit the Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. exhibit for more information about their products and services that will be of service to you.

JOHNS HOPKINS UNIVERSITY PRESS
2715 North Charles Street
Baltimore, MD 21218
(Booth 1430)

Johns Hopkins University Press publishes scholarly and general interest books in psychiatry. Recent titles include: The Rise and Fall of the Biopsychosocial Model, by Nassir Ghaeni; Eating Disorders, 2nd ed., by Philip Mehler and Arnold Andersen; Developmental Disabilities From Childhood to Adulthood, edited by Roxanne Dryden-Edwards and Lee Combrinck-Graham; and Addiction and Art, edited by Patricia Santora, Margaret Dowell, and Jack Henningfield.

JONES & BARLETT
40 Tall Pine Drive
Sudbury, MA 01779
(Booth 1629)

Founded in 1983, Jones and Bartlett is a world-leading provider of instructional, assessment and learning-performance management solutions for the post-secondary, career and professional markets. We endeavor to develop educational programs and services that improve learning outcomes and enhance student achievement across a broad spectrum of academic, vocational and professional fields. Our products and services uniquely combine authoritative content from academia and industry thought-leaders with innovative,
proven and engaging technology applications that enable anytime, anywhere learning—revolutionizing how instructors teach, professionals train, and students learn. About Jones and Bartlett (<www.jbpub.com>).

**KAI GER P E R M A N E N T E**
1800 Harrison Street, 7th Floor
Oakland, CA 94612
(Booth 2005)

Kaiser Permanente believes their achievements are best measured by the health and wellness of the diverse communities they serve. That is why they provide a fully integrated system of care guided by values such as integrity, quality, service, and of course, results. That is also why they give their physicians the tools, flexibility, and freedom needed to get the best outcomes possible for their patients.

**K A R G E R P U B L I S H E R S**
26 West Avon Road, P.O. Box 529
Unionville, CT 06085
(Booth 1726)

Publications include: Chronotherapeutics for Affective Disorders; Lithium Treatment of Mood Disorders; Neurological Disorders in Famous Artists (Parts 1-3); the book series Advances in Biological Psychiatry; Advances in Psychosomatic Medicine; Key Issues in Mental Health; and Modern Trends in Pharmaco psychiatry; and the journals Dementia and Geriatric Cognitive Disorders, Human Development, Neurodegenerative Diseases, Neuropsychobiology, Psychopathology, and Psychotherapy and Psychosomatics.

**KI WIS S TAT**
Unit 1/48 Lismore Street, Waltham
Christchurch, 8011, New Zealand
(Booth 2306)

Kiwis STAT is the largest medical recruitment company in New Zealand and Australia. We organize fixed-term contracts for doctors wanting working holidays in a “no-sue” health system, in “Lord of the Rings” country. We provide a professional service that focuses on your employment, family, and leisure needs. Come and meet us at our booth and talk to Kiwis about becoming a Kiwi or Aussie Doctor.

**L A A M I S T A D F O U N D A T I O N, I N C.**
**L A K E W O O D C E N T E R**
8400 La Amistad Cove
Fern Park, FL 32730
(Booth 2206)

Owned and operated by La Amistad Foundation, Inc., Lakewood Center is a private, non-private, residential psychiatric treatment facility for adults with schizophrenia, autism, bipolar, and depression. The nursing, social work, activities, work program, and personal care staff provide a safe and active community. In addition, their Transitional Program helps develop independent functioning.

**LA L E T T R E D U P S Y C H I A T R E**
2, rue Sainte Marie
Courbevoie, Cedex, 92418 France
(Booth 425)

La Lettre du Psychiatre is a French publication specializing in psychiatry.

**L I L L Y U S A, L L C**
Lilly Corporate Center
Indianapolis, IN 46285
(Booth 734)

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers—through medicine and information—for some of the world’s most urgent medical needs.

530 Walnut Street
Philadelphia, PA 19106
(Booth 1616)

Lippincott Williams & Wilkins, a Wolters-Kluwer Health Company, is a leading international publisher of medical books, journals, and electronic media. We proudly offer specialized publications and software for physicians, nurses, students, and clinicians. Please visit our booth to browse our comprehensive product line.

**T H E L I T E B O O K C O M P A N Y L T D.**
#6, 941 South Railway Street, South
Medicine Hat, Alberta T1A 2W3 Canada
(Booth 634)

The Litebook Company pioneered portable light therapy in 2001 with the Litebook. Their patented LED technology produces bright, yet safe, diffused white light in the optimum blue and green wavelengths. Litebook is the only device with published data for SAD (Yale-led double-blind study). Litebook Elite™ features a sleek design, rechargeable lithium battery and timer for improved patient comfort and increased compliance.

**L I T T L E H I L L – A L I N A L O D G E**
Box G
Blairstown, NJ 07825
(Booth 2411)

Please visit the Little Hill – Alina Lodge exhibit for more information about their products and services that will be of interest to you.

**L O C U M T E N E N S **
2655 Northwinds Parkway
Alpharetta, GA 30009
(Booth 1729)

LocumTenens.com is a full-service agency providing temporary placement services for psychiatrists nationwide.
EXHIBITORS WITH PRODUCT/SERVICE DESCRIPTIONS

We offer excellent compensation, paid malpractice insurance, and the freedom and flexibility to decide when, where, and how often you want to work. To speak with a recruiter, call us at (800) 562-8663. Visit our website at <www.LocumTenens.com> and check out our Career Resource Center and free job board.

M

THE MAGSTIM COMPANY LIMITED
Spring Gardens, Whitland
Carmarthenshire, Wales UK SA34 0HR
(Booth 726)

Please visit The Magstim Company Limited exhibit for more information about their products and services that will be of interest to you.

MAGVENTURE, INC.
303 Perimeter Center North, Suite 300
Atlanta, GA 30346
(Booth 2138)

Please visit the MagVenture, Inc. exhibit for more information about magnetic stimulators for diagnostics and research.

MASSACHUSETTS GENERAL HOSPITAL ACADEMY
383 Main Avenue
Norwalk, CT 06851
(Booth 2310)

For healthcare professionals who value the highest standards of care, the Massachusetts General Hospital Psychiatry Academy provides world-renowned education that improves clinical practice and leads to better lives for patients and their families. Advanced teaching methods, an interactive learning format, and focus on solving real-world, practice-related challenges give the Academy international recognition for helping providers effectively treat psychiatric disorders. Visit <www.mghcme.org>.

MAXIM PHYSICIAN RESOURCES
(Booth 419)

Please visit the Maxim Physician Resources exhibit for more information about their products and services that will be of interest to you.

MAYO CLINIC
200 First Street, SW
Rochester, MN 55905
(Booth 925)

The Mayo Clinic Innovations in Psychiatry exhibit booth provides a look into Mayo's multidisciplinary approach to the practice of psychiatry and psychology. Learn how translational research programs and pharmacogenomic testing provide novel treatment options for patients worldwide. Find details about Mayo Clinic's Intensive Addiction Program, Pain Rehabilitation Center, Mood Disorder Unit, and Child and adolescent inpatient services. Also, obtain registration information for continuing medical education courses. Make the Mayo Clinic exhibit your first stop at the conference.

MBL COMMUNICATIONS, INC.
333 Hudson Street, 7 Floor
New York, NY 10013
(Booth 1730)

MBL Communications, Inc., an independent publishing and communications company, publishes the monthly peer-reviewed journals Primary Psychiatry® and CNS Spectrums®, Primary Psychiatry - NP/PA Edition, and Psychiatry Weekly™, the nation's only weekly psychiatric news service. Since 1994, MBL has also developed CNS-based print, web, and live programs for its 115,000 monthly readers, including Expert Panel Supplements and webcasts, BlackBox™ reference guides and related iPhone applications, and the biennial Alzheimer's Disease Summit™.

MCLEAN HOSPITAL
115 Mill Street
Belmont, MA 02478
(Booth 1735)

McLean Hospital is an international center for psychiatric treatment, teaching, and research, founded in 1811. McLean offers state-of-the-art diagnostic and treatment services across a full continuum that includes inpatient, residential, partial hospital and outpatient services. McLean also offers an expanded array of specialized academic programs for children and adolescents as well as dedicated services for older adults with Alzheimer's and other dementias. McLean houses the largest research program of any private psychiatric hospital in the world. As a major teaching affiliate of Harvard Medical School, McLean continues to educate the best and brightest mental health providers.

MECTA CORPORATION
19799 SW 95th Avenue, Suite B
Tualatin, OR 97062
(Booth 716)

MECTA, ECT Evidence Based Technology. Since 1973 MECTA has set the standard for unparalleled innovation based on research throughout four generations of electroconvulsive therapy (ECT) devices used for the treatment of depression. Exclusive features include an optimum 0.3 ms ultrabrief pulswidth including easy to use titration methodology to reduce cognitive side effects, and RMSManager ECT database. Stop by the MECTA Corporation booth to view the Electronic Medical Records software program.

MEDICAL ASSOCIATES CLINIC
1500 Associates Drive
Dubuque, IA 52002
(Booth 1901)

Please visit the Medical Associates Clinic exhibit for more information about their products and services that will be of interest to you.

MEDICAL BILLING PROFESSIONALS
P.O. Box 560
Royersford, PA 19468
(Booth 1337)

Let Medical Billing Professionals (MBP) submit your insurance claims for as little as $1.49 per claim. MBP has expertise in behavioral health billing and guarantees accurate claim submission by the next business day at the latest. Visit our booth for more information about our services.
MEDICAL DOCTOR ASSOCIATES
145 Technology Parkway, N.W.
Norcross, GA 30092
(Booth 1738)

Experience the difference quality makes. Medical Doctor Associates (MDA) is the quality leader in medical staffing. Whether you like a coastal, mountain, urban, or rural lifestyle, MDA has the opportunity for you. MDA provides the best protection in malpractice insurance available; and we are the largest organization that can. We have opportunities in all specialties and work with some of the largest healthcare networks in the industry. Call MDA today and find out how quality can start working for you. For more information contact (888) 383-6700 or <www.mdainc.com>.

MEDNET TECHNOLOGIES, INC.
1975 Linden Boulevard, Suite 407
Elmont, NY 11103
(Booth 320)

MedNet Technologies designs, hosts, and manages websites for medical practices, hospitals and other healthcare organizations. Clients range in size from small medical offices to teaching hospitals to medical societies. Developing and optimizing your web presence on the internet is our goal.

THE MENNINGER CLINIC
2801 Gessner Drive
Houston, TX 77080
(Booth 2235)

The Menninger Clinic, Houston, is a specialty psychiatric center for the treatment of adolescents and adults with difficult-to-treat brain and behavioral disorders as well as co-occurring conditions. Treatment integrates evidence-based and biopsychosocial therapies with rehabilitation. Neuropsychiatric assessments are available for adults and adolescents. Menninger also trains mental health professionals, conducts collaborative research and is affiliated with Baylor College of Medicine.

MENTALNOTE™
31101 Bancroft Drive
Novi, MI 48377
(Booth 633)

MentalNote™ is the preferred stand-alone electronic documenting management software for behavior health professionals. Progress notes, patient history, letters, billing summaries, and prescriptions are all automatically generated to your specifications and personalized, professional touches with a click of a box. Learn more about our highly anticipated MentalNote™ On-line (MNOL), the EHR and web-based version of MentalNote™. Visit booth #633 or contact us at <www.MentalNoteOnline.com> for more information.

MERCK
2000 Galloping Hill Road
Kenilworth, NJ 07033
(Booths 2216, 2314)

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. More for information, visit <www.merck.com>.

MERRILL LYNCH WEALTH MANAGEMENT
1400 Merrill Lynch Drive
Pennington, NJ 08534
(Booth 2237)

Merrill Lynch is one of the world's premier providers of wealth management, securities trading and sales, corporate finance, and investment banking services. Working with our clients as strategic partners, we create and execute winning solutions based on five unwavering principles: client focus, respect for the individual, teamwork, responsible citizenship, and integrity.

MHM SERVICES, INC.
1593 Spring Hill Road, Suite 610
Vienna, VA 22182
(Booth 1236)

MHM Services, Inc., is a leading national provider of healthcare services to state and local government agencies. From mental health and long-term care to medical and forensic services, our employees are dedicated to providing the highest quality of care for every population they serve. Today we serve over 275,000 individuals in hundreds of facilities across 15 states.

MINISTRY HEALTH CARE
900 Illinois Avenue
Stevens Point, WI 54481
(Booth 1814)

Ministry Health Care is currently looking for BC/BP psychiatrists to join our multi-specialty group in central and northern Wisconsin. We have different practices to fit your needs, with inpatient, outpatient, and child/adolescent psychiatry positions at two different locations that work with different practice philosophies. You have the choice of working with a multi-disciplinary, team approach, or an independent, flexible group.

N

NARSAD AND NARSAD ARTWORKS
761 West Lambert Road
Brea, CA 92821
(Booth 938)

NARSAD raises and distributes funds for scientific research into the causes, cures, treatments, and prevention of severe mental illnesses. NARSAD Artworks solicits art created by artists with mental illness and incorporates it into products such as note and holiday cards. NARSAD Artworks is the country’s clearinghouse for such art.
**EXHIBITORS WITH PRODUCT/SERVICE DESCRIPTIONS**

**NATIONAL DEATH INDEX**
3311 Toledo Road, Room 7316
Hyattsville, MD 20782
(Booth 534)

The National Death Index (NDI) is a central computerized index of death record information on file in the state vital statistics offices. Working with these states, NCHS established the NDI as a resource to aid epidemiologists and other health and medical investigators with their mortality ascertainment activities.

**NATIONAL INSTITUTE OF MENTAL HEALTH**
6001 Executive Blvd., Room 8184, MSC 9663
Bethesda, MD 20892
(Booth 1025)

The National Institute of Mental Health (NIMH), a component of the National Institutes of Health, Department of Health & Human Services, conducts and supports research on mental health and mental disorders. NIMH offers many publications, at no cost, to help people with mental disorders, health care practitioners, researchers, and the general public to gain a better understanding of mental illnesses and NIMH research programs. Some materials are available in Spanish.

**NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM**
2107 Wilson Boulevard, #1000
Arlington, VA 22201
(Booth 1031)

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) exhibit highlights the importance of alcohol research, prevention, and treatment for maintaining the health of the individual, the family, and the nation. The NIAAA exhibit features publications appropriate for the public, research findings for professionals and for policy makers, and research grant opportunities available for biomedical and social science researchers. A direct link to NIAAA’s web site will be available at this exhibit.

**NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)**
6001 Executive Boulevard, Suite 5213
Bethesda, MD 20892
(Booth 1033)

The National Institute on Drug Abuse (NIDA) is a Federal agency charged with supporting research on the causes, prevention, and treatment of all aspects of drug abuse including AIDS. The results of the NIDA-funded research offer this country’s best hope for solving the medical, social, and public health problems of drug abuse and addiction. Publications and research opportunities supporting these efforts will be made available.

**NATURE PUBLISHING GROUP**
75 Varick Street, Floor 9
New York, NY 10013
(Booth 1331)

Nature Publishing Group (NPG) brings leading scientific and medical research to your desktop. The NPG portfolio combines the continued excellence of Nature and its associated research and review journals, over 42 leading academic and society journals and eight Nature Clinical Practice journals. Visit Booth #1331 for free sample copies.

**NETSMART TECHNOLOGIES**
3500 Sunrise Highway
Great River, NY 11739
(Booth 2303)

Helper offers affordable and comprehensive Practice Management, EMR, electronic claims, e-Prescribing, credit card processing, and e-Learning software designed specifically for behavioral health. Helper is a division of Netsmart Technologies, a leading behavioral health software provider with over 18,000 customers nationwide, from solo, private practices to over 300 community mental health cents and 35+ state systems. Please visit the Netsmart Technologies exhibit for more information about their products and services that will be of interest to you. For more information visit <www.ntst.com>.

**NEURONETICS, INC.**
31 General Warren Boulevard
Malvern, PA 19355
(Booth 224)

Neuronetics is changing the way psychiatrists think about and treat major depression. Neuronetics’ fastest-growing, non-invasive, non-systemic treatment is now provided by over 130 U.S. providers. Visit APA booth #224 for a one-on-one demonstration, product risk information, to meet the experts, and to find out how it can benefit your patients and your practice. You may also contact us at <www.NeuroStarTMS.com> or (877) 660-7555 for more information.

**NEW YORK-PRESBYTERIAN HOSPITAL**
333 E. 38th Street, 5th Floor, Marketing
New York, NY 10016
(Booth 316)

NewYork-Presbyterian Hospital, Departments of Psychiatry, a recognized leader in clinical case, training, and research, offers a full continuum of expert diagnostic and treatment services for children, adolescents, adults, and the elderly with psychiatric, neuropsychiatric, behavioral, or emotional problems. Accomplished specialists in psychiatry, psychopharmacology, clinical psychology, and neurology provide the highest quality of care that includes the most recent scientific advances and state-of-the-art treatment options.

**THE NEW YORK TIMES**
613 South Avenue
Weston, MA 02493
(Booth 1632)

The New York Times (NYT) newspaper is the largest metropolitan newspaper in the U.S. The NYT is frequently relied upon as the official and authoritative reference for modern events. Please visit the NYT exhibit for 25% off home delivery and receive a free gift with your subscription.

**NORTH CAROLINA OFFICE OF RURAL HEALTH**
2009 Mail Service Center
Raleigh, NC 27699
(Booth 1911)

The North Carolina Office of Rural Health and Community Care provides quality mental health support to the rural and underserved areas of North Carolina. We offer placement in various facilities and practices.
providing service to under-served populations in rural or metropolitan communities. Loan repayment and other incentive options are available for psychiatrists seeking employment opportunities.

**NORTHERN LIGHT TECHNOLOGIES**
8971 Henri Bourassa West
Montreal, Quebec H4S 1P7 Canada
(Booth 816)

Northern Light Technologies produces the TRAVELITE, the 10,000 Lux high-output SATELITE Desk Lamp, FLAMINGO Floor Lamp, BOXELITE, ceiling track mounted SHOWOFF and the new LUXOR table lamp. Preferred by thousands of healthcare professionals, Northern Light Technologies is the supplier of choice for affordable, versatile, and adjustable bright light sources. UV-clean, flicker-free, and operating on 110V to 220V current. Call (800) 263-0066 or visit us at <www.northernlighttechnologies.com>.

**NOVARTIS PHARMACEUTICALS**
One Health Plaza
East Hanover, NJ 07936
(Booths 638, 1716, 2101, 2301)

Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs that help meet our customers’ medical needs and improve their quality of life.

**OREGON STATE HOSPITAL**
2600 Center Street, NE
Salem, OR 97301
(Booth 1906)

Oregon State Hospital, in Salem, Oregon, is a new hospital incorporating state-of-the-art architecture, treatment space, and technology by 2011. It is surrounded by ocean beaches, snow-covered mountains, and world famous wineries. You can ski, raft, fish, hike, boat, gold, game, and taste—and just about everything you could imagine—all within an hour’s drive. What more could you ask for? Please visit us at the Career Fair.

**OXFORD UNIVERSITY PRESS**
198 Madison Avenue
New York, NY 10016
(Booth 1330)

The Oxford University Press will feature the following new books: Cutter, Psychiatry, Second Edition; North, Goodwin and Guze’s Psychiatric Diagnosis, Sixth Edition; Mrzez, Psychiatric Pharmacogenomics; Zoromski, Demystifying Psychiatry; Starcevic, Anxiety Disorders in Adults, Second Edition; Frankland, The Little Psychotherapy Book; new Treatments That Work titles and the rest of Oxford’s leading list in psychiatry. Sample copies of the journal Schizophrenia are also available.

**PAMLAB, LLC**
4099 Highway, 190 East
Covington, LA 70470
(Booth 415)

Deplin is indicated for low plasma and/or low red blood cell folate with particular emphasis for those individuals who have a major depressive disorder that has not fully responded or may not fully respond to antidepressant therapy. Cerefolin® with NAC features N-acetylcysteine which targets the oxidative damage associated with mild cognitive impairment by reducing the neurotoxic effects of beta amyloid and hyperhomocysteinemia.

**PFIZER, INC.**
235 East 42nd Street
New York, NY 10017
(Booth 1816)

Please visit the Pfizer, Inc., Worldwide Pharmaceutical exhibit featuring: Chantix™ (varenicline), Goedon® (ziprasidone hydrochloride), and Pristiq™ (desvenlaxine extended-release tablets).

**PHILIPS CONSUMER LIFESTYLE**
710 North, 900 East
Pleasant Grove, UT 84062
(Booth 1838)

Winter blues affect an estimated 25 million Americans and light therapy is recommended by the APA as a first-line treatment. Philips Consumer Lifestyle (formerly Apollo Health) offers newly discovered blueware technology for fast relief. Come by booth 1838, call (801) 616-2850, or visit <www.lighttherapy.com> to learn about our medical professional demo units, authorization codes, and waiting room information kits.

**PHYSICIANS FOR A NATIONAL HEALTH PROGRAM**
29 East Madison, Suite 602
Chicago, IL 60602
(Booth 923)

Physicians for a National Health Program (PNHP) is a non-profit research and education organization of 17,000 physicians, medical students, and health professionals who support single-payer national health insurance.

**PINE REST CHRISTIAN MENTAL HEALTH SERVICES**
300 68th Street, S.E.
Grand Rapids, MI 49501-0165
(Booth 2013)

Pine Rest Christian Mental Health Services is celebrating our 100th anniversary this year. Pine Rest is a leader in behavioral health care and is the fifth largest free-standing behavioral health care organization in the country providing a continuum of services for all ages: prevention and education; psychological assessment and testing; outpatient counseling and therapy at over 20 clinical locations; residential services; day treatment; inpatient hospitalization and more. Visit us at booth 2013 or <www.pinterest.org> to learn more about our opportunities and services.
EXHIBITORS WITH PRODUCT/SERVICE DESCRIPTIONS

**PRACTICE FUSION**  
(Booth 217)

Please visit the Practice Fusion exhibit for more information about their products and services that will be of interest to you.

**PRACTICELINK.COM**  
415 Second Avenue  
Hinton, WV 25951  
(Booth 1913)

PracticeLink.com - The Online Physician Job Bank™ Find more than 14,000 practice opportunities in all specialties, nationwide on <www.practicelink.com>. Visit the <www.practicelink.com> Physician Job Bank or call (800) 776-8383 to discuss opportunities with a PracticeLink On Call™ Representative. PracticeLink is a free service for physicians. PracticeLink is not a search firm.

**PSYCHIATRIC SOLUTIONS, INC.**  
6640 Carothers Parkway  
Franklin, TN 37067  
(Booth 1832)

Psychiatric Solutions, Inc. (PSI) offers an extensive continuum of behavioral health programs to critically ill children, adolescents, and adults, and is the largest operator of owned or leased, freestanding psychiatric inpatient facilities with approximately 10,000 beds in 32 states, Puerto Rico, and the U.S. Virgin Islands.

**PSYCHIATRIC TIMES**  
(Booth 1821)

Please visit the Psychiatric Times exhibit for more information about their products and services that will be of interest to you.

**PSYCHIATRISTS ONLY, LLC**  
2970 Clairmont Road, Suite 650  
Atlanta, GA 30329  
(Booth 915)

Psychiatrists Only is a physician-owned and managed full-service, nationwide locum tenens and psychiatrists’ permanent placement agency. Full-service equals hassle-free service to their hospital, clinic, and mental health center clients and to their physicians. Their professional recruitment staff will keep on top of any issues and problems, and they will keep you fully informed during each step of the recruitment process.

**THE PSYCHIATRISTS’ PROGRAM**  
1515 Wilson Boulevard, Suite 800  
Arlington, VA 22209  
(Booth 916)

The Psychiatrists’ Program offers medical malpractice insurance and risk management resources to individual psychiatrists and behavioral healthcare groups. Participants have access to the toll-free Risk Management Consultation Service helpline, complimentary risk management seminars, Online Education Center and more. Coverage includes administrative defense benefits and forensic psychiatric services. Discounts available include part-time, early career, moonlighting residents, child/adolescent, and risk management. Visit us online at <www.psychprogram.com>!

**QTC MEDICAL SERVICES**  
21700 Copley Drive, Suite 200  
Diamond Bar, CA 91765  
(Booth 825)

QTC is the largest private provider of outsourced medical and disability examination services in the Nation. Built upon a focus of integrating information technology to achieve consistent, efficient, and accurate medical evaluations, our more than 28-year history has been marked by innovative, agency-focused services and positive working relationships. To learn more visit <www.QTCM.com>.

**RAPID PSYCHLER PRESS**  
(Booth 1336)

Please visit the Rapid Psychler Press exhibit for more information about their products and services that will be of interest to you.

**THE READING HOSPITAL AND MEDICAL CENTER**  
South 6th Avenue and Spruce Street  
West Reading, PA 19611  
(Booth 2309)

The Reading Hospital and Medical Center is a 672-bed, not-for-profit healthcare center providing comprehensive acute care, post-acute rehabilitation, behavioral, and occupational health services to the people of Berks and adjoining counties. Located in scenic Berks County, the main West Reading campus consists of a 22-building complex located on a 36-acre suburban campus. Learn more about our opportunities at <www.readingdocs.org>.

**RECKITT BENCKISER PHARMACEUTICALS**  
10710 Midlothian Turnpike, Suite 430  
Richmond, VA 23235  
(Booth 2330)

Reckitt Benckiser Pharmaceuticals is at the forefront providing educational resources and treatment options to physicians and patients dealing with the chronic relapsing disease of opioid dependence. Please visit their exhibit where Reckitt Benckiser clinical liaisons will be available to discuss the indications, and provide scientific information, and answer your questions about a unique treatment option.

**REGISTRY OF PHYSICIAN SPECIALISTS**  
1299 Newell Hill Place, Suite 100  
Walnut Creek, CA 94596  
(Booth 1724)

The Registry of Physician Specialists is a preferred provider of psychiatric and medical services to correctional facilities within the California Department of Correction and Rehabilitation since 1988. The Registry of Physician Specialists is currently seeking
mental health and other medical providers to join and provide services within opportunities nationwide. Please call (800) 882-0686 and speak with a Registry of Physician Specialists recruiter for more information.

**RIVervalley Behavioral Health**
1100 Walnut Street
Owensboro, KY 42301
(Booth 819)

RiverValley Consulting Services, a comprehensive healthcare provider located in Owensboro, Kentucky, provides the full range of outpatient behavioral healthcare services in seven surrounding counties and inpatient child/adolescent services. We provide various opportunities for physicians to develop their practices, in multiple sites utilizing telemedicine technology, while maintaining the autonomy of a private practice, making this corporation an ideal choice for any psychiatrist.

**Robert Young Center for Community Mental Health**
4600 Third Street
Moline, IL 61265
(Booth 2003)

Please visit the Robert Young Center for Community Mental Health exhibit for more information about their products and services that will be of interest to you.

**Rosecrance Health Network**
1021 Mulford Road
Rockford, IL 61107
(Booth 636)

Rosecrance Treatment Centers, located in Rockford, IL, 70 miles northwest of Chicago, is a private, not-for-profit organization that has a documented history of providing quality substance abuse treatment and prevention services for children, adolescents, adults, and families. Services include detoxification, inpatient, partial hospitalization, outpatient, continuing care, and recovery homes for young men and women. You can visit our website at <www.rosecrance.org>.

**Routledge**
270 Madison Avenue
New York, NY 10016
(Booth 1438)

Routledge publishes an impressive portfolio of psychology textbooks, professional books, and journals. We are offering a special 20% discount and free shipping to all attendees who place orders at our booth #1438! Featuring *Get the Diagnosis Right!* By Jerome Blackman and *Handbook of Clinical Sexuality for Mental Health Professionals* edited by Stephen B. Levine, et al. For more information visit <www.routledgemenalhealth.com>.

**Routledge Journals**
325 Chestnut Street, Suite 800
New York, NY 10016
(Booth 1434)

For two centuries, Taylor & Francis has been fully committed to the publication of scholarly information. Under our Routledge imprint, we publish a wide variety of journals in the psychiatric field. Visit the Routledge booth to view our products and to pick up free sample copies of our journals.

**Royal College of Psychiatrists**
17 Belgrave Square
London, SW1X 8PG United Kingdom
(Booth 1530)

This is the professional body for psychiatrists in the United Kingdom, but membership is available for overseas psychiatrists in the form of International Associateship. Journals include British Journal of Psychiatry and Advances in Psychiatric Treatment (see <www.rcpsych.org>). Please visit the exhibit to take free journal sample copies; get 20% off journal subscriptions; plus get 10% discount off book prices. To learn more about the College visit <www.rcpsych.ac.uk>.

**Sepracor**

In 2009, Sepracor Inc. became an indirect, wholly-owned U.S. subsidiary of DSP. Sepracor has several marketed products, including Lunesta® brand eszopicline. The DSP-Sepracor U.S. pharmaceutical candidate pipeline is focused principally in the central nervous system and respiratory areas. Visit <www.sepracor.com>.

**Secure TeleHealth**
9150 Harmony Drive
Pittsburgh, PA 15237
(Booth 223)

Please visit the Secure TeleHealth exhibit for more information about their products and services that will be of interest to you.

**Sepracor Inc.**
84 Waterford Drive
Marlborough, MA 01752
(Booth 2110)

Dainippon Sumitomo Pharma Co., Ltd., (DSP) is a multi-billion dollar Japanese company with a diverse portfolio of pharmaceuticals, animal health, food, and specialty products. In 2009, Sepracor Inc. became an indirect, wholly-owned U.S. subsidiary of DSP. Sepracor has several marketed products, including Lunesta® brand eszopicline. The DSP-Sepracor U.S. pharmaceutical candidate pipeline is focused principally in the central nervous system and respiratory areas. Visit <www.sepracor.com>.

**Sheppard Pratt Health System**
6501 North Charles Street
Baltimore, MD 21204
(Booth 1715)

Sheppard Pratt Health System (SPHS) is a private, nonprofit continuum of behavioral health and addiction services providing a full range of inpatients, partial, and...
outpatient services for children, adolescents, adults, and older adults. Specialty programs are also offered for the treatment of trauma disorders, eating disorders, and neuropsychiatric disorders. In addition, Sheppard Pratt operates psychiatric rehabilitation programs, special education schools, residential treatment centers, and therapeutic and community housing programs; manages general hospital psychiatric services, and also provides psychiatric services to nursing homes and life care communities. For 19 consecutive years, SPHS has been ranked among the top psychiatric hospitals in the U.S. by U.S. News and World Report.

**SHIRE PHARMACEUTICALS**
725 Chesterbrook Boulevard
Wayne, PA 19087
(Booth 216)

Shire is a leading global specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire centers its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Shire's size and structure allows the company to target new therapeutic areas as opportunities arise through in-licensing and acquisition efforts focused on products in niche markets with strong intellectual property protection in the U.S. and Europe. Shire's carefully selected portfolio, aligned with a relatively small-scale sales force, delivers strong results. For further information on Shire, please visit: <www.shire.com>.

**SINGING RIVER HOSPITAL BEHAVIORAL HEALTH SERVICES**
2809 Denny Avenue
Pascagoula, MS 39581
(Booth 2009)

Singing River Hospital Behavioral Health Services has the following at its facility: a 14-bed medical/psychiatric unit with senior track, Medicare-Medicaid, a 16-bed adult psychiatric unit, adult and senior structured outpatient programs; and a behavioral health outpatient physicians’ practice. Located in Singing River Hospital as part of Singing River Health System Pascagoula, Ocean Springs, Mississippi. We can be contacted at (228) 809-2273 and (228) 249-3305.

**SKYLAND TRAIL**
1961 North Druid Hills Road
Atlanta, GA 30329
(Booth 724)

Skyland Trail, an American Psychiatric Association's Gold Achievement Award winner, is a nationally recognized provider of high-quality, individualized, adult psychiatric services. It offers a full continuum of residential, partial, outpatient, and transitional services. Treatment encompasses care for individuals with cognitive, mood, and psychotic disorders, including dual diagnosis. Their primary care clinic also offers physical health services. For information call (404) 315-8333 or (866) 528-9593.

**SOCIAL SECURITY ADMINISTRATION**
6401 Security Boulevard, 3433 Annex
Baltimore, MD 21235
(Booth 2204)

The Social Security Administration's award winning website, <www.socialsecurity.gov> provides a wealth of information. The website includes new and improved online applications for disability and retirement benefits. Today, more and more people are doing business online, and we will demonstrate our online services, promote the extra help with Medicare prescription drug costs, and distribute Social Security publications.

**SOCIEDAD ESPANOLA DE PATOLOGIA DUAL (SEPD)**
Londres, 17
Madrid 28028 Spain
(Booth 11 – Exhibit Hall Lobby)

The 2nd International Congress Dual Disorders Addictive Behaviors and other Mental Disorders will take place October 5-8, 2011. This is a major meeting under the patronage of NIDA, WPA and other major institutions. This provides a platform for clinicians and researchers to exchange knowledge on a relevant topic. Visit the exhibit in the Exhibit Hall Lobby.

**SOMATIC LLC**
910 Sherwood Drive, Unit 23
Lake Bluff, IL 60044
(Booth 728)

Somatics LLC manufactures the Thymatron® System IV ECT instrument, now easier than ever to use (a single dial selects all functions), featuring the new Remote Treat Handle, ultra-brief 0.3 ms pulsewidth, Automatic Optimal Stimulus Selection at 0.3 and 0.5 ms, 4-channel monitor-printer, Postictal Suppression Index, automatic EEG Seizure Endpoint Detection, digital heart rate printout, and real-time on-screen monitoring via the GENIE™ IV, which also features newly-enhanced patient information software to interface with electronic record keeping systems and hospital networking platforms.

**SOS PROGRAMS & PARENTS PRESS**
1403 Mount Ayr Circle
Bowling Green, KY 42103
(Booth 1633)

SOS is a cognitive therapy program for adults and teens, and a behavior therapy program for children. These programs in both English and Spanish are easily implemented by your staff and your patients. Treatment planning is made easier and is endorsed by Albert Ellis. Come to the Publishers' Book Fair for a brief DVD demo and free resources for psychiatrists. Visit <www.sosprograms.com> for more information.
**Spartanburg Regional Healthcare System (SRHS)**

Spartanburg Regional Healthcare System (SRHS) is an integrated healthcare delivery system anchored by Spartanburg Regional Medical Center, a 540-bed teaching and research hospital. The system offers a range of specialized healthcare services that is unrivaled in its five-county service region, featuring world-class specialty centers making SRHS the region’s preferred provider of comprehensive healthcare services.

**Staff Care, Inc.**

Staff Care, Inc. is the nation’s leader in locum tenens staffing. Their role is to match qualified, independent contractor physicians with health care organizations requiring temporary physician services. Locum tenens physicians maintain patient care, referrals, and revenue by covering vacancies due to vacation/CME, staffing shortages, increased census, and other causes. Staff Care is also a proud sponsor of the Country Doctor of the Year award. Please visit their website at <www.staffcare.com> or call them at (800) 685-2272.

**Substance Abuse and Mental Health Services Administration (SAMHSA)**

Substance Abuse and Mental Health Services (SAMHSA) is a public health agency within the Department of Health and Human Services. The agency is responsible for improving the accountability, capacity, and effectiveness of the Nation’s substance abuse prevention, addiction treatment, and mental health services delivery system.

**SuiteMed, LLC**

SuiteMed, LLC exhibits for more information about their products and services that will be of interest to you.

**SZ Magazine**

SZ Magazine is a quarterly publication that provides information for health professionals and offers inspiration to individuals diagnosed with schizophrenia, their families, and caregivers. SZ Magazine features articles about schizophrenia therapies and medications, as well as personal stories. As a trusted source of information on mental wellness, readers learn coping techniques, industry trends, and treatment options.

**Teva Pharmaceuticals**

Teva Pharmaceuticals, the nation’s leading generic manufacturer, markets over 320 products and 1,100 SKUs. The company manufactures products in all major therapeutic areas, including immunosuppressive agents to prevent the rejection of kidney, liver, and heart allograft, as well as atypical antipsychotics for the management of severely ill schizophrenic patients.

**TheraManager, LLC**

TheraManager is an all-in-one, easy-to-use practice management and EMR software that provides scheduling, electronic billing, EMR, and electronic prescriptions, including renewal requests. It is designed for both solo psychiatrists and large mental health practices. The EMR is exceptional with multiple options including templates, a unique form capability that speeds creating notes by at least a factor often, and even stores handwriting. Please check us out.

**U.S. Army Civilian Corps**

Vast Opportunities. Exceptional Benefits. Rewarding Careers. Practice your specialty with one of the largest health care and dental care networks in the world. The Army Medicine Civilian Corps provides world-class health and dental care at more than 70 facilities throughout the U.S., Europe, and the Pacific. With over 2,500 positions available, come meet our recruiters and explore your opportunities.

**U.S. Department of State, Office of Medical Services**

The U.S. Department of State, Office of Medical Services offers a unique career in psychiatry in an overseas setting. They are looking for board-certified psychiatrists with at least five years of post-residency clinical experience in adult or child/adolescent psychiatry. The Department of State provides primary psychiatric care and preventative medical

**U.S. NAVY RECRUITING COMMAND**
5722 Integrity Drive
Millington, TN 38054
(Booth 2202)

With the U.S. Navy Medical Corps, become a leader within the medical world—with financial assistance available. Learn more at the Navy booth or visit <www.navy.com/healthcare>.

**U.S. PUBLIC HEALTH SERVICE**
(Booth 2409)

Please visit the U.S. Public Health Service exhibit for more information about their products and services that will be of interest to you.

**UPLIFT TECHNOLOGIES INC.**
19-10 Morris Drive
Dartmouth, NS B3B 1K8 Canada
(Booth 423)

Since 1993, Uplift Technologies has provided Day-Light Bright Light Therapy Systems that have been clinically proven and used by researchers worldwide! Day-Lights help those suffering from seasonal and non-seasonal conditions: The Winter Blues, Circadian Sleep Disorders, Jet Lag, or Shift Work Adjustment. Day-Light Bright Light Therapy Systems are built to meet the guidelines leading experts recommend for effective therapy. Visit our booth for more information.

**VA NORTHWEST HEALTH NETWORK**
P.O. Box 1035
Portland, OR 97207
(Booth 2111)

The VA Northwest Health Network is a system of B medical centers and 31 clinics throughout Alaska, Idaho, Oregon, and Washington. We can offer you the rare opportunity to help our nation’s veterans continue to lead strong, productive lives. We would love for you to join us. Visit <www.vacareers.va.gov> or email us at <visn20mentalhealthpositions@va.gov>.

**VALANT MEDICAL SOLUTIONS**
P.O. Box 21405
Seattle, WA 98111
(Booth 823)

“The Psychiatrist’s EasyMR”—Valant is the first and only company to offer a 100% web-based electronic medical record (EMR) and practice management suite designed exclusively for psychiatrists. Stop by Booth #823 for a live demo and feature details.

**VALIDUS PHARMACEUTICALS, LLC**
119 Cherry Hill Road, Suite 310
Parsippany, NJ 07054
(Booth 2230)

Equetro" (carbamazepine extended release) Capsules: Effectively treats acute manic and mixed episodes associated with Bipolar 1 Disorder. Marplan" (isocarboxazid) Tablets: For the treatment of major depressive disorders.

**VISTA STAFFING SOLUTIONS, INC.**
275 East 200 South
Salt Lake City, UT 84111
(Booth 1232)

VISTA Staffing Solutions helps you achieve your immediate career goals and plan your professional future. Find the perfect fit in locum tenens assignments, extended placements, or permanent positions in the U.S., or six- to twelve-month placements in Australia, New Zealand, Bermuda, and beyond. You control where, when, how, and how much you work. Visit <www.VistaStaff.com>, or call us at (800) 366-1884.

**W**

**W.W. NORTON**
500 574 Avenue
New York, NY 10110
(Booth 1529)

Norton Professional Books publishes high-quality books for psychiatrists, psychotherapists, psychologists, and other mental health professionals. New titles include: *The Neuroscience of Psychotherapy, Second Edition*; *Treating Child & Adolescent Mental Illness; The Dao of Neuroscience; The Behavioral Neuroscience of Adolescence; Kundalini Yoga for Complex Psychiatric Disorders*; and many more.

**WILEY - BLACKWELL**
(Booth 1624)

Please visit the Wiley - Blackwell exhibit for more information about their products and services that will be of interest to you.

**WORLD ASSOCIATION FOR SOCIAL PSYCHIATRY (WASP)**
44 Avenue de l’Armee Royale
Casablanca 20020 Morroco
(Booth 13)

The WASP 2010 20th World Congress will be held October 23-27, 2010. Please visit the World Association for Social Psychiatry exhibit for more information about this meeting.
EARLY MEETING REGISTRATION DISCOUNT:
Register during the 2010 Annual Meeting for Hawaii in 2011, and receive the 2010 meeting registration rates for 2011.

Why YOU should attend this meeting:
• **Update** your knowledge base
• **Earn** Category 1 CME credits
• **Network** with colleagues and meet your peers and industry leaders
• **Find** the right products and the best deals on the exhibit floor
• **Save** money on next year’s registration prices
• **Take advantage** of one of America’s greatest destinations with earlier ending sessions

This offer is only available onsite from May 21-26, 2010.

EARLY BIRD HOUSING:
From May 20-26, 2010 Secure Your First Choice Hotel for Hawaii 2011!

During the 2010 Annual Meeting Only (May 20-26), housing reservations for 2011 will be open to 2010 APA attendees

When this year’s Annual Meeting is closed, housing will be closed until December!

Visit [www.psych.org](http://www.psych.org) (May 20-26, 2010 only) and click on the links for the 2011 Annual Meeting or visit the Travel Planners booth in Lobby B, The Morial Convention Center.
Get your questions answered. Learn about new programs.

Visit the
APA Member Center
next to the APPI Bookstore in the Exhibit Hall, Morial Convention Center

Saturday, May 22  10:00 am - 4:00 pm
Sunday, May 23  10:00 am - 4:00 pm
Monday, May 24  10:00 am - 4:00 pm
Tuesday, May 25  10:00 am - 4:00 pm

Visit us online at www.psych.org
<table>
<thead>
<tr>
<th>Category</th>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCHITECTURAL/ENGINEERING FIRM</td>
<td>Cannon Design</td>
<td>328</td>
</tr>
<tr>
<td>COMPUTERIZED NEUROCOGNITIVE TESTING</td>
<td>CNS Vital Signs</td>
<td>827</td>
</tr>
<tr>
<td>CONSUMER MAGAZINE</td>
<td>SZ Magazine</td>
<td>1931</td>
</tr>
<tr>
<td>CORRECTIONAL HEALTH CARE</td>
<td>MHM Services, Inc.</td>
<td>1236</td>
</tr>
<tr>
<td>DIAGNOSTIC TOOLS</td>
<td>ANT - Advanced Neuro Technology</td>
<td>2335</td>
</tr>
<tr>
<td></td>
<td>BioBehavioral Diagnostics Company</td>
<td>2413</td>
</tr>
<tr>
<td></td>
<td>MagVenture A/S</td>
<td>2138</td>
</tr>
<tr>
<td>ECT</td>
<td>MECTA Corporation</td>
<td>716</td>
</tr>
<tr>
<td></td>
<td>Somatics LLC</td>
<td>728</td>
</tr>
<tr>
<td>EDUCATIONAL NON-PROFIT ASSOCIATION</td>
<td>American Academy of Psychiatry and the Law</td>
<td>922</td>
</tr>
<tr>
<td></td>
<td>American Association for Geriatric Psychiatry</td>
<td>227</td>
</tr>
<tr>
<td>EDUCATIONAL/PROFESSIONAL SUPPORT ORGANIZATIONS</td>
<td>American Association of Community Psychiatrists</td>
<td>1021</td>
</tr>
<tr>
<td></td>
<td>Substance Abuse and Mental Health Services Administration (SAMHSA)</td>
<td>926</td>
</tr>
<tr>
<td>ELECTRONIC HEALTH RECORDS/ELECTRONIC MEDICAL RECORDS</td>
<td>ASPMD, Inc.</td>
<td>2403</td>
</tr>
<tr>
<td></td>
<td>EMR-BEAR, LLC</td>
<td>2313</td>
</tr>
<tr>
<td></td>
<td>ICANotes</td>
<td>1736</td>
</tr>
<tr>
<td></td>
<td>MentalNote</td>
<td>633</td>
</tr>
<tr>
<td></td>
<td>Netsmart Technologies</td>
<td>2303</td>
</tr>
<tr>
<td></td>
<td>SuiteMed, LLC</td>
<td>2305</td>
</tr>
<tr>
<td></td>
<td>TheraManager LLC</td>
<td>1719</td>
</tr>
<tr>
<td></td>
<td>Valant Medical Solutions</td>
<td>823</td>
</tr>
<tr>
<td>FEDERAL GOVERNMENT</td>
<td>Defense Centers of Excellence (DCOE) for Psychological Health and Traumatic Brain Injury</td>
<td>2405</td>
</tr>
<tr>
<td>FINANCIAL SERVICES</td>
<td>Merrill Lynch</td>
<td>2237</td>
</tr>
<tr>
<td>HOSPITAL/RESIDENTIAL AND OUTPATIENT CLINICS</td>
<td>Austen Riggs Center</td>
<td>1722</td>
</tr>
<tr>
<td></td>
<td>Borgess Health</td>
<td>2002</td>
</tr>
<tr>
<td></td>
<td>Haven Behavioral Healthcare</td>
<td>2105</td>
</tr>
<tr>
<td></td>
<td>McLean Hospital</td>
<td>1735</td>
</tr>
<tr>
<td></td>
<td>The Menninger Clinic</td>
<td>2235</td>
</tr>
<tr>
<td></td>
<td>NewYork-Presbyterian Hospital</td>
<td>316</td>
</tr>
<tr>
<td></td>
<td>Pine Rest Christian Mental Health Services</td>
<td>2013</td>
</tr>
<tr>
<td></td>
<td>The Reading Hospital and Medical Center</td>
<td>2309</td>
</tr>
<tr>
<td>INSURANCE</td>
<td>The Psychiatrists' Program</td>
<td>916</td>
</tr>
<tr>
<td></td>
<td>American Professional Agency</td>
<td>2412</td>
</tr>
<tr>
<td>LIFE SCIENCES DATA COMPANY</td>
<td>CNS Response, Inc.</td>
<td>1825</td>
</tr>
<tr>
<td>LOCUM TENENS/RECRUITMENT</td>
<td>Favorite Physicians</td>
<td>2113</td>
</tr>
<tr>
<td></td>
<td>Global Medical Staffing</td>
<td>1810</td>
</tr>
<tr>
<td></td>
<td>Interim Physicians</td>
<td>1823</td>
</tr>
<tr>
<td></td>
<td>Medical Doctor Associates</td>
<td>1738</td>
</tr>
</tbody>
</table>

www.psych.org
EXHIBITORS BY PRODUCT/SERVICE LISTING

MAGAZINE
BP Magazine/esperanza .................................................................2134

MARKET RESEARCH
EXHIBITCHEK .............................................................................2233

MEDICAL BILLING SERVICE
Electromedical Products International, Inc. ..............................815
Fisher Wallace Laboratories .........................................................1238
The Magstim Company Limited ......................................................726
Medical Billing Professionals .........................................................1337
Neuronetics, Inc. ...........................................................................224

MEDICAL DEVICE
ACIGI Relaxation/Fujiiryoki ..........................................................2302

MEDICAL EDUCATION
15th World Congress of Psychiatry ..............................................14
American Physician Institute for Advanced Professional Studies ........................................824
Massachusetts General Hospital Academy ..................................2310
Sociedad Espanola de Patologia Dual (SEPDS) ...............................11
World Association for Social Psychiatry ....................................13

NON-PROFIT SELF-Help GROUP OR PROFESSIONAL ASSOCIATION
Alcoholics Anonymous .................................................................1234
American Board of Psychiatry and Neurology, Inc. .......................919
American College of Psychiatrists .................................................917
Association of Women Psychiatrists .............................................1023
Christian Medical Association, Psychiatry Section .......................936
International Psychogeriatric Association (IPA) ...............................826
Mayo Clinic ..................................................................................925
NARSAD and NARSAD Artworks .................................................938
National Institute of Mental Health .............................................1025
National Institute on Alcohol Abuse and Alcoholism .....................1031
Physicians for a National Health Program .....................................923

PHARMACEUTICAL COMPANIES
Alkermes, Inc. ...........................................................................1815, 2214
AstraZeneca Pharmaceuticals .......................................................416
Avanir Pharmaceuticals, Inc. .......................................................538
Bristol-Myers Squibb Company/Otsuka America Pharmaceutical, Inc. .....................................................1032
DSP/Sepracor Inc. ........................................................................2102
Dey Pharma, L.P. ..........................................................................2210
Forest Pharmaceuticals, Inc. .......................................................434
Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. ........................................................................733
Lilly USA, LLC .............................................................................734
Merck ..........................................................................................2216, 2314
Novartis Pharmaceuticals ............................................................638, 1716, 2101, 2301
Pamlab, LLC .................................................................................415
Pfizer, Inc. ....................................................................................1816
Reckitt Benckiser Pharmaceuticals .............................................2330
Sepracor Inc. ..............................................................................2110
Shire Pharmaceuticals ..................................................................216
TEVA Pharmaceuticals ..................................................................1723
Validus Pharmaceuticals, LLC .....................................................2230

PHARMACEUTICAL, DISEASE STATE AWARENESS
Boehringer Ingelheim Pharmaceuticals, Inc. ................................818

PHOTOTHERAPY
The Litebook Company Ltd. .........................................................634
Northern Light Technologies .........................................................816
Philips Consumer Lifestyle .........................................................1838
Uplift Technologies Inc. .................................................................423

PRACTICE MANAGEMENT
American Express® OPEN .........................................................737

PROFESSIONAL SUPPORT
Association of Gay and Lesbian Psychiatrists .........................932
ECNP Congress - European College of Neuropsychopharmacology ..................................................12
PSYCHIATRIC FACILITIES

Austin Lakes Hospital, Texas Neuro Rehab and Hickory Trail .................................................. 2212

Bassett Healthcare Network - Bassett Medical Center .............................................................. 1904

CBR Youth Connect ..................................................................................................................... 326

The Center for Eating Disorders at Sheppard Pratt ................................................................. 1717

Gould Farm .................................................................................................................................. 1933

La Amistad Foundation, Inc., Lakewood Center ...................................................................... 2206

Pine Rest Christian Mental Health Services ............................................................................ 2013

Psychiatric Solutions, Inc. ......................................................................................................... 1832

River Valley Behavioral Health ................................................................................................. 819

Sheppard Pratt Health System ................................................................................................... 1715

Singing River Hospital Behavioral Health Services ............................................................... 1909

Skyland Trail ............................................................................................................................. 724

PUBLISHERS/BOOKSELLERS

American Psychological Association .......................................................................................... 1636

BioMed Central .......................................................................................................................... 1538

Cambridge University Press ...................................................................................................... 1533

Clinical Psychiatry News ........................................................................................................... 720

Current Psychiatry/Quadrant Healthcom ............................................................................... 1620

Elsevier ......................................................................................................................................... 1429

Guilford Publications .................................................................................................................. 1534

Hogrefe Publishing ..................................................................................................................... 1630

Intellisphere, LLC ........................................................................................................................ 1435

Johns Hopkins University Press ............................................................................................... 1430

Jones & Bartlett ........................................................................................................................... 1629

Karger Publishers ........................................................................................................................ 1726

La Lettre du Psychiatre .............................................................................................................. 425

Lippincott Williams & Wilkins, Wolters-Kluwer .................................................................. 1616

MBL Communications, Inc. ......................................................................................................... 1730

Nature Publishing Group ............................................................................................................. 1331

The New York Times ................................................................................................................... 1632

Oxford University Press ............................................................................................................. 1330

Psychiatric Times ....................................................................................................................... 1821

Rapid Psychler Press ................................................................................................................... 1336

Routledge Journals ..................................................................................................................... 1434

Routledge ..................................................................................................................................... 1438

Royal College of Psychiatrists ................................................................................................... 1530

SOS Programs & Parents Press .................................................................................................. 1633

W.W. Norton .................................................................................................................................. 1529

Wiley - Blackwell ......................................................................................................................... 1624

RECRUITMENT

All Star Recruiting ...................................................................................................................... 2001

Allina Hospitals and Clinics ..................................................................................................... 2009

Army Healthcare Recruiting ..................................................................................................... 2012

BHR Corporation ....................................................................................................................... 1806

CareerStaff Unlimited ................................................................................................................. 215

Center for Family Guidance (CFG) ............................................................................................ 2006

CompHealth .................................................................................................................................. 2109

Department of Veterans Affairs ................................................................................................. 1804

Doctors Behavioral Health Center ............................................................................................. 2312

Duluth Clinic ................................................................................................................................ 2011

Floyd Behavioral Health Center ................................................................................................. 1905

Genesis Healthcare System ......................................................................................................... 1837

Group Health Permanente .......................................................................................................... 2311

Health Match BC ......................................................................................................................... 1902

HealthforceOntario Marketing and Recruitment Agency .......................................................... 1912

Hospital Corporation of America (HCA) .................................................................................. 2010

International Medical Recruitment ............................................................................................. 1910

Jackson & Coker .......................................................................................................................... 1802

Kaiser Permanente ...................................................................................................................... 2005

Kiwis STAT ................................................................................................................................... 2306

LocumTenens.com ....................................................................................................................... 1729

Maxim Physician Resources ....................................................................................................... 419

Medical Associates Clinic ........................................................................................................... 1901

Ministry Health Care .................................................................................................................... 1814

Netsmart Technologies ................................................................................................................. 2303

North Carolina Office of Rural Health ....................................................................................... 1911
**EXHIBITORS BY PRODUCT/SERVICE LISTING**

**PHYSICIAN FINDERS** .......................................................... 2429
**PIKES PEAK BEHAVIORAL HEALTH GROUP** .................. 2404
**PINE REST CHRISTIAN MENTAL HEALTH SERVICES** .... 2013
**PracticeLink.com** ................................................................. 1913
**Psychiatrists Only, LLC** ....................................................... 915
**QTC Medical Services** ......................................................... 825
**The Reading Hospital and Medical Center** ................. 2309
**Registry of Physician Specialists** .................................... 1724
**Robert Young Center for Community Mental Health** ...... 2003
**Spartanburg Regional** .......................................................... 2004
**Staff Care, Inc.** ................................................................. 924
**U.S. Army Civilian Corps** .................................................... 1903
**U.S. Navy Recruiting** ........................................................... 2202
**U.S. Public Health Service** ................................................... 2409
**VA Northwest Health Network** ........................................ 2111
**VISTA Staffing Solutions, Inc.** .......................................... 1232

**STATE/FEDERAL**

**FDA/ Division of Drug Marketing, Advertising, and Communications** ................. 2136
**National Institute on Drug Abuse (NIDA)** .................... 1033
**Oregon State Hospital** ......................................................... 1906
**Social Security Administration** ........................................... 2204
**U.S. Department of State, Office of Medical Services** ...... 1812

**SUBSTANCE ABUSE TREATMENT CENTERS**
**Rosecrance Health Network** .............................................. 636

**SUICIDE RESISTANT SOLUTIONS**
**Atlantic Coastal Supply, Inc.** ............................................. 1835

**TELEHEALTH NETWORK**
**Forefront Behavioral Telecare** ......................................... 2103

**THERAPEUTIC MASSAGE EQUIPMENT**
**ACIGI Relaxation/Fujiiryoki** ............................................... 2302
**RVJ International LLC /Happy Feet, Inc.** ......................... 324

**WEBSITE DESIGN SEARCH ENGINE OPTIMIZATION**
**MedNet Technologies, Inc.** .............................................. 320

---

**NEW ORLEANS, LA**
**MAY 22-26, 2010**

**EXHIBIT HALL RECEPTION**

**Monday, May 24**
**12:30 pm — 1:30 pm**

**Exhibit Hall B-D, First Level, Morial Convention Center**
Open to all registrants

Join us for fun, food, meet colleagues and visit the exhibits. Box lunch will be provided first come first served and soft drinks.
<table>
<thead>
<tr>
<th>CAREER FAIR EXHIBITORS</th>
<th>PUBLISHER’S BOOK FAIR EXHIBITORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Star Recruiting</td>
<td>American Psychological Association</td>
</tr>
<tr>
<td>Allina Hospitals and Clinics</td>
<td>BioMed Central</td>
</tr>
<tr>
<td>U.S. Army Healthcare Recruiting</td>
<td>Cambridge University Press</td>
</tr>
<tr>
<td>Bassett Healthcare Network - Bassett Medical</td>
<td>Current Psychiatry/Quadrant Healthcom</td>
</tr>
<tr>
<td>Center for Family Guidance (CFG)</td>
<td>Elsevier</td>
</tr>
<tr>
<td>Department of Veterans Affairs</td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>Doctors Behavioral Health Center</td>
<td>Hogrefe Publishing</td>
</tr>
<tr>
<td>duluth Clinic</td>
<td>Intellisphere, LLC</td>
</tr>
<tr>
<td>Favorite Physicians</td>
<td>Johns Hopkins University Press</td>
</tr>
<tr>
<td>Floyd Behavioral Health Center</td>
<td>Jones &amp; Bartlett</td>
</tr>
<tr>
<td>Global Medical Staffing</td>
<td>Lippincott Williams &amp; Wilkins, Wolters-Kluwer</td>
</tr>
<tr>
<td>Health Match BC</td>
<td>MBL Communications, Inc.</td>
</tr>
<tr>
<td>HealthForceOntario Marketing and Recruitment</td>
<td>Nature Publishing Group</td>
</tr>
<tr>
<td>Hospital Corporation of America (HCA)</td>
<td>The New York Times</td>
</tr>
<tr>
<td>International Medical Recruitment</td>
<td>Oxford University Press</td>
</tr>
<tr>
<td>Jackson &amp; Coker</td>
<td>Rapid Psychler Press</td>
</tr>
<tr>
<td>Kaiser Permanente</td>
<td>Routledge</td>
</tr>
<tr>
<td>Kiwis STAT</td>
<td>Royal College of Psychiatrists</td>
</tr>
<tr>
<td>Medical Associates Clinic</td>
<td>SOS Programs &amp; Parents Press</td>
</tr>
<tr>
<td>Ministry Health Care</td>
<td>W.W. Norton</td>
</tr>
<tr>
<td>Netsmart Technologies</td>
<td>Wiley - Blackwell</td>
</tr>
<tr>
<td>North Carolina Office of Rural Health</td>
<td></td>
</tr>
<tr>
<td>Oregon State Hospital</td>
<td></td>
</tr>
<tr>
<td>Pine Rest Christian Mental Health Services</td>
<td></td>
</tr>
<tr>
<td>PracticeLink.com</td>
<td></td>
</tr>
<tr>
<td>The Reading Hospital and Medical Center</td>
<td></td>
</tr>
</tbody>
</table>

**Robert Young Center for Community Mental Health** .......................................................2003
**Singing River Hospital Behavioral Health Services** ..................................................1909
**Spartanburg Regional** ....................................................................................................2004
**U.S. Army Civilian Corps** .................................................................................................1903
**U.S. Department of State, Office of Medical Services** ..............................................1812
**VA Northwest Health Network** ........................................................................................2111
“Each day is challenging.
Each day is different.
Each day is rewarding…”

Captein Paul Andreason, Psychiatrist,
U.S. Public Health Service Commissioned Corps

BE A LEADER IN MENTAL HEALTH.

Have you ever wished you could repay the brave men and women who protect our country every day? Now you can. As an officer in the U.S. Public Health Commissioned Corps, you will be practicing in a medical treatment facility in the United States and join an elite team that provides psychiatric services, counseling and family and group therapy to returning warriors, their family members, and military retirees.

The rewards are great, including health coverage, tax-free allowances for housing and food, 30 days of vacation each year—and the knowledge that you are helping those who serve. So, if you are a clinical psychiatrist or a licensed clinical behavioral health provider, please visit USPHS.gov or call 1-800-279-1605 to find out if this is the opportunity you’ve been waiting for.

READY TO MAKE A DIFFERENCE?
MEET WITH A COMMISSIONED CORPS OFFICER FACE-TO-FACE. VISIT OUR BOOTH AT THE CONFERENCE.
www.usphs.gov  1-800-279-1605

www.usphs.gov
1-800-279-1605

We’re recruiting
Psychiatrists.

Where all your skills come together to treat the most complex needs.

We offer challenging and rewarding careers that allow you to enrich the futures of people who need you.

> Loan repayment program
> State retirement package
> Excellent health insurance benefits
> Paid malpractice insurance

For career information, contact:
Michael Taylor
1-800-533-8847
michael.taylor@dhhs.nc.gov
www.dhhs.state.nc.us/dsohf/
Booth #1911

Now recruiting:
Psychiatrist • Neuropsychologists • Mental Health Nurse Practitioner

The Reading Hospital and Medical Center in West Reading, PA, is seeking candidates to fill the following openings:

Psychiatrist - Full-time outpatient position at our Main Campus

Neuropsychologists - Full-time inpatient and full-time inpatient/outpatient for our Post-Acute Rehabilitation Hospital

Mental Health Nurse Practitioner - Full-time outpatient (with some inpatient consultation) for our Mental Health Center

Excellent schools and colleges and a multitude of cultural, recreational, shopping and sporting attractions are in the vicinity.

You will enjoy country living with easy access to shore points, two airports and major metro areas, such as Philadelphia, Washington, DC and New York City.

To apply, send your CV to:
Maddie Wagner,
Physician Recruiter,
madeline.wagner@trhmg.org.

To learn more, visit our website:
www.readingdocs.org

Visit us at Booth Number 2309 at the American Psychiatric Association Annual Meeting in New Orleans

About Our Psychiatry Department

• 5+ year history
• 40-bed, state-of-the-art inpatient pavilion
• 2 partial-hospitalization programs
• Residential non-medical detoxification and rehabilitation center
• Intensive outpatient dual disorder program
• Multiple outpatient centers located throughout Berks County

What We Offer

• Competitive salary
• Medical/dental/life insurance
• Occurrence-based malpractice insurance
• Generous paid time off
• CME allowance
• Retirement plans
• Student loan forgiveness programs
Adult Psychiatrist:

Cumberland, Maryland, needed to work 32-40 hours per week in modern JCAHO Accredited State of Maryland Psychiatric Hospital, located in the beautiful mountains of Western Maryland. This position would serve as a unit physician for a 22-bed adult unit. This position would also serve as the leader of a multi-disciplinary treatment team including psychologists, social workers, occupational therapists and nurses. Position requires minimal contact with Managed Care Providers. This is a contractual position paying $110-$113 per hour with the availability of health benefits and 401K plans. Additional income is available by working on-duty (evenings, nights and weekends) coverage if interested. Send CV to Thomas B. Finan Center, Clinical Director, PO Box 1722, Cumberland, MD 21501-1722. Interested psychiatrists may also inquire by calling 1-888-854-0035. The Thomas B. Finan Center is an Equal Opportunity Employer

HUMAN RIGHTS AWARD

The Human Rights Award was established to recognize an individual and an organization whose efforts exemplify the capacity of human beings to act courageously and effectively to prevent human rights violations, to protect others from human rights violations and their psychiatric consequences, and to help victims recover from human rights abuses.

Nomination Procedures

APA members are asked to submit nominations by July 1, 2010 to:

Council on Psychiatry and Law
American Psychiatric Association
c/o Yoshiie Davison, Staff Liaison
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209
E-mail: advocacy@psych.org

The nomination letter should succinctly describe the contributions that are the basis for the nomination and be accompanied by a curriculum vitae of the nominee. The Council on Psychiatry and Law will serve as the award review panel in determining the recipients of this award. The recipients will receive a plaque which will be awarded during the Convocation at the APA’s Annual Meeting in May 2011.
Since 1875, Pikes Peak Behavioral Health Group has created help and hope for residents of Colorado Springs and surrounding areas. We provide a broad range of services to meet individual and family needs in mental health, substance abuse, and much more. Nationally recognized for our philosophy of recovery, we have outstanding opportunities for:

Licensed Psychiatrists (MD/DO)

If you share our vision of creating a mentally healthy community where the worth and dignity of every person is promoted and encouraged, we would like to talk with you. Stop by our booth to learn more about our dynamic team environment. We will be setting up interviews that will be conducted around the conference schedule.

Committed to being an employer of choice, Pikes Peak Behavioral Health Group offers a comprehensive benefits program in order to attract and retain the best employees. Feel free to contact Mariah McCarty, Manager of Recruiting at: 719-499-9540 or Mariah.McCarty@ppbhg.org. Visit us online at www.ppbhg.org.

PHYSICIAN FINDERS
Nationwide Physician Placement – 800-229-9759

THE BRATTLEBORO RETREAT, located in Brattleboro, Vermont, is pleased to announce immediate opportunities for three medical staff positions in our comprehensive psychiatric facility. We are seeking leaders in the following positions:

- Inpatient adult psychiatry, Inpatient Psychiatry for LGBT patients
- Outpatient psychiatry

http://www.brattlebororetreat.org – The Brattleboro Retreat webpage

PROVIDENCE BEHAVIORAL HEALTH HOSPITAL, located in Springfield, Massachusetts, is searching for a Medical Director in the following specialty areas, Substance Abuse Services, Adult Services and Child and Adolescent Services.

The facility has 124 inpatient beds and is comprised of 3 psychiatric units treating Adults, Older Adults, Child and Adolescents; a 30 bed inpatient Detoxification unit, an Acute Residential Treatment program for children and adolescents and a Methadone Maintenance Treatment Program.

http://www.mercycares.com/pages.asp?id=514

SUNPOINTE HEALTH would like to announce our search for an additional psychiatrist to join our team of 9 psychiatrists and 37 providers in our privately owned practice in State College, Pennsylvania.

Our group, founded in 1998, has tripled in size in the last 6 years. We occupy 28k square feet of beautiful office space, which is one of 9 practice sites in which we maintain a presence. Currently, we see over 4k patient visits each month.

http://forabrighterfuture.com/

For information about these positions and others, please contact Gene.Corbett@physicianfinders.com.

THE STRENGTH TO HEAL
through teamwork that goes beyond what’s necessary.

Capt. Kristy Hoyuela
Fort Sam Houston, Texas

“...you get to know your colleagues not just as physicians, but as people.”
As an Army psychiatrist, you will work with a variety of physicians who are leaders in their field. From examination to diagnosis and prescribing treatment, you’ll be equipped to help our Soldiers and their families to cope with emotional or mental illness. You’ll thrive in a collaborative environment that will expand your experience, your career and your life.

Stop by Booth No. 2012 or contact a member of the U.S. Army Health Care Team at 800-235-4963 or healthcare.goarmy.com/info/1407.
Ask about our two-year commitment for health care professionals ages 43-60.
**Exhibit Booths 11-14 are located in the Exhibit Hall Lobby.**

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Exhibitor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Sociedad Espanola de Patologia Dual (SEPD)</td>
</tr>
<tr>
<td>12</td>
<td>ECNP Congress - European College of Neuropsychopharmacology</td>
</tr>
<tr>
<td>13</td>
<td>World Association for Social Psychiatry</td>
</tr>
<tr>
<td>14</td>
<td>15th World Congress of Psychiatry</td>
</tr>
</tbody>
</table>

**The following booths are located in the Exhibit Hall.**

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Exhibitor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>215</td>
<td>CareerStaff Unlimited</td>
</tr>
<tr>
<td>216</td>
<td>Shire Pharmaceuticals</td>
</tr>
<tr>
<td>217</td>
<td>PracticeFusion</td>
</tr>
<tr>
<td>224</td>
<td>Neuronetics, Inc.</td>
</tr>
<tr>
<td>227</td>
<td>American Association for Geriatric Psychiatry</td>
</tr>
<tr>
<td>316</td>
<td>New York-Presbyterian Hospital</td>
</tr>
<tr>
<td>320</td>
<td>MedNet Technologies, Inc.</td>
</tr>
<tr>
<td>324</td>
<td>RVJ International LLC / Happy Feet, Inc.</td>
</tr>
<tr>
<td>326</td>
<td>CBR Youth Connect</td>
</tr>
<tr>
<td>328</td>
<td>Cannon Design</td>
</tr>
<tr>
<td>415</td>
<td>Pamlab, LLC</td>
</tr>
<tr>
<td>416</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>419</td>
<td>Maxim Physician Resources</td>
</tr>
<tr>
<td>423</td>
<td>Uplift Technologies Inc.</td>
</tr>
<tr>
<td>425</td>
<td>La Lettre du Psychiatre</td>
</tr>
<tr>
<td>434</td>
<td>Forest Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>534</td>
<td>National Death Index</td>
</tr>
<tr>
<td>538</td>
<td>Avanir Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>633</td>
<td>MentalNote</td>
</tr>
<tr>
<td>634</td>
<td>The Litebook Company Ltd.</td>
</tr>
<tr>
<td>636</td>
<td>Rosecrance Health Network</td>
</tr>
<tr>
<td>638</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>716</td>
<td>MECTA Corporation</td>
</tr>
<tr>
<td>720</td>
<td>Clinical Psychiatry News</td>
</tr>
<tr>
<td>724</td>
<td>Skyland Trail</td>
</tr>
<tr>
<td>726</td>
<td>The Magstim Company Limited</td>
</tr>
<tr>
<td>728</td>
<td>Somatics LLC</td>
</tr>
<tr>
<td>733</td>
<td>Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>734</td>
<td>Lilly USA, LLC</td>
</tr>
<tr>
<td>737</td>
<td>American Express® OPEN</td>
</tr>
<tr>
<td>815</td>
<td>Electromedical Products International, Inc.</td>
</tr>
<tr>
<td>816</td>
<td>Northern Light Technologies</td>
</tr>
<tr>
<td>818</td>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>819</td>
<td>River Valley Behavioral Health</td>
</tr>
<tr>
<td>823</td>
<td>Valant Medical Solutions</td>
</tr>
<tr>
<td>824</td>
<td>American Physician Institute for Advanced Professional Studies</td>
</tr>
<tr>
<td>825</td>
<td>QTC Medical Services</td>
</tr>
<tr>
<td>826</td>
<td>International Psychogeriatric Association (IPA)</td>
</tr>
<tr>
<td>827</td>
<td>CNS Vital Signs</td>
</tr>
<tr>
<td>828</td>
<td>Lexicor Medical Technology, LLC</td>
</tr>
<tr>
<td>915</td>
<td>Psychiatrists Only, LLC</td>
</tr>
<tr>
<td>916</td>
<td>The Psychiatrists’ Program</td>
</tr>
<tr>
<td>917</td>
<td>American College of Psychiatrists</td>
</tr>
<tr>
<td>919</td>
<td>American Board of Psychiatry and Neurology, Inc.</td>
</tr>
<tr>
<td>922</td>
<td>American Academy of Psychiatry and the Law</td>
</tr>
<tr>
<td>923</td>
<td>Physicians for a National Health Program</td>
</tr>
<tr>
<td>924</td>
<td>Staff Care, Inc.</td>
</tr>
<tr>
<td>925</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Booth Number</td>
<td>Exhibitor Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>1722</td>
<td>Austen Riggs Center</td>
</tr>
<tr>
<td>1723</td>
<td>TEVA Pharmaceuticals</td>
</tr>
<tr>
<td>1724</td>
<td>Registry of Physician Specialists</td>
</tr>
<tr>
<td>1726</td>
<td>Karger Publishers</td>
</tr>
<tr>
<td>1729</td>
<td>LocumTenens.com</td>
</tr>
<tr>
<td>1730</td>
<td>MBL Communications, Inc.</td>
</tr>
<tr>
<td>1735</td>
<td>McLean Hospital</td>
</tr>
<tr>
<td>1736</td>
<td>ICANotes</td>
</tr>
<tr>
<td>1738</td>
<td>Medical Doctor Associates</td>
</tr>
<tr>
<td>1802</td>
<td>Jackson &amp; Coker</td>
</tr>
<tr>
<td>1804</td>
<td>Department of Veterans Affairs</td>
</tr>
<tr>
<td>1806</td>
<td>BHR Corporation</td>
</tr>
<tr>
<td>1810</td>
<td>Global Medical Staffing</td>
</tr>
<tr>
<td>1812</td>
<td>U.S. Department of State, Office of Medical Services</td>
</tr>
<tr>
<td>1814</td>
<td>Ministry Health Care</td>
</tr>
<tr>
<td>1815</td>
<td>Alkermes, Inc.</td>
</tr>
<tr>
<td>1816</td>
<td>Pfizer, Inc.</td>
</tr>
<tr>
<td>1821</td>
<td>Psychiatric Times</td>
</tr>
<tr>
<td>1823</td>
<td>Interim Physicians</td>
</tr>
<tr>
<td>1825</td>
<td>CNS Response, Inc.</td>
</tr>
<tr>
<td>1832</td>
<td>Psychiatric Solutions, Inc.</td>
</tr>
<tr>
<td>1835</td>
<td>Atlantic Coastal Supply, Inc.</td>
</tr>
<tr>
<td>Booth Number</td>
<td>Exhibitor Name</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>1837</td>
<td>Genesis Healthcare System</td>
</tr>
<tr>
<td>1838</td>
<td>Philips Consumer Lifestyle</td>
</tr>
<tr>
<td>1901</td>
<td>Medical Associates Clinic</td>
</tr>
<tr>
<td>1902</td>
<td>Health Match BC</td>
</tr>
<tr>
<td>1903</td>
<td>U.S. Army Civilian Corps</td>
</tr>
<tr>
<td>1904</td>
<td>Bassett Healthcare Network - Bassett Medical Center</td>
</tr>
<tr>
<td>1905</td>
<td>Floyd Behavioral Health Center</td>
</tr>
<tr>
<td>1906</td>
<td>Oregon State Hospital</td>
</tr>
<tr>
<td>1909</td>
<td>Singing River Hospital Behavioral Health Services</td>
</tr>
<tr>
<td>1910</td>
<td>International Medical Recruitment</td>
</tr>
<tr>
<td>1911</td>
<td>North Carolina Office of Rural Health</td>
</tr>
<tr>
<td>1912</td>
<td>HealthforceOntario Marketing and Recruitment Agency</td>
</tr>
<tr>
<td>1913</td>
<td>PracticeLink.com</td>
</tr>
<tr>
<td>1931</td>
<td>SZ Magazine</td>
</tr>
<tr>
<td>1933</td>
<td>Gould Farm</td>
</tr>
<tr>
<td>2001</td>
<td>All Star Recruiting</td>
</tr>
<tr>
<td>2002</td>
<td>Borgess Health</td>
</tr>
<tr>
<td>2003</td>
<td>Robert Young Center for Community Mental Health</td>
</tr>
<tr>
<td>2004</td>
<td>Spartanburg Regional</td>
</tr>
<tr>
<td>2005</td>
<td>Kaiser Permanente</td>
</tr>
<tr>
<td>2006</td>
<td>Center for Family Guidance (CFG) Health Network</td>
</tr>
<tr>
<td>2009</td>
<td>Allina Hospitals and Clinics</td>
</tr>
<tr>
<td>2010</td>
<td>Hospital Corporation of America (HCA)</td>
</tr>
<tr>
<td>2011</td>
<td>Duluth Clinic</td>
</tr>
<tr>
<td>2012</td>
<td>Army Healthcare Recruiting</td>
</tr>
<tr>
<td>2013</td>
<td>Pine Rest Christian Mental Health Services</td>
</tr>
<tr>
<td>2101</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>2102</td>
<td>DSP/Sepracor Inc.</td>
</tr>
<tr>
<td>2103</td>
<td>Forefront Behavioral Telecare</td>
</tr>
<tr>
<td>2105</td>
<td>Haven Behavioral Healthcare</td>
</tr>
<tr>
<td>2109</td>
<td>CompHealth</td>
</tr>
<tr>
<td>2110</td>
<td>Sepracor Inc.</td>
</tr>
<tr>
<td>2111</td>
<td>VA Northwest Health Network</td>
</tr>
<tr>
<td>2113</td>
<td>Favorite Physicians</td>
</tr>
</tbody>
</table>
SUBSCRIBE TO
PSYCHIATRIC SERVICES

Each issue covers an array of topics, with a focus on people with serious mental illness:

• Evidence-based and best practices: delivering effective services and programs
• Recovery-oriented, client-centered care: how systems are being transformed
• Racial-ethnic disparities in care: how they arise and how to overcome them
• Criminal justice involvement and homelessness: diversion and housing programs
• Use of medications: improving adherence, monitoring trends and treatment adequacy
• Medicaid changes and recent court cases: what they mean for your practice

Visit the APPI Bookstore for more information or to subscribe.
Bookstore Hours: Saturday, May 22 to Tuesday, May 25, 10:00am - 4:00pm

The First and Last Word in Psychiatry
www.appi.org • Toll Free: 1-800-368-5777 • Fax: 703-907-1091 • Email: appi@psych.org
Priority Code AH1025
APA Member Benefits and Services
That Make a Difference!

RECEIVE DISCOUNTS ON QUALITY SERVICES for you and your practice with these additional benefits:

■ Professional Benefits
  • Free Web Page on PsychSites.com
    Promote your practice, career, and expertise to patients and colleagues
  • FDA-mandated drug Alerts by Email
    Sign up for secure online drug and patient safety alerts through the Health Care Notification Network (HCNN)
  • Clinical Reference Applications at the Point-of-Care
    Receive 20% discount off retail pricing on electronic subscription products through Epocrates
  • APA Job Bank
    Online career search and recruitment
  • American Psychiatric Publishing, Inc. (APPI)
    Receive a 10% discount on all APPI titles (Members-in-Training receive 25% off APPI titles)

■ Financial Tools
  • Merrill Lynch Retirement and Investment Planning
    Meet your short and long-term retirement and financial planning goals
  • Bank of America Credit Cards and Financial Tools
    Earn WorldPoints™ Rewards
  • Soleras Payment Systems
    Affordable tools to effectively manage patient payments

■ Professional Liability Insurance and Money Saving Legal Consultation
  • The Psychiatrists’ Program
    Medical malpractice insurance for psychiatrists
  • Legal Consultation
    Find money-saving legal consultation with APA’s Legal Information and Consultation Plan (separate fee)

■ Personal Benefits
  • Car Rentals
    Substantial discounts from Alamo, Avis, Budget, Hertz, or National
  • Magazine Subscriptions
    Save up to 50% off regular subscription rates on magazines
  • Save on Office Expenses
    Receive APA member discounts on FedEx shipping and Penny-Wise Office Supplies

Learn more about these benefits and other services at www.psych.org/Membership

QUESTIONS? Contact APA Answer Center
Call Toll-Free: 1-888-35-PSYCH • Email: apa@psych.org • From outside the U.S. and Canada call: 1-703-907-7300
<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaronson, Scott T.</td>
<td>Baez-Sierra, Deyadira</td>
</tr>
<tr>
<td>Abbas, Muhammad A.</td>
<td>Bag, Muhammad R.</td>
</tr>
<tr>
<td>Abbey, Susan E.</td>
<td>Bailey, John T.</td>
</tr>
<tr>
<td>Abdallah, Chadi</td>
<td>Baker, Allison S.</td>
</tr>
<tr>
<td>Abuela, John</td>
<td>Baldwin, David</td>
</tr>
<tr>
<td>Abouzaid, Safiya</td>
<td>Bailey, Ruben D.</td>
</tr>
<tr>
<td>Abrams, Alan A.</td>
<td>Balfour, Margaret</td>
</tr>
<tr>
<td>Abramson, Ronald</td>
<td>Balis, Theodora G.</td>
</tr>
<tr>
<td>Abreu, Lena</td>
<td>Bakoski, Victoria</td>
</tr>
<tr>
<td>Acosta-Heriberto, Juliana</td>
<td>Ball, Samuel A.</td>
</tr>
<tr>
<td>Adams, Curtis N., Jr.</td>
<td>Ball, Valdesha</td>
</tr>
<tr>
<td>Adams, Julie</td>
<td>Balon, Richard</td>
</tr>
<tr>
<td>Addison, Jean M.</td>
<td>Bandelow, Borwin</td>
</tr>
<tr>
<td>Adelson, Stewart L.</td>
<td>Bandstra, Belinda S.</td>
</tr>
<tr>
<td>Adler, Lawrence</td>
<td>Baptista, Trino J.</td>
</tr>
<tr>
<td>Afifi, Saraham</td>
<td>Barak, Nir</td>
</tr>
<tr>
<td>Aggarwal, Neil K.</td>
<td>Barak, Yoram</td>
</tr>
<tr>
<td>Agid, Ofir</td>
<td>Barber, Jacques P.</td>
</tr>
<tr>
<td>Ahmed, I.</td>
<td>Barber, Mary E.</td>
</tr>
<tr>
<td>Aizenstein, Howard</td>
<td>Barkley, Russel A.</td>
</tr>
<tr>
<td>Akkisi Kumsar, Neslihan</td>
<td>Barlow, Carolee</td>
</tr>
<tr>
<td>Akin, Will M.</td>
<td>Baron, David A.</td>
</tr>
<tr>
<td>Alam, Faouzi</td>
<td>Barr, Ellen F.</td>
</tr>
<tr>
<td>Lao, Adeikola</td>
<td>Barreia, Paul J.</td>
</tr>
<tr>
<td>Alcorn, Harry, Jr.</td>
<td>Bateman, Anthony W.</td>
</tr>
<tr>
<td>Ali, Asghar-Ali A.</td>
<td>Bates, Lisa M.</td>
</tr>
<tr>
<td>All, Mohamed</td>
<td>Batki, Steven L.</td>
</tr>
<tr>
<td>Almeida, Karla</td>
<td>Bauer, Amy M.</td>
</tr>
<tr>
<td>Alphs, Larry</td>
<td>Bauer, Michael</td>
</tr>
<tr>
<td>Al-Saaidi, Sam</td>
<td>Baum, Antonia L.</td>
</tr>
<tr>
<td>Amin, Mona</td>
<td>Beck, Judith S.</td>
</tr>
<tr>
<td>Amir, Asad</td>
<td>Becker, Daniel F.</td>
</tr>
<tr>
<td>An, Hoyoung</td>
<td>Beezhold, Julian</td>
</tr>
<tr>
<td>Anderson, Alan A.</td>
<td>Beighley, Paul</td>
</tr>
<tr>
<td>Anson, Andrew</td>
<td>Belfort, Edgard</td>
</tr>
<tr>
<td>Anzia, Joan M.</td>
<td>Bellocchio, Elizabeth</td>
</tr>
<tr>
<td>Apiquaian, Rogelio</td>
<td>Beinap, Barri</td>
</tr>
<tr>
<td>Appelbaum, Paul S.</td>
<td>Bender, Donna S.</td>
</tr>
<tr>
<td>Apter, Gisèle</td>
<td>Benedek, Elissa P.</td>
</tr>
<tr>
<td>Arean, Patricia A.</td>
<td>Benes, Francine M.</td>
</tr>
<tr>
<td>Arlinghaus, Kimberly</td>
<td>Benitez, Joachim</td>
</tr>
<tr>
<td>Arnold, Lesley M.</td>
<td>Benjamin, Sheldon</td>
</tr>
<tr>
<td>Ascher-Svanum, Haya</td>
<td>Bennett, Robert M.</td>
</tr>
<tr>
<td>Ash, Peter</td>
<td>Benyamuna, Amine</td>
</tr>
<tr>
<td>Aslam, Sunay P.</td>
<td>Benson, Eugene</td>
</tr>
<tr>
<td>Amsal, Lalla</td>
<td>Berk, Michael</td>
</tr>
<tr>
<td>Atjijian, Silvia</td>
<td>Berksom, Sarah</td>
</tr>
<tr>
<td>Atkins, Robert M.</td>
<td>Berlin, Jon S.</td>
</tr>
<tr>
<td>Atri, Ashutosh</td>
<td>Bernstein, Carol A.</td>
</tr>
<tr>
<td>Auger, R. Robert</td>
<td>Bernhard, Hans-Rudolf</td>
</tr>
<tr>
<td>Avasthi, Ranjan</td>
<td>Bestha, Durga</td>
</tr>
<tr>
<td>Axelsson, Alan</td>
<td>Bhugra, Dinesh</td>
</tr>
<tr>
<td>Aydin, Cahide</td>
<td>Bishop-Baier, Margaret</td>
</tr>
<tr>
<td>Ayuso, Jose Luis</td>
<td>Biskin, Robert</td>
</tr>
<tr>
<td>Azeem, Muhammad Waqar</td>
<td>Bjork, James M.</td>
</tr>
<tr>
<td></td>
<td>Black, Donald W.</td>
</tr>
<tr>
<td></td>
<td>Blake, Martin</td>
</tr>
<tr>
<td></td>
<td>Bianco, Roberto A.</td>
</tr>
</tbody>
</table>

226  www.psych.org
PRESENTER INDEX

Blasco-Fontecilla, Hilario .................................................. 139, 156
Block, Jared J. .............................................................. 78
Blunn, Nancee S. .......................................................... 112
Bodkin, Robert ............................................................ 112
Boetgter, Sonke ............................................................ 83, 149
Bokarius, Vladimir ........................................................ 80
Boland, Robert J. ............................................................ 72
Boton, James M. .......................................................... 109, 111, 123
Bonnie, Richard ............................................................. 122
Book, Howard E. .......................................................... 62
Boo, Andrew ................................................................. 72
Bossie, Cynthia A. ......................................................... 159, 160
Boutrous, Nash N. .......................................................... 88, 111, 146
Bowden, Charles .......................................................... 81, 150, 153
Boyce, Cheryl Anne ....................................................... 106
Boyer, Jenny ................................................................. 80
Bradley, John C. ........................................................... 77, 89
Brady, Kathleen ............................................................ 78, 90, 98
Brans, Mathew ............................................................... 68, 79, 156
Brandt, Douglas M. ....................................................... 78, 90
Brendel, David H. .......................................................... 78
Brendel, Rebecca W ........................................................ 89
Brietzke, Elisabeth .......................................................... 151, 152
Briones, David F. ........................................................... 100
Briscoe, Brian ............................................................... 145
Brod, Thomas M. ........................................................... 78
Bromander, Sara ............................................................ 143
Brooks, Beth Ann .......................................................... 92, 125
Brooks, John O. ............................................................... 97
Broudy, Carolyn A. .......................................................... 113
Brow, Richard P. ............................................................. 66, 79
Brown, Thomas E. ........................................................... 78, 94, 156
Brum Moraes, Juliana ...................................................... 139
Bruno, Nicolas ............................................................... 141
Bryan, Dirks ................................................................. 155
Buckley, Peter F. ............................................................ 63, 79, 88
Budney, Alan J. .............................................................. 98, 98, 121
Buie, Stephen E. ............................................................. 78
Buist, Anne ................................................................. 113
Bullock, Karen .............................................................. 123
Buoli, Massimiliano .......................................................... 141, 147
Burd, Ronald M. ............................................................. 94, 108
Burke, Jack D. ................................................................. 91
Burpee, Stacey ............................................................... 67
Burton, M. Caroline ......................................................... 88, 116
Busner, Joan ................................................................. 93, 156
Byatt, Nancy ................................................................. 144

Cabaniss, Deborah .......................................................... 67, 89
Cadenhead, Kristin S. ....................................................... 77
Cain, Tonier ................................................................. 109
Cain, Zachary ............................................................... 155
Calabrese, Joseph R .......................................................... 112, 119, 149, 152
Calderon-Abbo, Jose ........................................................ 68
Caligor, Eve ................................................................. 79, 124
Calzada, Esther J ............................................................. 82
Camarena, Enrique .......................................................... 80
Cameron, Carter S .......................................................... 80
Campayo, Antonio J .......................................................... 95, 123
Campbell, Frank R. .......................................................... 62
Campbell, Herbert .......................................................... 71
Campbell, W. Keith .......................................................... 78
Candilis, Philip J. ............................................................. 120
Canuso, Amy ............................................................... 79, 136
Cao, Xiaohua ............................................................... 139, 140

Caplan, Jason ............................................................... 124
Carballo, Juan J. ........................................................... 156
Cardoner, Narcis ............................................................ 153, 154
Caring, Joanie .............................................................. 112
Carney, Colleen E ........................................................... 76, 141
Carpenter, Linda L .......................................................... 65, 68, 99
Carpenter, William T ....................................................... 114, 121
Carroll, Ian R. ............................................................... 82
Carroll, Kathleen M. ......................................................... 122
Carter, Anne ................................................................. 108
Carter, Diana ................................................................. 81, 158
Case, Michael G. ........................................................... 160
Casey, Daniel E. ............................................................. 150
Casey, David A. ............................................................. 93
Castellano, Xavier .......................................................... 107
Castellanos, Daniel ......................................................... 100
Castilla-Puentes, Ruby C .................................................... 118, 119, 125
Castilla-Puentes, Wilma ................................................. 118–119
Castro-Loli, Pio I ............................................................. 153
Caudill, Marissa ............................................................ 140
Cavender, Jennifer .......................................................... 163
Cazoria, Pilar ................................................................. 160
Cebolla, Susana S ............................................................. 143
Ceranoglu, Tolga A ........................................................... 70
Cernovsky, Zack Z ........................................................... 93, 124, 148, 149
Certa, Kenneth M ........................................................... 80
Chak, Mady ................................................................. 161
Chan, Carley H .............................................................. 86
Chan, Jonathan ............................................................. 144
Chandra, Prakash ............................................................ 79, 92
Chanen, Andrew M ........................................................... 77
Chang, Charlene ........................................................... 143
Chang, Kiki ................................................................. 66, 97
Chao, Faye ................................................................. 124
Chapman, Aaron .......................................................... 124
Chapman, Daniel P .......................................................... 123, 138, 155, 164
Chaudhary, Ayesha .......................................................... 76
Chaves, Ana Cristina ........................................................ 160
Cheema, Faiz A ............................................................. 138
Chen, Donna T .............................................................. 120
Cheon, Jin Sook ............................................................. 157
Chiasson, Ann Marie ......................................................... 108
Childress, Ann .............................................................. 111–112, 156
Childress, Anna Rose ...................................................... 120
Chilton, Julie A .............................................................. 79, 115
Chiu, Simon ................................................................. 93, 148, 149
Cho, Young Ju ............................................................. 143
Choi, Jungmi ................................................................. 140
Choi-Kein, Lois W ........................................................... 112, 113, 120
Chung, Bowen ............................................................ 97
Chung, Moon Young ....................................................... 146
Cia, Alfredo H .............................................................. 80
Clark, David L .............................................................. 68
Clark, Michael R. .......................................................... 89
Clarkin, John F ............................................................. 79, 124
Classi, Peter ............................................................... 145, 155
Clayton, Anita H ............................................................ 115
Clayton, Paula J ............................................................. 107
Cloninger, C. Robert ......................................................... 69
Cobb, Robert .............................................................. 81
Coconcea, Cristinel M ....................................................... 123
Coensyn, Craig J ........................................................... 68
Coffey, Barbara ............................................................ 92
Coffey, C. Edward ........................................................ 86
Coffey, M. Justin ........................................................... 67
Cohen, Carl I ............................................................... 69, 69, 143
Cohen, Lewis M ............................................................. 72, 120
Cohen, Michael ............................................................ 78
Cohen, Mitchell J.M. ......................................................... 67, 143
PRESENTER INDEX

Fetterolf, Frank A. ............................................................... 141
Fier, Jennifer ........................................................................ 139
Finn, Carla ........................................................................... 62, 84
Finnegan, Michael W. ..................................................... 162
Fiorello, Andrea .................................................................. 71
First, Michael B. .................................................................. 107
Fisher, Carrie ....................................................................... 101
Fishman, Robert S. .......................................................... 159, 160
Fitzelson, Elisabeth M ........................................................ 113
Fitzpatrick, Kathleen K. .................................................... 64
Flynn, Christopher ............................................................. 71
Flynn, David ........................................................................ 108
Flynn, Meredith B. ............................................................ 140
Fochtmann, Laura J. ............................................................ 63, 64, 83, 110, 163
Fonagy, Peter ........................................................................ 81, 113, 120, 124
Forero, Jorge .......................................................................... 119
Forester, Brent P. .............................................................. 106
Forstein, Marshall .............................................................. 106
Fosdick, Cara ....................................................................... 142
Foulks, Edward F. .............................................................. 83, 100
Foudas, Anne L. .................................................................. 109
Franck Pato, Clara .............................................................. 141
Francesco, Kathleen S. ...................................................... 100
Frank, Ellen .......................................................................... 96
Frank, Julia B. ....................................................................... 67
Frascella, Joseph .................................................................. 99, 106
Frasci, Karel J. ..................................................................... 147
Freedman, Robert .............................................................. 64, 89, 97
Fremam, Ellen ...................................................................... 115
Freudenreich, Oliver .......................................................... 89
Freu, Benicio ................................................................. 165
Friedman, Joseph H. .......................................................... 104
Friedman, Joshua .................................................................. 147
Friedman, Matthew J. ........................................................ 63, 114
Friedman, Nora ..................................................................... 79
Friedman, Richard C. ........................................................ 114
Friedman, Susan Hatters ................................................... 93, 147, 157
Frometa, Ayne ...................................................................... 144
Frye, Mark A. ....................................................................... 106, 112, 154
Fu, Dong-Jing ....................................................................... 159
Fujii, Ryuichi ......................................................................... 157
Fung, Kenneth D. .................................................................. 94
Furukawa, Toshiaki A. ......................................................... 62, 121, 153

Gerbert, Barbara ..................................................................... 122
Germain, Anne ....................................................................... 76
Gershwind, Daniel ............................................................... 105
Ghasemi, S. Nassir .............................................................. 78, 81, 107, 150, 154
Ghanem, Mohamed ........................................................... 125
Giedd, Jay N. ........................................................................ 106
Gillette, Joan ......................................................................... 109
Ginsberg, Lawrence D. ...................................................... 148, 151
Ginzburg, Harold M. ........................................................... 80
Girard, Kristine A. ............................................................... 63, 114
Gittin, David .......................................................................... 104
Glenn, Tasha .......................................................................... 152, 154
Glick, Ira D. .................................................................. 66, 70, 141
Glick, Rachel L. .................................................................... 76, 97
Glick, Mark A. ....................................................................... 120
Goethe, John W. .................................................................. 109, 116, 118, 123
Goff, Donald .......................................................................... 92
Gogineni, R. Rao ................................................................. 82
Goisman, Robert M. ............................................................ 79
Gold, Mark ........................................................................... 112
Goldberg, David ................................................................. 67, 87
Goldberg, Jeffrey ................................................................... 79
Goldberg, Joseph F. ............................................................ 119
Goldfinger, Stephen M. ....................................................... 94, 100, 121
Goldman, Howard H. ........................................................ 105
Goldman, Marina ................................................................... 80
Goldman, Morris B. ........................................................... 78
Goldstein, Stacia ................................................................. 124
Goldstein, Tina ...................................................................... 96
Gommoll, Carl ....................................................................... 150
Gonzalez, Hector M. ........................................................... 77
Goodkin, Karl ........................................................................ 125
Goodman, David W. ........................................................... 155
Goodman, Jeanne ................................................................... 62
Gopal, Arun ......................................................................... 77
Gordy, Tracy R. ..................................................................... 94, 108
Gorelick, David A. ............................................................. 100, 121
Gould, Todd ......................................................................... 107
Graber, Cheryl ....................................................................... 138
Graciouso, Barbara L. .......................................................... 150
Grady-Weilky, Tania A. ........................................................ 67, 70, 119
Graf, Marc ............................................................................. 110
Graham, Stephen M. .......................................................... 158
Granacher, Robert P. ......................................................... 90
Granger, Renee ...................................................................... 151, 154
Grant, Jon E. ......................................................................... 139, 155, 163
Grant, Steven ......................................................................... 120
Grau, Arturo P. ..................................................................... 119
Gray, Sheila Haffter ............................................................. 76
Greco, Nicholas IV .............................................................. 93
Green, Alan L. ....................................................................... 71, 98
Green, Stephen ...................................................................... 110
Greenberg, William M. ....................................................... 69, 150
Greenfield, Shelly F. ............................................................ 78, 89
Greist, John ......................................................................... 162
Griffin, Margaret L. ............................................................. 98, 148
Griffith, Ezra E. ..................................................................... 67
Griffith, James L. .................................................................... 78, 88
Grossberg, George T. ........................................................... 86, 93
Guggenheim, Frederick G. ............................................... 72, 87
Guio-Pabla, Christine J. ..................................................... 150, 152
Guiller, Angela ...................................................................... 159
Gunderson, John G. ............................................................ 79, 89, 95, 110, 112, 120, 125
Gunter, Gariane ..................................................................... 88
Gupta, Aarti ......................................................................... 139
Gupta, Swapnil ................................................................. 143
Gurr, Reuel E. ................................................................. 114, 141
Gurrera, Ronald J. .............................................................. 160, 161

Gabbard, Glen O. ................................................................. 79, 84, 87, 95, 108, 112, 118, 125
Gabbe, Mary S. ..................................................................... 139
Gaebel, Wolfgang ............................................................... 88
Galanter, Marc ...................................................................... 69, 112
Gallon, Joan E. ..................................................................... 164
Galynker, Igor I. ..................................................................... 140, 142, 144, 146, 147, 149, 162, 164
Garrett, Michael .................................................................... 121
Gaspar, Enrique ..................................................................... 143
Gastelum, Emily ................................................................... 67, 72
Gastfriend, David R. ........................................................... 161, 162
Gathright, Molly .................................................................... 122
Gau, Susan Shur-Fen ........................................................... 156
Gaudiano, Brandon A. ........................................................ 94
Gaviria, Silvia ........................................................................ 80, 119
Geddes, John ......................................................................... 89
Gelenberg, Alan J. .................................................................. 63
Geller, Jeffrey ......................................................................... 113
George, Mark S. ..................................................................... 91, 115
Georges, Hebert ..................................................................... 145
Georgeva, Galina J. ............................................................. 148
Gerard, Stephanie ................................................................... 140
Gerbar, Patricia L. .................................................................. 66, 79

163rd Annual Meeting 229
### PRESENTER INDEX

#### H

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ha, Ju-Won</td>
<td>138</td>
</tr>
<tr>
<td>Habib, Samir</td>
<td>108</td>
</tr>
<tr>
<td>Hackman, Ann L.</td>
<td>69</td>
</tr>
<tr>
<td>Haerl, Sophia</td>
<td>142</td>
</tr>
<tr>
<td>Hales, Deborah J.</td>
<td>79, 86, 88, 91, 94</td>
</tr>
<tr>
<td>Hall, Olivier</td>
<td>59</td>
</tr>
<tr>
<td>Hall, James</td>
<td>89, 110</td>
</tr>
<tr>
<td>Halmi, Katherine A.</td>
<td>64, 87, 109</td>
</tr>
<tr>
<td>Halpern, John H.</td>
<td>63</td>
</tr>
<tr>
<td>Haltzman, Scott D.</td>
<td>68</td>
</tr>
<tr>
<td>Halverson, Jerry L.</td>
<td>80, 99</td>
</tr>
<tr>
<td>Hamarman, Stephanie</td>
<td>79</td>
</tr>
<tr>
<td>Hamlin, Ed</td>
<td>78</td>
</tr>
<tr>
<td>Hammerness, Paul G.</td>
<td>148</td>
</tr>
<tr>
<td>Han, Dong Hyun</td>
<td>151</td>
</tr>
<tr>
<td>Han, Sang Ick</td>
<td>154</td>
</tr>
<tr>
<td>Haney, Margaret</td>
<td>121</td>
</tr>
<tr>
<td>Hankins, Brandi</td>
<td>48</td>
</tr>
<tr>
<td>Haq, Fasihah</td>
<td>142</td>
</tr>
<tr>
<td>Harbin, Henry</td>
<td>105</td>
</tr>
<tr>
<td>Hare, Todd</td>
<td>72</td>
</tr>
<tr>
<td>Harpel, Joanne</td>
<td>76, 116</td>
</tr>
<tr>
<td>Harris, Toi</td>
<td>122</td>
</tr>
<tr>
<td>Harvey, Philip D.</td>
<td>148, 160, 161</td>
</tr>
<tr>
<td>Harvey, Renee</td>
<td>112</td>
</tr>
<tr>
<td>Hasin, Deborah S.</td>
<td>98, 121</td>
</tr>
<tr>
<td>Hasler, Gregor</td>
<td>70</td>
</tr>
<tr>
<td>Hassan, Farah S.</td>
<td>140</td>
</tr>
<tr>
<td>Hassan, Mariam</td>
<td>152, 153</td>
</tr>
<tr>
<td>Hatt, Shikvumar S.</td>
<td>78</td>
</tr>
<tr>
<td>Heckel, Sally</td>
<td>84</td>
</tr>
<tr>
<td>Heim, Christine</td>
<td>48</td>
</tr>
<tr>
<td>Heinsen, Robert K.</td>
<td>96</td>
</tr>
<tr>
<td>Hellerstein, David J.</td>
<td>123</td>
</tr>
<tr>
<td>Helmer, Amanda</td>
<td>108</td>
</tr>
<tr>
<td>Henderson, Melinda S.</td>
<td>92</td>
</tr>
<tr>
<td>Hendren, Robert L.</td>
<td>66</td>
</tr>
<tr>
<td>Hendriksen, Marielle</td>
<td>86</td>
</tr>
<tr>
<td>Herazo, Edwin</td>
<td>149</td>
</tr>
<tr>
<td>Herbert, Sarah E.</td>
<td>95</td>
</tr>
<tr>
<td>Herbst, Luis G.</td>
<td>152</td>
</tr>
<tr>
<td>Herman, Barry K.</td>
<td>78, 90, 118</td>
</tr>
<tr>
<td>Hernández-Ribas, Rosa</td>
<td>153, 154</td>
</tr>
<tr>
<td>Herr, Matthew</td>
<td>139</td>
</tr>
<tr>
<td>Heru, Alison M.</td>
<td>104</td>
</tr>
<tr>
<td>Hien, Denise</td>
<td>78</td>
</tr>
<tr>
<td>Hilderbrand, Richard</td>
<td>72</td>
</tr>
<tr>
<td>Hilty, Donald M.</td>
<td>84, 89</td>
</tr>
<tr>
<td>Hinton, Devon</td>
<td>65, 82, 83</td>
</tr>
<tr>
<td>Hinton, Ladson</td>
<td>61</td>
</tr>
<tr>
<td>Hirata, John</td>
<td>79</td>
</tr>
<tr>
<td>Hirshkowitz, Max</td>
<td>66</td>
</tr>
<tr>
<td>Hlastala, Stefanie A.</td>
<td>96</td>
</tr>
<tr>
<td>Hobday, Gabrielle</td>
<td>96</td>
</tr>
<tr>
<td>Hoffman, Perry D.</td>
<td>89, 110</td>
</tr>
<tr>
<td>Hoffman, William F.</td>
<td>162</td>
</tr>
<tr>
<td>Hoffpaur, Sarah</td>
<td>68</td>
</tr>
<tr>
<td>Hoge, Steven K.</td>
<td>122</td>
</tr>
<tr>
<td>Hoge, Peter</td>
<td>95</td>
</tr>
<tr>
<td>Holland, Eric</td>
<td>98, 162</td>
</tr>
<tr>
<td>Holzinger, Florian</td>
<td>66, 67, 98</td>
</tr>
<tr>
<td>Holtzheiser, Paul</td>
<td>98, 99, 115, 125</td>
</tr>
<tr>
<td>Hong, Chang Hyung</td>
<td>157</td>
</tr>
<tr>
<td>Hong, Elliot</td>
<td>107</td>
</tr>
<tr>
<td>Hong, Minha</td>
<td>158</td>
</tr>
<tr>
<td>Hong, Yang</td>
<td>146</td>
</tr>
<tr>
<td>Hong, Youjin</td>
<td>139</td>
</tr>
</tbody>
</table>

### I

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iarvici, Doris M.</td>
<td>67, 76</td>
</tr>
<tr>
<td>Ibrahim, Fayaz A.</td>
<td>69</td>
</tr>
<tr>
<td>Inczedy-Farkas, Gabriella</td>
<td>143</td>
</tr>
<tr>
<td>Insel, Thomas</td>
<td>96</td>
</tr>
<tr>
<td>Iosifescu, Dan V.</td>
<td>121, 154</td>
</tr>
<tr>
<td>Isenberg, Keith</td>
<td>149</td>
</tr>
<tr>
<td>Ishiyama, Takeo</td>
<td>161</td>
</tr>
<tr>
<td>Islami, Sadaf</td>
<td>82</td>
</tr>
<tr>
<td>Ismail, Mostafa K.</td>
<td>128</td>
</tr>
</tbody>
</table>

### J

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jadresic, Enrique</td>
<td>119</td>
</tr>
<tr>
<td>Jaffe, Eli</td>
<td>71</td>
</tr>
<tr>
<td>Jain, Rakesh</td>
<td>148, 155</td>
</tr>
<tr>
<td>Jandakhanian, Thulasiram</td>
<td>143</td>
</tr>
<tr>
<td>Jiang, Sae-Heon</td>
<td>148</td>
</tr>
<tr>
<td>Janicek, Philip G.</td>
<td>78, 163</td>
</tr>
<tr>
<td>Javed, Qaiser Q.</td>
<td>119, 147</td>
</tr>
<tr>
<td>Javier, Pena</td>
<td>49</td>
</tr>
<tr>
<td>Jeevarakshahan, Shamala</td>
<td>63</td>
</tr>
<tr>
<td>Jennings, Gillian</td>
<td>142, 146, 149, 164</td>
</tr>
<tr>
<td>Jensen, Sine</td>
<td>162</td>
</tr>
<tr>
<td>Jeong-He, Seok</td>
<td>154</td>
</tr>
<tr>
<td>Jermendy, Agnes</td>
<td>145</td>
</tr>
<tr>
<td>Jeste, Dilp V.</td>
<td>88, 98</td>
</tr>
<tr>
<td>Joshi, Michael D.</td>
<td>70</td>
</tr>
<tr>
<td>Jimenez-Trevino, Luis</td>
<td>163</td>
</tr>
<tr>
<td>Jimerson, David C.</td>
<td>109</td>
</tr>
<tr>
<td>Jindu, Yonghua</td>
<td>154</td>
</tr>
<tr>
<td>Jope, Schoemaker</td>
<td>161</td>
</tr>
<tr>
<td>Johnson, Paula</td>
<td>80</td>
</tr>
<tr>
<td>Johnson, Sarah B.</td>
<td>77, 108</td>
</tr>
<tr>
<td>Johnston, Megan</td>
<td>63, 121</td>
</tr>
<tr>
<td>Johnstone, Eve C.</td>
<td>109</td>
</tr>
</tbody>
</table>

---

*Note: The page numbers provided are speculative and may not reflect the actual page numbers in the document.*
Mercader, Carolina .................................................................143, 144
Merkel, Richard L. ....................................................................71
Meyer, Donald J. .........................................................................92
Meyer, Fremont .................................................................77, 118
Meyer, Jonathan M. ....................................................................160
Meyer-Lindenber, Andreas ............................................................70
Meyers, Diana ...............................................................................96
Mian, Ayesha ..............................................................................82
Michels, Robert ..........................................................................79
Micciano, Armando S. .................................................................157
Miettunen, Jouko ........................................................................118, 144, 161
Mihai, Adreana A. ......................................................................71
Milev, Rouman V. ......................................................................121
Miller, Earl K. ...........................................................................93
Miller, Gary E. ...........................................................................93
Miller, Gregory ..........................................................................124
Min, Jungwon .............................................................................138
Mintz, David L. .........................................................................90, 108
Mirza, Bushra F. ........................................................................144
Mischoulon, David .....................................................................119, 148
Misra, Sahana .............................................................................120
Misti, Shaila ................................................................................81, 158
Mitchell, James E. ......................................................................64, 70, 109
Mittal, Sukriti ............................................................................62, 69, 87, 105
Moanai, Javad ...........................................................................152
Moen, Richelle ..........................................................................109
Moffic, Evan ..............................................................................124
Mohandas, E. .............................................................................101
Montaner, Julio ..........................................................................122–123
Montgomery, Stuart ..................................................................150, 153, 154
Montoya, Ivan D. .........................................................................82, 98
Moran, Scott ...............................................................................89
Morse, Eric D. ............................................................................72
Morse, Gary ...............................................................................69
Mosier, Jessica ..........................................................................80
Moutier, Christine .....................................................................115
Mrazek, David A. .......................................................................92, 94, 110, 125, 146
Mucic, Davor ............................................................................109
Mukherjee, Dahlia .....................................................................87
Muniz, Rafael ............................................................................155, 156
Munoz, Kristine ..........................................................................142
Muñoz, Rodrigo A. .....................................................................80, 109, 152, 154
Musalek, Michael ......................................................................88
Musgnung, Jeff ..........................................................................150, 152
Mushtat, David .........................................................................125
Mushef, Jeremy S. ......................................................................94, 108
Muskin, Philip R. .......................................................................106
Mustafa, Husain ..........................................................................68, 107
Myers, Michael F. ......................................................................62, 84, 86, 104, 122
Myers, Wade ............................................................................72, 110
Nemath, Ali ..................................................................................80
Nemoro, Charles B. ...................................................................65
Newcomer, John W. ...................................................................83, 142, 147, 156, 161
Newton, Thomas ........................................................................118
Ng, Anthony T. ..........................................................................76
Nicol, Ginger E. .........................................................................83, 142, 147, 156
Nicolò, Giuseppe .........................................................................78, 95, 124
Nielson, Jimmi ...........................................................................160
Nierenberg, Andrew A. ............................................................81, 89, 96, 152, 153
Ninan, Philip T. ..........................................................................104, 152
Nino, Johanna ............................................................................138
Nivoli, Alessandra ......................................................................139
Noel, Richard L. ..........................................................................93
Nonacs, Ruta M. .......................................................................113
Nordon, Clementine ....................................................................163
Norris, Donna M. .....................................................................99
Noteboom, Amenieke A. ............................................................86
Nothman, Makh T. .....................................................................72, 92
Nunes, Edward V. .....................................................................89, 121
Nunes, Sandra Odebrecht Vargas ..............................................147, 162
Nurenberg, Jeffrey R. ..................................................................50
Nyberg, Svante ..........................................................................146, 148
Nyhus, Nidene J. .......................................................................69
O’Brien, Charles P. .....................................................................90, 98, 111
Ochsner, Kevin N. .....................................................................72, 87
Odilag, Brian L. ..........................................................................139, 163
Oepen, Godehard ........................................................................163
O’Gorman, Cedric .......................................................................150, 153
Oh, Hyeon Young .......................................................................141
Okusaga, Olaoluwa O. .................................................................118
Oldham, John M. ......................................................................66, 69, 108, 110, 112
Olin, Jason T. ............................................................................163
Olsen, John L. ............................................................................152
Ong, Jason .................................................................................76
Oquendo, Maria ........................................................................116, 125, 156
O’Reardon, John .......................................................................108, 163
Osiński, Alphonse ......................................................................122
Oslin, David ...............................................................................72
Osufsky, Howard J. ...................................................................69, 88, 100, 113
Osufsky, Joy D. .........................................................................88, 113
Ospina, Jorge .............................................................................125
Ostacher, Michael J. ...................................................................81, 152, 153
Ostrow, David G. .......................................................................63
O’Sulllivan, Michael ....................................................................109
Owen, Randall ...........................................................................150, 152, 153, 154
Ozerdem, Aysegul .....................................................................65, 83
Pakh, Clare .................................................................................90
Palmer, Brian A. .......................................................................89, 110
Pandina, Gahan ..........................................................................159
Pang, Peng ................................................................................145
Pappadopulos, Elizabeth ..............................................................150, 151, 153, 154
Paradies, Herbert .......................................................................91
Parikh, Sagar ............................................................................121
Paris, Joel F. ...............................................................................77
Park, Han Kyul ...........................................................................142, 144, 156
Passik, Steven ...........................................................................82, 83, 149
Patel, Arita R. ............................................................................121
Patel, Jayendra ..........................................................................104
Patel, Meeta ...............................................................................152
Pati, Uday ...................................................................................91
Patkar, Ashwin A. .....................................................................138, 148, 150, 162
<table>
<thead>
<tr>
<th>Presenter Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bara, Barbara</td>
<td>122</td>
</tr>
<tr>
<td>Rothschild, Anthony J.</td>
<td>94, 104, 144</td>
</tr>
<tr>
<td>Roy-Byrne, Peter</td>
<td>65, 66</td>
</tr>
<tr>
<td>Rucio, Gusbert</td>
<td>113</td>
</tr>
<tr>
<td>Rubin, Jonathan</td>
<td>148, 155, 157</td>
</tr>
<tr>
<td>Rue, David S.</td>
<td>68</td>
</tr>
<tr>
<td>Rueda-James, German E.</td>
<td>147</td>
</tr>
<tr>
<td>Rueda-Lara, Maria Adelaida</td>
<td>119</td>
</tr>
<tr>
<td>Ruiz, Amanda</td>
<td>89</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>80, 82, 88</td>
</tr>
<tr>
<td>Rumjnow, Anne</td>
<td>162</td>
</tr>
<tr>
<td>Rudnell, James R.</td>
<td>92</td>
</tr>
<tr>
<td>Runnels, Patrick S.</td>
<td>113</td>
</tr>
<tr>
<td>Russakoff, L. Mark</td>
<td>78</td>
</tr>
<tr>
<td>Russo, Leo</td>
<td>125</td>
</tr>
<tr>
<td>Rutherford, Bret R.</td>
<td>150</td>
</tr>
<tr>
<td>Ryan, Deirdre</td>
<td>81, 158</td>
</tr>
<tr>
<td>Rychik, Abe M.</td>
<td>95</td>
</tr>
<tr>
<td>Saad, Emma</td>
<td>120</td>
</tr>
<tr>
<td>Sachdeva, Shilpa</td>
<td>162</td>
</tr>
<tr>
<td>Sacks, Stanley</td>
<td>98</td>
</tr>
<tr>
<td>Sadiq, Afia</td>
<td>105</td>
</tr>
<tr>
<td>Saeed, Sy A.</td>
<td>78</td>
</tr>
<tr>
<td>Safar, Laura</td>
<td>95</td>
</tr>
<tr>
<td>Safer, Debra L.</td>
<td>70</td>
</tr>
<tr>
<td>Safran, Marc A.</td>
<td>106</td>
</tr>
<tr>
<td>Sagman, Doron</td>
<td>151, 114</td>
</tr>
<tr>
<td>Sahakian, Barbara</td>
<td>114</td>
</tr>
<tr>
<td>Sajatovic, Martha</td>
<td>97, 157</td>
</tr>
<tr>
<td>Salloum, Ilshane</td>
<td>65</td>
</tr>
<tr>
<td>Salzer, Alicia J.</td>
<td>106</td>
</tr>
<tr>
<td>Samuel, Janine</td>
<td>142, 146, 164</td>
</tr>
<tr>
<td>Sands, Diana</td>
<td>76</td>
</tr>
<tr>
<td>Saunders, Ramotse</td>
<td>79</td>
</tr>
<tr>
<td>Savin, Daniel M.</td>
<td>93</td>
</tr>
<tr>
<td>Saxon, Andrew</td>
<td>104</td>
</tr>
<tr>
<td>Schatzberg, Alan F.</td>
<td>66, 69, 80, 84, 95, 100, 106, 163</td>
</tr>
<tr>
<td>Schiffer, Randolph B.</td>
<td>86</td>
</tr>
<tr>
<td>Schlaepfer, Thomas</td>
<td>69</td>
</tr>
<tr>
<td>Schlozman, Steven</td>
<td>73</td>
</tr>
<tr>
<td>Schmidt, Chester W.</td>
<td>94, 108</td>
</tr>
<tr>
<td>Schmidt, Winsor C.</td>
<td>93</td>
</tr>
<tr>
<td>Schnurr, Paula</td>
<td>63</td>
</tr>
<tr>
<td>Schoedel, Kerri</td>
<td>147</td>
</tr>
<tr>
<td>Schoener, Gary R.</td>
<td>62</td>
</tr>
<tr>
<td>Schumehl, James Q.</td>
<td>90</td>
</tr>
<tr>
<td>Schuckit, Marc</td>
<td>98</td>
</tr>
<tr>
<td>Schudlen, Jeffrey D.</td>
<td>64</td>
</tr>
<tr>
<td>Schulz, S. Charles</td>
<td>71, 77, 109</td>
</tr>
<tr>
<td>Schuppert, Marieke H.M.</td>
<td>112</td>
</tr>
<tr>
<td>Schuster, James</td>
<td>64</td>
</tr>
<tr>
<td>Schwartz, Michael A.</td>
<td>100, 107</td>
</tr>
<tr>
<td>Schwartz, Robert P.</td>
<td>82</td>
</tr>
<tr>
<td>Schwartz, Victor I.</td>
<td>97, 113</td>
</tr>
<tr>
<td>Scott, Charles L.</td>
<td>89, 110</td>
</tr>
<tr>
<td>Scully, James H. Jr.</td>
<td>80, 105, 113</td>
</tr>
<tr>
<td>Secin, Ricardo</td>
<td>125</td>
</tr>
<tr>
<td>Seo, Wan Seok</td>
<td>156</td>
</tr>
<tr>
<td>Sepitaka, Jussi K.M.</td>
<td>163</td>
</tr>
<tr>
<td>Sertan, Andreae L.</td>
<td>108, 118</td>
</tr>
<tr>
<td>Sesak, Susan R.</td>
<td>107</td>
</tr>
<tr>
<td>Shafer, David</td>
<td>107</td>
</tr>
<tr>
<td>Shah, Amy</td>
<td>147</td>
</tr>
<tr>
<td>Shahabuddin, Arif</td>
<td>147</td>
</tr>
<tr>
<td>Shalam, Amin</td>
<td>144</td>
</tr>
<tr>
<td>Shannachoff-Khalsa, David</td>
<td>108, 118</td>
</tr>
<tr>
<td>Shapiro, Edward Robert</td>
<td>90, 112, 116</td>
</tr>
<tr>
<td>Sharfstein, Joshua</td>
<td>51</td>
</tr>
<tr>
<td>Sharfstein, Steven S.</td>
<td>88, 100, 109</td>
</tr>
<tr>
<td>Shea, Shawn C.</td>
<td>79</td>
</tr>
<tr>
<td>Sheehan, David V.</td>
<td>151</td>
</tr>
<tr>
<td>Sheline, Yvette</td>
<td>69, 97</td>
</tr>
<tr>
<td>Shinn, Ruth S.</td>
<td>95</td>
</tr>
<tr>
<td>Shin, Chun-Jin</td>
<td>141</td>
</tr>
<tr>
<td>Shin-fuku, Naotaka</td>
<td>115</td>
</tr>
<tr>
<td>Shinozaki, Gen</td>
<td>146</td>
</tr>
<tr>
<td>Shiroma, Paula</td>
<td>67</td>
</tr>
<tr>
<td>Shoyinka, Susunmolu O.</td>
<td>67, 100</td>
</tr>
<tr>
<td>Shrvastava, Amresh</td>
<td>63, 121</td>
</tr>
<tr>
<td>Shyu, Irene</td>
<td>116, 140</td>
</tr>
<tr>
<td>Sibrava, Nicholas J.</td>
<td>162</td>
</tr>
<tr>
<td>Siefert, Caleb J.</td>
<td>150</td>
</tr>
<tr>
<td>Siggins, Lorraine D.</td>
<td>114</td>
</tr>
<tr>
<td>Sikirica, Mirko</td>
<td>160</td>
</tr>
<tr>
<td>Silberman, Edward K.</td>
<td>76, 89</td>
</tr>
<tr>
<td>Silk, Kenneth R.</td>
<td>70, 89, 104, 110</td>
</tr>
<tr>
<td>Silva, Hernán</td>
<td>146</td>
</tr>
<tr>
<td>Silva, Paula</td>
<td>143, 163</td>
</tr>
<tr>
<td>Silverman, Morton</td>
<td>97</td>
</tr>
<tr>
<td>Simon, Robert I.</td>
<td>82, 95</td>
</tr>
<tr>
<td>Singh, Jaskaran</td>
<td>160</td>
</tr>
<tr>
<td>Sinha, Rajita</td>
<td>78</td>
</tr>
<tr>
<td>Sivrioglu, Yusuf</td>
<td>76</td>
</tr>
<tr>
<td>Sklar, Pamela</td>
<td>105</td>
</tr>
<tr>
<td>Skodol, Andrew E.</td>
<td>107, 112</td>
</tr>
<tr>
<td>Sledge, William H.</td>
<td>116</td>
</tr>
<tr>
<td>Slotema, Christina C.</td>
<td>141</td>
</tr>
<tr>
<td>Smith, David W.</td>
<td>124</td>
</tr>
<tr>
<td>Smith, Delaney</td>
<td>143</td>
</tr>
<tr>
<td>Smith, Dwight</td>
<td>79, 161</td>
</tr>
<tr>
<td>Smith, Eric G.</td>
<td>107, 146</td>
</tr>
<tr>
<td>Smith, Gwenn</td>
<td>97</td>
</tr>
<tr>
<td>Smith, Mary Kay</td>
<td>70</td>
</tr>
<tr>
<td>Smith, Tyler C.</td>
<td>122</td>
</tr>
<tr>
<td>Snyder, Solomon H.</td>
<td>94, 105</td>
</tr>
<tr>
<td>Soares, Claudio N.</td>
<td>115</td>
</tr>
<tr>
<td>Sohal, Vikaas</td>
<td>96</td>
</tr>
<tr>
<td>Sohi, Mannohandee</td>
<td>138, 150</td>
</tr>
<tr>
<td>Soloff, Paul H.</td>
<td>92</td>
</tr>
<tr>
<td>Soltsys, Stephen M.</td>
<td>67</td>
</tr>
<tr>
<td>Song, Young-Heon</td>
<td>158</td>
</tr>
<tr>
<td>Sood, Aradhana</td>
<td>63</td>
</tr>
<tr>
<td>Sorel, Eliot</td>
<td>80, 83, 116</td>
</tr>
<tr>
<td>Sorensen, Roger G.</td>
<td>120</td>
</tr>
<tr>
<td>Sorrentino, Erica</td>
<td>70</td>
</tr>
<tr>
<td>Sorrentino, Renee M.</td>
<td>93</td>
</tr>
<tr>
<td>Spear, Linda Patia</td>
<td>106</td>
</tr>
<tr>
<td>Speier, Anthony</td>
<td>113</td>
</tr>
<tr>
<td>Spera, Allan</td>
<td>163</td>
</tr>
<tr>
<td>Spertber, Jacob E.</td>
<td>67, 79</td>
</tr>
<tr>
<td>Spiegel, David</td>
<td>97, 120</td>
</tr>
<tr>
<td>Spila, Bozena</td>
<td>152</td>
</tr>
<tr>
<td>Spinelli, Margaret</td>
<td>76, 113</td>
</tr>
<tr>
<td>Spitznas, Cecelia M.</td>
<td>122</td>
</tr>
<tr>
<td>Springate, Benjamin</td>
<td>96</td>
</tr>
<tr>
<td>Spurgeon, Joyce A.</td>
<td>77</td>
</tr>
<tr>
<td>Spyker, Daniel A.</td>
<td>159, 160</td>
</tr>
<tr>
<td>Staal, Steven S.</td>
<td>148</td>
</tr>
<tr>
<td>Stahl, Stephen</td>
<td>104, 161</td>
</tr>
<tr>
<td>Stankowski, Joy</td>
<td>93</td>
</tr>
<tr>
<td>Starr, Barbara H.</td>
<td>62, 67</td>
</tr>
<tr>
<td>Starr, Harriette L.</td>
<td>155, 156</td>
</tr>
<tr>
<td>Stein, Bradley D.</td>
<td>143, 147</td>
</tr>
</tbody>
</table>
**PRESENTER INDEX**

| Stein, Murray B. | 65 |
| Steiner, Hans | 88 |
| Stenback, Karis A. | 144 |
| Stevens, Anne W. | 78 |
| Stewart, Donna E. | 89 |
| Stewart, Jonathan T. | 63 |
| Stigler, Kimberly A. | 79, 156 |
| Stoddard, Frederick J. | 69, 70 |
| Stoddard, Joel | 69 |
| Stotland, Nada L. | 89, 106, 114 |
| Strain, James J. | 120 |
| Strakowski, Stephen M. | 70, 91 |
| Strasbourg, Kate | 113 |
| Streeter, Chris C. | 146 |
| Stroupis, T. Scott | 89 |
| Sudak, Donna M. | 67, 73, 79 |
| Suetusugi, Masatomo | 160 |
| Sukhara, Javeed | 77 |
| Sullivan, Patrick | 105 |
| Summners, Richard F. | 111 |
| Summners, Scott M. | 144 |
| Sun, Ning | 133, 140 |
| Suppes, Trisha | 107, 114 |
| Surman, Craig B. | 112 |
| Susman, Virginia L. | 111 |
| Sussman, Matthew | 152 |
| Sutcliffe, James | 79 |
| Swanson, James M. | 107–108 |
| Swartz, Holly A. | 96 |
| Swedo, Susan | 64 |
| Sylvia, Louisa G. | 81, 152 |
| Szabo, Steven T. | 162 |
| Szarek, Bonnie L. | 109, 116, 118, 123 |
| Szegedi, Armin | 96, 152, 160 |
| Szigethy, Eva | 70 |
| Szpindel, Isaac | 155 |
| Szycik, Gregor R. | 146, 161 |
| T | |
| Tackett, Jennifer | 77 |
| Tafesse, Eskinder | 151 |
| Taft, Zebulon | 83, 100, 110 |
| Talbott, John A. | 72 |
| Tanda, Rajiv | 78 |
| Tapert, Susan F. | 107 |
| Tardiff, Kenneth J. | 82 |
| Targum, Steven D. | 96 |
| Tassie, Hina | 79, 115 |
| Taupin, Allan | 108 |
| Taylor, Craig B. | 70, 104 |
| Taylor, Janet E. | 124 |
| Te Wildt, Bert T. | 146, 161 |
| Tellez-Vargas, Jorge | 125 |
| Temporini, Humberto | 51 |
| Teshima, John S. | 67 |
| Tewari, Nidhi | 69, 80 |
| Thase, Michael E. | 65, 81, 90, 99, 119, 151, 152, 153 |
| Theochari, Irini | 140, 159 |
| Theilman, Samuel | 71 |
| Thomas, Kathleen K. | 92 |
| Thommi, Saiah | 150, 154 |
| Thompson, Christopher | 89 |
| Thompson, Kenneth S. | 64, 69, 113 |
| Thompson, Captane P. | 76 |
| Thorpe, Michelle | 141, 144 |
| Thorsen, Paul | 65 |
| Tillman, Jane G. | 76, 112 |
| Tjoa, Christopher W. | 100 |
| Tohen, Mauricio | 65 |
| Townsend, Mark H. | 88 |
| Trace, Martin G. | 110 |
| Trestman, Robert L. | 89 |
| Trimble, Michael | 86 |
| Trivedi, Madhukar H. | 66, 89, 153, 154 |
| Trivedi, Reena | 67 |
| Truong, Kiet T.V. | 68 |
| Trzepacz, Paula | 62 |
| Tseng, Kuan-Chiao | 157 |
| Tsuang, John W. | 86 |
| Tsuang, Ming T. | 121 |
| Tucker, Phebe M. | 69, 100 |
| Turel, Jeffrey M. | 149 |
| Turkington, Douglas | 90, 95, 108, 110 |
| Turner, Norris | 160 |
| Tuzzo, Dan | 63 |

| U | |
| Uemura, Vivian | 139, 147, 162 |
| Ursano, Robert J. | 63 |

| V | |
| Vadhy, Swapna | 67 |
| Vailant, George E. | 69, 111 |
| Vaksa, Yakir K. | 144 |
| Van, Henricus | 86 |
| Van Ameringen, Michael | 162 |
| Van Boeijen, Christine A. | 88 |
| Van Den Oord, Edwin, J.C.G. | 98 |
| Van Wittum, Pieter Joost | 156 |
| Van Wel, Bas E.B. | 112 |
| Vanderpool, Donna | 62, 68, 110 |
| Vannucci, Elizabeth | 145 |
| Varughese, Sean | 163 |
| Vaswani, Meera | 100, 111, 118 |
| Vaswani, Sanjay | 88 |
| Vavrusova, Livia | 88 |
| Vela, Ricardo M. | 80 |
| Velásquez, Elvia | 119 |
| Vemuri, Mytlee | 97 |
| Venk, Jacob | 83, 156 |
| Vercella, Helen | 64 |
| Verduin, Marcia L. | 100 |
| Vermaani, Monica | 66, 79 |
| Viguera, Adele | 113 |
| Villauer, Jennice | 123 |
| Vince, Bradley | 156 |
| Vinson, Sarah | 77 |
| Vogel-Sciabilla, Suzanne E. | 122 |
| Volkow, Nora D., 72, 90, 98, 99, 104, 105, 107–108, 110, 114 |
| Volman, Susan | 107 |
| Volpp, Serena Y. | 106 |

<p>| W | |
| Wahlbeck, Kristian | 107 |
| Wahlström, Carl M. | 92 |
| Walaszek, Art | 67 |
| Wakup, John T. | 66, 89 |
| Walsh, B. Timothy | 98 |
| Wang, Junling | 17 |
| Wang, Po W. | 97 |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warner, Christopher H.</td>
<td>120</td>
</tr>
<tr>
<td>Waseem, Atif</td>
<td>142</td>
</tr>
<tr>
<td>Washington, Harriet A.</td>
<td>124</td>
</tr>
<tr>
<td>Weiss, Caroline</td>
<td>143, 145</td>
</tr>
<tr>
<td>Watanabe, Norio</td>
<td>153</td>
</tr>
<tr>
<td>Weber, Natalya S.</td>
<td>153</td>
</tr>
<tr>
<td>Webster, Cecil R.</td>
<td>122, 142</td>
</tr>
<tr>
<td>Weerasekera, Priyanthu</td>
<td>79, 86</td>
</tr>
<tr>
<td>Weiden, Peter</td>
<td>77, 159, 161</td>
</tr>
<tr>
<td>Weinberger, Daniel R.</td>
<td>99</td>
</tr>
<tr>
<td>Weine, Stevan</td>
<td>83</td>
</tr>
<tr>
<td>Weiner, Elyse D.</td>
<td>68</td>
</tr>
<tr>
<td>Weiner, Richard</td>
<td>107</td>
</tr>
<tr>
<td>Weingroff, Jolie</td>
<td>140</td>
</tr>
<tr>
<td>Weinstein, Aviv</td>
<td>121</td>
</tr>
<tr>
<td>Weinstein, Faye M.</td>
<td>80</td>
</tr>
<tr>
<td>Weinstein, Henry C.</td>
<td>80</td>
</tr>
<tr>
<td>Weiser, Richard</td>
<td>155</td>
</tr>
<tr>
<td>Weiss, Mitchell G.</td>
<td>71</td>
</tr>
<tr>
<td>Weiss, Roger D.</td>
<td>62, 98</td>
</tr>
<tr>
<td>Wells, Kenneth B.</td>
<td>96, 97</td>
</tr>
<tr>
<td>Wells, Trevor</td>
<td>162</td>
</tr>
<tr>
<td>West, Joyce C.</td>
<td>63, 64, 95, 123</td>
</tr>
<tr>
<td>Westermeyer, Joseph</td>
<td>71</td>
</tr>
<tr>
<td>Wetherington, Cora Lee</td>
<td>78</td>
</tr>
<tr>
<td>Wexler, Micaela P.</td>
<td>140</td>
</tr>
<tr>
<td>Whalen, Gerald</td>
<td>79</td>
</tr>
<tr>
<td>Wheels, Joani</td>
<td>113</td>
</tr>
<tr>
<td>Widzowski, Daniel</td>
<td>148</td>
</tr>
<tr>
<td>Wijal, Sharon</td>
<td>156</td>
</tr>
<tr>
<td>Wilens, Timothy E.</td>
<td>156</td>
</tr>
<tr>
<td>Wilk, Joshua</td>
<td>63</td>
</tr>
<tr>
<td>Williams, Deidre E.</td>
<td>124</td>
</tr>
<tr>
<td>Wills, Celia E.</td>
<td>64</td>
</tr>
<tr>
<td>Winhusen, Theresa</td>
<td>78</td>
</tr>
<tr>
<td>Winstead, Daniel K.</td>
<td>100</td>
</tr>
<tr>
<td>Winstead, Nathaniel S.</td>
<td>122</td>
</tr>
<tr>
<td>Wise, Inge</td>
<td>63</td>
</tr>
<tr>
<td>Wise, Michael Jan</td>
<td>63, 122</td>
</tr>
<tr>
<td>Wisner, Katherine L.</td>
<td>76</td>
</tr>
<tr>
<td>Witte, Michael M.</td>
<td>160</td>
</tr>
<tr>
<td>Wolf, Robert</td>
<td>114</td>
</tr>
<tr>
<td>Wong, Felicia K.</td>
<td>88</td>
</tr>
<tr>
<td>Wonseok, Choi</td>
<td>138</td>
</tr>
<tr>
<td>Woodbury-Farina, Michael A.</td>
<td>93</td>
</tr>
<tr>
<td>Woods, Scott W.</td>
<td>121</td>
</tr>
<tr>
<td>Woolley, Stephen B.</td>
<td>116</td>
</tr>
<tr>
<td>Wrenn, Glenda</td>
<td>97</td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>73, 79, 90, 108</td>
</tr>
<tr>
<td>Wulsin, Lawson R.</td>
<td>91</td>
</tr>
<tr>
<td>Wynn, Pe S</td>
<td>163</td>
</tr>
<tr>
<td>Xu, Yong</td>
<td>139, 140, 146</td>
</tr>
<tr>
<td>Yeung, Albert</td>
<td>77, 116, 140, 144</td>
</tr>
<tr>
<td>Yildirim, Yilmaz</td>
<td>83, 142</td>
</tr>
<tr>
<td>Yohanan, Monique</td>
<td>81, 91</td>
</tr>
<tr>
<td>Yoon, Jin-Sang</td>
<td>146, 148, 158</td>
</tr>
<tr>
<td>Youche, Sharon</td>
<td>156, 157</td>
</tr>
<tr>
<td>Young, Melinda L.</td>
<td>80</td>
</tr>
<tr>
<td>Yudofsky, Stuart C.</td>
<td>115, 118</td>
</tr>
<tr>
<td>Zachar, Peter</td>
<td>107</td>
</tr>
<tr>
<td>Zanarini, Mary C.</td>
<td>66, 92, 97, 120, 140</td>
</tr>
<tr>
<td>Zarate, Carlos</td>
<td>119</td>
</tr>
<tr>
<td>Zarif, Nashwa</td>
<td>125</td>
</tr>
<tr>
<td>Zeannah, Charles</td>
<td>88</td>
</tr>
<tr>
<td>Zhang, Jing</td>
<td>89</td>
</tr>
<tr>
<td>Zhao, Bing</td>
<td>139, 140</td>
</tr>
<tr>
<td>Zedonis, Douglas M.</td>
<td>64</td>
</tr>
<tr>
<td>Ziegler, Penelope</td>
<td>86</td>
</tr>
<tr>
<td>Zimbres, Paula</td>
<td>67</td>
</tr>
<tr>
<td>Zimmerman, Mark</td>
<td>83, 116, 123, 152</td>
</tr>
<tr>
<td>Zonana, Howard V.</td>
<td>122</td>
</tr>
<tr>
<td>Zorick, Todd</td>
<td>86, 138</td>
</tr>
<tr>
<td>Zucker, Kenneth J.</td>
<td>98</td>
</tr>
<tr>
<td>Zun, Leslie</td>
<td>123, 147</td>
</tr>
<tr>
<td>Zurowski, Mateusz</td>
<td>94</td>
</tr>
</tbody>
</table>

Z

Y

X

Yager, Joel                           | 63, 109 |
Yang, Chunxia                          | 139, 140 |
Yang, Hyunjoo                          | 140 |
Yang, Jun                              | 123 |
Yaseen, Zimri                          | 144 |
Yatham, Lakshmi N.                     | 65, 121 |
Yehuda, Rachel                         | 98 |
Yen, Jack                              | 63 |
Yeomans, Frank E.                      | 79, 124 |
INDICATIONS
GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients.

DOSE AND ADMINISTRATION
Schizophrenia: GEODON Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosages may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. The safety and efficacy of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment. Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in short-term, placebo-controlled clinical trials. Treatment with conventional antipsychotic drugs may increase mortality.

The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. GEODON (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis (see WARNINGS).

CONTRAINDICATIONS
QT Prolongation
Because of ziprasidone’s dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by other drugs, GEODON is contraindicated in patients with a known history of QT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see WARNINGS). Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. An additive effect of ziprasidone and other drugs that prolong the QT interval cannot be excluded. Therefore, ziprasidone should not be given with dofetilide, sotalol, quinidine, other Class la and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, meprobamate, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. Ziprasidone is also contraindicated with other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning [see WARNINGS]. Ziprasidone is contraindicated in individuals with a known hypersensitivity to the product.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of dementia-related psychosis (see BOXED WARNING).

QT Prolongation and Risk of Sudden Death: Ziprasidone use should be avoided in combination with other drugs that are known to prolong the QT interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QT interval. Such drugs should not be prescribed with ziprasidone. Ziprasidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias [see CONTRAINDICATIONS].

QT Prolongation in Clinical Trials: A study directly comparing the QT/QTc prolonging effect of oral ziprasidone with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. In this study, the effect of ziprasidone on QTc length was not augmented by the presence of a metabolic inhibitor (ketonazole...
200 mg twice daily). In placebo-controlled trials, oral ziprasidone increased the QTc interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials the electrocardiograms of 2,298 (0.06%) patients who received GEODON and 1,440 (0.23%) patients who received placebo revealed QTc intervals exceeding the potentially clinically relevant threshold of 500 msec. In the ziprasidone-treated patients, neither case suggested a role of ziprasidone. QT Prolongation and Torsade De Pointes Some drugs that prolong the QT/QTc interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearer for larger increases (20 msec and greater) but it is possible that smaller QT/QTc prolongations may also increase risk, or increase it in susceptible individuals. Although torsade de pointes has not been observed in association with the use of ziprasidone in premarketing studies and experience is too limited to rule out an increased risk, there have been rare post-marketing reports (in the presence of multiple confounding factors) (see ADVERSE REACTIONS). A study evaluating the QT/QTc prolonging effect of intramuscular ziprasidone, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of ziprasidone (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular ziprasidone is 50% higher than the recommended therapeutic dose. The mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QTc interval. The mean increase in QTc from baseline for ziprasidone was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QTc from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patients had a QTc interval exceeding 500 msec. As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking ziprasidone at recommended doses. The premarketing experience for ziprasidone did not reveal an excess risk of mortality for ziprasidone compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, ziprasidone’s larger prolongation of QTc length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for ziprasidone than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval. Electrolyte Disturbances May Increase The Risk of QT Prolongation It is recommended that patients being considered for ziprasidone treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. Persistently prolonged QTc intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECGs measures are effective in detecting such patients. Rather, ziprasidone should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements >500 msec. Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. Tardive Dyskinesia A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. If signs and symptoms of tardive dyskinesia appear in a patient on ziprasidone, drug discontinuation should be considered. Hyperglycemia and Diabetes Mellitus Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical anti-psychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia. PRECAUTIONS Leukopenia, Neutropenia, and Agranulocytosis In clinical trial and postmarketing experience, events of leukopenia/neutropenia and agranulocytosis (including fatal cases) have been reported temporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored during the first few months of therapy and should discontinue GEODON at the first sign of decline in WBC in the absence of other causative factors. Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3) should discontinue GEODON and have their WBC followed until recovery. Rash In premarketing trials with ziprasidone, about 5% of patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was related to dose of ziprasidone, although the finding might also be explained by the longer exposure time in the higher dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, ziprasidone should be discontinued. Orthostatic Hypotension Ziprasidone may induce orthostatic hypotension associated with diziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α1-adrenergic antagonist properties. Syncope was reported in 0.6% of the patients treated with ziprasidone. Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures In clinical trials, seizures occurred in 0.4% of patients treated with ziprasidone. There were confounding factors that may have contributed to the occurrence of seizures in many of these cases. As with other antipsychotic drugs, ziprasidone should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer’s dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Dysphagia Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer’s dementia, and ziprasidone and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia (see BOXED WARNING and Increased Mortality in Elderly Patients with Dementia-Related Psychosis in WARNINGS: Hyperprolactinemia As with other drugs that antagonize dopamine D2 receptors, ziprasidone elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic
administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive and Motor Impairment Somnolence was a commonly reported adverse reaction in patients treated with ziprasidone. In the 4- and 6-week placebo-controlled trials, somnolence was reported in 14% of patients on ziprasidone compared to 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since ziprasidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that ziprasidone therapy does not affect them adversely. Priapism One case of priapism was reported in the premarketing database. Body Temperature Regulation Although not reported with ziprasidone in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Suicide The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for ziprasidone should be written for the smallest quantity of capsules consistent with good patient management in order to reduce overdose risk. Patients With Concomitant Illnesses Clinical experience with ziprasidone in patients with certain concomitant systemic illnesses is limited. Ziprasidone has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QT prolongation and orthostatic hypotension with ziprasidone, caution should be observed in cardiac patients (see QT Prolongation and Risk of Sudden Death in WARNINGS and Orthostatic Hypotension in PRECAUTIONS). Information for Patients To assure safe and effective use of GEODON, the information and instructions provided in the patient information should be discussed with patients. Laboratory Tests Patients being considered for ziprasidone treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be replaced before proceeding with treatment. Patients who are started on diuretics during Ziprasidone therapy need periodic monitoring of serum potassium and magnesium. Discontinue ziprasidone in patients who are found to have persistent QT measurements >500 msec (see WARNINGS).

DRUG INTERACTIONS

(1) Ziprasidone should not be used with any drug that prolongs the QT interval. (2) Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, ziprasidone may enhance the effects of certain antihypertensive agents. (4) Ziprasidone may antagonize the effects of levodopa and dopamine agonists. Effect of Other Drugs on Ziprasidone Carbamazepine, 200 mg bid for 21 days, resulted in a decrease of approximately 35% in the AUC of ziprasidone. Ketonazole, a potent inhibitor of CYP3A4, 400 mg qd for 5 days, increased the AUC and Cmax of ziprasidone by about 35-40%. Cimetidine, 800 mg qd for 2 days, did not affect ziprasidone pharmacokinetics. Co-administration of 30 mL of Maalox® did not affect ziprasidone pharmacokinetics. Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. Effect of Ziprasidone on Other Drugs In vitro studies revealed little potential for ziprasidone to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and little potential for drug interactions with ziprasidone due to displacement. Ziprasidone 40 mg bid administered concomitantly with lithium 450 mg bid for 7 days did not affect the steady-state level or renal clearance of lithium. In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. Ziprasidone 20 mg bid did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vivo results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrophan. There was no statistically significant change in the urinary dextromethorphan/dextrophan ratio. NONCLINICAL TOXICOLOGY Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime carcinogenicity studies were conducted with ziprasidone in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice, there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice. Ziprasidone had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hyperprolactinemia in PRECAUTIONS). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of S. typhimurium in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: Ziprasidone increase time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m² basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m² basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m² basis). The fertility of female rats was reduced. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery The effect of ziprasidone on labor and delivery in humans is unknown. Nursing Mothers It is not known whether ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breastfeed. Pediatric Use The safety and effectiveness of ziprasidone in pediatric patients have not been established. Geriatric Use Of the total number of subjects in clinical studies of ziprasidone, 2.4 percent were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. ADVERSE REACTIONS Adverse Findings Observed in Short-term, Placebo-Controlled Trials The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. Adverse Events Associated With Discontinuation Schizophrenia: Approximately 4.1% (2/50) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 2.2% (6/273) on placebo. The most common reaction associated with dropout was rash, including 7 dropouts for rash among ziprasidone patients (1%) compared to no placebo patients (see PRECAUTIONS). Bipolar Mania: Approximately 6.5% (18/273) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 3.7% (5/136) on placebo. The most common reactions associated with dropout in the ziprasidone-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash and vomiting, with 2 dropouts for each of these reactions among ziprasidone patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse events. Adverse Events at an Incidence of ≥5% and at Least Twice the Rate of Placebo The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (6%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31%), extrapyramidal symptoms (31%), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that
occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Body as a Whole—asthenia, accidental injury, chest pain. Cardiovascular—tachycardia. Digestive—nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous—extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory—respiratory tract infection, rhinitis, cough increased. Skin and Appendages—rash, fungal dermatitis. Special Senses—abnormal vision. Bipolar Mania: Body as a Whole—headache, asthenia, accidental injury. Cardiovascular—hypertension. Digestive—nausea, diarrhea, dry mouth, vomiting, increased salivation, tongue edema, dysphagia. Musculoskeletal—myalgia. Nervous—somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypertension, speech disorder. Respiratory—pharyngitis, dyspnea. Skin and Appendages—fungal dermatitis. Special Senses—abnormal vision. Dose Dependency An analysis for dose response in the schizophrenia 4-study pool revealed an apparent relation of adverse reaction to dose for the following reactions: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dysphonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. Extrapiramidal Symptoms (EPS) The incidence of reported EPS for ziprasidone patients in the short-term, placebo-controlled schizophrenia trials was 14% vs. 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale (for EPS) and the Barnes Akathisia Scale (for akathisia) did not generally show a difference between ziprasidone and placebo. Dystonia Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. Elevated risk of acute dystonia is observed in males and younger age groups. Vital Sign Changes Ziprasidone is associated with orthostatic hypotension (see PRECAUTIONS). Weight Gain in short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of ≥2% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for ziprasidone (10%) compared to placebo (4%). A median weight gain of 0.5 kg was observed in ziprasidone patients compared to no median weight change in placebo patients. Weight gain was reported as an adverse event in 0.4% of both ziprasidone and placebo patients. During long-term therapy with ziprasidone, a categorization of patients at baseline on the basis of body mass index (BMI) revealed the greatest mean weight gain and highest incidence of clinically significant weight gain (>7% of body weight) in patients with low BMI (<23) compared to normal (23-27) or overweight patients (>27). There was a mean weight gain of 1.4 kg for those patients with a "low" baseline BMI, no mean change for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients who entered the program with a "high" BMI. ECG Changes Ziprasidone is associated with an increase in the QT interval (see WARNINGS). In the schizophrenia trials, ziprasidone was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. Other Adverse Events Observed During the Premarketing Evaluation of Ziprasidone in Schizophrenia Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare adverse events are those occurring in fewer than 1/1000 patients. Body as a Whole—Frequency: abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, acneiform eruption; Infrequent: alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses—Frequency: fungal dermatitis. Infrequent: conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia. Rare: eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. Urinary System—Frequency: impotence, abnormal ejaculation, amenorrhea, hemorrhagia, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmsia, glycosuria. Rare: gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. Adverse Findings Observed in Trials of Intramuscular Ziprasidone In these studies, the most commonly observed adverse reactions associated with the use of intramuscular ziprasidone (≥5%) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were headache (13%), nausea (12%), and somnolence (20%). Adverse Events at an Incidence of ≥1% in Short-Term Fixed-Dose Intramuscular Trials The following list enumerates the treatment-emergent adverse events that occurred in ≥1% of patients during acute therapy with intramuscular ziprasidone: Body as a Whole—headache, injection site pain, anorexia, dry mouth, back pain. Cardiovascular—postural hypotension, hypertension, bradycardia, vasodilation. Digestive—nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous—dizziness, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypotonia, cogwheel rigidity, paresthesia, personality disorder, psychoses, speech disorder. Respiratory—rhinitis. Skin and Appendages—furunculosis, sweating. Urogenital—dysmenorrhea, priapism. Other Events Observed During Post-marketing Use Adverse reaction reports not listed above that have been received since market introduction include rare occurrences of the following—Cardiac Disorders: Tachycardia, torsade de pointes (in the presence of multiple confounding factors), (see WARNINGS); Digestive System Disorders: Swollen Tongue; Reproductive System and Breast Disorders: Galactorrhea, priapism; Nervous System Disorders: Facial Droop, neuroleptic malignant syndrome, serotonin syndrome (alone or in combination with serotonergic medicinal products), tardive dyskinesia, Psychiatric Disorders: Insomnia, mania/hypomania, Skin and subcutaneous Tissue Disorders: Allergic reaction (such as allergic dermatitis, angioedema, orofacial edema, urticaria), rash; Urogenital System Disorders: Enuresis, urinary incontinence; Vascular Disorders: Postural hypotension, syncope. Drug Abuse and Dependence Controlled Substance Class Ziprasidone is not a controlled substance. OVERDOSAGE In premarketing trials in over 5400 patients, accidental or intentional overdosage of oral ziprasidone was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (200/95).
IMPORTANT SAFETY INFORMATION

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with certain other QT-prolonging drugs. GEODON has a greater capacity to prolong the QTc interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first. Hypokalemia may increase the risk of QT prolongation and arrhythmia.

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely. Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.